/start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/anvandaradministration/2019-05-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/car-t-cellsprovtagning/2025-04-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/origami-2/2025-04-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pereli/2025-04-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/quantum-wild-ac220-168/2025-04-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/on-call/2025-04-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dellphi-306-studien/2025-04-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/noac-9/2025-04-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mevpro-2/2025-04-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/codebreak301/2025-04-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mevpro-1/2025-03-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/orig-ami-3/2025-03-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/direktstart/2025-02-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/galaxies-lung-301-gsk4428859a/2025-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/treat-ctdna/2025-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/destiny-her2-low/2025-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/correct-/2025-02-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/origami-3/2025-02-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/akir-001/2025-02-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tilvance-301-studien/2025-02-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dareon-7/2025-01-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/melody/2025-01-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/orig-ami2/2025-01-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/uso---bc/2024-12-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/qpl---brostcancer/2024-12-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/swe-switch/2024-12-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imcode004--bo45230/2024-12-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fourlight-2-c4391025/2024-12-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ipa-studien/2024-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sgndv-001kn-d74/2024-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gsk-222730-spartacus--b7-h4/2024-11-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk2870-010/2024-11-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hyperion/2024-11-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/grand-slam/2024-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/temozolomide-plus-lomustine-versus-temozolomide-for--mgmt-promoter-methylated-glioblastoma/2024-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/artscan-vi/2024-11-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/magstage/2024-11-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/allvos/2024-11-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/efs-frailty-in-lung-cancer/2024-11-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sarong-/2024-11-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/jazz--zanihertwo/2024-11-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/solucom/2024-11-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk3543/2024-11-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/alxn1210-tma-313/2024-10-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scandium-iii/2024-10-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lion/2024-10-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/adiuvo-2/2024-10-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bellwave-011-mk1026-011/2024-10-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/seqcureneo/2024-10-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/golseek-1--ca073-1020/2024-10-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sprintr-real/2024-10-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/trofuse-020/2024-09-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sgncea5c-001-ceacam5/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/odx-mm-001/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/idunn/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/chro761a12101-michro/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/medal/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/guide.mrd2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/robocop/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fatigue-pet-studie/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/rocknrol-1/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/channel/2024-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imcode-003/2024-09-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cmlstop/2024-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/espac-6/2024-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prisma-prism-mel-301/2024-09-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/relativity-127/2024-08-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/beamion-lung-2/2024-08-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/jade-studien--219885/2024-08-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-2870-009/2024-08-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-2870-005/2024-08-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bgb-11417-301/2024-08-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/golden-gate-20190360/2024-08-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mdt-bridge/2024-08-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/selsa/2024-08-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/waveline-006/2024-05-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cartitude-6/2024-05-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/carma-01/2024-05-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/v940-005/2024-05-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/omaha-004/2024-05-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/omaha-003/2024-05-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/abbvie-m18-868/2024-04-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bi1808-studien/2024-04-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/veritac-2/2024-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ewall/2024-03-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/predict-hpv-hnc/2024-03-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/monumental-6/2024-03-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pipn/2024-03-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/teneriffa-/2024-03-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/caaa617a12402/2024-03-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/arastep-21492/2024-02-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/22-bi-1910-01/2024-02-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/beamion-lung-1-1479-0001/2024-02-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/important/2024-02-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/melbank-studien/2024-01-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pred-hh-markstudien/2024-01-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/azur2/2024-01-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/meteroid/2024-01-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/horizon-01/2024-01-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/merlin/2024-01-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/onkovir/2024-01-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/-m20-621/2024-01-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/breton-bgb-16673-101/2024-01-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cardiocare/2024-01-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/andromeda-studien/2023-12-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bnt-113-01-studien/2023-12-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/triplex-studien/2023-11-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/haitils-studien/2023-11-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bo44426---krascendo-lung-170---studien/2023-11-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fortitude101-amgen-552-studien/2023-11-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bio-me-studien/2023-11-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/-f8394-201-fore/2023-11-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/swecraniol/2023-10-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/svep53-studien/2023-10-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/v940-001-studien/2023-10-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/harbor-blu263-1201/2023-10-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/effipec/2023-10-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/eris/2023-10-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/kartos-studien-/2023-10-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/kandova/2023-10-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keyvibe-010/2023-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dwell-time/2023-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/piscatin/2023-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/commodore-bo42161/2023-08-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scan-all/2023-08-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/decidualcellstudien2/2023-08-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/providhe/2023-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ariadne-studien/2023-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/k-sab/2023-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imole/2023-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/peak-/2023-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tropion-breast032/2023-08-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/spc11-01-110/2023-07-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ac220-a-u202/2023-07-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/asf-bc/2023-07-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/itcc-101apal2020d/2023-07-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/profertil/2023-06-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mesacapp/2023-06-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ca055-026/2023-06-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ld-venex-studien/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mimir-studien-89zr-atezolizumab-petct/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-6482-022/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cloudin-6-bnt211-01/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nmdsg14-b-2/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fapi-46fapi-pet/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/zuma-4/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/19-bi-1808-01/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/eros/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prevent-a-call/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bi-1206-03-monkey/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cctl019g2201j--cassiopeja/2023-06-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/libretto-432-studien/2023-06-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/firefly-2/2023-06-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prodigyn/2023-05-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/arm/2023-05-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bnt122-01/2023-05-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/destiny-12/2023-05-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/salfladmet/2023-05-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/espac-4/2023-05-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ascend--4/2023-05-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/eucharis/2023-05-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ascape/2023-05-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/i-conic-studien/2023-04-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/optimering-infor-stor-kolorektalcancer-kirurgi/2023-04-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/majestec-9/2023-04-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prias/2023-04-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/optunebehandling-for-patienter-med-glioblastom--patienternas-narstaendes-och-personalens-uppfattning-av-behandlingen---en-kvalitativ-intervju-samt-enkat-studie/2023-04-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fibroneer/2023-04-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ironman/2023-04-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/primordium/2023-04-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cancerrehabilitering-vid-matstrups-eller-magsackscancer/2023-03-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/advantage/2023-03-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/serom/2023-03-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/first-rly-4008-101/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/asc4first/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sirpa-ca059-001/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/allovir-adeno-alvr105-/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/magnetismm-7-studien/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/certis-1/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/majestec-7/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/neogap-neogap-crc-01/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biwac-bi-1403-0001--brightline/2023-03-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/in-mind/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/loxo-20022-btk/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dovacc/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/asab/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk2140-004/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/postmonarche/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/neo-act/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bgb3111-lte1-roll-overstudie/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/seamark/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/xnk-urotelialcancer/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/columbus-ad/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/brightline-1/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sensi-ex/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bio-melanom/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/avanzar/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gemore/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/-isga-studien-pre-gat01/2023-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pro-glio/2023-03-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tabanetoc/2023-03-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/colon-z/2023-03-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/crlm-z/2023-03-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dragon-sarcopenia-/2023-03-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mariposa-2/2023-03-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/taormina-studien/2023-03-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/preopanc-3/2023-03-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scanpan-1/2023-02-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/t-rex/2023-02-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/palbociclib/2023-01-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nsgo-ctu-hero-/2023-01-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cnis793b12301/2023-01-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/relativity-123/2023-01-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keyform-008/2023-01-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/popcorn/2022-11-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/metro/2022-11-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-c93gog-3064engot-en15/2022-11-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lidera/2022-11-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/halo/2022-10-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biobladder/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tropics-04/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk6482-012/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pris/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pelvex-ii-studien/2023-07-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/breakwater/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cirkos/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/costar/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/g-definer/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sens-studien/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prep-studien/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/axsana/2022-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/star-trec/2022-10-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/salflac/2022-08-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/incb81776-101-axl-mer/2022-08-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mo41552/2022-08-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/rm26/2022-08-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sgns40-002-seasam/2022-08-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/kartlaggning-av-hematologiska-maligniteter-hos-patienter-med-mojlig-arftlig-predisposition/2022-07-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/en-fas-1b2-first-in-human-doseskalerings--och-expansionsstudie-av-xmt-1536-hos-patienter-med-solida-tumorer-som-sannolikt-uttrycker-napi2b/2022-06-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/script-aml-studying-conditioning-regimen-in-pediatric-transplantation-aml/2022-06-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/telepik2/2022-05-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/miltenyi-/2022-05-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cc-90010-gbm-002/2022-05-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hypo-m1/2022-05-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/start-net/2022-05-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ago-ovar-2.292022-04-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/inotuzumab/2022-03-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ludo-n/2022-03-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/carfilzomib/2022-03-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ponatinib/2022-03-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/polargo/2022-03-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/inform2-nivent/2022-03-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ipmn/2022-03-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/parpanc/2022-03-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/relativity-098/2022-03-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/altamira/2022-03-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lbl-2018/2022-02-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/b-nhl-2013/2022-02-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/en-undersokning-om-smartrelaterade-erfarenheter-hos-svenska-vuxna-med-cancer/2022-02-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ccs1477-02/2022-02-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ccs1477-01/2022-02-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/onc001-cl-001/2022-02-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/psmaddition/2022-02-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gct3013-01/2022-02-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/modelle-001/2022-01-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/soulmate/2022-01-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/asac/2022-01-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/timepoint/2021-12-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-365/2021-12-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/enrgy/2021-11-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/transcend/2021-11-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/evi-3/2021-11-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cell-protect---isa-hc-nk/2021-11-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/loxo-btk-18001/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/immu-lc/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tinca-ii--njurcancer/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mypal/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dsa-ll-studien/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gct-3013-05/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ros-studien/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/immunologisk-aktivitet-hos-melanomtumorer/2021-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nex-18/2021-11-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fas-i-studie-incb-99318-122-incyte/2021-11-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/swedish-anal-carcinoma-study/2021-11-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sgntuc-016/2021-10-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ruby-del-2/2021-10-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/destiny-breast09/2021-10-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bite-u-20190505/2021-10-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ipcm/2021-10-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scan-mi/2021-09-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/magsnow/2021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sentineo/2021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/postmagmri/2021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/erfarenheter-av-vakuumassisterade-excisioner-av-forandringar-i-brost-vae/2021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/magtotal/2021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/breastcc/2021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sentinot-2.02021-09-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/paced/2021-09-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/summist/2021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scandium-ii/2021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-b21-gog.30532021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/psma-fore/2021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-b49/2021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nipu-studien--ca209-7h4/2021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biobanksstudien-lungcancer/2021-09-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk6482-015/2021-08-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gct-3013-022/2021-07-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/spencer/2021-07-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk6482-005/2021-07-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hexabody-01/2021-07-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/capitello-292/2021-07-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/listo/2021-06-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prevalence/2021-06-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scout/2021-05-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pdm-mbc-/2021-05-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bio-muse/2021-05-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/proper-2/2021-04-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/navigate/2021-04-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pcr1001/2021-04-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prommel-studien/2021-04-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/covaxid-kll/2021-04-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prorect-studien/2021-04-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pacos/2021-03-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/amplitude/2021-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gsk-209012/2021-03-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/transform-2/2021-02-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/transform-1/2021-02-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/zeal-1l-/2021-02-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prepec-studien/2021-02-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mermaid-1/2021-01-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mr-divide/2021-01-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-866/2020-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/code-break-200/2020-12-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/exclaim2/2020-12-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/phys-can-styrketraningsstudie/2020-12-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/genomikstudien-brost/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/induce-4/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/blu-667-2303/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bite-cc93269-mm-001/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/heat-aml/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/momentum-sra-mmb-301/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/adore/2020-12-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/re-screen/2020-11-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/neo-aegis/2020-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/needs/2020-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/optima/2020-11-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/destiny06/2020-11-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ameera/2020-11-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tas-120-202-soffa/2020-11-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tak788-3001/2020-11-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/webbaserad-symtomovervaktning-vid-avancerad-lungcancer/2020-10-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/megalit/2020-10-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ho156-aml/2020-10-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/polar-bear/2020-10-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-a18--engot-cx11/2020-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nordictripnbg-19-01-swebcg-19-01/2020-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biolungstudien/2020-09-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/rhovac/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dalia/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ipla/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cccs-covid-cast-studien/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cor10012/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/induce-3/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/effect/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-7339-007-agent/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/thyro-nuke/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ruby/2020-08-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/advance-ii/2020-07-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-76k-ca20976k/2020-06-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/the-fiol-study-/2020-05-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ho150-aml/2020-05-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/assure/2020-05-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pro-hodgkin/2020-04-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nordcml013/2020-04-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hd21/2020-04-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/beatcc/2020-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/breclim/2020-03-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/psma-recidiv/2020-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/direct/2020-02-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lokon003/2020-02-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-73l-/2020-02-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lxh254x2102/2020-02-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nivo-ilp/2019-12-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pcia-laserstudie/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/artscan-iv/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/psff-blodburna-vavnadsprov/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/exintric/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pantumime/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/down-stagingstudie-lever/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/orchard/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/karmma-3/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mbg453-mds/2019-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/kllvacc-2017/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tatoo2/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/relapc/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ator-1017/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pcyc-1145/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/synkron-studien/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/vigas/2019-12-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imfdhac_impact-of-fixed-dentures-in-head-and-neck-cancer-/2019-11-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dbcg-rt-natural-studien/2019-11-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-937/2019-11-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/intrigue-studien/2019-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/alltogether-/2019-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dream-5/2019-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/canopy-1/2019-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ca209-171/2019-11-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-905/2019-11-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prove-studien/2019-11-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bh-studien/2019-11-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mateeo/2019-11-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/talapro-2/2019-11-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ace-cl-311/2019-10-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/205801-entree/2019-10-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/canova/2019-10-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/capitello-290/2019-10-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/athena/2019-10-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nucog-vi/2019-10-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bgg-311-305/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bob/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/brigatinib-3001/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/brigatinib-2002/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-555/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/transform/2020-01-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/kiadis/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/graphite/2019-09-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/a.r.r.o.w-22019-09-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/destiny/2019-09-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/clee011a2207/2019-08-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/commands-ace-536-mds-002/2019-07-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/probio2/2019-07-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/voc/2019-07-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fight-302/2019-07-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bosupeg/2019-07-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/norpact-12/2019-06-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biome-studien/2019-06-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/viden/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/entree/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mir-studien/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/racc/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/iloc/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/solstice/2019-06-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/predix-ii-her2/2019-06-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/panfam1/2019-06-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ctc---cirkulerande-tumorcellsstudien/2019-06-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ipep/2019-06-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tadpole-g/2019-05-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gen-esofagus-studie/2019-05-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pilgrim/2019-05-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pavo-mmy1004/2019-05-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bright-b1371019/2019-05-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/iso-cc-007-agent/2019-04-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biobank-esofagusventrikel/2019-04-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cando/2019-04-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cyst-studie-saliv-studie/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cyststud/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fimmun-pancreas-tumor/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/frosenor/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/adoele/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-7902-003/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/predicting-fatigue-after-allo-hsct/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/matterhorn/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/-pneu-stem-v114-022/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hapirect/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/qolicol/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/watch-and-wait/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/con-studien/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nmdsg14b/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nmdsg14a/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pci-32765can3001/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/2215-cl-0302/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tempo-studien/2019-04-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/zeus/2019-04-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/magnitude/2019-04-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/onconova-04-302/2019-04-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/54767414amy3001/2019-04-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bo39813/2019-04-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/allopurinol-all2.02019-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/seal-studien/2019-03-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/methronomic/2019-03-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/asa-crclm-2014/2019-03-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nmsg2415-ked/2019-03-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ird-nmsg2315/2019-03-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bcma-mmy1001/2019-03-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-7902-004/2019-03-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nor-graspall-2016-akut-lymfatiskt-leukemi-all/2019-03-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/phrancesca-mo40628/2019-03-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prothym/2019-02-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biolymph/2019-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/expacd/2019-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/psma-primar-prostatacancer2/2019-02-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ben-r/2019-02-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ben-c/2019-02-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/c16029-takeda-millenium/2019-02-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/impower030/2019-02-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ator-1015/2019-02-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/eortc-vu34/2019-02-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/exceptional-responders/2019-02-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/canfour/2019-02-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/artscan-v/2019-01-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-9132/2019-01-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/stop-gist-ssg-xxv/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ibru-on-off-studien/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/valeria/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/citadel-203/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nz-dtx-001/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-3475-587/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/atevacc2/2019-01-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/melanom-provtagning/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/glow-cll3011/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/can3001/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/javelin-blasa/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/proceed2/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/vision/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/psma-pet-studien/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/embark-mdv-3100-12/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/combi-aplus3/2019-01-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/intense/2019-01-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/zuma-7/2019-01-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pemborlizumab-mk-3475-051/2019-01-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/graspanc/2018-12-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/17403-bay-1163877/2018-12-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/achiles/2018-12-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/who-cares/2018-11-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/larct-us/2018-10-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bemp/2018-10-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/secombit/2018-10-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/illuminate/2018-10-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/opinion/2018-10-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bgb-3111-304/2018-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/act-on-me/2018-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/s-ramp/2018-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/trust2/2018-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/az-odin-pet2/2018-09-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/scan-b/2018-09-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pemdac/2018-09-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/affibody-3/2018-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/genmab-gct1015-04/2018-09-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/embrace-ii/2018-09-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/17-bi-1206-02/2018-09-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ca224-047/2018-08-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-789/2018-07-02 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cat-studien/2018-06-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pac203/2018-05-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tulip/2018-05-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/repomed/2018-04-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/car-19/2018-04-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hovon-141/2018-03-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/b-701-u21/2018-03-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imagyn050/2018-03-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cpkc412a2408/2018-03-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lokon002/2018-02-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ca017-003/2018-02-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/enrich/2018-02-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imroz/2018-02-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-908/2018-02-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/aurora/2018-01-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/monarche/2018-01-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-5222/2018-01-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tahoe-_-m16-2892/2017-12-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/adaura/2017-12-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/asteroid/2017-12-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bold-1/2017-11-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prodat/2017-11-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-901-ca209-901/2017-11-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/combi-i/2017-11-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/secar-i/2017-10-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dastop-2/2017-10-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/artemids-cc-4047-mm-015/2017-10-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nmsg-2013/2017-10-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/opacin/2017-10-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dursab/2017-10-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pasiphae2/2017-10-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/glag/2017-10-04 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/panorama-3-clbh589d2222/2017-09-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prefer-preserve-fertility/2017-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/onconova-04-30/2017-08-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/quazar-aza-mds-003/2017-08-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/javelin-renal-1018/2017-08-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/exelixis-xl184-401/2017-06-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/trim/2017-06-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/direktstudien/2017-06-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/prima-_-pr-30-5017-c/2017-05-31 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/auto-lymfom/2017-05-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sakk-3514/2017-05-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/compleement-1/2017-05-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/iliad/2017-05-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/arasens/2017-05-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/profound/2017-05-17 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cv006-studien/2017-05-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/geometry-mono-cinc280a2201/2017-05-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-522/2017-05-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/inspire_onconova-04-30/2017-04-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-602-ca209-602/2017-04-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pallas/2017-03-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pepacaka/2017-03-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-714/2017-03-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/puma-ner-1301/2017-03-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/preben/2017-03-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/viable/2017-03-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/solar-1/2017-03-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/panorama_3/2017-03-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cpdr001e2201/2017-03-07 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-057/2017-02-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mastiff/2017-02-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mars/2017-02-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-051/2017-02-16 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lasec-studien-lymphedema-after-surgery-for-endometrial-cancer2/2017-02-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/alt-gist/2017-02-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/podec/2017-02-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lume-bionis/2017-02-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/proper/2017-02-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-274/2017-02-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/spcg-17-pcastt/2017-01-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/triangle/2017-01-25 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/livskvalitet-for-patienter-med-malignt-melanom/2017-01-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/c-inc280-a2108/2017-01-24 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/swea-studien4/2017-01-18 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pet-boost/2017-01-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/pro-cns/2017-01-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nordic-8/2017-01-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nordic-9/2017-01-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/testiscab/2017-01-03 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/avanova/2016-12-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/melmart/2016-12-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/melanomprovtagning/2016-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cirkulerande-tumor-dna/2016-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/icap/2016-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/arches-/2016-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/titan-pcr3002-/2016-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/embark--mdv-3100-13/2016-12-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/rethink/2016-12-22 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tumorfaktorers-betydelse-vid-behandling-av-malignt-melanom/2016-12-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/minimalinvasiv-isolerad-hyperterm-perfusion-mi-ilp/2016-12-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/analys-av-exosomer-i-samband-med-isolerad-hyperterm-perfusion-for-behandling-av-metastaserande-malignt-melanom/2016-12-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/immunologiska-effekter-vid-behandling-av-metastaser-fran-malignt-melanom/2016-12-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/aramis/2016-12-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/iobt-kohortstudie/2016-12-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/physsurg-b/2016-12-19 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-451-ca209-451/2016-12-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mistral/2016-12-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/artscan-iii/2016-12-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bayer/2016-12-08 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/dna-pkinhib2/2016-11-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/roar2/2016-11-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/galahad/2016-11-30 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fandango/2016-11-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/abc-se/2016-11-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/morris2/2016-11-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/gen701/2016-11-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/i4t-mc-jvcz2/2016-11-10 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-170-pmbcl-och-richter-phase-ii/2016-11-01 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/maverric/2016-10-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ca209238/2016-10-21 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/palaestra/2016-10-20 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/phys-can/2016-10-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mateo/2016-10-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sirt-net/2016-10-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-177/2016-10-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/jsbf/2016-10-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/iluminet/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/et-nec/2016-10-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/spcg-15/2016-10-05 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/altaii/2016-09-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tailordose-ii/2016-09-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/trem/2016-09-29 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ca209067/2016-09-28 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/male-breast-cancer-study/2016-09-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/breast-cancer-in-pregnancy/2016-09-27 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/micro-rnactc/2019-06-11 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-3475-181/2016-09-26 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/the-scandium-studien/2016-09-23 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/neape_nordic-extended-abdominoperineal-excision-study--/2016-09-14 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/paola-1/2016-09-13 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nt-probnp/2016-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/engot-ov-23ewoc-1/2016-09-12 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/kaitlin/2016-09-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/grace/2016-09-09 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/alascca/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-199/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/abc-studien/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-3475-252-keynote-252/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-ca-209-548/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-ca209-498/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/atlas/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/checkmate-209-401/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/m12-914-brocade/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ssgxx/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nintedanib/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-204/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mk-3475-048-keynote-048/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hovon-132-aml/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lymrit-3701/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/senomic/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/antibiotika-studien/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/adm-studien/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/b-cap/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bevmar/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/im-201/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ici-pcrb/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/sandpiper/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/alpharadinabiraterone/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/vinsor/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/modul/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/fluoheart/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-100-mk-3475/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/ip-ov/2019-05-15 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/engot/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-173-fas-i/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/keynote-119/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/olympia/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cobc/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/predix-her-2/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bi-breeast/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/picc-pac/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/neptune/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/thora/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/oligo/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/repac/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/odx-003/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/artforce-headneck/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/cetmet2/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/imilt/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/rosett/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/phoneme/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/mat02/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/senomac/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/tarzel/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/lumb/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/bevpac/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/impassion-130/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/flt-pet.mr2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/predix-luma/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/hilus/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/nucog-i-vingem/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/paraply/2016-09-06 /start/samverkan/vara-uppdrag/forskning/cancerstudier-i-sverige/studier/biomarkorer-under-behandling-av-prostatacancer/2016-09-06 /start/norr/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 /start/stockholm-gotland/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 /start/syd/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 /start/sydost/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 /start/mellansverige/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 /start/vast/vara-uppdrag/forskning/cancerstudier-i-sverige/2024-11-06 https://kb.localhost:5000/2024-06-18 https://kb.localhost:5000/prenumerationer/2020-02-28 https://kb.localhost:5000/importera-referenslista/2021-02-25 https://kb.localhost:5000/mina-sidor/2022-02-10 https://kb.localhost:5000/logga-in/2020-01-28 https://kb.localhost:5000/logga-in/glomt-losenord/2020-01-24 https://kb.localhost:5000/logga-in/skapa-konto/2025-05-06 https://kb.localhost:5000/logga-in/aterstall-losenord/2020-01-24 https://kb.localhost:5000/om-kunskapsbanken/2022-02-10 https://kb.localhost:5000/om-kunskapsbanken/om-vardprogram/2025-05-19 https://kb.localhost:5000/om-kunskapsbanken/om-vardforlopp/2022-02-10 https://kb.localhost:5000/om-kunskapsbanken/om-regimbiblioteket/2022-02-10 https://kb.localhost:5000/om-kunskapsbanken/integritetspolicy/2025-07-01 https://kb.localhost:5000/tillganglighetsredogorelse/2021-11-16 https://kb.localhost:5000/om-kakor/2022-10-24 https://kb.localhost:5000/diagnoser/alarmsymtom/2020-02-28 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/2020-01-28 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/anemi/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/anala-symtom/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/aptitloshet-mattnadskansla-viktnedgang/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/attacksymtom/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/buksymtom/2022-04-28 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/bukfynd/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/blodning/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/brostsymtom/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/feber-och-infektioner/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/flush/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/gulsot-och-gallstas/2020-02-18 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/hjarta/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/hud/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/huvud--och-halssymtom/2020-02-14 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/knol/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/laborationsavvikelser/2022-04-28 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/luftvagarna/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/lymfkortel-forstorad/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/metastasfynd/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/nattsvettningar/2020-01-28 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/neurologiska-symtom/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/skelettfynd/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/skelettsymtom/2024-04-18 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/smarta/2024-04-18 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/sar-som-inte-laker/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/trotthet-och-sjukdomskansla/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/underlivsfynd-kvinnor/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/underlivsfynd-man/2020-01-28 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/urinvagarna/2020-02-17 https://kb.localhost:5000/diagnoser/alarmsymtom/alarmsymtom/ventrombos/2020-02-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/2022-04-11 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/2020-02-10 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/introduktion/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/introduktion/flodesschema-for-vardforloppet/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardforlopp/arbetsgruppens-sammansattning2/2020-01-22 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/sammanfattning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/malgrupp/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/standardiserat-vardforlopp/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/lagstod/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/inledning/evidensgradering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/mal-med-vardprogrammet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/bakgrund-och-orsaker/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/bakgrund-och-orsaker/diffust-storcelligt-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/bakgrund-och-orsaker/primart-mediastinalt-storcelligt-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/bakgrund-och-orsaker/burkittlymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/bakgrund-och-orsaker/Primart-diffust-storcelligt-B-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/bakgrund-och-orsaker/4.5paverkbara-faktorer-for-att-minska-risken2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/arftlighet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/Utredning-enligt-standardiserat-vardforlopp/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/Utredning-enligt-standardiserat-vardforlopp/rontgenologisk-utredning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/Utredning-enligt-standardiserat-vardforlopp/ovrig-utredning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/Utredning-enligt-standardiserat-vardforlopp/ovrig-utredning/utredning-vid-pcnsl/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/Utredning-enligt-standardiserat-vardforlopp/performance-status-whoecog/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/registrering/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diagnostik/diagnosbesked/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kategorisering-av-tumoren/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation--till-patologen/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kategorisering-av-tumoren/patologi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kategorisering-av-tumoren/patologi/diffust-storcelligt-b-cellslymfom-dlbcl/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/stadieindelning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/kliniska-prognosfaktorer-ipi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/kliniska-prognosfaktorer-ipi/CNS-IPI/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/kliniska-prognosfaktorer-ipi/Primart-CNS-lymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/kliniska-prognosfaktorer-ipi/kliniska-prognostiska-markorer-som-f.n.-ej-rekommenderas-i-rutinbruk2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/biomarkorer/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/biomarkorer/ursprungscell/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/biomarkorer/bcl2/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/biomarkorer/MYC-och-dubbelhit/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/prognosfaktorer/stadieindelning-av-burkittlymfom-st-jude/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/multidisciplinar-konferens/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/patologi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/patologi/subtypning-av-dlbcl/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/prognosfaktorer/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/primar-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/primar-behandling/aaipi--0-patienter-80-ar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/primar-behandling/aaipi--1-patienter-80-ar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/primar-behandling/aaipi--23/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/primar-behandling/aaipi--3-patienter-80-ar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/primar-behandling/aaipi--3-patienter-80-ar/dosering-av-metotrexat-och-cytarabin-i-kombination-med-r-chopr-choep/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/konsoliderande-stralbehandling/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/konsoliderande-stralbehandling/skelettengagemang/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/konsoliderande-stralbehandling/bulkig-sjukdom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/nedsatt-allmantillstand/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/nedsatt-hjartfunktion/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/alder-80-ar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/testisengagemang/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/sarskild-behandling-for-speciella-patientgrupper/primart-cns-engagemang/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/kurativt-syftande-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/kurativt-syftande-behandling/tidigt-aterfall--car-t/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/kurativt-syftande-behandling/sent-aterfall--behandling-med-inriktning-mot-hogdosbehandling-med-autologt-stamcellsstod/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/kurativt-syftande-behandling/sent-aterfall--behandling-med-inriktning-mot-hogdosbehandling-med-autologt-stamcellsstod/schema-for-stamcellsmobilisering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/patienter-som-inte-ar-aktuella-for-kurativt-syftande-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-aterfall/symtomlindrande-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-med-inriktning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-med-inriktning/allogen-stamcellstransplantation/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-recidiv-i-cns/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-recidiv-i-cns/recidiv-begransat-till-cns/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/diffust-storcelligt-b-cellslymfom/behandling-av-recidiv-i-cns/recidiv-samtidigt-i-cns-och-systemiskt/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hogmalignt-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hogmalignt-b-cellslymfom/patologi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hogmalignt-b-cellslymfom/primar-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hogmalignt-b-cellslymfom/behandling-av-aterfall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-mediastinalt-storcelligt-b-cellslymfom/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-mediastinalt-storcelligt-b-cellslymfom/patologi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-mediastinalt-storcelligt-b-cellslymfom/utredning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-mediastinalt-storcelligt-b-cellslymfom/primar-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-mediastinalt-storcelligt-b-cellslymfom/responsutvardering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-mediastinalt-storcelligt-b-cellslymfom/behandling-av-aterfall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/patologi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/utredning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/prognosfaktorer/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/primar-behandling/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/primar-behandling/primarbehandling-for-yngre-patienter/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/primar-behandling/primarbehandling-for-aldre-patienter/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/primar-behandling/patienter-som-inte-anses-tala-hogdos-metotrexat/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/primar-behandling/att-tanka-pa-vid-behandling-av-cns-lymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/behandling-av-aterfall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/primart-diffust-storcelligt-b-cellslymfom-i-cns/primara-viteroretinala-lymfom-pvrl/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/patologi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/stadieindelning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/primar-behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/primar-behandling/gmall-b-allnhl-2002/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/primar-behandling/cns-profylax/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/primar-behandling/riskgruppering-enligt-bfm-stadium-enligt-murphy-st-jude/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/primar-behandling/behandlingsschema-for-bfm-2004/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/burkittlymfom/behandling-av-aterfall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/posttransplantations-relaterad-lymfoproliferativ-sjukdom-ptld/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/posttransplantations-relaterad-lymfoproliferativ-sjukdom-ptld/undergrupper/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/posttransplantations-relaterad-lymfoproliferativ-sjukdom-ptld/behandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/t-cellshistiocytrikt-storcelligt-b-cellslymfom-thrlbcl/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/primart-kutant-diffust-storcelligt-b-cellslymfom--leg-type/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/ebv-positivt-diffust-storcelligt-b-cellslymfom-uns/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/ebv-positivt-mucocutant-sar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/diffust-storcelligt-b-cellslymfom-associerat-med-kronisk-inflammation/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/intravaskulart-storcelligt-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/lymfomatoid-granulomatos/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/alk-positivt-storcelligt-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/plasmablastiskt-lymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/primart-effusionslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/ovriga-former-av-aggressiva-b-cellslymfom/b-cellslymfom-oklassificerbart-med-drag-intermediara-mellan-diffust-storcelligt-b-cellslymfom-och-klassiskt-hodgkin-lymfom-gray-zone-lymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/kriterier-for-car-t/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/remitteringsgang/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/bridging-terapi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/specifika-biverkningar-av-car-t-celler/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/uppfoljning-och-sena-biverkningar-efter-behandling-med-car-t-celler/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/uppfoljning-och-sena-biverkningar-efter-behandling-med-car-t-celler/bakgrund/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/uppfoljning-och-sena-biverkningar-efter-behandling-med-car-t-celler/uppfoljningsprogram/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/uppfoljning-och-sena-biverkningar-efter-behandling-med-car-t-celler/uppfoljningsprogram/fran-utskrivningen-till-dag-100/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/car-t-cellsbehandling-vid-aggressiva-b-cellslymfom/uppfoljning-och-sena-biverkningar-efter-behandling-med-car-t-celler/uppfoljningsprogram/fortsatt-uppfoljning-efter-dag-100/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/pet-i-behandlingsutvardering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/primart-mediastinalt-storcelligt-b-cellslymfom/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/komplett-remission-cr/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/partiell-remission-pr/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/relaps-eller-progressiv-sjukdom-pd/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/responskriterier/stabil-sjukdom-sd/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/blodprodukter/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/infektionsprofylax-efter-hogdosbehandling/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/hepatit-b/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/hepatit-b/hbsag-negativ-anti-hbc-positiv-patient/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/herpesvirus/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/pneumocystis-jiroveci/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/allman-svampprofylax-candida-etc/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/g-csf/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/infektionsbehandling/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/tumorlyssyndromprofylax/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/osteoporosprofylax/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab2/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab2/sen-neutropeni-lon/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab2/rituximab-inducerade-interstitiella-lungforandringar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab2/akuta-transfusionsreaktioner/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/bakgrund/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/kliniska-och-laboratoriemassiga-kriterier-for-malignitetsassocierad-hlh/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/primarbehandling-av-malignitets-triggad-hlh/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/primarbehandling-av-hlh-under-kemoterapi/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/langsiktig-behandling-av-lymfomassocierad-hlh/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/behandling-med-cytokinhammare-vid-hlh/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/behandling-av-car-hlh-och-annan-immunterapi-associerad-hlh/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfom-associerad-hlh/uppfoljning-av-hlh/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/sexualitet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/fertilitet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/fertilitet/kvinnor/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/fertilitet/man/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/fysisk-aktivitet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/primart-cns/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/hygien-och-isolering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/munvard/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/nutrition/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/skotsel-av-central-infart-till-blodkarl/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/car-t-cellsbehandling/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/alopeci--haravfall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/fatigue/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/benmargspaverkan/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/neuropati/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/illamaende/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/information-om-biverkningar/forstoppning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/infektionskanslighet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/munhygien/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/fysisk-aktivitet/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/hud/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/vaccinationer/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/feber/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/rokning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/alkohol/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/egenvard/komplementar-och-alternativ-medicin/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/palliativ-vard-och-insatser/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/palliativ-vard-och-insatser/palliativ-behandling-av-patienter-med-aggressiva-b-cellslymfom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/kontroll-av-aterfall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/kontroll-av-aterfall/uppfoljning-av-patienter-i-komplett-remission/2025-04-04 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/kontroll-av-aterfall/patienter-utan-recidiv-efter-2-ar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/ansvar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/underlag-for-nivastrukturering/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/syfte-och-mal/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/innehall/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/inklusionskriterier/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/exklusionskriterier/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2025-06-17 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-palliativregistret/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/cytostatikaregimer/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/referenser/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/adjungerade-medlemmar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/2021-03-31 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/provtagningsanvisning/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/anamnestisk-remissinformation/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/analyser/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2025-04-03 https://kb.localhost:5000/diagnoser/aggressiva-b-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/koder-och-beteckningar/2025-04-03 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/sammanfattning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/standardiserat-vardforlopp/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/lagstod/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/evidensgradering/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/inledning/forkortningsordlista/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/mal-med-vardprogrammet/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/bakgrund-och-orsaker/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken-for-cancer/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/bakgrund-och-orsaker/bakgrund-och-orsaker-till-akut-lymfatisk-leukemi/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/arftlighet/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/symtom-och-tidig-utredning/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/checklista-vid-all/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/blodprover/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/benmargsundersokning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/likvorundersokning/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/klinisk-undersokning-samsjuklighet-och-funktionsstatus/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/radiologi/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/klinisk-fysiologi/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/tandlakarbedomning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/planerad-behandling-enligt-alltogether-protokoll-18-45-ar-eller-nopho-all-2008nopho-lite-over-45-ar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/utredning/biobank/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/diagnosbesked/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/psykosocialt-omhandertagande-och-existentiella-fragor/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/fertilitetsbevarande-atgarder/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/diagnostik/all-under-graviditet/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/patologins-roll-i-den-diagnostiska-processen/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/anvisningar-for-provtagarens-hantering-av-provet/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/anvisningar-for-provtagarens-hantering-av-provet/benmargsprov/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/anvisningar-for-provtagarens-hantering-av-provet/lumbalpunktion-for-likvorundersokning-samt-cns-leukemi/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/anamnestisk-remissinformation/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/klassificering-av-tumoren/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/klassificering-av-tumoren/morfologi/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/klassificering-av-tumoren/immunfenotyp/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/klassificering-av-tumoren/genetik/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/prognosfaktorer/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/prognosfaktorer/minimalmeasurable-residual-disease-mrd/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/prognosfaktorer/metoder-for-mrd-analyser/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/prognosfaktorer/malsattning-med-analys-av-mrd/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kategorisering-av-leukemin-och-prognosfaktorer/forekomst-av-philadelphiakromosom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/multidisciplinar-konferens/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/primar-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/primar-behandling/val-av-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/primar-behandling/forbehandling-och-profylax-mot-tumorlyssyndrom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/primar-behandling/forbehandling-och-profylax-mot-tumorlyssyndrom/forbehandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/primar-behandling/forbehandling-och-profylax-mot-tumorlyssyndrom/riskvardering-och-forebyggande-behandling-av-tumorlyssyndrom/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-45-ar/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-45-ar/villkor-for-behandling-enligt-alltogether/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-45-ar/studier-etikprovning-och-rapportering/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-45-ar/utredning-och-start-av-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-45-ar/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/utredning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/studier-etikprovning-och-rapportering/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/behandlingsoversikt/2023-11-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/behandlingsoversikt/speciella-behandlingsovervaganden-for-hogriskgruppen/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/utvardering-med-mrd/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/riskgruppering-vid-behandlingsstart/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/riskgruppering-efter-behandlingsstart/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/cns-sjukdom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/testikelengagemang-av-all/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-4665-ar-enligt-nopho-all-2008-med-dosreduktion/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/mediastinalt-engagemang/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-65-ar-och-kurativ-intention/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-65-ar-och-kurativ-intention/behandlingsoversikt/2023-11-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-65-ar-och-kurativ-intention/patientregistrering/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-65-ar-och-kurativ-intention/studier-och-etikgodkannande/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-65-ar-och-kurativ-intention/utvardering-med-mrd/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-65-ar-och-kurativ-intention/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-75-ar-eller-yngre-med-icke-kurativ-intention/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-75-ar-eller-yngre-med-icke-kurativ-intention/behandlingsoversikt/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-b-all-och-t-all/behandling-av-patienter-med-biologisk-alder-over-75-ar-eller-yngre-med-icke-kurativ-intention/behandling-av-cns-leukemi-testisengagemang-och-mediastinal-bulky-disease/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/patienter-med-biologisk-alder-under-60-ar/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/patienter-med-biologisk-alder-under-60-ar/12.1.1cns-profylax-vid-alder--60-ar2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/patienter-med-biologisk-alder-under-60-ar/tidpunkt-for-allo-hsct/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/patienter-med-biologisk-alder-6075-ar/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/cns-profylax2/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/patienter-med-biologisk-alder-over-75-ar/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/primarbehandling-av-ph-positiv-all/cns-profylax22/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all/remissionsbedomning-och-mrd-monitorering-vid-ph-positiv-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/burkitt-leukemi/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/lymfoblastlymfom/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/bakgrund/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/konditionering-vid-allo-hsct/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/betydelse-av-mrd-infor-allo-hsct/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/klinisk-betydelse-av-mrd-efter-allo-hsct/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/klinisk-betydelse-av-mrd-efter-allo-hsct/monitorering-av-mrd-efter-allo-hsct/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/klinisk-betydelse-av-mrd-efter-allo-hsct/ph-negativ-b-all-eller-t-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/klinisk-betydelse-av-mrd-efter-allo-hsct/ph-positiv-all/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/behandling-med-tki-efter-allo-hsct/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/allogen-stamcellstransplantation-allo-hsct/1kompletterande-cns-profylax/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/autolog-hematopoetisk-stamcellstransplantation/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/definition-av-aterfall-och-refraktar-sjukdom/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/utredning-vid-aterfall/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/prognos/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/behandling-med-kurativ-intention/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/behandling-med-palliativ-inriktning/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/behandling-vid-refraktar-sjukdom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/allmanna-overvaganden/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/multidisciplinar-konferens/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/deltagande-i-kliniska-studier/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/allmanna-principer-och-mal/cns-profylax/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/sarskilda-behandlingsovervaganden-vid-extramedullart-aterfall-och-refraktar-sjukdom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/sarskilda-behandlingsovervaganden-vid-extramedullart-aterfall-och-refraktar-sjukdom/extramedullart-aterfall-refraktar-sjukdom-och-lymfoblastlymfom/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/sarskilda-behandlingsovervaganden-vid-extramedullart-aterfall-och-refraktar-sjukdom/extramedullart-aterfall-refraktar-sjukdom-och-lymfoblastlymfom/cns-sjukdom/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/sarskilda-behandlingsovervaganden-vid-extramedullart-aterfall-och-refraktar-sjukdom/extramedullart-aterfall-refraktar-sjukdom-och-lymfoblastlymfom/allo-hsct/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/sarskilda-behandlingsovervaganden-vid-extramedullart-aterfall-och-refraktar-sjukdom/extramedullart-aterfall-refraktar-sjukdom-och-lymfoblastlymfom/car-t/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/konventionell-kombinerad-cytostatikabehandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/konventionell-kombinerad-cytostatikabehandling/mal-och-risker-med-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/konventionell-kombinerad-cytostatikabehandling/gangse-behandlingsregimer/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/konventionell-kombinerad-cytostatikabehandling/ovriga-regimer/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/riktad-och-subgruppsspecifik-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/riktad-och-subgruppsspecifik-behandling/philadelphianegativ-b-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-negativ-b-all-och-t-all/riktad-och-subgruppsspecifik-behandling/t-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-positiv-all/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-positiv-all/behandlingssvikt-vid-alder-upp-till-75-ar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-positiv-all/behandlingssvikt-vid-alder-upp-till-75-ar/mutationsanalys-och-val-av-tki/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-positiv-all/behandlingssvikt-vid-alder-upp-till-75-ar/val-av-behandling-att-kombinera-med-tki/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/ph-positiv-all/behandlingsvikt-vid-alder-over-75-ar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/blodprodukter/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/virusprofylax/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/svampprofylax/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/svampprofylax/vid-ph-negativ-all/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/svampprofylax/vid-ph-positiv-all/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/protonpumpshammare/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/t-pneumocystis-jiroveci-pneumoni-pjp-profylax/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/antibiotikaprofylax/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/trombosprofylax/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/steroidkomplikationer/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/vaccination/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/understodjande-vard/levnadsvanor/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/palliativ-vard-och-insatser/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/palliativ-vard-och-insatser/palliativ-vard-och-insatser-for-patienter-med-all/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/palliativ-vard-och-insatser/brytpunktssamtal/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/palliativ-vard-och-insatser/narstaendepenning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/inledning/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/allman-och-specifik-omvardnad/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/allman-och-specifik-omvardnad/skotsel-av-central-infart/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/allman-och-specifik-omvardnad/munvard/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/allman-och-specifik-omvardnad/nutrition/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/allman-och-specifik-omvardnad/kost-vid-neutropeni/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/allman-och-specifik-omvardnad/sexuell-halsa/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/benmargspaverkan/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/fatigue/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/gastrointestinala-biverkningar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/haravfall/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/illamaende/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/infektionskanslighet/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/mukosit/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/allmanna-biverkningar/smakforandringar/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/specifika-biverkningar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/specifika-biverkningar/buksmarta/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/specifika-biverkningar/neuropati/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/specifika-biverkningar/steroidkomplikationer/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-biverkningar/specifika-biverkningar/trombosemboli/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/fysisk-aktivitet/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/existentiella-fragor/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/barn-som-narstaende/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/omvardnad-och-rehabilitering/atergang-till-arbete-och-skola/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/egenvard/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/egenvard/levnadsvanor/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/egenvard/komplementar-och-alternativ-medicin/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/egenvard/solvanor/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/egenvard/akut-kontakt-med-en-hematologenhet/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/egenvard/kunskap-och-stod/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/uppfoljning-for-att-tidigt-upptacka-eventuella-aterfall/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/ansvar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/avslut-av-uppfoljning/2024-06-26 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/uppfoljning/bakgrund-och-evidenslage/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/underlag-for-nivastrukturering/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kvalitetsregister/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-akut-lymfatisk-leukemi/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kvalitetsregister/cancerregistret/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/Kvalitetsindikatorer-och-malnivaer/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/referenser/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/forslag-pa-fordjupning/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/vardprogramgruppen/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-08-24 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/forbehandling/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-all.--dosreduktion-av-nopho-all-20082025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-negativ-all.-behandlingsprotokoll-for-patienter-over-65-ar-och-kurativ-intention2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all-behandlingsprotokoll-yngre-patienter/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/ph-positiv-all-behandlingsprotokoll-aldre-patienter---svallewall/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/kurer-vid-behandlingssviktaterfall-med-remissionssyfte/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/cns-leukemi/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/testisengagemang/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/bulky-disease-mediastinalt/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/behandling-med-hogdos-metotrexat-055-gm2dygn/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/leukovorinfolinsyra-rescue/2025-06-09 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/patientinformation-om-registrering-av-personuppgifter-i-blodcancerregistret/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardprogram/funktionsstatus-enligt-who/2025-06-10 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/introduktion/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/introduktion/om-akut-myeloisk-leukemi/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/introduktion/flodesschema-for-vardforloppet/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/ingang-till-standardiserat-vardforlopp2/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/ingang-till-standardiserat-vardforlopp2/valgrundad-misstanke/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/ingang-till-standardiserat-vardforlopp2/kommunikation-och-delaktighet/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/utredning-och-beslut-om-behandling/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/utredning-och-beslut-om-behandling/3.1-utredningsforlopp2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/utredning-och-beslut-om-behandling/1.6-multidisciplinar-konferens-mdk2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/utredning-och-beslut-om-behandling/3.2-klassifikation-och-beslut-om-behandling2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/utredning-och-beslut-om-behandling/3.3-omvardnad-rehabilitering-och-understodjande-vard2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/utredning-och-beslut-om-behandling/3.4-kommunikation-och-delaktighet2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/behandling/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/uppfoljning/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/indikatorer-for-uppfoljning2/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-kvalitet/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2020-06-29 https://kb.localhost:5000/diagnoser/akut-lymfatisk-leukemi-all/vardforlopp/arbetsgruppens-sammansattning2/2020-06-29 https://kb.localhost:5000/diagnoser/aml/2022-04-07 https://kb.localhost:5000/diagnoser/aml/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/aml/vardprogram/sammanfattning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/malgrupp/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/standardiserat-vardforlopp/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/lagstod/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/evidensgradering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/inledning/forkortningslista/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mal-med-vardprogrammet/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/bakgrund-och-orsaker/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/bakgrund-och-orsaker/epidemiologi/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/bakgrund-och-orsaker/naturalhistoria-och-etiologi/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/arftlighet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/arftlighet/handlaggning-vid-misstanke-pa-arftlig-predisposition/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/Symtom-och-tidig-utredning/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/Symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/Symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/Symtom-och-tidig-utredning/tidig-diagnostik/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/oversikt/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/benmargsprov-rekommenderade-analyser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/blodprov-rekommenderade-analyser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/next-generation-sequencing-ngs/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/konstitutionellt-dna/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/ovrig-utredning/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/ovrig-utredning/lumbalpunktion/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/ovrig-utredning/radiologi/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/ovrig-utredning/tandlakarbedomning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/vardera-funktionsstatus-och-samsjuklighet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/ta-stallning-till-om-inklusion-i-studie-ar-mojlig/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/diagnosbesked/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/diagnosbesked/information-om-diagnos/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/omvardnad-och-rehabilitering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/omvardnad-och-rehabilitering/barn-som-narstaende/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/diagnostik/omvardnad-och-rehabilitering/existentiella-fragor/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/klassificering-och-remissionskriterier/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/klassificering-och-remissionskriterier/kriterier-for-komplett-remission-cr/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/indelningens-syfte/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/cytogenetiska-och-molekylargenetiska-fynd/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/cytogenetiska-och-molekylargenetiska-fynd/genetisk-lag-risk/2024-01-23 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/cytogenetiska-och-molekylargenetiska-fynd/genetisk-intermediar-risk/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/cytogenetiska-och-molekylargenetiska-fynd/genetisk-hog-risk/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/andra-leukemirelaterade-prognosfaktorer/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/patientrelaterade-prognosfaktorer-alder-funktionsstatus-och-samsjuklighet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/responsrelaterade-riskfaktorer/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/responsrelaterade-riskfaktorer/tidig-responsevaluering-dag-15-marg/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/riskgruppering-och-indikationer-for-allo-sct-i-cr-1/responsrelaterade-riskfaktorer/responsrelaterade-hogriskfaktorer-i-samband-med-remissionsbedomning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/2022-06-22 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/analys-av-mrd/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/mrd-analys-med-molekylargenetisk-metod/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/mrd-analys-med-molekylargenetisk-metod/mrd-analys-av-mutation-i-npm1/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/mrd-analys-med-molekylargenetisk-metod/mrd-analys-av-core-binding-factor-leukemia-cbf-t821-och-inv16/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/mrd-analys-med-flodescytometri/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/mrd-monitorering-efter-avslutad-primarbehandling-med-kemoterapi/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/mrd--measurable-residual-disease/mrd-monitorering-post-allo-hsct/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/multidisciplinara-konferenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/primarbehandling-av-aml-ej-apl-sammanfattande-rekommendationer/2023-12-03 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/rekommenderade-cytostatikakurer/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/rekommenderade-cytostatikakurer/induktions--och-konsolideringsbehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/rekommenderade-cytostatikakurer/cytostatikakurer-nar-dosreduktion-anses-nodvandigt-vid-behandlingsstart/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/rekommenderade-cytostatikakurer/sviktbehandlingar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/vilka-patienter-bor-erbjudas-remissionssyftande-cytostatikabehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/generellt-om-val-av-cytostatika-i-primarbehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/hur-brattom-ar-det-att-starta-behandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/dosreduktion-vid-remissionssyftande-cytostatikabehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/tidig-reinduktion/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/sviktbehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/cytostatikabehandling-vid-aml--bakgrund-och-allmanna-overvaganden/cytostatikabehandling-vid-nedsatt-hjart--och-njurfunktion/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/primar-behandling/primarbehandling-av-aldre-aml--speciella-overvaganden/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/riskgruppsindelning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/hog-tidig-dodlighet-vid-apl/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/akut-omhandertagande-vid-misstanke-om-apl/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/behandlingsval-bakgrund/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/behandlingsval-bakgrund/cns-profylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/rekommenderade-behandlingsregimer-vid-apl/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/rekommenderade-behandlingsregimer-vid-apl/induktions--och-konsolideringsbehandling-vid-apl-atraato/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/koagulopati/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/differentieringssyndrom/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/pseudotumor-cerebri/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/leukocytos-vid-ato--atra/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/hepatotoxicitet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/aspekter-pa-ato/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/qt-tidsforlangning-vid-behandling-med-ato/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/understodjande-vard-vid-apl/infektionsprofylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/remissionsbedoming-och-monitorering-av-mrd-vid-apl/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/remissionsbedoming-och-monitorering-av-mrd-vid-apl/komplett-remission/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/remissionsbedoming-och-monitorering-av-mrd-vid-apl/mrd-monitorering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/behandling-av-apl-recidiv/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/behandling-av-apl-recidiv/recidiv-efter-atra--ato-som-primarbehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/behandling-av-apl-recidiv/recidiv-efter-atra-eller-cytostatika-som-primarbehandling-ej-ato-exponerad/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/akut-promyelocytleukemi-apl/behandling-av-apl-recidiv/uppfoljning-med-mrd-och-transplantation-vid-andra-remission/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/blastisk-plasmacytoid-dendritcellsneoplasi-bpdcn/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/handlaggning-av-nagra-speciella-kliniska-situationer/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/handlaggning-av-nagra-speciella-kliniska-situationer/cns-leukemi/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/handlaggning-av-nagra-speciella-kliniska-situationer/myelosarkom/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/handlaggning-av-nagra-speciella-kliniska-situationer/hyperleukocytos/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/handlaggning-av-nagra-speciella-kliniska-situationer/tumorlyssyndrom-tls/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/handlaggning-av-nagra-speciella-kliniska-situationer/aml-som-debuterar-under-graviditet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/2022-06-22 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/inledning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/hla-typning-och-donatorsokning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/donator/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/benmarg-eller-perifera-blodstamceller/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/2022-07-04 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/allo-sct-i-forsta-remission/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/aml-med-lagriskgenetik-galler-ej-apl/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/aml-med-intermediarriskgenetik/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/aml-vid-hogriskgenetik/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/allo-sct-i-cr2-hos-tidigare-ej-allogentransplanterade/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/indikationer-for-allo-sct/allo-sct-vid-refraktar-aml-tidigare-ej-allogentransplanterade/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/post-allo-uppfoljning-och-profylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/post-allo-uppfoljning-och-profylax/uppfoljning-efter-allo-hsct-vid-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/post-allo-uppfoljning-och-profylax/underhallsbehandling-med-sorafenib-vid-flt3-itd-aml-post-allo-hsct/2023-12-14 https://kb.localhost:5000/diagnoser/aml/vardprogram/allo-sct-vid-aml/aterfall-efter-allo-sct/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/asct/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/underhallsbehandling/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/underhallsbehandling/inledning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/underhallsbehandling/underhallsbehandling-med-il-2-och-histamin/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/underhallsbehandling/underhallsbehandling-med-hypometylerande-cytostaticum/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/underhallsbehandling/underhallsbehandling-med-midostaurin-vid-flt3-positiv-aml/2022-06-22 https://kb.localhost:5000/diagnoser/aml/vardprogram/underhallsbehandling/underhallsbehandling-med-midostaurin-vid-flt3-positiv-aml/underhallsbehandling-med-midostaurin-vid-flt3-positiv-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/behandling-av-aterfall/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/behandling-av-aterfall/diagnostik-vid-misstankt-aterfall/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/behandling-av-aterfall/behandling-av-patienter-med-aterfall/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/behandling-av-aterfall/behandling-av-patienter-med-aterfall/nya-regimer/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/behandling-av-aterfall/behandling-av-patienter-med-aterfall/aterfall-efter-allo-hsct/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/oversikt/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/blodprodukter/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/infektionsprofylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/infektionsprofylax/antibakteriell-profylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/infektionsprofylax/antiviral-profylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/infektionsprofylax/svampprofylax/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/tillvaxtfaktorer/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/fertilitetsbevarande-atgarder/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/fertilitetsbevarande-atgarder/man/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/understodjande-vard/fertilitetsbevarande-atgarder/kvinnor/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/oversikt/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/atergang-till-arbete-och-studier/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/allmanna-infektionsforebyggande-atgarder/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/fatigue-och-fysisk-aktivitet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/nutritionsbehandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/nutritionsbehandling/kost-vid-neutropeni/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/munhalsa/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/sexuell-halsa/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/skotsel-av-central-infart-till-blodkarl/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/direktinlaggning-pa-hematologisk-avdelning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/benmargspaverkan/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/fatigue/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/haravfall--alopeci/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/illamaende/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/smakforandringar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/gastrointestinala-biverkningar-forstoppning-och-diarre/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/levnadsvanor/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/levnadsvanor/tobak/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/levnadsvanor/alkohol/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/levnadsvanor/fysisk-aktivitet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/levnadsvanor/matvanor/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/komplementar-och-alternativ-medicin/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/solvanor/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/vaccinationer/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/vad-foranleder-akut-kontakt-med-hematologenhet/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/egenvard/kunskap-och-stod-till-patient-och-narstaende/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/palliativ-vard-och-insatser/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/palliativ-vard-och-insatser/palliativ-behandling-av-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/palliativ-vard-och-insatser/palliativ-vard-av-patienter-med-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/palliativ-vard-och-insatser/brytpunkt-brytpunktssamtal/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/palliativ-vard-och-insatser/palliativregistret/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/palliativ-vard-och-insatser/narstaendepenning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/mrd-monitorering-efter-avslutad-primarbehandling-med-kemoterapi/2022-06-22 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/ansvar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/avslut-av-uppfoljning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/underlag-for-nivastrukturering/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/underlag-for-nivastrukturering/remissionssyftande-behandling-av-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning-av-cancervarden/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-akut-myeloisk-leukemi/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning-av-cancervarden/uppfoljning-av-patientrapporterade-matt/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/kvalitetsindikatorer-och-malnivaer/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer-faststallda-i-samrad-med-svensk-forening-for-hematologi-sfh/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/kvalitetsindikatorer-och-malnivaer/andra-kvalitetsparametrar-som-foljs-i-kvalitetsregistret/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikator-for-nationell-uppfoljning-av-standardiserat-vardforlopp-for-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/referenser2/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/forslag-pa-fordjupning/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/forslag-pa-fordjupning/litteratur/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/forslag-pa-fordjupning/lankar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/2021-06-30 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/vardprogramgruppen/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/tidigare-medlemmar-av-vardprogramgruppen/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/funktionsstatus-enligt-who/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/provtagningsanvisning-for-benmarg-och-blod/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/provtagningsanvisning-for-benmarg-och-blod/referenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/klassifikation-av-aml-enligt-who/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/klassifikation-av-aml-enligt-who/referenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/klassifikation-av-aml-enligt-icc-2022/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/klassifikation-av-aml-enligt-icc-2022/referenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/genetiska-avvikelser-vid-aml/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/genetiska-avvikelser-vid-aml/referenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/antracykliner/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/antracykliner/1.1-val-av-antracyklinpreparat-och-dosering2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/antracykliner/1.2-kumulativ-kardiotoxicitet2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/antracykliner/1.3-atgarder-vid-extravasering-av-antracyklinpreparat2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/2.-cytarabin2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/2.-cytarabin/2.1-dosering-och-administrationsform2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/2.-cytarabin/2.2-cerebellar-toxicitet-och-dosering-till-aldre-samt-vid-nedsatt-njurfunktion2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/3.amsakrin2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/4.-etoposid2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/5.-purinanaloger2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/Azacitidin/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/decitabin/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/7.-Gemtuzumab-ozogamicin2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/8.-Kinasinhibitorer2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/8.-Kinasinhibitorer/gilteritinib/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/9.-vyxeos2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/venetoclax/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/idh-hammare/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/glasdegib/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/cc-486-peroral-hypometylerare/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/tagraxofusp/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/AML-specifik-behandling/referenser/2023-12-13 https://kb.localhost:5000/diagnoser/aml/vardprogram/hereditara-myeloiska-maligniteter/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/hereditara-myeloiska-maligniteter/referenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/patientinformation/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/summary-of-the-swedish-national-aml-care-program-for-adult-patients/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/the-care-program/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/initial-management/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/intensive-treatment/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/allogeneic-stem-cell-transplantation/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/measurable-residual-disease-mrd-determination/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/other-treatments/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/special-problems/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/health-care-requirements/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/quality-indicators/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/aml-registry/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardprogram/summary-in-english/referenser/2023-12-08 https://kb.localhost:5000/diagnoser/aml/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/aml/vardforlopp/introduktion/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2019-11-29 https://kb.localhost:5000/diagnoser/aml/vardforlopp/introduktion/om-akut-myeloisk-leukemi/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/introduktion/flodesschema-for-vardforloppet/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/ingang-till-standardiserat-vardforlopp2/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/ingang-till-standardiserat-vardforlopp2/valgrundad-misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/ingang-till-standardiserat-vardforlopp2/kommunikation-och-delaktighet/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/utredning-och-beslut-om-behandling/3.1-utredningsforlopp2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/utredning-och-beslut-om-behandling/1.6-multidisciplinar-konferens-mdk2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/utredning-och-beslut-om-behandling/3.2-klassifikation-och-beslut-om-behandling2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/utredning-och-beslut-om-behandling/3.3-omvardnad-rehabilitering-och-understodjande-vard2023-07-07 https://kb.localhost:5000/diagnoser/aml/vardforlopp/utredning-och-beslut-om-behandling/3.4-kommunikation-och-delaktighet2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/behandling/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/uppfoljning/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/indikatorer-for-uppfoljning2/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-kvalitet/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2023-07-07 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2019-11-27 https://kb.localhost:5000/diagnoser/aml/vardforlopp/arbetsgruppens-sammansattning2/2019-11-27 https://kb.localhost:5000/diagnoser/akut-leukemi/2022-03-23 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/2022-03-23 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-11 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/ingang-till-standardiserat-vardforlopp2/2022-03-23 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2022-03-23 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/ingang-till-standardiserat-vardforlopp2/valgrundad-misstanke/2022-03-23 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/ingang-till-standardiserat-vardforlopp2/hantering-av-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/utredning-och-beslut-om-behandling/2022-03-23 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/indikatorer-for-uppfoljning2/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/val-av-koder/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-med-start-av-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-11-08 https://kb.localhost:5000/diagnoser/akut-leukemi/forkortat-vardforlopp/2025-11-11 https://kb.localhost:5000/diagnoser/akut-onkologi/2020-02-28 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/2020-03-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/sammanfattning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/inledning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/inledning/inriktning-vid-akut-omhandertagande/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/inledning/evidensgradering/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/mal-med-vardprogrammet/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/symtomoversikt/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/anemi-malignitetsassocierad/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/anemi-malignitetsassocierad/bakgrund/2020-03-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/anemi-malignitetsassocierad/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/anemi-malignitetsassocierad/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/anemi-malignitetsassocierad/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/akuta-forvirringstillstand/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/bakgrund/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/symtom/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/inledande-handlaggning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/observandum/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/oversikt-fortsatt-handlaggning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/blodning/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/frakturriskpatologisk-fraktur/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/frakturriskpatologisk-fraktur/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/frakturriskpatologisk-fraktur/symtom/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/frakturriskpatologisk-fraktur/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/frakturriskpatologisk-fraktur/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/frakturriskpatologisk-fraktur/lankar/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/bakgrundvanliga-orsaker/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/oversikt-fortsatt-handlaggning/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hjarnmetastaserhjarntumorer/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/bakgrundvanliga-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/symtom/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/inledande-handlaggning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/hyperkalcemi/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/bakgrundvanliga-orsaker/2023-10-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/symtom/2023-10-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/inledande-handlaggning/2020-03-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/observandum/2020-03-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/oversikt-fortsatt-handlaggning/2020-03-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/immunrelaterade-biverkningar-vid-behandling-med-checkpointhammare/lankar/2024-05-07 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/kolit/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/kolit/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/kolit/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/kolit/inledande-handlaggning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/kolit/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/kolit/lankar/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/luftvagsobstruktion/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/luftvagsobstruktion/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/luftvagsobstruktion/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/luftvagsobstruktion/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/luftvagsobstruktion/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/luftvagsobstruktion/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/bakgrundvanliga-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/neutropen-febersepsis/lankar/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/bakgrund/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/observandum/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perforation-av-magtarmkanalen/lankar/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perikardvatska-malign/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perikardvatska-malign/bakgrundvanliga-orsaker/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perikardvatska-malign/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perikardvatska-malign/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perikardvatska-malign/fortsatt-handlaggning/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/perikardvatska-malign/lankar/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/pleuravatska-malign/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/pleuravatska-malign/bakgrundvanliga-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/pleuravatska-malign/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/pleuravatska-malign/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/pleuravatska-malign/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/pleuravatska-malign/lankar/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/ryggmargskompression/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/bakgrundvanliga-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/suicidrisk/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/observandum/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/oversikt-fortsatt-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tarmobstruktion/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/bakgrund/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/symtom/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/inledande-handlaggning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/observandum/2023-04-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/oversikt-fortsatt-handlaggning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tromboslungemboli/lankar/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tumorlyssyndrom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tumorlyssyndrom/bakgrundvanliga-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tumorlyssyndrom/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tumorlyssyndrom/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tumorlyssyndrom/oversikt-fortsatt-handlaggning/2020-03-25 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/tumorlyssyndrom/lankar/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vena-cava-superior-syndrom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vena-cava-superior-syndrom/bakgrund/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vena-cava-superior-syndrom/symtom/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vena-cava-superior-syndrom/inledande-handlaggning/2019-11-27 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vena-cava-superior-syndrom/oversikt-fortsatt-handlaggning/2019-11-29 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vena-cava-superior-syndrom/lankar/2025-06-19 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/2020-01-02 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/bakgrund/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/riskfaktorer-for-trombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-djup-ventrombos-dvt-i-nedre-extremitet/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-djup-ventrombos-dvt-i-nedre-extremitet/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-djup-ventrombos-dvt-i-nedre-extremitet/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-djup-ventrombos-dvt-i-nedre-extremitet/vardniva-riskstratifiering/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-djup-ventrombos-dvt-i-nedre-extremitet/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/djup-ventrombos-i-ovre-extremitet-inklusive-venos-trombos-i-anslutning-till-olika-typer-av-centrala-venosa-infarter/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/djup-ventrombos-i-ovre-extremitet-inklusive-venos-trombos-i-anslutning-till-olika-typer-av-centrala-venosa-infarter/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/djup-ventrombos-i-ovre-extremitet-inklusive-venos-trombos-i-anslutning-till-olika-typer-av-centrala-venosa-infarter/orsak/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/djup-ventrombos-i-ovre-extremitet-inklusive-venos-trombos-i-anslutning-till-olika-typer-av-centrala-venosa-infarter/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/djup-ventrombos-i-ovre-extremitet-inklusive-venos-trombos-i-anslutning-till-olika-typer-av-centrala-venosa-infarter/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-lungemboli/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-lungemboli/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-lungemboli/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-lungemboli/vardniva-riskstratifiering/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/cancerassocierad-lungemboli/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/vena-cava-inferior-trombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/vena-cava-inferior-trombos/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/vena-cava-inferior-trombos/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/vena-cava-inferior-trombos/behandling/2023-04-17 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/mesenterialvenstrombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/mesenterialvenstrombos/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/mesenterialvenstrombos/utlosande-faktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/mesenterialvenstrombos/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/mesenterialvenstrombos/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/portavenstrombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/portavenstrombos/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/portavenstrombos/utlosande-faktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/portavenstrombos/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/portavenstrombos/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/levervenstrombos-vena-hepatica-budd-chiaris-syndrom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/levervenstrombos-vena-hepatica-budd-chiaris-syndrom/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/levervenstrombos-vena-hepatica-budd-chiaris-syndrom/utlosande-faktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/levervenstrombos-vena-hepatica-budd-chiaris-syndrom/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/levervenstrombos-vena-hepatica-budd-chiaris-syndrom/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/njurvenstrombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/njurvenstrombos/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/njurvenstrombos/utlosande-faktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/njurvenstrombos/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/njurvenstrombos/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/sinustrombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/sinustrombos/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/sinustrombos/utlosande-faktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/sinustrombos/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/sinustrombos/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/ovarialvenstrombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/ovarialvenstrombos/symtom-och-diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/ovarialvenstrombos/riskfaktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/ovarialvenstrombos/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/tromboflebit-ytlig-ventrombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/tromboflebit-ytlig-ventrombos/symtom/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/tromboflebit-ytlig-ventrombos/riskfaktorer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/tromboflebit-ytlig-ventrombos/diagnostik/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/venos-trombos/venos-trombos-pa-ovanliga-stallen/tromboflebit-ytlig-ventrombos/behandling/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/formaksflimmer-och-cancer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/mekanisk-klaffprotes-och-cancer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/val-av-behandling-doak-eller-lmh/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/behandlingstid/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/recidiv-av-venos-trombos-under-pagaende-behandling-med-antikoagulantia/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/profylax-av-venos-trombos/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/hepariner/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/warfarin/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/doak/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/doak/lakemedelsinteraktioner-mellan-doak-och-antitumorala-lakemedel/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/doak/lakemedelsinteraktioner-mellan-doak-och-antitumorala-lakemedel/onkologiska-lakemedel-som-har-kanda-farmakokinetiska-interaktioner-med-doak/2023-10-05 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/doak/lakemedelsinteraktioner-mellan-doak-och-antitumorala-lakemedel/ovriga-granskade-onkologiska-preparat-utan-kanda-farmakokinetiska-interaktioner-med-doak/2023-04-21 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/behandling-med-antikoagulantia-vid-cancerassocierad-venos-trombos/doak/lakemedelsinteraktioner-mellan-doak-och-antitumorala-lakemedel/onkologiska-lakemedel-med-kanda-farmakodynamiska-interaktioner-med-doak/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/handlaggning-och-behandling-av-blodningar-hos-patienter-med-cancer/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/handlaggning-och-behandling-av-blodningar-hos-patienter-med-cancer/handlaggning-av-blodningar-hos-patienter-med-cancer-som-behandlas-med-antitrombotiska-lakemedel/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/handlaggning-och-behandling-av-blodningar-hos-patienter-med-cancer/lakemedel-som-kan-anvandas-vid-blodning/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/atgard-infor-ingrepp-och-operationer-avseende-antitrombotisk-behandling-hos-cancerpatienter/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/referenser/2025-03-07 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/arbetsgrupp-bilaga-trombos-och-blodning/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/arbetsgrupp-bilaga-trombos-och-blodning/arbetsgruppens-medlemmar/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/arbetsgrupp-bilaga-trombos-och-blodning/jav-och-andra-bindningar/2023-04-18 https://kb.localhost:5000/diagnoser/akut-onkologi/vardprogram/bilaga-1--trombos-och-blodning/arbetsgrupp-bilaga-trombos-och-blodning/bilagans-forankring/2023-04-18 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/2020-02-28 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/2023-12-12 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-12-11 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2023-12-12 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/utredning/2020-01-22 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/utredning/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/utredning/Utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/utredning/Avslutande-samtal-med-patienten/2020-01-22 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/arbetsgruppens-sammansattning2/2025-01-30 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/vardforlopp/bilaga-1-kodningsvagledning/2024-12-11 https://kb.localhost:5000/diagnoser/allvarliga-ospecifika-symtom/forkortat-vardforlopp/2025-11-20 https://kb.localhost:5000/diagnoser/analcancer/2022-04-07 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/sammanfattning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/inledning/2020-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/inledning/standardiserat-vardforlopp/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/inledning/lagstod/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/inledning/evidensgradering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/mal-med-vardprogrammet/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/incidens-riskfaktorer-och-prognos/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/incidens-riskfaktorer-och-prognos/anatomi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarprevention/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarprevention/levnadsvanor/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/screening/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/arftlighet/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/symtom-och-tidig-utredning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/symtom-och-tidig-utredning/initial-utredning-av-misstankt-analcancer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/bedomning-pa-kirurg--eller-onkologklinik/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/radiologisk-diagnostik/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/radiologisk-diagnostik/bedomning-av-terapisvarpavisande-av-residual-tumor/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/tnm-klassifikation/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/tnm-klassifikation/stadiefordelning-vid-insjuknande/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/klinisk-diagnostik/diagnosbesked/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/patologins-roll-i-den-diagnosiska-processen/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/anvisningar-for-provtagarens-hantering-av-provet/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/anamnestisk-remissinformation/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/utskarningsanvisningar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/analyser/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/lsilhsil/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/superficiell-skivepitelcancer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/skivepitelcancer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/adenocarcinom/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/rekommendationer-for-utformning-av-svarstext/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/patologisk-diagnostik/klassificering-av-tumoren/koder-och-beteckningar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/multidisciplinar-konferens/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/bakgrund/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/val-av-behandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/stralbehandlingens-doser/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/behandlingsteknik/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/cytostatika/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/behandlingsschema-radiokemoterapi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/stralbehandlingens-volymer--targetritning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/riskorgan/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/vid-nedsatt-allmantillstand-eller-hog-samsjuklighet/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/brachyterapi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/protonbehandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/radiokemoterapi/Akuta-biverkningar-under-radiokemoterapi-/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/kirurgi-som-primarbehandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/kirurgi-som-primarbehandling/pre-terapeutisk-stomi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/kirurgi-som-primarbehandling/lokal-excision/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/kirurgi-som-primarbehandling/abdominoperineal-rektumexcision-ape-i-primarbehandlingen/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/behandling-av-anal-intraepitelial-neoplasi-ain/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/behandling-av-primart-metastaserad-sjukdom/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/behandling-av-primart-metastaserad-sjukdom/oligometastaser/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/behandling-av-primart-metastaserad-sjukdom/metastaskirurgi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/behandling-av-primart-metastaserad-sjukdom/medicinsk-behandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/primarbehandling/behandling-av-primart-metastaserad-sjukdom/lokal-behandling-vid-metastaserad-sjukdom/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/behandling-av-resttumor-och-aterfall/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/behandling-av-resttumor-och-aterfall/salvagekirurgi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/behandling-av-resttumor-och-aterfall/rebestralning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/behandling-av-resttumor-och-aterfall/metastaskirurgi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-omvardnad-vid-diagnos/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-omvardnad-vid-diagnos/smarta/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-omvardnad-vid-diagnos/tarmbiverkningar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-omvardnad-vid-diagnos/nutrition/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-omvardnad-vid-diagnos/benmargspaverkan/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-behandling-fore-och-under-behandling-av-analcancer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-behandling-fore-och-under-behandling-av-analcancer/omvardnad-vid-akuta-biverkningar-av-stralbehandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/understodjande-behandling-fore-och-under-behandling-av-analcancer/omvardnad-vid-akuta-biverkningar-av-cytostatika/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/postoperativt-omhandertagande-vid-salvagekirurgi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-och-rehabilitering-vid-seneffekter/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/1lopande-cancerrehabilitering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/1lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/omvardnad-och-rehabilitering/1lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/egenvard/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/egenvard/nationella-riktlinjer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/egenvard/rokning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/egenvard/alkohol/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/egenvard/komplementar-och-alternativmedicin/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/mal-med-uppfoljningen/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/sjalvrapportering-av-symtom/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/kontroll-av-aterfall/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/2020-03-18 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-onkologisk-behandling/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-onkologisk-behandling/kliniska-kontroller/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-onkologisk-behandling/radiologisk-uppfoljning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-onkologisk-behandling/rehabiliteringsbedomning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-onkologisk-behandling/vid-tecken-pa-aterfall/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-lokal-excision-av-t1-tumor--2-cm/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/forslag-till-uppfoljningsintervall/efter-salvagekirurgi/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/ansvar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/avslut-av-uppfoljning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/Uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/palliativ-vard-och-insatser/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/underlag-for-nivastrukturering/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/kvalitetsregister-och-malnivaer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/kvalitetsregister-och-malnivaer/kvalitetsregister/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/kvalitetsregister-och-malnivaer/cancerregistret/2024-03-01 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/indikatorer-och-malnivaer/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/referenser2/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/2020-03-18 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2020-03-18 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/regionala-representanter/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/vardprogramgruppens-medlemmar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-02-21 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/2023-08-10 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-04-15 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/analcancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/basalcellscancer/2024-11-07 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/sammanfattning/2024-10-28 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/malgrupp/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-03-04 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-03-04 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/standardiserat-vardforlopp/2025-03-04 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/lagstod/2025-03-04 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-03-04 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/mal-med-vardprogrammet/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/bakgrund/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/bakgrund/histopatologisk-klassifikation/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/bakgrund/lokalisation/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/prognos/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/ultraviolett-stralning-och-andra-externa-riskfaktorer/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/tidigare-hudtumor/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/immunsuppression/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/lakemedel/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/alder-och-hudtyp/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/andra-riskfaktorer/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/arftlighet/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/primar--och-sekundarprevention/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/primar--och-sekundarprevention/primarprevention/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/primar--och-sekundarprevention/sekundarprevention/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/arftlighet/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/arftlighet/molekylargenetisk-testning/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/arftlighet/remiss-till-klinisk-genetisk-eller-onkogenetisk-mottagning/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/arftlighet/gorlins-syndrom/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/symtom/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/symtom/symtom-och-kliniska-fynd/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/dermatoskopi/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/andra-preoperativa-icke-invasiva-diagnostiska-metoder/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/differentialdiagnoser/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/patologisk-anatomisk-diagnos/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/definitioner-av-hogrisk--och-lagrisktumor/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/definitioner-av-hogrisk--och-lagrisktumor/hogrisktumor/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/definitioner-av-hogrisk--och-lagrisktumor/lagrisktumor/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/definitioner-av-lokalt-avancerad-och-metastaserad-sjukdom/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/definitioner-av-lokalt-avancerad-och-metastaserad-sjukdom/lokalt-avancerad-bcc/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/definitioner-av-lokalt-avancerad-och-metastaserad-sjukdom/metastaserad-bcc/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/utredning/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/diagnostik/diagnosbesked/2024-10-28 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/generella-anvisningar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hudpreparat/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/specialanalyser/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/excision/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/stansbiopsi-och-shavebiopsi/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/kyrettage/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-primartumoren/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-metastaserad-sjukdom/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/multidisciplinar-konferens/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/destruktiva-behandlingar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/destruktiva-behandlingar/metodik/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/destruktiva-behandlingar/indikationer/2024-10-29 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/destruktiva-behandlingar/att-tanka-pa-vid-destruktiv-behandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/topikal-medicinsk-behandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/topikal-medicinsk-behandling/imikvimod/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/topikal-medicinsk-behandling/5-fluorouracil/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/topikal-medicinsk-behandling/fotodynamisk-terapi/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/topikal-medicinsk-behandling/jamforelse-mellan-imikvimod-5-fu-och-pdt/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/kirurgisk-behandling-av-basalcellscancer/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/mohs-kirurgi/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/mohs-kirurgi/tekniken/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/mohs-kirurgi/indikationer/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/mohs-kirurgi/mohs-kirurgi-kontra-konventionell-kirurgi/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/mohs-kirurgi/remittering-och-prioriteringar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/stralbehandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/stralbehandling/indikationer/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/stralbehandling/biverkningar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/systemisk-behandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/systemisk-behandling/hedgehog-hammare/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/behandling/systemisk-behandling/immunbehandling-med-pd-1-hammare/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/cancerrehabilitering/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/psykosociala-aspekter-vid-bcc/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/sexuell-halsa/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-destruktiva-behandlingar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-topikal-medicinsk-behandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-kirurgi-inklusive-mohs-kirurgi/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-stralbehandling/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-hedgehog-hammare/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-immunbehandling/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/omvardnad-och-rehabilitering/specifik-omvardnad-vid-bcc/omvardnad-i-samband-med-maligna-tumorsar-orsakade-av-bcc/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/egenvard/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/egenvard/hudkontroller/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/egenvard/sunda-solvanor/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/egenvard/levnadsvanor/2024-10-28 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/egenvard/komplementar-och-alternativ-medicin/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/palliativ-vard-och-insatser/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning/ny-behovsbedomning-for-rehabilitering-och-levnadsvanor/2024-10-28 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning/ansvar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/nivastrukturering/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/uppfoljning-av-cancervarden/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/referenser/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/vardprogramgruppen/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-11-12 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/vardprogramgruppen/tidigare-medlemmar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/arftliga-syndrom-med-forhojd-risk-for-basalcellscancer-bcc/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/gorlins-syndrom--kompletterande-information-om-kontroller/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/bap1-tumor-predispositionssyndrom-bap1-tpds/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/xeroderma-pigmentosum/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/bazex-dupre-christols-syndrom/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/okulokutan-albinism/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/curry-jones-och-happle-tinscherts-syndrom/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/familjer-med-multipla-bcc/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-1-arftlighet--fordjupningsmaterial/referenser-bilaga-1/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-2-stralbehandling-vid-basalcellscancer-fordjupningsmaterial/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-2-stralbehandling-vid-basalcellscancer-fordjupningsmaterial/praktiskt-genomforande-av-stralbehandling/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-2-stralbehandling-vid-basalcellscancer-fordjupningsmaterial/behandlingsrekommendationer/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-2-stralbehandling-vid-basalcellscancer-fordjupningsmaterial/referenser-bilaga-2/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-3-praktiskt-tillvagagangssatt-vid-kryokirurgisk-teknik/2025-03-03 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-3-praktiskt-tillvagagangssatt-vid-kryokirurgisk-teknik/open-cone-spray-teknik/2024-10-25 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-3-praktiskt-tillvagagangssatt-vid-kryokirurgisk-teknik/kyrettage/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-3-praktiskt-tillvagagangssatt-vid-kryokirurgisk-teknik/bedovning/2024-10-18 https://kb.localhost:5000/diagnoser/basalcellscancer/vardprogram/bilaga-3-praktiskt-tillvagagangssatt-vid-kryokirurgisk-teknik/referenser-bilaga-3/2024-10-18 https://kb.localhost:5000/diagnoser/binjuretumorer/2022-02-10 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/2021-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/sammanfattning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/2.2forandringar-jamfort-med-tidigare-version2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/standardiserat-vardforlopp/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/lagstod/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/evidensgradering/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/vardnivaer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/inledning/termer-och-forkortningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/mal-med-vardprogrammet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/primar-prevention/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/arftlighet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/utredning-enligt-standardiserat-vardforlopp/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/utredning-enligt-standardiserat-vardforlopp/alarmsymtom/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/utredning-enligt-standardiserat-vardforlopp/standardiserat-vardforlopp/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/utredning-enligt-standardiserat-vardforlopp/standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/utredning-enligt-standardiserat-vardforlopp/standardiserat-vardforlopp/ingaende-ledtider/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/utredning-enligt-standardiserat-vardforlopp/diagnosbesked/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kategorisering-av-tumoren/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/multidisciplinar-konferens-mdk/2023-01-15 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/bakgrund-och-orsaker/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/2023-01-15 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/klinisk-vardering/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/bilddiagnostik-se-aven-appendix/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/bilddiagnostik-se-aven-appendix/bilddiagnostik-av-binjuretumor-hos-patient-med-aktuell-eller-tidigare-malignitet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/hormonutredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/biopsi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/utredning/omvardnadsaspekter-vid-utredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/incidentalom/uppfoljning/2023-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/bakgrund-och-orsaker/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/utredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/utredning/bilddiagnostik/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/utredning/biokemisk-utredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/utredning/biopsi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjuremetastaser/behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/bakgrund-och-orsaker/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/arftliga-former/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/symtom-och-tidig-utredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/anamnes/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/biokemisk-screening/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/biokemisk-screening/tolkning-av-biokemisk-screening-se-aven-avsnitt-om-felkallor-nedan/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/biokemisk-screening/diagnostiska-felkallor/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/biokemisk-screening/nivadiagnostik/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning/bilddiagnostik/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning-av-metabola-komplikationer-kardiovaskular-risk-och-bentathet/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning-av-metabola-komplikationer-kardiovaskular-risk-och-bentathet/cushings-syndrom-cs/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/utredning-av-metabola-komplikationer-kardiovaskular-risk-och-bentathet/mild-autonom-hyperkortisolism/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/kirurgi/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/kirurgi/cushings-syndrom-cs/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/kirurgi/mild-autonom-hyperkortisolism/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/pre--och-perioperativ-handlaggning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/pre--och-perioperativ-handlaggning/preoperativ-bedomning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/pre--och-perioperativ-handlaggning/behandling-av-hypertoni-hypokalemi-diabetes/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/pre--och-perioperativ-handlaggning/blodfortunnande-profylaktisk-behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/pre--och-perioperativ-handlaggning/profylax-vid-kirurgi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/behandling/pre--och-perioperativ-handlaggning/preoperativ-kortisolsankning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/postoperativ-uppfoljning-och-behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/uppfoljning-och-aterfall/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/uppfoljning-och-aterfall/opererade-patienter/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kortisolproducerande-binjuretumorer/uppfoljning-och-aterfall/icke-opererade-patienter/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/bakgrund-och-orsaker/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/arftlighet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/screening/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/screening/definition-av-hogriskpopulationer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/screening/genomforande-och-utsvarande-av-test/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/screening/handlaggning-av-patienter-med-forhojd-arr/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/konfirmerande-test/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/bilddiagnostik/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/bilddiagnostik/dt-av-binjurarna/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/utredning/bilddiagnostik/binjurevenskateterisering-bvk/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/behandling/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/behandling/kirurgi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/behandling/kirurgi/pre--och-perioperativt-omhandertagande/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/behandling/kirurgi/operation/2023-01-15 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/behandling/kirurgi/postoperativt-omhandertagande/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/behandling/farmakologisk-behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/uppfoljning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/aldosteronproducerande-binjuretumorer/uppfoljning/postoperativ-uppfoljning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/bakgrund-och-orsaker/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/arftlighet/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/biokemi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/bilddiagnostik/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/bilddiagnostik/dt-och-mr/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/bilddiagnostik/pet-dt/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/bilddiagnostik/123i-mibg-skintigrafi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/cytologi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/utredning/audiogram/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/kirurgi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/kirurgi/val-av-metod/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/kirurgi/pre-operativt-omhandertagande/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/kirurgi/alfa-receptorblockad/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/kirurgi/perioperativt-omhandertagande/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/huvud-hals-paragangliom-hhpgl/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/behandling/metastaserad-sjukdom/2023-01-15 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-sporadisk-sjukdom-utan-tecken-till-malignitet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-sporadisk-sjukdom-utan-tecken-till-malignitet/biokemi/2023-02-07 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-sporadisk-sjukdom-utan-tecken-till-malignitet/radiologi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-malignbevisat-metastaserad-sjukdom/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-malignbevisat-metastaserad-sjukdom/klassifikation/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-malignbevisat-metastaserad-sjukdom/biokemi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-malignbevisat-metastaserad-sjukdom/radiologi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/uppfoljning/misstankt-malignbevisat-metastaserad-sjukdom/arftlig-sjukdom/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/feokromocytom-och-paragangliom/aterfall/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/bakgrund-och-orsaker/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/arftlighet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/utredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/utredning/bilddiagnostik/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/utredning/Hormonutredning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/kirurgi/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/Onkologisk-behandling/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/Onkologisk-behandling/adjuvant-behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/Onkologisk-behandling/adjuvant-behandling/14.4.2.1.1lagrisk-binjurebarkscancer-stadium-iiii-r0-kirurgi-och-ki-67--10-2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/Onkologisk-behandling/adjuvant-behandling/hogrisk-binjurebarkscancer-stadium-iiii-r1-eller-rx-kirurgi-och-ki-67--10-/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/Onkologisk-behandling/palliativ-behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/behandling/Endokrinmedicinsk-behandling/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/binjurebarkscancer-acc/uppfoljning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/palliativ-vard-och-insatser/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/psykosocialt-stod/2024-05-14 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/arbetssatt-inom-cancervarden/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-efter-kirurgi/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-efter-kirurgi/observationer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/illamaende-och-krakningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/tarmfunktion/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/mukosit/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/16.8.4minskning-av-antalet-vita-blodkroppar2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/fatigue/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/haravfall/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/lukt--och-smakforandringar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/neurologiska-symtom/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/hudreaktioner/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-medicinsk-onkologisk-behandling/fertilitet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/16.9omvardnad-vid-mitotanbehandling2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/16.9omvardnad-vid-mitotanbehandling/biverkningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/omvardnad-och-rehabilitering/16.9omvardnad-vid-mitotanbehandling/blodprovstagning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/egenvard/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/egenvard/nationella-riktlinjer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/egenvard/fysisk-aktivitet/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/egenvard/rokning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/egenvard/komplementar-och-alternativ-medicin/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/egenvard/alkohol/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/underlag-for-nivastrukturering/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsregister/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsregister/kvalitetsregister-for-binjuretumorer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsregister/cancerregistret/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/referenser/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-02-01 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/22.4tidigare-medlemmar-i-vardprogramgruppen2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/patologins-roll-i-den-diagnosiska-processen/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/klassificering-av-tumoren/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/analyser/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/feokromocytom-samt-abdominala-paragangliom/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/koder-och-beteckningar/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/kvalitetsarbete-for-patologin/2020-03-02 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/kvalitetsdokument-for-patologi/referenser/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/avseende-adrenala-incidentalom-ai/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/bakgrund/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/dt-teknik-vid-karakteristik-av-binjureincidentalom/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/nationella-rekommendationer/2023-01-16 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/for-svensk-forening-for-bild--och-funktionsmedicin-och-svensk-uroradiologisk-forening/2023-01-12 https://kb.localhost:5000/diagnoser/binjuretumorer/vardprogram/radiologiskt-appendix-till-vardprogram-binjuretumorer/referenser/2023-01-16 https://kb.localhost:5000/diagnoser/brostcancer/2022-04-07 https://kb.localhost:5000/diagnoser/brostcancer/forkortat-vardforlopp/2025-11-18 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/2020-03-18 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/sammanfattning/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/inledning/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/inledning/standardiserat-vardforlopp/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/inledning/lagstod/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/inledning/evidensgradering/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/mal-med-vardprogrammet/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2024-07-12 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/insjuknande-och-dodlighet-i-brostcancer-isverige/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/insjuknande-och-dodlighet-i-brostcancer-isverige/insjuknande-och-dodlighet-i-olika-aldersgrupper-over-tid/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/insjuknande-och-dodlighet-i-brostcancer-isverige/geografiska-skillnader-i-insjuknande-och-dodlighet/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/overlevnad2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/kan-vi-lita-pa-statistiken/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/kan-vi-lita-pa-statistiken/insjuknande/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/kan-vi-lita-pa-statistiken/dodlighet2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/kan-vi-lita-pa-statistiken/overlevnad2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/definition/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/naturalforlopp-patogenes/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/riskfaktorer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/sociodemografiska-faktorer/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/genetiska-faktorer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/reproduktiva-faktorer/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/exogena-och-endogena-hormoner/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/livsstil-kroppskonstitution/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/mammografisk-brostdensitet/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/mojliga-riskfaktorer-for-brostcancer2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bakgrund-och-orsaker/orsaker/mindre-troliga-och-omtvistade-riskfaktorer2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/primar-prevention/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/screening/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/screening/mammografiscreening/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/molekylargenetisk-utredning/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/brca1-och-brca2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/palb2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/tp53/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/ovriga-gener-associerade-med-kanda-tumorsyndrom-och-en-starkt-okad-brostcancerrisk-cdh1-pten-stk11/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/genetiska-varianter-associerade-med-mattligt-forhojd-brostcancerrisk/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/genetiska-varianter-associerade-med-mattligt-forhojd-brostcancerrisk/atm-bard1-chek2-rad51c-och-rad51d/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/genetiska-varianter-associerade-med-mattligt-forhojd-brostcancerrisk/varianten-brca1-c.5096ga-p.arg1699gln-r1699q2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/bakgrund/genetiska-varianter-associerade-med-mattligt-forhojd-brostcancerrisk/nf1/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/utredning-av-misstankt-arftlighet/2024-07-12 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/utredning-av-misstankt-arftlighet/kriterier-for-utredning-av-misstankt-arftlighet-hos-brostcancerpatienter/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/utredning-av-misstankt-arftlighet/kriterier-for-utredning-av-misstankt-arftlighet-hos-friska-familjemedlemmar/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/utredning-av-misstankt-arftlighet/cancergenetisk-utredning/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/bilddiagnostik/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/bilddiagnostik/mammografi/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/bilddiagnostik/ultraljud-och-magnetresonanstomografi/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/screening-for-annan-cancer-associerad-med-brca1-respektive-brca2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/riskreducerande-kirurgi/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-personer-med-patogen-variant-eller-familjart-okad-risk/medicinsk-prevention/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-brostcancerpatienter-med-patogen-variant-i-hogpenetrant-brostcancergen/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-brostcancerpatienter-med-patogen-variant-i-hogpenetrant-brostcancergen/riskreducerande-kirurgi/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-brostcancerpatienter-med-patogen-variant-i-hogpenetrant-brostcancergen/riskreducerande-kirurgi/kontralateral-riskreducerande-mastektomi-vid-primar-brostcancer/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-brostcancerpatienter-med-patogen-variant-i-hogpenetrant-brostcancergen/riskreducerande-kirurgi/brostbevarande-kirurgi-vs-mastektomi-vid-arftlig-brostcancer/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-brostcancerpatienter-med-patogen-variant-i-hogpenetrant-brostcancergen/riskreducerande-kirurgi/riskreducerande-salpingooforektomi-i-samband-med-arftlig-brostcancerrisk/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/arftlighet/handlaggning-av-brostcancerpatienter-med-patogen-variant-i-hogpenetrant-brostcancergen/medicinsk-behandling/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/symtom-och-tidig-utredning/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/symtom-och-tidig-utredning/klinisk-undersokning2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/trippeldiagnostik/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/klinisk-mammografi-och-tomosyntes/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/ultraljud/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/magnetisk-resonanstomografi-mrt/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/kontrastforstarkt-mammografi/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/galaktografi/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/preoperativ-indikering-och-preparatrontgen/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/bilddiagnostik/utvecklingslinjer-for-bilddiagnostik/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/vavnadsbiopsi-och-cytologi/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/diagnostik/diagnosbesked/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/patologins-roll-i-den-diagnostiska-processen/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/cytologimaterial-och-biopsier/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/cytologimaterial-och-biopsier/cytologimaterial/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/cytologimaterial-och-biopsier/biopsier/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/vavnadsresektat/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/vavnadsresektat/excisioner-och-resektat-utan-cancerdiagnos-diagnostisk-excision/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/vavnadsresektat/partiell-mastektomi-och-mastektomi/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/lymfkortelpreparat/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/lymfkortelpreparat/portvaktskortel/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/lymfkortelpreparat/axillpreparat/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anamnestisk-remissinformation/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anamnestisk-remissinformation/cytologimaterial-ocheller-biopsier/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anamnestisk-remissinformation/partiell-mastektomi-mastektomi-marginalbit-utvidgad-resektion-diagnostisk-excision/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anamnestisk-remissinformation/portvaktskortel/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/anamnestisk-remissinformation/axillpreparat/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/klassificering-av-tumoren/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/utvardering-av-preoperativt-behandlingssvar/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kategorisering-av-tumoren2/molekylara-analyser/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/multidisciplinar-konferens/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/multidisciplinar-konferens/sammansattning-av-det-multidisciplinara-teamet/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/multidisciplinar-konferens/vilka-patienter-bor-diskuteras/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/multidisciplinar-konferens/vilka-aterfall-bor-diskuteras/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/multidisciplinar-konferens/kunskapslage/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/2024-07-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Indikationer-for-preoperativ-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Indikationer-for-preoperativ-behandling/lokalt-avancerad-brostcancer-labc/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Indikationer-for-preoperativ-behandling/operabel-brostcancer-i-stadium-23/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/allmanna-principer-for-preoperativ-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/allmanna-principer-for-preoperativ-behandling/innan-start-av-preoperativ-behandling/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/allmanna-principer-for-preoperativ-behandling/tata-remissionsbedomningar-under-preoperativ-behandling/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/allmanna-principer-for-preoperativ-behandling/betydelse-och-definition-av-patologiskt-komplett-remission-pcr/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/val-av-cytostatika/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/preoperativ-behandling-av-trippelnegativ-brostcancer/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Preoperativ-behandling-vid-her2/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Preoperativ-behandling-vid-her2/trastuzumab/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Preoperativ-behandling-vid-her2/dubbel-her2-receptorblockad/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/Preoperativ-behandling-vid-her2/val-av-cytostatikabehandling-vid-preoperativ-behandling-av-her2-positiv-brostcancer/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/efter-preoperativ-behandling/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/preoperativ-endokrin-behandling/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/12-preoperativ-behandling/preoperativ-endokrin-behandling/val-av-preoperativ-endokrin-behandling/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/val-av-kirurgisk-behandling/2024-07-12 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-primartumoren-brostbevarande-kirurgi/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-primartumoren-brostbevarande-kirurgi/onkoplastikkirurgiska-tekniker-vid-brostbevarande-kirurgi/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-primartumoren-brostbevarande-kirurgi/Marginaler-vid-brostbevarande-kirurgi/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-primartumoren-mastektomi/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-axillen/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-axillen/portvaktskortelbiopsi-i-samband-med-preoperativ-behandling/2025-06-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgi-vid-lokoregionala-aterfall/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgi-av-brosttumoren-vid-metastaserande-sjukdom/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/kirurgisk-behandling-vid-duktal-cancer-in-situ/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/kanslomassiga-reaktioner/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/rekonstruktion-med-implantat/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/rekonstruktion-med-implantat2/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/rekonstruktion-med-stjalkade-lambaer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/rekonstruktion-med-fri-lamba/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/Rekonstruktion-av-brostvarta/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/fettransplantation/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/fordelar-och-nackdelar-med-olika-rekonstruktionsmetoder/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/fordelar-och-nackdelar-med-direkt--respektive-senrekonstruktion/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/riskreducerande-mastektomi-vid-arftlig-brostcancer/2024-07-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/rekonstruktiv-kirurgi/rekonstruktion-efter-mastektomi/anaplastiskt-storcellslymfom-relaterat-till-brostimplantat/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kirurgisk-behandling/lymfodembehandling-kirurgiska-metoder/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-av-cancer-in-situ/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-av-cancer-in-situ/pleomorf-lobular-cancer-in-situ-lcis/2024-07-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-av-cancer-in-situ/duktal-cancer-in-situ-dcis/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-kvarvarande-brost-efter-brostbevarande-kirurgi-vid-kortelnegativ-n0-invasiv-brostcancer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-kvarvarande-brost-efter-brostbevarande-kirurgi-vid-kortelnegativ-n0-invasiv-brostcancer/mojligheter-att-avsta-fran-stralbehandling-mot-brostet-vid-invasiv-hormonreceptorpositiv-lagrisktumor/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-kvarvarande-brost-efter-brostbevarande-kirurgi-vid-kortelnegativ-n0-invasiv-brostcancer/partiell-brostbestralning/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-kvarvarande-brost-efter-brostbevarande-kirurgi-vid-kortelnegativ-n0-invasiv-brostcancer/fraktionering/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-kvarvarande-brost-efter-brostbevarande-kirurgi-vid-kortelnegativ-n0-invasiv-brostcancer/boost/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-toraxvaggen-efter-mastektomi-vid-kortelnegativ-n0-invasiv-brostcancer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-brost-toraxvagg-och-regionala-kortlar-vid-kortelpositiv-n-brostcancer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-brost-toraxvagg-och-regionala-kortlar-vid-kortelpositiv-n-brostcancer/fraktionering/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-brost-toraxvagg-och-regionala-kortlar-vid-kortelpositiv-n-brostcancer/targetvolymer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-mot-brost-toraxvagg-och-regionala-kortlar-vid-kortelpositiv-n-brostcancer/targetvolymer/parasternalbestralning/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/stralbehandling-efter-preoperativ-systemisk-behandling/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/ledtider/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/ordningsfoljd-och-sakerhet-vid-sekventiellkonkomittant-systemisk-behandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/biverkningar/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/invasiv-brostcancer2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/invasiv-brostcancer2/n0-sjukdom/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/invasiv-brostcancer2/pn-tumor--efter-partiell-mastektomi/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/invasiv-brostcancer2/n-sjukdom--efter-mastektomi/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/postoperativ-stralbehandling/invasiv-brostcancer2/duktal-cancer-in-situ/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-medicinsk-behandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/bakgrund/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/antracyklin/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/tillagg-av-taxan/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/antracyklinfria-regimer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/dostat-cytostatika/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/antracyklin-jamfort-med-taxan/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/val-av-taxan/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/behandlingslangd-och-dosering/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/postoperativ-cytostatikabehandling-med-antracyklin-och-taxan/optimal-sekvens/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/tillagg-av-andra-cytostatika/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/tillagg-av-andra-cytostatika/kapecitabin/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/tillagg-av-andra-cytostatika/karboplatin/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/genexpressionsanalys-infor-beslut-om-adjuvant-cytostatika/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/genexpressionsanalys-infor-beslut-om-adjuvant-cytostatika/oncotype-dx/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/genexpressionsanalys-infor-beslut-om-adjuvant-cytostatika/mammaprint/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/genexpressionsanalys-infor-beslut-om-adjuvant-cytostatika/prosigna/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/genexpressionsanalys-infor-beslut-om-adjuvant-cytostatika/endopredict/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/genexpressionsanalys-infor-beslut-om-adjuvant-cytostatika/sammanfattning/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/tillaggsbehandling-med-cytostatika-for-her2-negativ-brostcancer/ledtider-for-cytostatikabehandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/bakgrund/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/bakgrund/effekt-av-endokrin-behandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/bakgrund/definition-av-menopaus/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-premenopausala-patienter-ar-05/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-premenopausala-patienter-ar-05/tillagg-av-lhrh-analog-till-tamoxifen/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-premenopausala-patienter-ar-05/lhrh-analog-kombinerad-med-ai/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-premenopausala-patienter-ar-05/hormonell-uppfoljning/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-postmenopausala-patienter-ar-05/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-postmenopausala-patienter-ar-05/aromatashammare-i-5-ar/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrinbehandling-for-postmenopausala-patienter-ar-05/sekvensbehandling-med-ai-och-tam/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/forlangd-endokrin-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/forlangd-endokrin-behandling/bakgrund/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/forlangd-endokrin-behandling/studiedata/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/forlangd-endokrin-behandling/beslutsverktyg-for-att-stodja-beslutet-om-forlangd-endokrin-behandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/biverkningsprofil/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/biverkningsprofil/tamoxifen/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/biverkningsprofil/aromatashammare/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/biverkningsprofil/forlangd-endokrin-behandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/biverkningsprofil/osteoporos/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/postoperativ-malriktad-lakemedelsbehandling-med-cdk-46-hammare/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/endokrinbehandling-och-malriktade-lakemedel-for-hormonreceptorpositiv-brostcancer/endokrin-behandling-vid-duktal-cancer-in-situ/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/adjuvant-trastuzumab/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/adjuvant-trastuzumab/effekt/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/adjuvant-trastuzumab/behandlingslangd/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/adjuvant-trastuzumab/hjartbiverkningar2/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/postoperativ-tillaggsbehandling-for-patienter-i-lag-risk-for-aterfall/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/postoperativ-tillaggsbehandling-for-patienter-i-hog-risk-for-aterfall/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/postoperativ-tillaggsbehandling-for-patienter-i-hog-risk-for-aterfall/antracykliner-och-antracyklinfria-regimer/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/postoperativ-tillaggsbehandling-for-patienter-i-hog-risk-for-aterfall/pertuzumab/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/systemisk-tillaggsbehandling-vid-her2-positiv-brostcancer/postoperativ-tillaggsbehandling-for-patienter-i-hog-risk-for-aterfall/neratinib/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/postoperativ-behandling-med-bisfosfonater-och-denosumab/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/postoperativ-behandling-med-bisfosfonater-och-denosumab/effekt/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/postoperativ-behandling-med-bisfosfonater-och-denosumab/indikation/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/postoperativ-behandling-med-bisfosfonater-och-denosumab/val-av-bisfosfonat-och-regim/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/postoperativ-behandling-med-bisfosfonater-och-denosumab/denosumab/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/Postoperativ-medicinsk-behandling/postoperativ-tillaggsbehandling-med-ovriga-mediciner/postoperativ-behandling-med-parp-hammare/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/2024-07-12 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/bakgrund/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/utredning/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/kirurgi/2025-06-30 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/stralbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/cytostatikabehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/malstyrd-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/endokrin-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/annan-systemisk-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/brostcancer-under-graviditet/behandling/understodjande-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-och-graviditet/graviditet-efter-brostcancerbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/fertilitetsbevarande-atgarder-och-preventivmedel/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/fertilitetsbevarande-atgarder-och-preventivmedel/fertilitetsbevarande-atgarder-vid-brostcancerbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/fertilitetsbevarande-atgarder-och-preventivmedel/fertilitetsbevarande-atgarder-vid-brostcancerbehandling/bakgrund/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/fertilitetsbevarande-atgarder-och-preventivmedel/fertilitetsbevarande-atgarder-vid-brostcancerbehandling/frysning-av-embryon-agg-och-aggstocksvavnad/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/fertilitetsbevarande-atgarder-och-preventivmedel/fertilitetsbevarande-atgarder-vid-brostcancerbehandling/gnrh-behandling-for-bevarande-av-fertilitet-i-samband-med-cytostatikabehandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/fertilitetsbevarande-atgarder-och-preventivmedel/preventivmedel-for-kvinnor-med-brostcancerbehandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/bakgrund/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/primarutredning/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/molekylargenetisk-testning/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/primar-endokrin-behandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/preoperativ-cytostatikabehandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/kirurgi/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/postoperativ-stralbehandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/postoperativ-endokrin-behandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/postoperativ-cytostatikabehandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/postoperativ-anti-her2-behandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/onkologisk-behandling-vid-metastaserad-sjukdom/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/onkologisk-behandling-vid-metastaserad-sjukdom/vid-hormonreceptorpositivher2-negativ-metastaserad-brostcancer/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/onkologisk-behandling-vid-metastaserad-sjukdom/18.11.2-vid-her2-positiv-brostcancer2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/onkologisk-behandling-vid-metastaserad-sjukdom/vid-trippelnegativ-brostcancer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancerbehandling-av-aldre2/uppfoljning-efter-behandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/bakgrund/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/utredning-och-utvardering-av-behandlingseffekt/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/forsta-linjens-behandling/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/forsta-linjens-behandling/evidens-kring-cdk-46-hammare/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/forsta-linjens-behandling/endokrin-behandling-som-singelbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/forsta-linjens-behandling/behandlingsval-vid-visceral-kris/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/andra-linjens-behandling/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/andra-linjens-behandling/endokrin-behandling-i-kombination-med-malsokande-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/andra-linjens-behandling/endokrin-behandling-som-singelbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/andra-linjens-behandling/cytostatikabehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/andra-linjens-behandling/cdk-46-hammare-som-andra-linje-efter-progression-pa-cdk-46-hammare-i-forsta-linjen/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/endokrin-behandling-i-kombination-med-malsokande-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/endokrin-behandling-som-singelbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/parp-hammare-vid-gbrca-mutation/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/cytostatikabehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/antikropp-lakemedelskonjugat/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-hormonreceptor-positivher2-negativ-mbc/tredje-eller-senare-linjens-behandling/behandlingsmojligheter-vid-hormonreceptor-positivher2-lag-mbc/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/forsta-linjens-behandling/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/forsta-linjens-behandling/dubbel-her2-blockad-i-kombination-med-cytostatika/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/forsta-linjens-behandling/behandlingsalternativ-hos-skorare-patienter/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/forsta-linjens-behandling/behandlingsalternativ-vid-tidigt-aterfall-inom-12-manader-efter-avslutad-anti-her2-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/andra-linjens-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsprinciper-vid-her2-positiv-brostcancer/tredje-eller-senare-linjens-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/forsta-linjens-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/forsta-linjens-behandling/checkpointhammare-plus-cytostatika/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/forsta-linjens-behandling/behandlingsalternativ-om-checkpointhammare-inte-ar-en-lamplig-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/forsta-linjens-behandling/patienter-med-germline-brca-mutation/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/andra-linjens-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsalgoritmer-vid-trippelnegativ-mbc/tredje-eller-senare-linjens-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/allmant/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/behandling/lokalbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/systemisk-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/systemisk-behandling/hormonreceptor-positivher2-negativ-brostcancer/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/systemisk-behandling/her2-positiv-brostcancer/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/systemisk-behandling/trippelnegativ-brostcancer/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/systemisk-behandling/patienter-med-germline-brca12-mutation-och-cns-metastaser-fran-her2-negativ-brostcancer/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-hjarnmetastaserad-brostcancer/leptomeningeal-carcinomatos/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/skelettstarkande-antiresorptiv-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-oligometastatisk-sjukdom/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-oligometastatisk-sjukdom/bakgrund/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-oligometastatisk-sjukdom/randomiserade-studier/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-oligometastatisk-sjukdom/sakerhet-vid-stereotaktisk-ablativ-stralbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/behandling-av-metastaserad-sjukdom2/behandlingsstrategier-vid-oligometastatisk-sjukdom/sammanfattning/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/brostcancer-hos-man/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/riskvardering/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/antracykliner/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/antracykliner/riskbedomning-och-monitorering/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/antracykliner/langtidsuppfoljning-1-ar/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/anti-her2-behandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/anti-her2-behandling/monitorering/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/kapecitabine/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/endokrin-behandling/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/cdk-46-hammare/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kardioonkologi/checkpointhammare/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/lokoregionalt-aterfall-inkl.-kontralateralt-regionalt-aterfall2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/phyllodestumor-borderline-malign/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/pagets-sjukdom/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/ockult-brostcancer-axillar-lymfkortelmetastas-av-brostcancer-med-ockult-brostcancer/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/inflammatorisk-brostcancer/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/tumorer-med-sallsynt-histologi/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/tumorer-med-sallsynt-histologi/luminal-lika-morfologiska-t.ex.-tubular-och-biomarkormassiga-lagrisktumorer2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/tumorer-med-sallsynt-histologi/trippelnegativa-histologiska-subtyper-med-relativt-god-prognos/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/handlaggning-av-speciella-kliniska-situationer/tumorer-med-sallsynt-histologi/trippelnegativa-histologiska-subtyper-med-samre-prognos/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/tillvaxtfaktorer-g-csf/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/antiemetikabehandlingar/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-ostrogenbristsymtom/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-lokala-ostrogenbristsymtom/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-lokala-ostrogenbristsymtom/bakgrund/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-lokala-ostrogenbristsymtom/bakgrund/lokalbehandling-med-hormonella-preparat/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-lokala-ostrogenbristsymtom/bakgrund/ostriol/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-lokala-ostrogenbristsymtom/bakgrund/ostradiol/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/understodjande-behandling2/behandling-av-lokala-ostrogenbristsymtom/bakgrund/lokalbehandling-med-icke-hormonella-preparat/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/psykosociala-aspekter-vid-brostcancer/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/kontaktsjukskoterska/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/lopande-cancerrehabilitering/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/grundlaggande-och-specialiserad-rehabilitering/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/egenvard2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/egenvard2/levnadsvanor/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/egenvard2/hudvard-vid-stralbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/egenvard2/fysisk-aktivitet/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/egenvard2/egenvard/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/egenvard2/komplementar-och-alternativ-medicin/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/palliativ-vard-och-palliativa-insatser/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/syfte-med-uppfoljning/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/tidigt-pavisande-av-aterfall/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/tidigt-pavisande-av-aterfall/lokoregionala-aterfall/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/tidigt-pavisande-av-aterfall/kontralateral-brostcancer/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/tidigt-pavisande-av-aterfall/fjarrecidiv/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/uppfoljningens-organisation/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning2/befintliga-riktlinjer/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/bakgrund/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/nuvarande-nivastrukturering-och-utveckling/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/nuvarande-nivastrukturering-och-utveckling/regional-strukturering/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/nuvarande-nivastrukturering-och-utveckling/nationell-nivastrukturering/2024-07-09 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning-av-cancervarden/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-brostcancer-nkbc/2024-10-29 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsindikatorer-och-malnivaer2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/vardprogramgruppens-sammansattning/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/vardprogramgruppens-medlemmar/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/adjungerade-forfattare/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/tidigare-medlemmar-i-vardprogramgruppen/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/jav-och-andra-bindningar/2024-07-06 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/vardprogramgruppen2/vardprogrammets-forankring/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/referenser/2025-02-24 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/forord/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/2022-05-19 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/preparat-med-cancer-invasiv-ocheller-in-situ/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/preparat-utan-pavisad-cancer/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/mikroskopisk-undersokning-och-bedomning/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/mikroskopisk-undersokning-och-bedomning/gradering-av-in-situ-cancer-och-subtypning/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/mikroskopisk-undersokning-och-bedomning/gradering-av-invasiv-brostcancer/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/mikroskopisk-undersokning-och-bedomning/stadieindelning/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--grundpanel-for-alla-invasiva-tumorer/2022-05-19 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--grundpanel-for-alla-invasiva-tumorer/sammanfattning/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--grundpanel-for-alla-invasiva-tumorer/ostrogen--och-progesteronreceptorstatus--immunhistokemisk-metod/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--grundpanel-for-alla-invasiva-tumorer/proliferationsmarkor-ki67--immunhistokemisk-metod/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--grundpanel-for-alla-invasiva-tumorer/her2-status--analysmetoder/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--tillaggsanalyser/2022-05-25 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--tillaggsanalyser/tumorinfiltrerande-lymfocyter-stil/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--tillaggsanalyser/histopatologisk-utvardering-av-preoperativt-neoadjuvant-behandlingssvar/2024-07-05 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--tillaggsanalyser/pd-l1-analys/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--tillaggsanalyser/genexpressionsprofilering/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/biomarkoranalyser--tillaggsanalyser/genomisk-profilering--dna-analys/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2022-05-19 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/makroskopisk-beskrivning/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/mikroskopiutlatande/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/koder-och-beteckningar/2022-05-19 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/koder-och-beteckningar/snomed-kodning/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/forfattare-kvast-gruppen-for-brostpatologi/2024-07-12 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for-patologi/referenser/2024-02-07 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/syfte/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/inledning/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/target-och-riskorgan/2025-02-28 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/forberedelser-och-verifikation/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/begreppsforklaringar/2025-06-04 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/stralbehandling-mot-brost/2025-06-04 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/partiell-stralbehandling-mot-brost/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/stralbehandling-mot-brost-eller-brostkorgsvagg-och-regionala-lymfkortlar/2025-06-04 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/faltexempel-och-beams-eye-view-bev-pa-dosplaner/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/referenser/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/riktlinjer-for-volymer-och-teknik-vid-stralbehandling-av-brostcancer/appendix-1-rekommendationer-vid-andningsanpassad-stralbehandling-av-brostcancer/2025-02-27 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bilaga-3/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bilaga-3/introduktion/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bilaga-3/risk-for-uppgradering-till-malignitet/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bilaga-3/handlaggning-och-uppfoljning-av-b3-lesioner/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardprogram/bilaga-3/referenser/2025-06-26 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-12 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2024-01-24 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-12-19 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/utredning-och-beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/brostcancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/brostcancerscreening/2024-11-03 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/sammanfattning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/inledning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/inledning/introduktion/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/inledning/forkortningar/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/mal-med-vardprogrammet/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/socialstyrelsens-foreskrifter-och-allmanna-rad/2024-10-18 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/definition-av-malpopulation-och-cancer-i-relation-till-screeningen/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/definition-av-malpopulation-och-cancer-i-relation-till-screeningen/definition-av-malpopulation/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/definition-av-malpopulation-och-cancer-i-relation-till-screeningen/definition-av-cancer-i-relation-till-screeningen/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/epidemiologi/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/epidemiologi/incidens/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/epidemiologi/dodlighet/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/epidemiologi/overlevnad-och-prevalens/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/screeningprinciper/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/positiva-effekter/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/negativa-effekter/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/negativa-effekter/overdiagnostik/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/negativa-effekter/falskt-positiva/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/negativa-effekter/falskt-negativa/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/negativa-effekter/oro/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screening--principer-och-effekter/effekter-av-brostcancerscreening/negativa-effekter/smarta-vid-kompression/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/hip-studien/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/screeningprogrammets-utveckling-i-sverige/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/aktuellt-screeningprogram/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/aktuellt-screeningprogram/i-sverige/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/aktuellt-screeningprogram/i-europa/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/utvardering-av-nya-screeningmetoder/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/utvardering-av-nya-screeningmetoder/mammografiskt-tata-brost/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/utvardering-av-nya-screeningmetoder/riskbaserad-screening/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprogrammets-utveckling/utvardering-av-nya-screeningmetoder/artificiell-intelligens-i-screening/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/definition-av-individ-och-patient/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/lagstod/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/ansvarsfordelning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/screeningprocess/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/vilka-ska-kallas/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/vilka-ska-kallas/kvinnor-med-skyddad-identitet-eller-skyddad-folkbokforingsadress/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/vilka-ska-kallas/kvinnor-som-saknar-folkbokforingsadress-samt-papperslosa-kvinnor/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/vilka-ska-kallas/screening-i-annan-region/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/vilka-ska-kallas/utlandssvenskar-och-gransarbetare/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/kallelse/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/sparrlista/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/informerat-deltagande/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/informerat-deltagande/informationsmaterial/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/hogt-deltagande/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/hogt-deltagande/ny-kallelse-till-dem-som-uteblivit/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/hogt-deltagande/paminnelser-via-sms/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/hogt-deltagande/tillganglig-brostcancerscreening/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kallelsehantering-och-deltagande/hogt-deltagande/klinisk-bedomning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/mammografisjukskoterskans-kompetens-och-utbildning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/mammografisjukskoterskans-kompetens-och-utbildning/krav-och-kompetens/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/mammografisjukskoterskans-kompetens-och-utbildning/upplarning-i-bildtagning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokning-med-mammografi/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokning-med-mammografi/bemotande/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokning-med-mammografi/information-vid-undersokningstillfallet/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokning-med-mammografi/brostschablon-och-frageformular/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/projektioner/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/generella-bildkriterier-och-positionering/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/kriterier-for-kraniokaudal-positionering/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/kriterier-for-mediolateral-oblik-positionering/2024-10-24 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/brostkompression/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/undersokningsteknik/brostkompression/adekvat-kompression-och-kompressionsplatta/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/straldos-och-bildkvalitet/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/straldos-och-bildkvalitet/optimering/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/straldos-och-bildkvalitet/diagnostisk-referensniva/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/anpassad-bildtagning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/anpassad-bildtagning/gravida-och-ammande-kvinnor/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/anpassad-bildtagning/kvinnor-med-funktionsnedsattning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/anpassad-bildtagning/kvinnor-med-implantat/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/anpassad-bildtagning/kvinnor-som-genomgatt-kirurgi/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/omtag-av-bilder/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/systematiskt-kvalitetsarbete/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/systematiskt-kvalitetsarbete/positioneringskvalitet/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildtagning/systematiskt-kvalitetsarbete/tekniska-kvalitetskontroller-av-rontgenutrustning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/arbetsmiljo/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/krav-pa-medicinteknisk-utrustning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/visningsprotokoll/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeninggranskning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeninggranskning/dubbelgranskning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeninggranskning/symtom/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeninggranskning/bifynd/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeningbeslut/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeningbeslut/frisk/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeningbeslut/diskussion/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeningbeslut/tekniskt-omtag/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeningbeslut/selektion/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/screeningbeslut/selektion/selektionsutredning-och-undersokningskoder/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/kompetenskrav-for-brostradiologer/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/kompetenskrav-for-brostradiologer/uppratthalla-kompetens/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/kompetenskrav-vid-screeninggranskning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/kompetenskrav-vid-screeninggranskning/fjarrgranskning-av-bilder/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/intervallcanceranalys/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/kvalitetssakring-och-kompetenskrav/medicinskt-ansvarig-lakare/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bildgranskning/granskning-med-artificiell-intelligens/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/svarshantering/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/svarshantering/svarsbrev/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/svarshantering/svarsbrev/normalsvar-s1/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/svarshantering/svarsbrev/tekniskt-omtag-s2/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/svarshantering/svarsbrev/ofullstandig-undersokning-s3-och-s4/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kommunikation-och-information/2024-10-18 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kvalitetsregister/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kvalitetsregister/undersokningskoder/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kvalitetsregister/fyndkoder/2024-10-21 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kvalitetsregister/fyndkoder/vardprogramgruppens-fyndkoder/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/referenser/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/forslag-pa-fordjupning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/vardprogramgruppen/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-1-positionering/2024-10-28 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-1-positionering/vardering-av-undersokning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-1-positionering/vardering-av-undersokning/presentation-av-undersokningen/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-1-positionering/ergonomi/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/2024-10-18 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/inledning/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/inledning/fordelar-och-nackdelar-med-brostcancerscreening/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/informationspaket/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/konsekvent-ordval/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/information-i-kallelse-och-svarsbrev/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/fordjupad-information-pa-1177.se2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/sarskilda-informationsinsatser/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/sarskilda-informationsinsatser/for-kvinnor-som-inte-deltar/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/sarskilda-informationsinsatser/for-personer-med-brost-som-inte-far-en-kallelse/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/sarskilda-informationsinsatser/strategier-for-okad-kunskap-hos-allmanhet-profession-och-beslutsfattare/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/kommunikationsstrategi/oversikt/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/budskap-malgrupper-och-kanaler/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/budskap-malgrupper-och-kanaler/tydliga-budskap/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/malgrupper-och-ambassadorer/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/informations--och-kommunikationskanaler/2024-10-01 https://kb.localhost:5000/diagnoser/brostcancerscreening/vardprogram/bilaga-2-underlag-till-kommunikationsplan/ansvarsfordelning/2024-10-01 https://kb.localhost:5000/diagnoser/buksarkom/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/forkortat-vardforlopp/2025-11-12 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/sammanfattning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/inledning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-01-20 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/inledning/standardiserat-vardforlopp/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/inledning/lagstod/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/inledning/evidensgradering/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/mal-med-vardprogrammet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/bakgrund-och-orsaker/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-prevention/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/arftlighet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/retroperitoneala-mjukdelssarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/intraabdominella-mjukdelssarkom-intraperitoneala/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/gynekologiska-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/misstanke/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-att-starta-utredning-enligt-standardiserat-vardforlopp/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-retroperitoneala-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-retroperitoneala-sarkom/sarkomtyp-och-gradering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-retroperitoneala-sarkom/sarkomtyp-och-gradering/radiologi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-retroperitoneala-sarkom/sarkomtyp-och-gradering/vavnadsdiagnostik/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-retroperitoneala-sarkom/stadium/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-intraabdominella-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-intraabdominella-sarkom/sarkomtyp-och-gradering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-intraabdominella-sarkom/sarkomtyp-och-gradering/radiologi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-intraabdominella-sarkom/sarkomtyp-och-gradering/vavnadsbunden-diagnostik/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-intraabdominella-sarkom/stadium/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-av-gynekologiska-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-av-gynekologiska-sarkom/transvaginalt-och-transabdominellt-ultraljud/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/basutredning-av-gynekologiska-sarkom/vavnadsbunden-diagnostik/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/diagnostik/diagnosbesked/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/diagnostik-gist/2023-02-08 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/biopsier/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/histologiskt-material-resektat-och-andra-operationspreparat/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kategorisering-av-tumoren/information-i-pad-utlatandetsremissens-svarsdel/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/multidisciplinar-konferens-mdk/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/multidisciplinar-konferens-mdk/recidiv/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/val-av-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/kirurgi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/kirurgi/marginaler/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/intraabdominella-och-retroperitoneala-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/intraabdominella-och-retroperitoneala-sarkom/preoperativ-behandling/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/intraabdominella-och-retroperitoneala-sarkom/postoperativ-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/gist/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/gist/preoperativ-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/gist/postoperativ-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/primar-behandling/onkologisk-behandling/aggressiv-fibromatos-desmoida-tumorer/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/aterfall/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/aterfall/val-av-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/aterfall/lokalrecidiv/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/val-av-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/lungmetastasering/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/annan-begransad-metastasering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/intraabdominella-och-retroperitoneala-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/intraabdominella-och-retroperitoneala-sarkom/medicinsk-behandling/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/intraabdominella-och-retroperitoneala-sarkom/stralbehandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/solitary-fibrous-tumour/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/gist/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/gist/medicinsk-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/behandling-av-aterfall-och-avancerad-sjukdom/avancerad-sjukdom/generaliserad-sjukdom/gist/stralbehandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/nutrition/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/nutrition/nutritionsstatus/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/nutrition/nutritionsbehandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/nutrition/nutritionsbehandling/vitamin--och-mineralsupplementering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/nutrition/nutritionsbehandling/kost-med-anpassad-konsistens/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/palliativ-vard-och-insatser/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/min-vardplan/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-diagnosbesked/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-kirurgi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-stralbehandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-cytostatikabehandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-behandling-med-tyrosinkinashammare-tki/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/rehabiliteringsinsatser-vid-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/rehabiliteringsinsatser-vid-sarkom/sexualitet/2024-06-26 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/rehabiliteringsinsatser-vid-sarkom/fertilitet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/rehabiliteringsinsatser-vid-sarkom/fysisk-aktivitet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/omvardnad-och-rehabilitering/rehabiliteringsinsatser-vid-sarkom/backenrehabilitering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/nationella-riktlinjer/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/rokning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/komplementar-och-alternativ-medicin/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/alkohol/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/fysisk-aktivitet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/egenvard-vid-onkologisk-behandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/egenvard-vid-onkologisk-behandling/infektionskanslighet/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/egenvard-vid-onkologisk-behandling/vaccinationer/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/egenvard-vid-onkologisk-behandling/hud/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/egenvard/egenvard-vid-onkologisk-behandling/hudvard-vid-stralbehandling/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/mal-med-uppfoljningen/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2024-06-26 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/sjalvrapportering-av-symtom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/kontroll-av-aterfall-retroperitoneala-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/kontroll-av-aterfall-retroperitoneala-sarkom/uppfoljningsintervall-hoggradiga-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/kontroll-av-aterfall-retroperitoneala-sarkom/forslag-till-uppfoljningsintervall-laggradiga-sarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/kontroll-av-aterfall-gist/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/kontroll-av-aterfall-gist/forslag-till-uppfoljningsintervall-hogrisk-gist-som-behandlas-adjuvant/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/kontroll-av-aterfall-gist/forslag-till-uppfoljningsintervall-intermediara-och-laggradiga-gist/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/ansvar/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/avslut-av-uppfoljning/2024-06-26 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/bakgrund-och-evidenslage/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/bakgrund-och-evidenslage/mjukdelssarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/uppfoljning/bakgrund-och-evidenslage/metoder-for-uppfoljning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/underlag-for-nivastrukturering/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsregister/2023-01-20 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsregister/cancerregistret/2023-01-20 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsindikatorer/2023-01-20 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/referenser/2023-01-20 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/vardprogramgruppen/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/vardprogramgruppen/vardprogrammets-forankring/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar-och-hantering-av-prover-pa-laboratorium/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/hantering-av-resektat/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/immunhistokemi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/molekylarpatologi/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/histopatologisk-diagnos-vid-retroperitoneala-och-intra-abdominella-sarkom-forutom-gist-och-gynsarkom/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/histologisk-gradering-av-sarkom/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/kvalitetsdokument-for-patologi/kvalitetsarbete-for-patologin/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/sammanfattning/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/bakgrund-och-orsaker/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/bakgrund-och-orsaker/epidemiologi/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/bakgrund-och-orsaker/etiologi/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/symtom--uterussarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/bilddiagnostik/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/bilddiagnostik/kvalificerat-ultraljud/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/bilddiagnostik/3-fas-dt/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/bilddiagnostik/mrt/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/bilddiagnostik/pet-dt/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/utredning--uterussarkom/bilddiagnostik/pet-mrt/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-02-08 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/figo-stadieindelning-for-uterussarkom-2009/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/figo-stadieindelning-for-uterussarkom-2009/leiomyosarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/figo-stadieindelning-for-uterussarkom-2009/adenosarkom-endometriestromasarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/klassificering-av-tumoren/2023-02-08 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/klassificering-av-tumoren/diagnoser-inkl.-snomedkoder2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/klassificering-av-tumoren/immunhistokemiska-fargningar-som-kan-vara-till-hjalp-vid-tumortypning/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/kategorisering-av-tumoren/klassificering-av-tumoren/molekylaranalyser-vid-gynekologiska-sarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/smooth-muscle-tumor-of-uncertain-malignant-potential-stump/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/kirurgi/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/postoperativ-behandling-av-uterussarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/postoperativ-behandling-av-uterussarkom/lms/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/postoperativ-behandling-av-uterussarkom/laggradigt-ess-hoggradigt-ess-ous-eller-as/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/postoperativ-behandling-av-uterussarkom/laggradigt-ess/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/postoperativ-behandling-av-uterussarkom/hoggradigt-ess-och-ous/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/primar-behandling/postoperativ-behandling-av-uterussarkom/as/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/aterfall/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/kirurgi/2022-03-18 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/medicinsk-behandling/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/medicinsk-behandling/lms/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/medicinsk-behandling/laggradigt-ess/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/behandling-av-aterfall-och-primart-avancerad-sjukdom/medicinsk-behandling/hoggradigt-ess-oes-och-as/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/omvardnad-och-rehabilitering/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/uppfoljning/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/uppfoljning/klimakteriella-symtom-efter-behandling/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/referenser/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/arbetsgrupp-bilaga-gynekologiska-sarkom/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/arbetsgrupp-bilaga-gynekologiska-sarkom/arbetsgruppens-medlemmar/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/arbetsgrupp-bilaga-gynekologiska-sarkom/tidigare-medlem-i-arbetsgruppen/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/arbetsgrupp-bilaga-gynekologiska-sarkom/jav-och-andra-bindningar/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/gynekologiska-sarkom/arbetsgrupp-bilaga-gynekologiska-sarkom/bilagans-forankring/2022-03-16 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/bilddiagnostik/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/bilddiagnostik/3-fas-dt/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/bilddiagnostik/mrt/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/Vardprogram/bilddiagnostik/hybridmodaliteter/2020-10-22 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/introduktion/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/Valgrundad-misstanke/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/Remiss-till-utredning/2024-11-08 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2025-01-13 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/buksarkom/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/2022-04-07 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/sammanfattning/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/malgrupp/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-10-02 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-10-02 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/standardiserat-vardforlopp/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/lagstod/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/evidensgradering/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/inledning/forkortningar/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/mal-med-vardprogrammet/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bakgrund/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bakgrund/bakgrund/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bakgrund/orsaker-och-riskfaktorer/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bakgrund/paverkbara-faktorer-for-att-minska-risken/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bakgrund/primar-prevention/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/screening/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/bakgrund/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/precisionsmedicin-vid-pankreascancer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/arvsanlag-med-koppling-till-hog-risk-for-pankreascancer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/arvsanlag-med-koppling-till-hog-risk-for-pankreascancer/peutz-jegherstk-11/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/arvsanlag-med-koppling-till-hog-risk-for-pankreascancer/cdkn2a/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/arvsanlag-med-koppling-till-hog-risk-for-pankreascancer/arftlig-pankreatit/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/arvsanlag-med-koppling-till-hog-risk-for-pankreascancer/ovriga-syndrom-med-okad-risk-for-pankreascancer/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/arvsanlag-med-koppling-till-hog-risk-for-pankreascancer/familjart-okad-risk-for-pankreascancer/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/utredning/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/genetisk-testning-vid-pankreascancer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/genetisk-testning-vid-pankreascancer/vem-skall-rekommenderas-genetisk-screening-avseende-mojlig-arftligt-okad-risk-for-pankreascancer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/genetisk-testning-vid-pankreascancer/6.5.2behandlingsprediktiv-testning2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/genetisk-testning-vid-pankreascancer/vem-ansvarar-for-den-konstitutionella-genetiska-testningen/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/kontroller/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/kontroller/vilka-bor-erbjudas-kontroller/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/arftlighet-och-kontrollprogram-for-familjar-pankreascancer/kontroller/kontrollprogrammets-utforande/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/bakgrund/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/handlaggning-av-huvudgangs-ipmn-och-blandtyp-av-huvudgangs--och-sidogangs-ipmn/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/handlaggning-av-sidogangs-ipmn/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/handlaggning-av-sidogangs-ipmn/konservativ-behandling/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/handlaggning-av-sidogangs-ipmn/kriterier-for-kirurgi/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/handlaggning-av-sidogangs-ipmn/val-av-kirurgi/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/diagnostik/handlaggning-av-sidogangs-ipmn/intraoperativt-fryssnitt/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/uppfoljning-efter-pankreasresektion-for-ipmn/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/onkologisk-behandling/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/intraduktal-papillar-mucinos-neoplasi-ipmn/sma-icke-definierbara-cystor/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/symtom-och-tidig-utredning/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/symtom-och-tidig-utredning/kontakt-med-slutenvard-om-standardiserade-vardforlopp/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/bilddiagnostisk-utredning/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/bilddiagnostisk-utredning/bilddiagnostik/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/bilddiagnostisk-utredning/upptackt-av-metastaser/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/bilddiagnostisk-utredning/klinisk-stadieindelning/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/tumormarkorer-och-neuroendokrin-screening/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/endoskopisk-diagnostik-och-biopsi/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/differentialdiagnostisering/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/differentialdiagnostisering/kronisk-pankreatit/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/differentialdiagnostisering/autoimmun-pankreatit/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/diagnosbesked/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/diagnostik/omvardnad-och-rehabilitering/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/solida-lesioner/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/cystiska-tumorer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/fryssnitt/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/kvalitetsuppfoljning/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hantering-av-operationspreparat/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hantering-av-operationspreparat/markering-av-resektionsytor-pa-operationspreparatet/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hantering-av-mellannalsbiopsi/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hantering-av-finnalsbiopsi/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/anamnestisk-remissinformation/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/klassificering-av-tumoren/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/klassificering-av-tumoren/diagnostik-av-pankreastumorer-pa-operationspreparat/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/klassificering-av-tumoren/diagnostik-av-mellannalsbiopsier-finnalsbiopsier-och-mikrobiopsier/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/klassificering-av-tumoren/diagnostik-av-finnalsaspirat-och-borstprov/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/histologisk-kategorisering-av-tumoren/klassificering-av-tumoren/molekylarpatologiska-analyser/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/multidisciplinar-konferens/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/val-av-behandling/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/val-av-behandling/behandlingsoversikt-kirurgi/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/val-av-behandling/behandlingsoversikt-onkologi/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/preoperativ-stentbehandling/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/preoperativ-utredning-bedomning-och-behandling/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/pankreatoduodenektomi-pd/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/ventrikelanastomos/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/pankreasanastomos/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/pankreasanastomos/antekolisk-kontra-retrokolisk-jejunumslynga/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/lymfadenektomi/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/13.3.5utvidgad-pankreatektomi-venresektion-artarresektion-eller-multivisceral-resektion2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/13.3.5utvidgad-pankreatektomi-venresektion-artarresektion-eller-multivisceral-resektion/pankreatoduodenektomi-med-venresektion/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/13.3.5utvidgad-pankreatektomi-venresektion-artarresektion-eller-multivisceral-resektion/pankreatoduodenektomi-med-artarresektion/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/13.3.5utvidgad-pankreatektomi-venresektion-artarresektion-eller-multivisceral-resektion/multivisceral-kirurgi/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/hogersidig-eller-proximal-pankreasresektion/pankreatoduodenektomi-vid-fjarrmetastaser/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/distal-eller-vanstersidig-pankreasresektion-dp/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/distal-eller-vanstersidig-pankreasresektion-dp/standardresektion/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/distal-eller-vanstersidig-pankreasresektion-dp/utvidgad-resektion-ramps/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/distal-eller-vanstersidig-pankreasresektion-dp/distal-pankreatektomi-med-resektion-av-truncus-coeliacus-modifierad-appleby/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/ovriga-resektioner/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/ovriga-resektioner/total-pankreatektomi-tp/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/ovriga-resektioner/central-pankreatektomi-cp/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/minimalinvasiv-kirurgi/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/13.7postoperativ-vard-efter-pankreasresektion2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/onkologisk-behandling-vid-kurativ-intention/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/onkologisk-behandling-vid-kurativ-intention/neoadjuvant-behandling/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/onkologisk-behandling-vid-kurativ-intention/konverteringsbehandling/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/onkologisk-behandling-vid-kurativ-intention/adjuvant-behandling/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/onkologisk-behandling-vid-kurativ-intention/prognos--och-behandlingsprediktiva-markorer/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kurativt-syftande-behandling/omvardnad-och-rehabilitering-vid-pankreaskirurgi/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/palliativ-kirurgi-vid-icke-resektabel-tumor/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/palliativ-kirurgi-vid-icke-resektabel-tumor/palliativa-atgarder-vid-explorativ-laparotomi/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/endoskopi-och-avlastning-i-palliativ-situation/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/endoskopi-och-avlastning-i-palliativ-situation/ercp-med-plaststent-eller-metallstent/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/endoskopi-och-avlastning-i-palliativ-situation/perkutan-transhepatisk-kolangiografi-ptc/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/endoskopi-och-avlastning-i-palliativ-situation/dranering-av-gallvagarna-guidad-med-endoskopiskt-ultraljud-eus/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/endoskopi-och-avlastning-i-palliativ-situation/duodenal-obstruktion/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/onkologisk-behandling-i-palliativ-situation/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/onkologisk-behandling-i-palliativ-situation/lokalt-avancerad-pankreascancer/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativt-syftande-cancerbehandling/onkologisk-behandling-i-palliativ-situation/systemiskt-spridd-pankreascancer/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/behandling-av-aterfall/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/behandling-av-aterfall/aterfall--lokala/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/behandling-av-aterfall/aterfall--systemiska-metastaserande/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/nutrition-vid-pankreascancer/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/preoperativ-nutrition/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/postoperativ-nutrition/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/nutrition-vid-icke-operabel-pankreascancer/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/nutrition-vid-duodenalstent/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/exokrin-pankreassvikt/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/understodjande-vard/diabetes/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativ-vard-och-palliativa-insatser/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativ-vard-och-palliativa-insatser/symtomlindring/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativ-vard-och-palliativa-insatser/matleda/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativ-vard-och-palliativa-insatser/fatigue/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativ-vard-och-palliativa-insatser/smarta/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/palliativ-vard-och-palliativa-insatser/ikterus-ascites-m.m2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/egenvard/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/egenvard/19.1-levnadsvanor2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/egenvard/19.2-komplementar-och-alternativ-medicin2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/egenvard/19.3-matvanor2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/egenvard/19.4-patientforening2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/kontroll-av-aterfall/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/ansvar/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/nivastrukturering/2024-10-02 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kvalitetsregister/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kvalitetsregister/nationella-kvalitetsregistret-for-tumorer-i-pankreas-och-periampullart/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kvalitetsregister/uppfoljning-av-patientrapporterade-matt/2024-06-19 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kvalitetsregister/cancerregistret/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-10-02 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/referenser2/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/vardprogramgruppen/2021-03-12 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-06-26 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilddiagnostik-vid-pankreascancer/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilddiagnostik-vid-pankreascancer/dt-pankreas-protokollforslag-oversiktlig/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilddiagnostik-vid-pankreascancer/dt-pankreas-protokollforslag-i-detalj/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilddiagnostik-vid-pankreascancer/checklista-for-radiologisk-bedomning-av-pankreascancer-infor-mdk/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilddiagnostik-vid-pankreascancer/referenser/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/innehall/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/i.-instruktioner-for-preparathantering-fore-formalinfixering2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/ii.-klinisk-information2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering2021-09-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering/orientering-och-inspektion/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering/identifiering-och-tuschmarkning-av-resektionsytorna/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering/axiell-skivningsteknik/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering/inspektion-av-det-uppskivade-preparatet/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering/tillvaratagande-av-material-till-mikroskopi/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iii.-instruktioner-for-utskarning-av-operationspreparat-efter-formalinfixering/baddning-och-lokalisering-av-lymfknutor/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/iv.-hantering-av-pankreasbiopsier2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet2021-09-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/duktalt-adenokarcinom-och-dess-varianter/2024-06-24 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/pankreatisk-intraepitelial-neoplasi-panin/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/intraduktal-papillar-mucinos-neoplasi-ipmn/2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/mucinos-cystisk-neoplasi-mcn/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/serost-cystadenom-sca/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/solid-pseudopapillar-tumor-spt/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/endokrina-tumorer-och-blandad-neuroendokrin-icke-neuroendokrin-neoplasi-minen/2021-09-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/acinarcellskarcinom/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/v.-information-som-ska-inga-i-patologutlatandet/kronisk-pankreatit/2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/vi.-rekommendationer-for-rapportering2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/vii.-snomed-koder2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/viii.-referenser2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/ix.-lista-over-forkortningar2024-06-13 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/x.-medlemmar-i-kvast-studiegruppen2024-06-18 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardprogram/bilaga-2-kvalitetsdokument-for-patologi/bilaga-till-kvast-dokumentet/2021-09-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/introduktion/2024-11-29 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2023-01-03 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2023-01-03 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-29 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-29 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-29 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-29 https://kb.localhost:5000/diagnoser/bukspottkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/2020-02-28 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sammanfattning/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/inledning/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mal-med-vardprogrammet/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/bakgrund/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/stralbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/kirurgi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/cytostatika/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/immunterapi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/basal-kroppskannedom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/allman-bakgrund/vardniva/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/kartlaggning-och-bedomning-av-patientens-rehabiliteringsbehov/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/kartlaggning-och-bedomning-av-patientens-rehabiliteringsbehov/bedomning-av-rehabiliteringsbehov/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/kartlaggning-och-bedomning-av-patientens-rehabiliteringsbehov/information-och-egenvardsrad/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/kartlaggning-och-bedomning-av-patientens-rehabiliteringsbehov/multidisciplinart-team/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/kartlaggning-och-bedomning-av-patientens-rehabiliteringsbehov/uppfoljning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/stralbehandling-och-medicinsk-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/kirurgi/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/bakteriell-overvaxt/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/gallsaltsmalabsorption/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/stralpaverkan-i-rektum/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/bakgrund-och-orsaker/laktosintolerans/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/symptom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/symptom/defekationsrubbningar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/symptom/diarre-knipsmartor-och-uppblasthet/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/symptom/rektala-blodningar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/utredning/defekationsrubbningar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/utredning/diarre-knipsmartor-och-uppblasthet/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/utredning/rektala-blodningar/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/basal-symptomlindrande-behandling-och-egenvardsrad/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/tarmreglerande-lakemedel/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/lakemedel-mot-uppblasthet/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/inkontinensskydd/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/hudskydd/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/6.4.1.6tarmtomningstraning-toalettgympa-backenbottentraning-och-fotpall2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/matvanor-och-kostrad/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/analpropp/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/lakemedel/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/transanal-irrigation-tai/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/perkutan-tibialisnervstimulering-ptns-och-sakralnervmodulering-snm/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/stomi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/6.4.2specialiserad-behandling-vid-defekationsrubbningar-diarre-knipsmartor-och-uppblasthet/behandling-av-bakteriell-overvaxt-samt-gallsaltsmalabsorption/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-stralproktopati/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-stralproktopati/basal-information/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-stralproktopati/specialiserad-behandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-stralproktopati/specialiserad-behandling/lakemedelsbehandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-stralproktopati/specialiserad-behandling/hyperbar-oxygenbehandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/behandling/behandling-av-stralproktopati/specialiserad-behandling/endoskopisk-behandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/mag-tarmbesvar2/uppfoljning/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/bakgrund-och-orsaker/efter-stralbehandling-eller-cytostatika/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/bakgrund-och-orsaker/efter-kirurgi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/symptom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/symptom/bristande-sexuell-lust-och-orgasmstorning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/symptom/genital-smarta/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/utredning/bristande-sexuell-lust/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/utredning/genital-smarta/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/samtal/2025-05-06 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/ostrogensubstitution/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/lokalt-verkande-ostrogen/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/testosteronbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/backenbottentraning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/7.1sexuell-och-hormonell-dysfunktion-hos-kvinnor/behandling-och-atgarder/hjalpmedel/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/erektil-dysfunktion/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/erektil-dysfunktion/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/behandling-och-atgarder/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/testosteronbrist/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/testosteronbrist/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/testosteronbrist/symptom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/testosteronbrist/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/sexuell-och-hormonell-dysfunktion-hos-man/testosteronbrist/behandling-och-atgarder/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/sexuell-och-hormonell-dysfunktion/uppfoljning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/blastomningssvarigheter-pa-grund-av-hypoton-urinblasa/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/blastomningssvarigheter-pa-grund-av-uretrastrikturer/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/anstrangningsinkontinens/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/uretarstrikturer/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/fistlar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/kirurgi/foljdeffekter-av-cystektomi-och-urinavledning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/stralbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/stralbehandling/blastomningssvarigheter-pa-grund-av-uretrastrikturer/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/stralbehandling/sen-stralcystit/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/stralbehandling/uretarstrikturer/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/bakgrund-och-orsaker/stralbehandling/fistlar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/symptom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/basal-utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/basal-utredning/anamnes/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/basal-utredning/residualurinmatning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/basal-utredning/formular/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/basal-utredning/provtagning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/utvidgad-specialiserad-utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/utvidgad-specialiserad-utredning/uretrocystoskopi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/utvidgad-specialiserad-utredning/urodynamisk-undersokning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/utvidgad-specialiserad-utredning/mrt-och-dt-over-urinvagar-och-backenomradet-samt-ultraljud/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/utredning/utvidgad-specialiserad-utredning/gynekologisk-undersokning-och-rektalundersokning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-hypoton-urinblasa/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-hypoton-urinblasa/basal-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-hypoton-urinblasa/specialiserad-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-uretrastriktur/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-uretrastriktur/specialiserad-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-svullnad-efter-stralbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/blastomningssvarigheter-pa-grund-av-svullnad-efter-stralbehandling/basal-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/anstrangningsinkontinens/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/anstrangningsinkontinens/basal-behandling-och-egenvardsrad/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/anstrangningsinkontinens/specialiserad-behandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/trangningsinkontinens-och-tata-urintrangningar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/trangningsinkontinens-och-tata-urintrangningar/basal-behandling-och-egenvardsrad/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/trangningsinkontinens-och-tata-urintrangningar/specialiserad-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/sen-stralcystit-med-eller-utan-hematuri/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/sen-stralcystit-med-eller-utan-hematuri/basal-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/sen-stralcystit-med-eller-utan-hematuri/specialiserad-behandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/sen-stralcystit-med-eller-utan-hematuri/hogspecialiserad-behandling-vid-allvarlig-stralcystit/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/avflodeshinder-pa-grund-av-uretarstrikturer/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/avflodeshinder-pa-grund-av-uretarstrikturer/specialiserad-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/fistlar/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/behandling/fistlar/specialiserad-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/urinvagsbesvar/uppfoljning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/bakgrund-och-orsaker/kirurgi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/bakgrund-och-orsaker/stralbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/bakgrund-och-orsaker/cytostatika/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/symptom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/basal-behandling-och-egenvardsrad/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/analgetika/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/annan-lakemedelsbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/fysioterapi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/specialiserad-behandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/specialiserad-behandling/injektionsbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/specialiserad-behandling/neuromodulation/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/specialiserad-behandling/kirurgi/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/specialiserad-behandling/9.5.4smartenhet-och-smartrehabilitering2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/smarta2/behandling/uppfoljning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/bakgrund-och-orsaker/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/bakgrund-och-orsaker/riskfaktorer/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/symptom/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/utredning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/basal-behandling-och-egenvard/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/basal-behandling-och-egenvard/kompressionsbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/basal-behandling-och-egenvard/egenvard/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/tillaggsbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/tillaggsbehandling/lymfpulsatorbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/tillaggsbehandling/manuellt-lymfdranage-mld/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/tillaggsbehandling/kirurgisk-behandling/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/tillaggsbehandling/lakemedelsbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/tillaggsbehandling/10.5.5behandling-av-hudinfektioner2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/lymfodem2/uppfoljning/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/kvalitetsarbete/2023-06-27 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/adjungerade-forfattare/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/jav-och-andra-bindningar2/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/vardprogramgruppen/vardprogrammets-forankring2/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/referenser2/2025-04-30 https://kb.localhost:5000/diagnoser/backencancerrehabilitering/vardprogram/bilaga-1---lankbibliotek/2025-04-30 https://kb.localhost:5000/diagnoser/cancerrehabilitering/2020-02-28 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sammanfattning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/inledning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-05-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/inledning/forandringar/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/inledning/lagstod/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/inledning/evidensgradering/2024-05-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/inledning/ordlista/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/mal-med-vardprogrammet/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/definitioner/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/definitioner/vardprogrammets-definition-av-cancerrehabilitering/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/definitioner/socialstyrelsens-definition-av-rehabilitering/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/ansvar/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/ansvar/prioriteringar-utifran-behov/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/ansvar/aktiv-overlamning/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/kartlaggning-och-dokumentation/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/behov-och-insatser-utifran-fyra-omraden/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-olika-nivaer/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-olika-nivaer/insatser-i-relation-till-cancervardforloppet/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/information/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/levnadsvanor/2024-05-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/egenvard/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/kontaktsjukskoterska/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/kartlaggning-och-bedomning-av-behov/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/min-vardplan/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-grundlaggande-niva/min-vardplan/fordjupning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-sarskild-niva/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-sarskild-niva/specialiserad-kompetens/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-sarskild-niva/generisk-modell-for-rehabilitering/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-sarskild-niva/fordjupad-bedomning-av-profession-med-specialiserad-kompetens/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-sarskild-niva/radgivande-samtal-och-kvalificerad-radgivning-vid-ohalsosamma-levnadsvanor/2024-05-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/rehabiliteringsplan/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/rehabiliteringsplan/rehabiliteringsplanens-innehall/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-avancerad-niva/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-avancerad-niva/team-och-teamarbete/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-avancerad-niva/team-och-teamarbete/fordjupning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/insatser-pa-avancerad-niva/samverkans--och-samordningsinsatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/rehabiliteringsprocessen/exempel-pa-insatser-pa-grundlaggande-sarskild-och-avancerad-niva/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/kvalitetsindikatorer-och-malnivaer/individanpassad-information-dialog-och-samrad/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsregister/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/kvalitetsindikatorer-och-malnivaer/prom-och-prem-matningar/2025-05-21 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/kommunikation-mellan-vardaktorer/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/aktiv-overlamning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/fram-till-cancerdiagnos/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/patientens-cancerbehandlande-team/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/fast-vardkontakt/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/Kontaktsjukskoterska/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/prehabilitering/kurator/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/fatigue/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/fatigue/bedomning-och-utredning-av-fatigue/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/fatigue/behandling-av-cancerrelaterad-fatigue/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/haravfall/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/illamaende/2024-05-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/kognitiv-funktionsnedsattning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/bakgrund-och-orsaker/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/prevention-och-diagnostik/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/insatser-sarskild-niva/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/egenvard/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/tillaggsbehandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/lymfodem/uppfoljning-och-utvardering/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/smarta/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/stralningsrelaterade-besvar/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/stralningsrelaterade-besvar/behandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/cytostatikautlost-perifer-neuropati/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/cytostatikautlost-perifer-neuropati/behandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/symtom-och-biverkningar-som-kan-paverka-funktionsformaga/cytostatikautlost-perifer-neuropati/fordjupning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/insatser-pa-de-olika-nivaerna/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/fordjupning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/fordjupning/personlig-adl-och-instrumentell-adl/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/fordjupning/balans-i-aktivitet-och-halsa/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/fordjupning/fatigue/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/kartlaggning-och-information/fordjupning/bedomningsinstrument/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/rekommendationer-for-fysisk-aktivitet/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/effekter-av-fysisk-aktivitet-och-traning-under-och-efter-cancerbehandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/betydelse-av-att-begransa-fysisk-inaktivitet-och-stillasittande/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/sarskilda-hansynstagande-vid-traning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/insatser-pa-de-olika-nivaerna/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/fordjupning/2023-12-05 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/fordjupning/vetenskapligt-underlag-for-fysisk-aktivitet-och-traning-vid-cancersjukdom/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/fordjupning/fysioterapeut--eller-instruktorsledd-traning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/fordjupning/fysisk-traning-och-aterinsjuknande/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/fordjupning/fysisk-aktivitet-och-traning-vid-samsjuklighet/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-stralbehandling/fordjupning/allvarliga-handelser-och-skador-relaterat-till-traning-under-och-efter-cancerbehandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-medicinsk-cancerbehandling/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-medicinsk-cancerbehandling/insatser-pa-de-olika-nivaerna/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-medicinsk-cancerbehandling/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/biverkningar-av-medicinsk-cancerbehandling/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/dyspne-andnod/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/dyspne-andnod/insatser-pa-de-olika-nivaerna/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/dyspne-andnod/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/dyspne-andnod/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/dyspne-andnod/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/dyspne-andnod/fordjupning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/fatigue/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/fatigue/sexuell-halsa/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/fatigue/insatser-pa-de-olika-nivaerna/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/fatigue/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/fatigue/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/fysiska-insatsomraden/fatigue/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/samtal-och-information/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/kartlaggning-och-fordjupad-bedomning/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/kartlaggning-och-fordjupad-bedomning/identifiering-av-sarbarhetsfaktorer-och-resurser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/suicidrisk/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/suicidrisk/strukturerad-suicidriskbedomning/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/krisreaktion/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/akut-och-forlangd-stressreaktion/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/posttraumatisk-stress/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/angest/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/depression/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/radsla-for-aterfall/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/uppfoljning-av-psykisk-halsa/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/insatser-pa-de-olika-nivaerna/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/psykiska-insatsomraden/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/sexuell-halsa/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/fertilitet-och-reproduktion/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/narstaende/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/barn-som-anhoriga/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/sarskilt-sarbara-grupper/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/forsakringsmedicin/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/intrade-i-arbetslivet-eller-atergang-till-tidigare-arbete-eller-annan-sysselsattning/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/stod-tillsammans-med-ideella-organisationer/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/stod-tillsammans-med-ideella-organisationer/exempel-pa-regionala-initiativ/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/stod-tillsammans-med-ideella-organisationer/exempel-pa-regionala-initiativ/hjartats-hus/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/stod-tillsammans-med-ideella-organisationer/exempel-pa-regionala-initiativ/kraftens-hus/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/stod-tillsammans-med-ideella-organisationer/exempel-pa-regionala-initiativ/livsgnistan/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/stod-tillsammans-med-ideella-organisationer/exempel-pa-regionala-initiativ/ljuspunkten/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/internet-som-informationskalla/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/insatser-pa-de-olika-nivaerna/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/sociala-insatsomraden/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/existentiella-fragor-och-existentiell-kris/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/existentiell-ensamhet/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/andliga-och-religiosa-fragor/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/existentiellt-forhallningsatt-och-stod/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/insatser-pa-de-olika-nivaerna/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/insatser-pa-de-olika-nivaerna/grundlaggande-insatser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/insatser-pa-de-olika-nivaerna/sarskilda-insatser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/existentiella-insatsomraden/insatser-pa-de-olika-nivaerna/avancerade-insatser/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/tobak/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/tobak/behandlingssammanfattning/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/tobak/uppfoljning-efter-avslutad-cancerbehandling/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/tobak/egenvard/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/alkohol/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/langvariga-eller-sena-komplikationer/matvanor-och-fysisk-aktivitet/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/komplementar--och-integrativ-medicin-kim/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/komplementar--och-integrativ-medicin-kim/information-och-tillganglighet/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/komplementar--och-integrativ-medicin-kim/traningsdosering-och-traningseffekt/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/komplementar--och-integrativ-medicin-kim/fordjupning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/referenser/2023-11-06 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-11-01 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering/vardprogram/bilaga-1--insatstabell/2023-11-02 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/2024-03-18 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sammanfattning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/inledning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/inledning/malgrupp/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/inledning/lagstod/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/inledning/evidensgradering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mal-med-vardprogrammet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/medicinsk-bakgrund/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/politisk-bakgrund/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/rehabilitering-och-cancerrehabilitering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/cancerrehabilitering-anpassad-efter-barnets-alder/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/stod-till-familjen/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bakgrund-och-orsaker/vardprogrammets-utformning/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nivastruktur-och-teamarbete/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nivastruktur-och-teamarbete/aktiva-overlamningar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nivastruktur-och-teamarbete/information-och-delaktighet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nivastruktur-och-teamarbete/min-vardplan/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nivastruktur-och-teamarbete/patientinformation-om-cancerlakemedel/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nivastruktur-och-teamarbete/rehabiliteringsplan/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/barncancer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/barncancer/akuta-leukemier/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/barncancer/hjarntumorer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/barncancer/solida-tumorer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/barncancer/lymfom/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/barncancer/cancerbehandling-med-risk-for-komplikationer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/generella-insatser/bedomning/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/generella-insatser/insats/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/sarskilda-insatser/bedomning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/sarskilda-insatser/insats/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/avancerade-insatser/bedomning/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/psykisk-halsa/avancerade-insatser/insats/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/generella-insatser/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/avancerade-insatser/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/rehabilitering-efter-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/rehabilitering-efter-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/rehabilitering-efter-cancerbehandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/sociala-konsekvenser/rehabilitering-efter-cancerbehandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/prehabilitering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-under-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-under-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-under-cancerbehandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-under-cancerbehandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-efter-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-efter-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-efter-cancerbehandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-efter-cancerbehandling/sarskilda-insatser/forandring-i-natverket/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forskola-och-skola/rehabilitering-efter-cancerbehandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-barn-upp-till-12-ar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-barn-upp-till-12-ar/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-barn-upp-till-12-ar/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-barn-upp-till-12-ar/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-ungdomar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-ungdomar/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-ungdomar/generella-insatser/efter-avslutad-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-ungdomar/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/insatser-for-ungdomar/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/fore-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/fore-behandling/frysbevaring-av-spermier/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/fore-behandling/frysbevaring-av-mogna-agg-och-aggstocksvavnad--flickor-efter-menarche/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/fore-behandling/studier-med-frysbevaring-av-prepubertal-gonadvavnad/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/under-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/efter-avslutad-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/efter-avslutad-cancerbehandling/frysbevaring-av-agg/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kroppsuppfattning-sexuell-halsa-och-fertilitet/fertilitetsbevarande-atgarder/efter-avslutad-cancerbehandling/frysbevaring-av-spermier/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/smarta/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/smarta/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/smarta/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/smarta/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/somn/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/somn/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/somn/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/somn/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/generella-insatser/bedomning-av-nutritionsbehov-samt-vanliga-biverkningar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/generella-insatser/screening-av-malnutrition/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/sarskilda-insatser/nutritionsbehandling-vid-undernaring/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/sarskilda-insatser/nutritionsbehandling-vid-overvikt/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/sarskilda-insatser/at--och-svaljsvarigheter/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/sarskilda-insatser/illamaende-infor-och-under-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/sarskilda-insatser/rehabilitering-efter-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/nutrition/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/neurogen-blasrubbning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/neurogen-blasrubbning/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/neurogen-blasrubbning/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mag-tarmkanal-och-urinvagar/neurogen-blasrubbning/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/prehabilitering-infor-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/prehabilitering-infor-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/prehabilitering-infor-cancerbehandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/prehabilitering-infor-cancerbehandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-under-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-under-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-under-cancerbehandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-under-cancerbehandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-efter-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-efter-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-efter-cancerbehandling/sarskilda-insatser/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/rehabilitering-efter-cancerbehandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/mun--och-tandhalsa/akuta-och-sena-komplikationer-i-munhalan/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/inaktivitet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/cns-tumorer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/cytostatikainducerad-neuropati/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/stralningsrelaterad-stramhet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/infektioner/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/rehabilitering-vid-graft-versus-host-disease-gvhd/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/sarskilda-insatser/benskorhet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fysisk-funktionsformaga-aktivitetsformaga-och-fysisk-aktivitet/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/under-prehabilitering-och-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/under-prehabilitering-och-cancerbehandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/under-prehabilitering-och-cancerbehandling/sarskilda-insatser/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/efter-avslutad-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/efter-avslutad-behandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/fatigue/efter-avslutad-behandling/sarskilda-och-avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/under-prehabilitering-och-under-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/under-prehabilitering-och-under-behandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/under-prehabilitering-och-under-behandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/under-prehabilitering-och-under-behandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/efter-avslutad-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/efter-avslutad-behandling/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/efter-avslutad-behandling/sarskilda-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/kognition/efter-avslutad-behandling/avancerade-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/tal-sprak-och-kommunikation/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/tal-sprak-och-kommunikation/prehabilitering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/tal-sprak-och-kommunikation/rehabilitering-under-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/tal-sprak-och-kommunikation/rehabilitering-efter-cancerbehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/tal-sprak-och-kommunikation/rehabilitering-efter-cancerbehandling/kognitiva-kommunikationssvarigheter/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/horsel/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/horsel/generella-insatser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/horsel/avancerade-insatser/2024-03-15 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/horsel/habiliterande-insatser-vid-horselnedsattning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/syn/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/syn/prehabilitering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/syn/rehabilitering-under-cancerbehandlingen/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/syn/rehabilitering-efter-cancerbehandlingen/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/stod-vid-overgang-fran-barn--till-vuxenvard/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/uppfoljning-av-cancervarden/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/uppfoljning-av-cancervarden/svenska-barncancerregistret/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/uppfoljning-av-cancervarden/rekommenderade-kva-koder/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/uppfoljning-av-cancervarden/rekommenderade-kva-koder/kodning-av-rehabiliteringsplan/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/uppfoljning-av-cancervarden/rekommenderade-kva-koder/kodning-av-min-vardplan-som-en-del-cancerrehabiliteringsprocessen/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forslag-pa-fordjupning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forslag-pa-fordjupning/kroppsuppfattning-sexuell-halsa-och-fertilitet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forslag-pa-fordjupning/psykisk-halsa/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/forslag-pa-fordjupning/forskola-och-skola/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/patient-och-narstaendeforetradare/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-04-10 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/stodjande-regionalt-cancercentrum/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/referenser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/tidig-akut-rehabilitering-efter-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/tidig-akut-rehabilitering-efter-behandling/preoperativ-bedomning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/tidig-akut-rehabilitering-efter-behandling/postoperativ-inneliggande-rehabilitering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/tidig-akut-rehabilitering-efter-behandling/rehabilitering-efter-postoperativ-sjukhusvistelse/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsuppfoljning-efter-avslutad-medicinsk-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsuppfoljning-efter-avslutad-medicinsk-behandling/beskrivning-av-multiprofessionell-uppfoljning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsuppfoljning-efter-avslutad-medicinsk-behandling/tidpunkter-for-utredning-och-stod-for-barn-med-cns-tumor/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsatgarder/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsatgarder/neurokognitiv-rehabilitering/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsatgarder/skolinterventioner/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsatgarder/fysisk-aktivitet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/rehabiliteringsatgarder/familjebehandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/overforing-till-vuxenlivet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-1--riktlinjer-for-att-utreda-och-rehabilitera-barn-med-tumor-i-centrala-nervsystemet/referenser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/bakgrund/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/bakgrund/definitioner/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/arbetssatt-for-psykosocialt-stod/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/arbetssatt-for-psykosocialt-stod/psykosocialt-team/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/arbetssatt-for-psykosocialt-stod/basstandard-for-resurser-tidigt-i-vardprocessen/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/arbetssatt-for-psykosocialt-stod/basstandard-for-resurser-under-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/arbetssatt-for-psykosocialt-stod/basstandard-for-resurser-efter-avslutad-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/arbetssatt-for-psykosocialt-stod/ovriga-aktiviteter/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/kuratorns-uppgifter/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-2--basstandard-for-psykosocialt-stod-till-barn-och-familjer-inom-barncancervarden/referenser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/ha-kannedom-om-vanliga-reaktioner/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/minska-stress/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/underlatta-kanslomassigt-stod/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/kom-ihag-familjen-och-kompisar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/framja-halsosamma-och-vardagliga-rutiner/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-3--forebyggande-psykosociala-insatser-vid-cancer/referenser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/blodning/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/efterfoljande-cancer/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/gvhd-relaterade-och-immunterapirelaterade-slemhinneskador/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/infektion/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/karies-och-gingivit/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/kirurgisk-paverkan-pa-munhala/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/kraniofacial-utvecklingspaverkan/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/mukosit/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/muntorrhet/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/osteonekros/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/smakforandring/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/smarta/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/tandutvecklingsstorningar/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/trismus/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-4--akuta-och-sena-komplikationer-i-munhalan-relaterade-till-onkologisk-behandling/referenser/2024-03-13 https://kb.localhost:5000/diagnoser/cancerrehabilitering-for-barn-och-ungdom/vardprogram/bilaga-5--nordic-protocol-for-neuropsychological-follow-up-of-children-treatedfor-brain-tumor--revision-2023/2024-03-15 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/2020-02-28 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/vardprogrammets-forankring/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/forandringar-jamfort-med-foregaende-version/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/lagstod/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/evidensgadering/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/definitioner/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/inledning/standardiserat-vardforlopp/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/mal-med-vardprogrammet/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallgangscancer/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallgangscancer/incidens-internationellt/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallgangscancer/incidens-i-sverige/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallgangscancer/etiologi/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallblasecancer/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallblasecancer/incidens-i-sverige/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/epidemiologi-och-etiologi/gallblasecancer/etiologi/2020-01-03 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/naturalhistoria/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/naturalhistoria/gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/naturalhistoria/gallgangscancer/intrahepatisk-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/naturalhistoria/gallgangscancer/perihilar-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/naturalhistoria/gallblasecancer/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/gallblasepolyper/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/gallblasepolyper/surveillance-overvakning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/primar-skleroserande-kolangit-psc/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/primar-skleroserande-kolangit-psc/inledning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/primar-skleroserande-kolangit-psc/surveillance-overvakning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/primar-skleroserande-kolangit-psc/gallblasepolyp-och-psc/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/primar-skleroserande-kolangit-psc/tumormarkorer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/primar-skleroserande-kolangit-psc/borstcytologi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/koledokuscystor/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/primar-prevention/pancreaticobiliar-maljunction/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/radiologi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/radiologi/gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/radiologi/gallgangscancer/diagnos-stadieindelning-och-resektabilitetsbedomning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/radiologi/gallgangscancer/tidig-diagnostik/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/radiologi/gallblasecancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/indikation-for-cytologi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/anvisningar-for-provtagning-av-cytopatologi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/cytopatologiska-metoder/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/cytopatologisk-bedomning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/cytologiska-diagnostiska-kategorier/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/cytologiska-diagnostiska-kategorier/kodning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/fluorescence-in-situ-hybridisering-fish/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/borstcytologi/fluorescence-in-situ-hybridisering-fish/bedomningskriterier-for-urovysion-pa-gallgang/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/tidig-diagnostik/kolangioskopi/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/gallvagsavlastning/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/gallvagsavlastning/tekniker-for-gallvagsavlastning/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/gallvagsavlastning/gallvagsavlastning-preoperativt/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/gallvagsavlastning/stenttyper/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/gallvagsavlastning/levervolym-som-bor-draneras/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/prevention-och-diagnostik/gallvagsavlastning/metoder-for-att-minska-risken-for-tumoroklusion-av-stent/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/symtombeskrivning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/symtombeskrivning/intrahepatisk-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/symtombeskrivning/perihilargallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/symtombeskrivning/gallblasecancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/kliniska-fynd/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/kliniska-fynd/laboratorieprover/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/diagnos/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/stadieindelning/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/stadieindelning/gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/stadieindelning/gallgangscancer/intrahepatisk-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/stadieindelning/gallgangscancer/perihilar-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/symtom-kliniska-fynd-stadieindelning/stadieindelning/gallblasecancer/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/inledning/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/hantering-av-operationspreparat/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/hantering-av-operationspreparat/kirurgens-hantering-av-operationspreparat/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/hantering-av-operationspreparat/patologens-hantering-av-operationspreparat/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/tumorklassifikation-enligt-who-2010-och-tnm8/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/tumorklassifikation-enligt-who-2010-och-tnm8/intrahepatisk-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/tumorklassifikation-enligt-who-2010-och-tnm8/perihilar-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/tumorklassifikation-enligt-who-2010-och-tnm8/gallblasecancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/antal-tumorer-och-storlek/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/makroskopiskt-vaxtmonster/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/histologiska-tumortyper-gradering-och-differentialdiagnostik/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/kapselengagemang-och-relation-till-omgivande-strukturer-och-organ/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/intravasal-tumorvaxt/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/lymfkortelmetastaser/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/intrahepatisk-gallgangscancer/icke-tumorost-leverparenkym/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/makroskopiskt-vaxtmonster/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/tumorstorlek/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/histologiska-tumortyper-och-gradering/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/mikroskopisk-och-perineural-tumorspridning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/pt-stadier/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/lymfkortelmetastaser/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/perihilar-gallgangscancer/icke-tumorost-leverparenkym/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/gallblasecancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/gallblasecancer/incidentellt-pavisad-cancer-i-kolecystektomipreparat-och-premaligna-prekursorlesioner/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/gallblasecancer/makroskopiskt-vaxtsatt/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/gallblasecancer/histologiska-tumortyper/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/gallblasecancer/pt-stadier/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/gallblasecancer/tumorspridning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/histopatologisk-tumorklassifikation/grundlaggande-parametrar-for-ptnm-klassifikation-och-svarsrapportering/andra-viktiga-prognostiska-parametrar/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/multidisciplinar-konferens/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/resektabilitet/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/gallgangshinder/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/atgarder-vid-forvantad-for-liten-kvarvarande-levervolym-efter-resektionskirurgi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/preoperativ-diagnostisk-laparoskopi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/leverresektion/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/resektion-av-lobus-caudatus/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/Resektion-av-portavenen/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/lymfkortelutrymning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/gallgangsrekonstruktion/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/postoperativ-vard/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/leversvikt/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/perihilar-gallgangscancer/uppfoljning-i-oppenvard/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/intrahepatisk-gallgangscancer/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/levertransplantation-vid-gallgangscancer/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/levertransplantation-vid-gallgangscancer/bakgrund/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/levertransplantation-vid-gallgangscancer/kombinerad-stral--och-cytostatikabehandling-innan-transplantation-och-underhallsbehandling/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallgangscancer/levertransplantation-vid-gallgangscancer/transplantation/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/tillstand-i-gallblasan-och-gallgang-med-okad-risk-for-malignitet/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/tillstand-i-gallblasan-och-gallgang-med-okad-risk-for-malignitet/porslinsgallblasa/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/tillstand-i-gallblasan-och-gallgang-med-okad-risk-for-malignitet/kronisk-kolecystit/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/tillstand-i-gallblasan-och-gallgang-med-okad-risk-for-malignitet/mirizzis-syndrom/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/tillstand-i-gallblasan-och-gallgang-med-okad-risk-for-malignitet/gallblasepolyper/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/gallblasecancer-i-tidigt-stadium/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/gallblasecancer-i-tidigt-stadium/tis-t1a-och-t1b/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/gallblasecancer-i-tidigt-stadium/T2/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/gallblasecancer-avancerat-stadium/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/gallgangsresektion/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/kortelutrymning/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/pankreatikoduodenektomi-for-att-uppna-radikalitet/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/omfattning-av-leverresektion/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/operation-vs-palliation-vid-avancerade-stadier/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/laparoskopisk-eller-oppen-kirurgi/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/stadieindelning-med-laparoskopi-och-laparoskopiskt-ultraljud/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/aterfall/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/kirurgi-vid-gallblasecancer/uppfoljning-efter-kurativ-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/for-liten-kvarvarande-levervolym-efter-resektionskirurgi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/for-liten-kvarvarande-levervolym-efter-resektionskirurgi/hur-ange-behovet-av-kvarvarande-levervolym-och-vilka-gransvarden-finns/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/for-liten-kvarvarande-levervolym-efter-resektionskirurgi/portavensembolisering/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/peri--och-postoperativ-vard/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/neoadjuvant-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-behandling/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/onkologisk-behandling-vid-palliativ-sjukdom/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/onkologisk-behandling-vid-palliativ-sjukdom/cytostatika/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/onkologisk-behandling-vid-palliativ-sjukdom/malriktade-lakemedel-och-immunterapi/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/onkologisk-behandling-vid-palliativ-sjukdom/stralbehandling/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/primar-behandling/onkologisk-behandling/onkologisk-behandling-vid-palliativ-sjukdom/radioembolisering-selective-internal-radiation-therapy-sirt-och-transarteriell-kemoembolisering-tace/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/egenvard/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/egenvard/livsstilsfaktorer/2023-07-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/egenvard/skotsel-av-dranage/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/egenvard/nar-ska-patienten-uppsoka-sjukvard/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/uppfoljning-och-behandling-av-aterfall/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/2023-07-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/stod-information-och-delaktighet/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/stod-information-och-delaktighet/fasta-vardkontakter/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/stod-information-och-delaktighet/aktiva-overlamningar/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/stod-information-och-delaktighet/information-och-fortlopande-dialog-under-sjukdomsforloppet/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/halsorelaterad-livskvalitet/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/ikterus/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/klada/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/smarta/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/kolangit/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/fatigue-trotthet/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/besvar-fran-mag-tarmkanalen/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/blodning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/ascites/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/understodjande-vard/att-framja-livskvalitet-genom-symtomlindring/bedoma-och-behandla-symtom-under-sjukdomsforloppet/symtom-i-sen-palliativ-fas/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/rehabilitering/2024-06-26 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/psykosocialt-omhandertagande/2023-07-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/bekraftande-omvardnad/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/skotsel-av-yttre-gallvagsdranage-ptc-dranage/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/omvardnadsdiagnoser/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/perioperativ-vard/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/perioperativ-vard/vatske--och-elektrolytbalansen/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/perioperativ-vard/nutrition/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/perioperativ-vard/koagulationsrubbning/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/perioperativ-vard/postoperativ-smartlindring/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/omvardnadsaspekter/perioperativ-vard/infektion/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/palliativ-vard/2019-12-02 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/underlag-for-nivastrukturering/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/kvalitetsregister/2024-02-26 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/kvalitetsregister/svenska-registret-for-cancer-i-lever-och-gallvagar/2024-02-26 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/kvalitetsregister/cancerregistret/2024-03-01 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/referenser/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/vardprogramgruppen/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/vardprogramgruppen/remissinstanser/2020-01-07 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/forkortningar/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/bilaga-1.-farmakologiskt-behandlingsforslag-vid-klada2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardprogram/bilaga-2.-aktuella-omvardnadsdiagnoser-genom-sjukdomsforloppet2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/2024-11-25 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/gallblase-och-gallvagscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/hjarna/2023-09-22 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/2023-09-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sammanfattning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/inledning/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-05-23 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/inledning/standardiserat-vardforlopp/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/inledning/lagstod/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/inledning/evidensgradering/2025-05-23 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/mal-med-vardprogrammet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bakgrund-och-orsaker/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-prevention/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-prevention/primar-prevention-for-tumorer-i-hjarna-ryggmarg-och-dess-hinnor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-prevention/levnadsvanor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/arftlighet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/arftlighet/indikation-for-arftlighetsutredning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/arftlighet/indikation-for-arftlighetsutredning/individkriterier/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/arftlighet/indikation-for-arftlighetsutredning/familjekriterier/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/arftlighet/syndrom-med-okad-risk-att-utveckla-cns-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/2019-11-27 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/epileptiska-anfall/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/huvudvark/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/personlighetsforandring/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/fokala-bortfallssymtom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/symtom-vid-okat-intrakraniellt-tryck/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/ovriga-symtom/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/ovriga-symtom/synstorning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/ovriga-symtom/psykiska-symtom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/sammanstallning-av-klinisk-neurologiska-fynd-enligt-nano-skalan/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/smarta/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/motoriska-symtom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/sensoriska-symtom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/paverkan-pa-blas--och-tarmfunktionen-och-andra-autonoma-symtom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/cauda-equina-syndrom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/symtom-kliniska-fynd-och-utredning-vid-ryggmargstumor/syringomyeli/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/symtom-och-tidig-utredning/utredning-vid-misstankt-ryggmargstumor/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/neuroradiologisk-utredning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/remiss-for-radiologisk-undersokning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/metodval/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/diagnostisk-preterapeutisk-mr-och-pet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/neuronavigation-under-operation-med-hjalp-av-mr-och-pet--intraoperativ-mr/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/postoperativ-mr-och-pet/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/pseudoprogress/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/pseudoregress/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologiska-undersokningsmetoder/tumorer-i-ryggmargen/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/radiologens-roll/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/det-radiologiska-utlatandet/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/matning-av-storlek-pa-hjarntumorer/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/rano-kriterierna-for-hoggradiga-gliom-i-hjarnan/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/rano-kriterierna-for-laggradiga-gliom-i-hjarnan/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/rano-kriteriernas-anvandning-postoperativt-hjarntumorer/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/rano-kriteriernas-anvandning-postoperativt-hjarntumorer/rano-kriterier-vid-immunterapi/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/utredning/radiologens-bedomning-och-utlatande/rano-rekommendationer-for-anvandning-av-aminosyra-pet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/diagnosbesked/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/diagnostik/omvardnad-och-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/provhantering/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/provhantering/vavnadshantering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/provhantering/intraoperativ-diagnostik/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/provhantering/cytologiska-preparat/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformationdet-neuropatologiska-utlatandet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformationdet-neuropatologiska-utlatandet/anamnestisk-remissinformation/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformationdet-neuropatologiska-utlatandet/det-neuropatologiska-utlatandet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformationdet-neuropatologiska-utlatandet/det-neuropatologiska-utlatandet/beskrivande-del/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformationdet-neuropatologiska-utlatandet/det-neuropatologiska-utlatandet/bedomningsdel/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/biomarkorer/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/9.4.2.1isocitratdehydrogenas-idh2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/1p19q-kodeletion/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/mgmt/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/atrx/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/ki-67/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/tp53/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/histon-h3-k27m/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/braf-v600e/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/dna-metyleringsprofil/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/vuxen-typ-av-diffusa-gliom-glioblastom-grad-4-astrocytom-grad-24-och-oligodendrogliom-grad-23/egfr-amplifiering-kromosom-710-status-och-tert--promotormutation-cdkn2ab-forlust/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/pilocytiskt-astrocytom-pa-who-grad-1/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/introduktion/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/supratentoriellt-ependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/supratentoriellt-ependymom/supratentoriellt-ependymom-zfta-fusion-positivt/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/supratentoriellt-ependymom/supratentoriella-ependymom-yap1-fusion-positivt/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/ependymom-i-bakre-skallgropen/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/ependymom-i-bakre-skallgropen/bakre-skallgrops-grupp-a-ependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/ependymom-i-bakre-skallgropen/bakre-skallgrops-grupp-b-ependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/spinalt-ependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/spinalt-ependymom/spinalt-ependymom-mycn-amplifierat/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/myxopapillart-ependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/ependymom-who-grad-iiii/subependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/medulloblastom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/germinalcellstumorer/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/germinalcellstumorer/biomarkorer-i-diagnostiken-av-gct/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/meningeom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/meningeom/meningeom-grad-1/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/meningeom/meningeom-grad-2/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kategorisering-av-tumoren/meningeom/meningeom-grad-3/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/multidisciplinar-konferens/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/multidisciplinar-konferens/ny-medicinsk-bedomning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/Inledning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/utredning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/kontrastladdande-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/icke-kontrastladdande-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/tumor-i-bakre-skallgropen/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/tumorer-i-medellinjen/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/val-av-operationsmetod/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/preoperativa-forberedelser/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/preoperativ-handlaggning/kortisonbehandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/biopsi/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/operation-vid-misstanke-om-hogmalign-tumor--kontrastladdande-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/operation-vid-misstanke-om-lagmalign-tumor--icke-kontrastladdande-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/operation-vid-misstanke-om-pilocytiskt-astrocytom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/operation-vid-tumor-i-bakre-skallgropen2/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/operation/operation-vid-misstanke-om-germinalcellstumor2/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/litt-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/tumorer-i-hjarnan/postoperativ-resektionskontroll/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/Intramedullara-tumorer/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/Intramedullara-tumorer/utredning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/Intramedullara-tumorer/preoperativ-handlaggning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/Intramedullara-tumorer/postoperativ-resektionskontroll/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/Perioperativa-komplikationer/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/val-av-behandlinghandlaggning-av-meningeom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/kirurgisk-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/preoperativa-forberedelser/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/operationsteknik/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/spinala-meningeom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/neurokirurgisk-handlaggning/meningeom/neurokirurgisk-sarvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii-iv/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii-iv/glioblastom-idh-wt-eller-idh-mut-who-grad-iv/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii-iv/astrocytom-idh-muterat-who-grad-3/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii-iv/oligodendrogliom-who-grad-3/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii/val-av-onkologisk-behandling-vid-lagmaligna-gliom-who-grad-ii/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii/oligodendrogliom-idh-mut-och-deletion-av-1p19q-eller-nos-who-grad-ii/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii/diffust-astrocytom-idh-mut-gemistocytart-astrocytom-idh-mut-diffust-astrocytom-idh-wt-diffust-astrocytom-nos-samtliga-who-grad-ii.-diffust-astrocytom-idhwt-med-molekylara-drag-av-glioblastom-who-grad-iv2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii/pleomorft-xantoastrocytom-who-grad-ii-och-anaplastiskt-pleomorft-xantoastrocytom-who-grad-iii/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/astrocytara-och-oligodendrogliala-tumorer-grad-iii/pilocytiska-astrocytom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/spinala-astrocytara-och-oligodendrogliala-tumorer2/2025-06-04 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/ependymom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/ependymom/inledning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/ependymom/utredning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/ependymom/onkologisk-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/ependymom/onkologisk-behandling/postoperativ-stralbehandling-vid-intrakraniella-ependymom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/ependymom/onkologisk-behandling/postoperativ-stralbehandling-vid-spinala-ependymom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/medulloblastom--primarbehandling/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/medulloblastom--primarbehandling/Inledning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/medulloblastom--primarbehandling/utredning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/medulloblastom--primarbehandling/onkologisk-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/Inledning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/utredning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/tumorklassifikation/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/onkologisk-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/germinom/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/germinom/germinom-icke-metastaserad-sjukdom-inklusive-bifokal-sjukdom-utan-annan-spridning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/germinom/germinom-metastaserad-sjukdom-inklusive-ofullstandigt-stadieindelad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/icke-germinom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/icke-germinom/icke-germinom-icke-metastaserad-sjukdom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/icke-germinom/icke-germinom-metastaserad-sjukdom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/rent-teratom-moget-eller-omoget-utan-malign-transformation/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/intrakraniella-germinalcellstumorer/bakgrund-till-stralbehandlingsrekommendationer/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/meningeom-who-grad-1/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/meningeom-who-grad-2/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/anaplastiska-meningeom-who-grad-3/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/optikusskidemeingeom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/spinala-meningeom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/stralbehandling/stralinducerade-meningeom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/onkologisk-behandling/meningeom/medicinsk-behandling-vid-meningeom/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/postoperativ-omvardnad-och-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/respiration/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/cirkulation/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/nutrition/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/elimination/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/hud/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/smarta/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/mobilisering/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/sinnesintryck/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/kommunikation/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/kunskap-och-utveckling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/psykosocialt/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/omvardnad-och-rehabilitering/neurologstatus/somn/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-stralbehandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-stralbehandling/akuta-och-subakuta-biverkningar/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-stralbehandling/pseudoprogress/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-stralbehandling/sena-biverkningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-stralbehandling/behandling-av-biverkningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-cytostatika/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-cytostatika/temozolomid/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-cytostatika/lomustin/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-cytostatika/vinkristin/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-cytostatika/prokarbazin/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/primar-behandling/biverkningar-av-onkologisk-behandling/biverkningar-av-ttfields/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/kirurgi/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/kirurgi/hog--och-lagmaligna-gliom-reoperation/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/stralbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/medicinsk-behandling/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/medicinsk-behandling/astrocytara-och-oligodendrogliala-tumorer-intrakraniella-och-spinala-tumorer/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/medicinsk-behandling/ependymom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/medicinsk-behandling/medulloblastom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/medicinsk-behandling/germinalcellstumorer/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/behandling-av-aterfall/medicinsk-behandling/meningeom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/kortisonbehandling-vid-diagnos/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/kortisonbehandling-i-anslutning-till-operation/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/kortisonbehandling-vid-stralbehandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/kortisonbehandling-under-langre-tid-i-symtomlindrande-syfte/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/somnstorningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/psykiska-biverkningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/gastritulcus/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/viktuppgang-och-forandrad-kroppsform--cushingoid-habitus/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/kortisonmyopati/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/hypertoni/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/hyperglykemi-och-diabetes/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/okad-infektionsrisk/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/osteoporos/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-tumorodem/biverkningar-av-systemisk-kortisonbehandling-samt-atgardprofylax/binjurebarkssvikt/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/epilepsibehandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/epilepsibehandling/val-av-antiepileptika/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/epilepsibehandling/behandling-av-status-epilepticus/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/epilepsibehandling/utsattande-av-aed-vid-hjarntumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/kognitiva-symtom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/tromboembolisk-sjukdom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/tromboembolisk-sjukdom/djup-ventrombos/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/tromboembolisk-sjukdom/lungemboli/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/tromboembolisk-sjukdom/behandling-av-dvtlungemboli/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/trotthet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/behandling-av-psykiska-symtom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/hormonella-rubbningar-efter-stralbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/sarskilda-aspekter-vid-ryggmargstumor/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/sarskilda-aspekter-vid-ryggmargstumor/smarta/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/sarskilda-aspekter-vid-ryggmargstumor/spasticitet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/sarskilda-aspekter-vid-ryggmargstumor/paverkan-pa-blas--och-tarmfunktion/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/korkort-och-bilkorning-vid-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/korkort-och-bilkorning-vid-tumor/epilepsi/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/korkort-och-bilkorning-vid-tumor/paverkan-av-syn-och-andra-funktioner/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/understodjande-vard/vapeninnehav-vapenlicens-och-riskyrken/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/sexualitet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/fertilitet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/fertilitet/assisterad-befruktning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/fertilitet/reproduktiva-och-hormonella-faktorers-paverkan-pa-risken-att-utveckla-gliom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/paverkan-av-graviditet-pa-progress-och-overlevnad-vid-gliom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/gliom-med-klinisk-symtomdebut-under-graviditet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/meningeom-i-samband-med-graviditet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/radiologi-under-graviditet/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/radiologi-under-graviditet/dt-och-mrt-hjarna-utan-och-med-kontrastmedel-under-graviditet/2020-03-05 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/radiologi-under-graviditet/dt-och-mrt-hjarna-utan-och-med-kontrastmedel-under-graviditet/dt-hjarna/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/radiologi-under-graviditet/dt-och-mrt-hjarna-utan-och-med-kontrastmedel-under-graviditet/mrt-hjarna/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/neurokirurgisk-behandling-under-graviditet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/onkologisk-behandling-under-graviditet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/forlossningsaspekter/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/epilepsi-och-graviditet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/etiska-aspekter-vid-gliom-och-blivande-foraldraskap/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/graviditet/antikonceptionell-hormonell-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/hrt-vid-klimakteriebesvar/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/sexualitet-fertilitet-och-graviditet/konsdysfori-konsbekraftande-vard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/palliativa-overvaganden-vid-behandling-av-patienter-med-maligna-gliom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/palliativa-overvaganden-vid-behandling-av-patienter-med-maligna-gliom/okat-intrakraniellt-tryck/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/palliativa-overvaganden-vid-behandling-av-patienter-med-maligna-gliom/personlighetsforandring-och-annan-kognitiv-paverkan/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/palliativa-overvaganden-vid-behandling-av-patienter-med-maligna-gliom/motorisk-dysfunktion/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/palliativa-overvaganden-vid-behandling-av-patienter-med-maligna-gliom/dysfagi/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/palliativa-overvaganden-vid-behandling-av-patienter-med-maligna-gliom/epilepsi/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/steroider/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/okat-intrakraniellt-tryck/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/kognitiv-paverkan/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/kognitiv-paverkan/oroangest/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/epilepsi-i-sent-palliativt-skede/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/tromboembolism/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/palliativ-vard-och-insatser/lakemedelsbehandling/lakemedelsbehandling-i-livets-slut/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/integrerat-arbetssatt/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad2/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/lopande-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/lopande-rehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/lopande-rehabilitering/grundlaggande-och-specialiserad-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kommunikation/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kommunikation/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kommunikation/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognition/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognition/kognitiva-nedsattningar/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognition/kognitiv-utredning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognition/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognition/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/personlighetsforandring/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/personlighetsforandring/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/personlighetsforandring/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/andning-och-cirkulation/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/andning-och-cirkulation/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/andning-och-cirkulation/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/nutrition/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/nutrition/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/nutrition/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/elimination/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/elimination/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/elimination/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/fysisk-aktivitet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/fysisk-aktivitet/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/fysisk-aktivitet/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/aktiviteter-i-dagliga-livet-och-atergang-i-arbete/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/aktiviteter-i-dagliga-livet-och-atergang-i-arbete/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/aktiviteter-i-dagliga-livet-och-atergang-i-arbete/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/trotthet-och-somn/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/trotthet-och-somn/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/trotthet-och-somn/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Hjarntrotthet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Hjarntrotthet/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Hjarntrotthet/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Hud-och-vavnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Hud-och-vavnad/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Hud-och-vavnad/atgard-rehabilitering/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/Huvudvark/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/Huvudvark/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/Huvudvark/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/Neurogen-smarta/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/Neurogen-smarta/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/Neurogen-smarta/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kanselnedsattning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kanselnedsattning/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/kanselnedsattning/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/epilepsi/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/epilepsi/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/epilepsi/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/psykosocialt/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/psykosocialt/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/psykosocialt/atgard-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/narstaende/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/narstaende/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/narstaende/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/barn-som-narstaende/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/barn-som-narstaende/atgard-omvardnad/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/narstaende/barn-som-narstaende/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/existentiellt-stod/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/existentiellt-stod/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/existentiellt-stod/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Sexualitet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Sexualitet/atgard-omvardnad/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/omvardnad-och-rehabilitering/omvardnad/Sexualitet/atgard-rehabilitering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/definitioner/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/ansats-till-att-hantera-livet-i-narvaro-av-cns-tumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/ansats-till-att-hantera-livet-i-narvaro-av-cns-tumor/aven-om-sjukvarden-inte-kan-bota-eller-bromsa-sjukdomen-finns-det-alltid-nagot-som-du-sjalv-eller-som-narstaende-kan-gora/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/ansats-till-att-hantera-livet-i-narvaro-av-cns-tumor/lara-av-andra/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/ansats-till-att-hantera-livet-i-narvaro-av-cns-tumor/diagnosbeskedet-ar-en-livsomvalvande-handelse-som-innebar-lopande-omstallningar/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/ansats-till-att-hantera-livet-i-narvaro-av-cns-tumor/forandrade-och-nya-roller-och-relationer/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/ansats-till-att-hantera-livet-i-narvaro-av-cns-tumor/planera-och-forsoka-hantera-en-god-dod/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/evidens-for-interventioner-rorande-egen-sjalvkannedom--en-del-av-egenvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/evidens-for-interventioner-rorande-egen-testning--en-del-av-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/evidens-for-interventioner-rorande-egen-hantering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/existentiell-halsa-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/social-halsa-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/psykisk-halsa-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/fysisk-halsa-halsoframjande-egenvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/kost-och-nutrition-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/somn-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/sexuell-halsa-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/ovrigt-halsoframjande-egenvard/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/egenvard-primarprevention-av-sekundara-sjukdomarnedsattningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-en-del-av-det-storre-begreppet-egenvard/egenvard-vid-mojliga-foljdsjukdomar-och-nedsattningar-dar-egenvard-kan-ha-positiv-effekt/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/definition/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/regelverk/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/utbredningprevalensanvandning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/evidens-for-antioxidanter/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/evidens-for-ketogen-kost/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/evidens-for-cannabinoider/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/komplementar-och-alternativ-medicin-och-behandling/mer-information/2024-02-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/bedomning-beslut-och-uppfoljning-av-egenvard-samt-ansvar-for-bedomningen/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/faktorer-vid-bedomning-och-beslut-om-egenvard/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/information-och-kunskap/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/dokumentation-utifran-planering-i-samrad-med-berorda/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/bistand-enligt-lag/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/medicintekniska-produkter/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/flodesschema-for-att-bedoma-och-utfora-egenvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/egenvard-vid-behandling-med-ttfields/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/egenvard-vid-behandling-med-ttfields/paverkan-pa-vardagsliv-och-livskvalitet/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-vid-ttfields-behandling-optune--en-del-av-egenvard-egenmedicineringmedicinteknisk-produkt/egenvard-vid-behandling-med-ttfields/utmaningar/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/samvard-i-samband-med-att-man-ska-fatta-beslut-kring-medicinsk-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/samvard-i-samband-med-vald-behandling-under-pagaende-behandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/samvard-i-samband-med-handelser-mellan-planerade-uppfoljningsmoten/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/samvard-i-samband-med-uppfoljning/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/samvard-i-samband-med-avslut-av-medicinsk-behandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/samvard-med-formell-vard--eller-omsorgspersonal/betydelsen-av-relationskontinuitet-for-samvard/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/narstaende-som-vardutovare/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/egenvard-for-narstaende/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/egenvard-och-samvard/barn-som-narstaende/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2025-07-07 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/uppfoljning-av-funktionsbedomning-symtomkontroll-och-halsoskattning-for-samtliga-diagnoser/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/hogmaligna-gliom-grad-iiiiv/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/lagmaligna-gliom-grad-ii/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/pilocytiska-astrocytom-grad-1/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/ependymom2/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/medulloblastom2/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/germinalcellstumorer2/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/meningeom2/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/meningeom2/accidentellt-upptackta-icke-symtomgivande-meningeom/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/kontroll-av-aterfall/meningeom2/symtomgivandeopereradestralbehandlade-meningeom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/ansvar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/avslut-av-uppfoljning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/underlag-for-nivastrukturering/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/cancerregistret/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/uppfoljning-och-utvardering-av-varden-via-kvalitetsregister-och-individuella-patientoversikter-till-gagn-for-varden-och-forskning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-for-tumorer-i-centrala-nervsystemet-cns-tumorer/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-for-tumorer-i-centrala-nervsystemet-cns-tumorer/interaktiv-rapport/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-for-tumorer-i-centrala-nervsystemet-cns-tumorer/kortrapport/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-for-tumorer-i-centrala-nervsystemet-cns-tumorer/kvalitetsindikatorer/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsregister/ipo-cns/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-05-23 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/referenser2/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/litteratur/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/litteratur/tumorklassifikation/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/litteratur/oversiktsartiklar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/relevanta-lankar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/relevanta-lankar/regionala-cancercentrum/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/relevanta-lankar/nationella-och-internationella-organisationer-och-databaser/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/relevanta-lankar/patientorganisationer/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/relevanta-lankar/nationella-vardprogram/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/forslag-pa-fordjupning/relevanta-lankar/nationellt-kvalitetsregister-for-cns-tumorer/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/vardprogramgruppen/2020-02-13 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/vardprogramgruppen/arbetsgrupper/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-1.-radiologisk-diagnostik2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-1.-radiologisk-diagnostik/mrt-protokoll-for-primar-malign-hjarntumor/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-1.-radiologisk-diagnostik/mrt-protokoll-for-spinala-gliom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-1.-radiologisk-diagnostik/mrt-protokoll-for-meningeom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-1.-radiologisk-diagnostik/checklista-for-radiologiskt-utlatande/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/patientpositionering-och-fixation/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/underlag-for-targetdefinition/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/underlag-for-dosplanering-/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/targetvolymer-och-riskorgan/2023-09-20 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/stralbehandlingsteknik/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/dosplanering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/stralkvalitet/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/verifikation-bildtagning-justering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandlingsplanering-och--teknik/dosspecifikation-och-fraktionering/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/laggradiga-gliom-who-grad-2/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/gliom-who-grad-3/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/glioblastom-who-grad-4/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/pilocytiska-astrocytom-who-grad-1/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/tumor-i-medulla-spinalis/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/ependymom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/medulloblastom/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/intrakraniella-germinalcellstumorer/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/meningeom/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/riktlinjer-for-oplanerade-behandlingsuppehall/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/stralbehandling-i-kombination-med-annan-behandling/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-2-stralbehandling/referenser/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bedomningsskalor/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bedomningsskalor/funktionsklass-funktionsstatus/2023-09-06 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bedomningsskalor/bedomning-av-narkosrisk-enligt-asa/2025-05-26 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/remissvagar/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/Handhavande-av-TTFields/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/Handhavande-av-TTFields/hantering-av-ttfields-optune/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/Handhavande-av-TTFields/optune--en-medicinteknisk-produkt/2025-05-20 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/Handhavande-av-TTFields/instruktioner-kring-anvandningen-av-ttfields/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/mall-egenvardsintyg-ttf/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardprogram/bilaga-7-nanoskalan/2025-05-19 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/introduktion/forandringar-sedan-foregaende-version/2024-11-11 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/ingang-till-standardiserat-vardforlopp2/2019-11-27 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/ingang-till-standardiserat-vardforlopp2/Valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/ingang-till-standardiserat-vardforlopp2/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling2/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/indikatorer-for-uppfoljning2/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/hjarna/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/2022-04-11 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/sammanfattning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/malgrupp/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/vardprogrammets-giltighetsomrade2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/standardiserat-vardforlopp2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/lagstod2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/mal-med-vardprogrammet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/mal-med-vardprogrammet/mal-for-handlaggning-och-behandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/mal-med-vardprogrammet/mal-for-inklusion-i-studier/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bakgrund-och-orsaker/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bakgrund-och-orsaker/orsaker-till-hodgkins-lymfom2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/arftlighet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/symtom-och-tidig-utredning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/utredning/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/utredning/vavnadsprovtagning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/utredning/bilddiagnostik/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/utredning/ovrig-utredning/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/diagnosbesked/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/diagnosbesked/barn-som-anhoriga/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/diagnostik/diagnosbesked/behov-av-tolk/2024-02-01 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/kategorisering-av-tumoren/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/stadieindelning-och-prognosfaktorer/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/stadieindelning-och-prognosfaktorer/stadieindelning-enligt-ann-arbor/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/stadieindelning-och-prognosfaktorer/prognosfaktorer/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/multidisciplinar-konferens/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/val-av-behandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/behandling-av-klassiskt-hodgkins-lymfom-laga-stadier/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/behandling-av-klassiskt-hodgkins-lymfom-avancerade-stadier/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/behandling-av-klassiskt-hodgkins-lymfom-avancerade-stadier/infektionsprofylax/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/behandling-av-klassiskt-hodgkins-lymfom-avancerade-stadier/hodgkins-lymfom-under-graviditet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/behandling-av-nlphl/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/behandling-av-nlphl/uppfoljning-av-nlphl/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/ronder/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/fixation2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/planerings-dt2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/targetdefinition2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/involved-node-radiotherapy-inrt/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/stralforberedelser/involved-site-radiation-therapy-isrt/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/fraktionering/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/riskorgan/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/riskorgan/guide-till-acceptabla-doser-och-volymer-vid-riskorgan/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/primar-behandling/stralbehandling/dosplanering/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/responskriterier/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/responskriterier/bedomning-av-behandlingsresultat-och-anvandning-av-fdg-petdt/2025-03-31 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/responskriterier/kvarvarande-lymfom-efter-avslutad-behandling/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/responskriterier/utvardering-av-immunterapi-med-fdg-pet/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/Primart-refraktar-sjukdom/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/aterfall-efter-2-cykler-abvd-foljt-av-stralbehandling/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/aterfall-efter-4-cykler-abvd-eller-2-abvd--2-avd/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/aterfall-efter-6-cykler-cytostatika-eller-primart-refraktar-sjukdom/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/stralbehandling-vid-aterfall2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/hogdosbehandling-med-stamcellsstod2/2025-04-03 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/konsolideringsbehandling-med-brentuximab-vedotin2/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/aterfall-efter-hogdosbehandling-med-stamcellstod2/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/yngre-patienter--6570-ar/allogen-stamcellstransplantation/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/aldre-patienter-70-ar/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/behandling-av-aterfall-och-refraktar-sjukdom/palliativ-behandling/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/levnadsvanor/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/blodprodukter/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/infektionsprofylax-efter-hogdosbehandling-med-stamcellsstod/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/hepatit-b-och-c/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/herpesvirus/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/pneumocystis-jirovecii/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/allman-svampprofylax-candida-etc/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/g-csf/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsprofylax-och-kroniska-infektioner/hivinfektion/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/infektionsbehandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/understodjande-vard/akuta-transfusionsreaktioner/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/kontaktsjukskoterska/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/aterkommande-behovsbedomning-for-patienter-och-narstaend/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/sexualitet/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitetsbevarande-atgarder/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitetsbevarande-atgarder/kvinnor/2025-04-03 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitetsbevarande-atgarder/man/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/fysisk-aktivitet/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/hygien-och-isolering/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/munvard/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/nutrition/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/skotsel-av-central-infart-till-blodkarl/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/psykosocialt-stod/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/alopeci--haravfall/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/fatigue/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/kognitiv-funktionsnedsattning/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/benmargspaverkan/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/neuropati/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/illamaende/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/forstoppning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/omvardnad-och-rehabilitering2/information-om-biverkningar/bleomycinbiverkan/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/levnadsvanor/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/inledning/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/infektionskanslighet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/munhygien/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/fysisk-aktivitet2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/hud/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/mage-och-tarm/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/vaccinationer/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/feber/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/nationella-riktlinjer/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/rokning/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/komplementar-och-alternativ-medicin/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/egenvard2/alkohol/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/palliativ-vard-och-insatser2/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/kontroll-av-aterfall/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/kontroll-av-aterfall/uppfoljning-av-patienter-i-komplett-remission/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/kontroll-av-aterfall/uppfoljning-av-nlphl/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/ansvar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/livslang-symtomkontroll-och-uppfoljning-av-sena-biverkningar/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/livslang-symtomkontroll-och-uppfoljning-av-sena-biverkningar/hjarta/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/livslang-symtomkontroll-och-uppfoljning-av-sena-biverkningar/tyreoidea/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/livslang-symtomkontroll-och-uppfoljning-av-sena-biverkningar/brost/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/livslang-symtomkontroll-och-uppfoljning-av-sena-biverkningar/lungor/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning/livslang-symtomkontroll-och-uppfoljning-av-sena-biverkningar/fertilitet/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/nivastrukturering/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/Svenska-lymfomregistret/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/Svenska-lymfomregistret/syfte-och-mal/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/Svenska-lymfomregistret/innehall/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/Svenska-lymfomregistret/inklusionskriterier/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/Svenska-lymfomregistret/exklusionskriterier/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/uppfoljning-av-cancervarden/Cancerregistret/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/forslag-pa-fordjupning2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/vardprogramgruppen2/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/vardprogramgruppen2/vardprogramgruppens-sammansattning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/vardprogramgruppen2/vardprogramgruppens-medlemmar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/vardprogramgruppen2/tidigare-medlemmar-i-vardprogramgruppen/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/vardprogramgruppen2/jav-och-andra-bindningar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/vardprogramgruppen2/vardprogrammets-forankring/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/referenser/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-1.-kvalitetsdokument-for-patologi2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/allmant/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/utredning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/behandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/illamaende/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/laga-blodvarden-och-infektionskanslighet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/tappa-haret/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/kemisk-lunginflammation/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/stickningar-och-domningar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/paverkad-sexualitet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/infertilitet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/trotthet/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/kanslig-hud/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/mag--och-tarmbesvar/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/biverkningar/stralbehandling/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-2.-patientinformation/uppfoljning/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/Bilaga-3.-sammanfattning-av-cancerbehandling2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/radiotherapy-protocol-for-hodgkin-lymphoma/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/patient-pre-treatment-preparation/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/pre-treatment-imaging/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/specificationof-treatment-prescription/2024-02-01 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/specificationof-treatment-prescription/volume-specification/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/specificationof-treatment-prescription/absorbed-dose-prescription/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/specificationof-treatment-prescription/fractionation-and-treatment-time/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/specificationof-treatment-prescription/relation-to-other-concomitant-therapies/2025-03-27 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/treatment-planning-and-delivery/2024-02-01 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/treatment-planning-and-delivery/treatment-technique/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/treatment-planning-and-delivery/dose-computation-and-optimization/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/treatment-planning-and-delivery/treatment-plan-evaluation/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/treatment-planning-and-delivery/image-guided-and-adaptive-treatment-delivery/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/treatment-planning-and-delivery/in-vivo-dosimetry/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/quality-management/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/quality-management/preparatory/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/quality-management/pre-treatment-specific-dosimetry/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/references/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-4.-radiotherapy-protocol-for-hodgkin-lymphoma/history-of-versions/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardprogram/bilaga-5-bleomycinkort/2025-03-26 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/introduktion/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/introduktion/flodesschema-for-vardforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/utredning-och-beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2021-09-02 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/hodgkins-lymfom/vardforlopp/arbetsgruppens-sammansattning2/2021-09-02 https://kb.localhost:5000/diagnoser/hudlymfom/2022-02-10 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/2023-09-11 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/sammanfattning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/inledning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/forandringar-som-medfor-resursbesparing/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/inledning/forkortningar2/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/mal-med-vardprogrammet/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bakgrund-och-orsaker/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bakgrund-och-orsaker/bakgrund/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bakgrund-och-orsaker/orsaker/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/arftlighet/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/mycosis-fungoides/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/sezarys-syndrom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/primart-kutana-cd30-lymfoproliferativa-sjukdomar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/primart-kutana-cd30-lymfoproliferativa-sjukdomar/primart-kutant-anaplastiskt-storcelligt-lymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/primart-kutana-cd30-lymfoproliferativa-sjukdomar/lymfomatoid-papulos/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/primart-kutant-akralt-cd8-t-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-t-cellslymfom/primar-kutan-smacellig-cd4-t-lymfoproliferativ-sjukdom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-b-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-b-cellslymfom/primart-kutant-marginalzonslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-b-cellslymfom/primart-kutant-follikelcenterlymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/primara-kutana-b-cellslymfom/primart-kutant-diffust-storcelligt-b-cellslymfom-leg-type/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/tidig-utredning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-tcellslymfom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-tcellslymfom/utredning-vid-mycosis-fungoides-eller-sezarys-syndrom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-tcellslymfom/utredning-vid-primart-kutana-cd30-lymfoproliferativa-sjukdomar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-tcellslymfom/utredning-vid-primart-kutana-cd30-lymfoproliferativa-sjukdomar/utredning-vid-primart-kutant-anaplastiskt-storcelligt-lymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-tcellslymfom/utredning-vid-primart-kutana-cd30-lymfoproliferativa-sjukdomar/utredning-vid-lymfomatoid-papulos/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-tcellslymfom/utredning-vid-primart-kutant-akralt-cd8-positivt-tcellslymfom-och-primar-kutan-smacellig-cd4-tlymfoproliferativ-sjukdom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/utredning-vid-primara-kutana-bcellslymfom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/diagnostik/diagnosbesked/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/mycosis-fungoides/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/mycosis-fungoides/flodescytometrisk-immunfenotyping-och-molekylargenetisk-monoklonalitetsundersokningar-av-perifert-blod-vid-mycosis-fungoides-eller-sezarys-syndrom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/sezarys-syndrom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/sezarys-syndrom/flodescytometrisk-immunfenotyping-och-molekylargenetiska-monoklonalitetsundersokningar-av-perifert-blod-vid-mycosis-fungoides-eller-sezarys-syndrom-se-avsnitt-8.4.1.1.12025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/primart-kutana-cd30-lymfoproliferativa-sjukdomar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/primart-kutana-cd30-lymfoproliferativa-sjukdomar/primart-kutant-anaplastiskt-storcelligt-lymfom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/primart-kutana-cd30-lymfoproliferativa-sjukdomar/lymfomatoid-papulos/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/primart-kutant-akralt-cd8-t-cellslymfom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-t-cellslymfom/primar-kutan-smacellig-cd4-t-lymfoproliferativ-sjukdom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-b-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-b-cellslymfom/primart-kutant-marginalzonslymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-b-cellslymfom/primart-kutant-follikelcenterlymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primara-kutana-b-cellslymfom/primart-kutant-diffust-storcelligt-b-cellslymfom-leg-typ/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/stadieindelning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/stadieindelning/stadieindelning-vid-mycosis-fungoides-och-sezarys-syndrom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/mycosis-fungoides-och-sezarys-syndrom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/mycosis-fungoides-och-sezarys-syndrom/storcellstranformation/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/primart-kutana-cd30-lymfoproliferativa-sjukdomar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/andra-primara-kutana-t-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/primara-kutana-b-cellslymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/multidisciplinar-konferens/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandlingsoversikt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/bakgrund/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/rekommendation-for-val-av-behandling-utifran-stadium-vid-mycosis-fungoides-och-sezarys-syndrom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/exspektans/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/mjukgorande-behandling/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/topikala-kortikosteroider/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/ljusbehandling/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/stralbehandling/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/helkroppsbestralning-med-elektroner-total-skin-electron-beam-therapy-tsebt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/topikal-klormetin/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/topikala-retinoider/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/topikal-kalcineurinhammare/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/topikal-imikvimod/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/skin-directed-therapy/fotodynamisk-terapi-pdt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/retinoider/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/interferon-alfa/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/cytostatika/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/antikroppsbaserad-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/extrakorporeal-fotoferes/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/allogen-stamcellstransplantation/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/histondeacetylashammare/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/antimikrobiell-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-mycosis-fungoides-och-sezarys-syndrom/genomgang-av-behandlingar-vid-mycosis-fungoides-och-sezarys-syndrom/systemisk-behandling/infektionsprofylax-vid-systembehandling/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-primara-kutana-cd30-lymfoproliferativa-sjukdomar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-primara-kutana-cd30-lymfoproliferativa-sjukdomar/oversikt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-primara-kutana-cd30-lymfoproliferativa-sjukdomar/behandling-av-primart-kutant-anaplastiskt-storcelligt-lymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-primara-kutana-cd30-lymfoproliferativa-sjukdomar/behandling-av-lymfomatoid-papulos/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-primart-kutant-akralt-cd8-positivt-tcellslymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-t-cellslymfom/behandling-av-primar-kutan-smacellig-cd4-t-lymfoproliferativ-sjukdom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-b-cellslymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-b-cellslymfom/behandlingsoversikt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-b-cellslymfom/behandling-av-primart-kutant-marginalzonslymfom-och-follikelcenterlymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/behandling-av-primart-kutana-b-cellslymfom/primart-kutant-diffust-storcelligt-b-cellslymfom-leg-type/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stralbehandling-vid-primart-kutana-lymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stralbehandling-vid-primart-kutana-lymfom/oversikt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stralbehandling-vid-primart-kutana-lymfom/doser-vid-lokal-stralbehandling/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/stralbehandling-vid-primart-kutana-lymfom/helkroppsbestralning-med-elektroner/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/responskriterier/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/responskriterier/mycosis-fungoides-och-sezarys-syndrom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/responskriterier/mycosis-fungoides-och-sezarys-syndrom/responskriterier-vid-klinisk-utvardering/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/responskriterier/mycosis-fungoides-och-sezarys-syndrom/responskriterier-vid-studier/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/responskriterier/ovriga-primara-kutana-lymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/levnadsvanor/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/oversikt/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/mjukgorande-behandling/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/hudinfektioner/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/badbehandling/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/fotvard/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/behandling-av-klada/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/understodjande-vard/understodjande-behandling-vid-cytostatikabehandling/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/kontaktsjukskoterska/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/psykosocialt-stod/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/sexuell-halsa/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitetsbesparande-atgarder/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/egenvard2/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/egenvard2/levnadsvanor/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/egenvard2/komplementar-och-alternativ-medicin/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/egenvard2/sol/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/egenvard2/vitaminer/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/egenvard2/huden/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/palliativ-vard-och-insatser2/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/palliativ-vard-och-insatser2/inledning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/palliativ-vard-och-insatser2/palliativ-behandling-av-hudlymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/uppfoljning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/uppfoljning/fornyad-behovsbedomning-av-rehabilitering-och-levnadsvanor/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/nivastrukturering/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/syfte-och-mal/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/innehall/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/innehall/inklusionskriterier/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/innehall/exklusionskriterier/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/innehall/snomed-koder/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsregister/cancerregistret/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/referenser/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/vardprogramgruppen/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/vad-ar-hudlymfom-allman-oversikt/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/mycosis-fungoides/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/sezarys-syndrom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/primart-kutant-anaplastiskt-storcelligt-tcellslymfom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/lymfomatoid-papulos/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-1-patientinformation/primara-kutana-b-cellslymfom/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-2--kvalitetsdokument-for-patologi/2025-06-18 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-3--provtagningsschema/2025-06-16 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-4--anmalningsrutiner-for-nmdk-hudlymfom/2025-06-17 https://kb.localhost:5000/diagnoser/hudlymfom/vardprogram/bilaga-5--anmalan-till-nmdk-hudlymfom/2025-06-16 https://kb.localhost:5000/diagnoser/hypofystumorer/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/2022-03-09 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/sammanfattning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2021-06-18 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.1-malgrupp2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.2-vardprogrammets-giltighetsomrade2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.3-forandringar-jamfort-med-tidigare-version2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.4-lagstod2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.5-vardering-av-det-vetenskapliga-underlaget2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.6-vardprogrammets-innehall2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/inledning/2.7-vardnivaer2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/mal-med-vardprogrammet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/arftlighet/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/arftlighet/hypofystumorer/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/arftlighet/hypofystumorer/familjart-isolerat-hypofysadenom-familial-isolated-pituitary-adenoma-fipa/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/arftlighet/hypofystumorer/arftliga-syndrom-associerade-med-hypofystumorer/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/arftlighet/hypofystumorer/aggressiva-hypofystumorer-och-hypofyskarcinom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/arftlighet/hypofyssvikt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/symtom-och-tidig-utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/biokemi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/bilddiagnostik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/bilddiagnostik/diagnostisk-mrt-och-dt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/bilddiagnostik/pet-dt-eller-pet-mrt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/symtom-tidiga-och-sena-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/tidig-upptackt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/diagnostik-och-utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/diagnostik-och-utredning/synskarpa-visus/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/diagnostik-och-utredning/synfalt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/diagnostik-och-utredning/synnervsatrofi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/diagnostik-och-utredning/ogonmotorik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/diagnostik-och-utredning/ovrig-ogonstatus/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/ogonundersokning-och-indikation-for-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/rehabilitering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/symtom-tidiga-och-sena-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/tidig-upptackt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/diagnostik-och-utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/synskarpa/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/synfalt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/ogonbottenfoto/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/optical-coherence-tomography/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/ogonmotorik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/behandlingsutvardering-och-uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/ogonstatus-och-synundersokning/barn--sarskilda-aspekter/rehabilitering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/diagnostik/diagnosbesked/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/val-av-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/kirurgi/indikationer-for-kirurgisk-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/kirurgi/val-av-kirurgisk-approach-och-teknik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/kirurgi/perioperativt-omhandertagande/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/kirurgi/postoperativt-omhandertagande/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/kirurgi/komplikationer-efter-kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/indikation-for-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/onskad-effekt-av-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/resultat-av-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/tidpunkt-for-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/stralbehandlingsteknik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/straldos/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/uppehall-av-antihormonell-behandling-under-stralbehandlingen/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/biverkningar-av-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/uppfoljning-efter-avslutad-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-hypofystumorer/rebestralning-av-hypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/indikation-for-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/stralbehandlingsteknik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/straldoser/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/interstitiellintrakavitar-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/forvantad-effekt-av-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/stralbehandling-av-kraniofaryngiom/biverkningar-efter-stralbehandling-av-kraniofaryngiom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/stralbehandling/remitteringsvagar-for-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/behandling/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/anvisningar-for-hur-provtagaren-ska-hantera-provet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/nf-pitnetnfpa/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/laktrotrof-pitnetadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/somatotrofa-pitnet-hypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/kortikotrof-pitnethypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/tyreotrof-pitnetadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/kraniofaryngiom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/cystor/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/aggressiva-hypofystumorerhypofyskarcinom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kategorisering-av-tumoren/hypofysapoplexi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/multidisciplinar-konferens/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/symtom-och-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/arftlighet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/bilddiagnostik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/biokemi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/patologi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/mdk/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/utredning/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/behandling/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/behandling/stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/behandling/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/uppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/uppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/postoperativa-komplikationer/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/uppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/bilddiagnostisk-uppfoljning-efter-hypofyskirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/uppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/ogonuppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/uppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/uppfoljning-av-hormonfunktionen-efter-operation-av-icke-hormonproducerande-hypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/uppfoljning-efter-operation-av-icke-hormonproducerande-hypofysadenom/uppfoljning-av-icke-hormonproducerande-makroadenom-som-inte-opereras/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/incidentalom-i-hypofysen/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/incidentalom-i-hypofysen/uppfoljning-av-incidentalom-i-hypofysen-utan-kliniska-eller-biokemiska-tecken-till-hormonrubbning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/graviditet-och-icke-hormonproducerande-hypofysadenom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/nfpa--non-functioning-pituitary-adenoma/barn/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/symtom-och-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/utredning/biokemi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/utredning/bilddiagnostik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/utredning/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/utredning/patologi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/utredning/diagnoskoder/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/biverkningar-av-dopaminagonister/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/resistenta-prolaktinom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/behandling/maligna-prolaktinom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/uppfoljning-och-behandlingsutvardering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/graviditet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/prolaktinom/barn--sarskilda-aspekter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/symtom-och-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/samsjuklighet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/utredning/biokemi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/utredning/bilddiagnostik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/utredning/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/utredning/diagnoskoder/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/kirurgi/preoperativ-behandling-med-somatostatinanaloger/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/oversikt-av-lakemedel/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/biverkningar/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/lakemedelsbehandling-rekommendationer-och-bakgrund/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/somatostatinanaloger-ssa-riktade-mot-sstr2-oktreotid-lanreotid--biokemisk-effekt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/effekter-pa-tumorstorlek/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/dopaminagonister--effekt-pa-biokemi-och-tumorstorlek/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/markorer-for-effekt-av-ssa/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/pegvisomant--singelbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/pegvisomant-ssa--kombinationsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/kabergolin-ssa--kombinationsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/pasireotid/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/lakemedelsbehandling/ovriga-kombinationsbehandlingar/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/behandling/stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/uppfoljning/postoperativ-uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/uppfoljning/uppfoljning-av-medicinskt-behandlade-patienter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/uppfoljning/aterfall/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/graviditet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/amning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/barn--sarskilda-aspekter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/barn--sarskilda-aspekter/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/barn--sarskilda-aspekter/bakgrund-och-orsaker/symtom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/barn--sarskilda-aspekter/bakgrund-och-orsaker/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/akromegali/barn--sarskilda-aspekter/bakgrund-och-orsaker/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/symtom-och-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/arftlighet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/kliniska-karaktaristika/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/biokemi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/biokemi/tolkning-av-biokemisk-screening-se-aven-avsnitt-om-felkallor-nedan/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/biokemi/diagnostiska-felkallor/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/bilddiagnostik/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/sinus-petrosus-kateterisering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/patologi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/multidisciplinar-konferens-mdk/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/utvardering-av-samsjuklighet-vid-pavisad-cushings-sjukdom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/utredning/diagnoskoder/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/forstahandsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/forstahandsbehandling/hypofyskirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/forstahandsbehandling/pre--och-perioperativ-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/hypofyskirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/lakemedelsbehandling/steroidsynteshammare/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/lakemedelsbehandling/lakemedel-riktade-mot-hypofystumoren/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/andrahandsbehandling/bilateral-adrenalektomi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandling/behandling-av-samsjuklighet-och-komplikationer/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandlingsutvardering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandlingsutvardering/utvardering-av-hypofysoperation/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandlingsutvardering/utvardering-av-stralbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandlingsutvardering/utvardering-av-medicinsk-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/behandlingsutvardering/atgarder-vid-utebliven-remission/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/glukokortikoidersattning-efter-hypofyskirurgi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/biokemisk-uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/ogonuppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/bilddiagnostisk-uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/multidisciplinar-konferens/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/atgarder-vid-aterfall/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/uppfoljning/samsjuklighet/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/graviditet-och-fertilitet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/omvardnad-och-rehabilitering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/symtom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/utredning/allmant/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/utredning/biokemisk-och-bilddiagnostisk-utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/behandling/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/behandling/hydrokortisonbehandling-postoperativt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/behandling/stralning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cushings-sjukdom/barn--sarskilda-aspekter/behandling/medicinsk-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/tsh-producerande-hypofystumorer--tshom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/tsh-producerande-hypofystumorer--tshom/bakgrund/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/tsh-producerande-hypofystumorer--tshom/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/tsh-producerande-hypofystumorer--tshom/utredning/diagnoskoder/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/tsh-producerande-hypofystumorer--tshom/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/tsh-producerande-hypofystumorer--tshom/langtidskonsekvenser/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/symtom-och-kliniska-fynd-hos-vuxna/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/debutsymtom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/symtom-under-uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/hypotalamisk-obesitas/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/hypotalamisk-obesitas/behandling-och-bakgrund-till-hypotalamisk-obesitas/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/hypotalamisk-obesitas/behandling-och-bakgrund-till-hypotalamisk-obesitas/hyperfagi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/hypotalamisk-obesitas/behandling-och-bakgrund-till-hypotalamisk-obesitas/minskad-energiomsattning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/hypotalamisk-obesitas/behandling-och-bakgrund-till-hypotalamisk-obesitas/hyperinsulinemi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/hypotalamisk-obesitas/behandling-och-bakgrund-till-hypotalamisk-obesitas/bariatrisk-kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/neuropsykiatriska-problem/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/symtom-och-kliniska-fynd/somnstorning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/hypofyssvikt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/anamnes-och-status/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/hormonell-utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/bilddiagnostik/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/ogonstatus-och-synundersokning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/ovriga-undersokningar/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/multidisciplinar-konferens-mdk/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/patologi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/bakgrund/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/kirurgisk-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/kirurgisk-behandling/perioperativt-omhandertagande/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/kirurgisk-behandling/komplikationer-efter-kirurgisk-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/stralbehandling-av-kraniofaryngiom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/stralbehandling-av-kraniofaryngiom/indikation-for-stralbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/stralbehandling-av-kraniofaryngiom/forvantad-effekt-av-stralbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/intracystisk-behandling-av-kraniofaryngiom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/behandling/lakemedelsbehandling-av-papillart-kraniofaryngiom/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/uppfoljning/behandlingsutvardering--bilddiagnostik/2025-01-17 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/uppfoljning/hypofyssvikt/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/uppfoljning/ogonuppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/uppfoljning/aterfall/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/uppfoljning/foljdsjukdomar/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/graviditet/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/barn--sarskilda-aspekter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/barn--sarskilda-aspekter/symtom-och-kliniska-fynd/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/barn--sarskilda-aspekter/symtom-under-uppfoljning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/barn--sarskilda-aspekter/hypofyssvikt-och-hormonersattning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/barn--sarskilda-aspekter/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kraniofaryngiom/barn--sarskilda-aspekter/utredning-och-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/bakgrund-och-orsaker/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/symtom-och-kliniska-fynd/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/arftlighet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/utredning/biokemi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/utredning/radiologi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/utredning/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/utredning/patologi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/utredning/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/behandling/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/behandling/stralbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/behandling/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/uppfoljning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/cystor/graviditet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/klinisk-karaktaristik-och-patologi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/utredning/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/behandlingsutvardering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/aggressiva-hypofystumorer-och-hypofyskarcinom/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/bakgrund/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/symtom-och-kliniska-fynd/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/utredning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/utredning/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/primar-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/neurokirurgisk-behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysapoplexi/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/bakgrund-och-orsaker/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/symtom-och-kliniska-fynd/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/arftlighet/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/biokemi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/ogonstatus-och-synundersokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/radiologi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/patologi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/lakemedelsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/lakemedelsbehandling/ersattningsbehandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/lakemedelsbehandling/symtombehandling-med-hogdos-glukokortikoider/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/utredning/stralningsbehandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/uppfoljning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofysit/graviditet/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/bakgrund-och-orsaker/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/utredning/klinisk-vardering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/utredning/biokemi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/utredning/diagnoskod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/fertilitet-och-graviditet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/peri--och-postoperativ-monitorering-och-behandling/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/peri--och-postoperativ-monitorering-och-behandling/kortison/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/peri--och-postoperativ-monitorering-och-behandling/vatskebalans/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/peri--och-postoperativ-monitorering-och-behandling/generell-hypofysfunktion/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/barn--sarskilda-aspekter/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/barn--sarskilda-aspekter/utredning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/barn--sarskilda-aspekter/utredning/klinisk-vardering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/barn--sarskilda-aspekter/utredning/biokemi/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/barn--sarskilda-aspekter/behandling/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/hypofyssvikt/barn--sarskilda-aspekter/uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/information-och-delaktighet/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/information-och-delaktighet/psykosocialt-stod/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/rehabilitering/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/preoperativ-information/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/postoperativ-omvardnad/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/neurologstatus/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/neurologstatus/andning-och-cirkulation/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/neurologstatus/nutrition/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/neurologstatus/elimination/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/neurologstatus/smarta/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/neurologstatus/mobilisering/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/specifik-omvardnad/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/specifik-omvardnad/likvorlackage/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/specifik-omvardnad/nas--och-sarvard/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/specifik-omvardnad/nasblodning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/specifik-omvardnad/hormonpaverkan-efter-kirurgi/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgi/postoperativ-uppfoljning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/egenvard/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/egenvard/rokning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/egenvard/alkohol/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/egenvard/fysisk-aktivitet/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/egenvard/hormonersattning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/utbildning-av-patient-och-narstaende/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/gh-behandling-hos-barn-och-ungdomar/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/sexuell-halsa/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/omvardnad-och-rehabilitering/sexuell-halsa/bakgrund/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kognitiv-dysfunktion-hos-barn-och-vuxna-patienter-med-hypofystumorer/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kognitiv-dysfunktion-hos-barn-och-vuxna-patienter-med-hypofystumorer/bakgrund-och-orsaker/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kognitiv-dysfunktion-hos-barn-och-vuxna-patienter-med-hypofystumorer/utredning-och-uppfoljning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/palliativ-vard-och-insatser/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/uppfoljning-av-varden/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/uppfoljning-av-varden/svenska-hypofysregistret/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/uppfoljning-av-varden/cancerregistret/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/forslag-pa-fordjupning/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/2024-07-05 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/vardprogrammets-nationella-arbetsgrupp/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/vardprogramgruppens-ovriga-medlemmar/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/referenser/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/bilaga-1-sjukregler/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/bilaga-2-forslag-pa-behandlingsstart-och-uppfoljning-av-vuxna-som-far-tillvaxthormon-gh/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/bilaga-3-forslag-pa-behandlingsstart-och-uppfoljning-av-barn-som-far-tillvaxthormon-gh/2024-07-04 https://kb.localhost:5000/diagnoser/hypofystumorer/vardprogram/bilaga-4-etomidatbehandling-vid-cushings-syndrom/2024-07-04 https://kb.localhost:5000/diagnoser/melanom/2022-04-11 https://kb.localhost:5000/diagnoser/melanom/vardprogram/2022-06-28 https://kb.localhost:5000/diagnoser/melanom/vardprogram/sammanfattning/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/inledning/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-07-04 https://kb.localhost:5000/diagnoser/melanom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/inledning/evidensgradering/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/mal-med-vardprogrammet/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/bakgrund/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/bakgrund/alder/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/bakgrund/lokalisation/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/bakgrund/overlevnad/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/orsaker/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/riskfaktorer-for-primara-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bakgrund-och-orsaker/riskfaktorer-for-primara-melanom/riskfaktorer-for-multipla-primara-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/primar--och-sekundarprevention/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/primar--och-sekundarprevention/yttre-riskfaktorer/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/primar--och-sekundarprevention/primarprevention/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/primar--och-sekundarprevention/sekundarprevention/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/primar--och-sekundarprevention/5.5-screeening2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/arftlighet/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/anamnes-klinisk-undersokning/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/dermatoskopi-och-teledermatoskopi/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/klassificering-av-melanom/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/ingang-till-standardiserat-vardforlopp-vf/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/ingang-till-standardiserat-vardforlopp-vf/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-svf/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/utredning-av-misstankt-melanom-med-eller-utan-start-av-svf/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-behandling-av-melanom-hos-gravida-och-barn2/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-behandling-av-melanom-hos-gravida-och-barn2/graviditet-och-melanom-inklusive-hormonell-substitution-ochp-piller/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-behandling-av-melanom-hos-gravida-och-barn2/melanom-hos-barn/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-behandling-av-melanom-hos-gravida-och-barn2/behandling-och-overlevnad/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-handlaggning-av-ovriga-melanom/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-handlaggning-av-ovriga-melanom/mukosala-melanom/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-handlaggning-av-ovriga-melanom/melanom-med-okand-primartumor/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kannetecken-och-tidig-utredning/diagnostik-och-handlaggning-av-ovriga-melanom/6.7.3-ogonmelanom2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/utredning-enligt-svf/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/excision-av-pigmenterade-hudforandringar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/excision-av-pigmenterade-hudforandringar/diagnostisk-excision/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/excision-av-pigmenterade-hudforandringar/partiella-biopsier/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/excision-av-pigmenterade-hudforandringar/remissuppgifter-vid-primar-utredning-av-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/excision-av-pigmenterade-hudforandringar/rad-vid-diagnostiska-oklarheter/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/diagnostik/diagnosbesked/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/generella-anvisningar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hudpreparat/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/sentinel-node-portvaktskortelsn/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primart-invasivt-melanom/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/utvidgad-excision/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/portvaktskortelbiopsi/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/terapeutisk-lymfkortelutrymning/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/excision-av-metastaslymfkortelutrymning-for-bedomning-av-preoperativ-neoadjuvant-behandlingseffekt/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/immunhistokemi-och-molekylara-analyser/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/immunhistokemi-och-molekylara-analyser/behandlingsprediktiva-analyser-av-melanom/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/immunhistokemi-och-molekylara-analyser/diagnostisk-molekylar-analys-av-oklara-melanocytara-tumorer/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/immunhistokemi-och-molekylara-analyser/bred-genetisk-profilering/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/tnm-klassifikation-och-stadieindelning2/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/dysplastiskt-nevus2/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/mpath-dx-2.0-klassifikation2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/multidisciplinar-konferens-mdk/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/kirurgisk-behandling-av-primart-invasivt-melanom/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/sentinel-node/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/sentinel-node/portvaktskorteln/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/sentinel-node/lymfkortelutrymning/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/sentinel-node/fjarrmetastasutredning/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/portvaktskortelskintigrafi/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/datortomografi-dt/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/petdt/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/magnetisk-resonanstomografi-mr/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/ultraljud/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/radiologisk-diagnostik-vid-malignt-melanom/viktigt-att-notera-om-kontrastmedel/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/behandling-vid-lokoregionalt-aterfall/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/behandling-vid-lokoregionalt-aterfall/aterfall-i-det-primara-arromradet/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/behandling-vid-lokoregionalt-aterfall/satellitmetastaser-och-in-transit-metastaser/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/behandling-vid-lokoregionalt-aterfall/lymfkortelaterfall/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kirurgisk-behandling/behandling-vid-lokoregionalt-aterfall/isolerad-hyperterm-perfusion-isolated-limb-perfusion-ilp/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/neoadjuvant-behandling/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/adjuvant-systemisk-behandling/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/adjuvant-systemisk-behandling/adjuvant-behandling-med-PD-1-hammare/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/adjuvant-systemisk-behandling/adjuvant-behandling-med-kinashammare/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/adjuvant-systemisk-behandling/adjuvant-behandling-med-ctla-4-hammare/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/adjuvant-systemisk-behandling/adjuvant-interferonbehandling/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/adjuvant-systemisk-behandling/adjuvant-cytostatikabehandling/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/pd-1-hammare-nivolumab-och-pembrolizumab/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/ctla-4-hammare-ipilimumab/2024-06-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/kombinationsbehandling-med-ctla-4--och-pd-1-hammare/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/relatlimab/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/vaccinering/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/immunstimulerande-genterapi/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/elektrokemoterapi/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/immunterapi-immunstimulerande-antikroppar/tebentafusp/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/perorala-kinashammare/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/perorala-kinashammare/braf-hammare-vemurafenib-dabrafenib-och-enkorafenib/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/perorala-kinashammare/mek-hammare-trametinib-kobimetinib-och-binimetinib/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/perorala-kinashammare/kombinationsbehandlingar-med-braf--och-mek-hammare/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/perorala-kinashammare/kinashammare-vid-ckit-muterat-melanom/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/perorala-kinashammare/ntrk-hammare/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/systembehandling-vid-hjarnmetastaserat-melanom/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/cytostatikabehandling/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/cytostatikabehandling/dakarbazin/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/cytostatikabehandling/temozolomid/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/cytostatikabehandling/ovriga-cytostatika/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/cytostatikabehandling/kombinationskemoterapi/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/cytostatikabehandling/andra-linjens-behandling/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/mojliga-framtida-behandlingar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/mojliga-framtida-behandlingar/terapeutiska-vacciner/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/mojliga-framtida-behandlingar/autologa-t-celler/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/behandling-av-spritt-icke-operabelt-melanom-hos-gravida/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/fertilitetsfragor-i-samband-med-onkologisk-behandling-med-immuncheckpointhammare-braf--eller-mek-hammare/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/fertilitetsfragor-i-samband-med-onkologisk-behandling-med-immuncheckpointhammare-braf--eller-mek-hammare/evidenslage/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/fertilitetsfragor-i-samband-med-onkologisk-behandling-med-immuncheckpointhammare-braf--eller-mek-hammare/immuncheckpointhammare/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/systemisk-behandling/systemisk-behandling-vid-spridd-icke-operabel-sjukdom/fertilitetsfragor-i-samband-med-onkologisk-behandling-med-immuncheckpointhammare-braf--eller-mek-hammare/malriktad-behandling-braf--och-mek-hammare/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/stralbehandling/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/stralbehandling/adjuvant-stralbehandling/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/stralbehandling/palliativ-stralbehandling/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/stralbehandling/stralbehandling-av-hjarnmetastaser/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-kirurgi/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-kirurgi/kirurgi-med-primar--eller-sekundarlakning/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-kirurgi/kirurgi-med-hudtransplantat/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-kirurgi/kirurgi-vid-lymfkortelutrymning-i-huvud-och-halsomradet/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-kirurgi/kirurgi-i-axill-och-inguinalt/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-kirurgi/senkomplikationer-efter-lymfkortelutrymning2/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-immunterapi/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-immunterapi/symtommonitorering-och-patientinformation/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/symtommonitorering-och-patientinformation/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/feber/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/hudbiverkningar/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/ogonbiverkningar/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/ledvark-och-muskelvark/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/fatigue/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/odem/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/mag--och-tarmbiverkningar/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-perorala-kinashammare/undersokningsresultat-provsvar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/illamaende/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/forstoppning/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/paverkan-pa-benmargen/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/hud--och-slemhinnor/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/neuropatier/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/kognitiv-paverkan/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/alopeci-haravfal/2023-12-12 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatika/fatigue/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/stralbehandling-vid-hjarnmetastaser/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/omvardnad-och-rehabilitering/omvardnad-av-maligna-tumorsar-vid-avancerad-melanomsjukdom/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/egenvard/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/egenvard/kontrollera-huden/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/egenvard/sunda-solvanor/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/egenvard/levnadsvanor/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/egenvard/komplementar-och-alternativ-medicin/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/palliativ-vard-och-insatser/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/syftet-med-uppfoljning/2024-06-15 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/trim-studien/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/riskfaktorer-for-uppkomst-av-melanom/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/prognos-och-prognosinstrument/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/uppfoljning-av-patienter-med-opererat-melanom-med-risk-for-lokoregionala-aterfall/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/uppfoljning-av-patienter-med-opererat-melanom-med-risk-for-lokoregionala-aterfall/uppfoljning-oavsett-riskkategori/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/uppfoljning-av-patienter-med-opererat-melanom-med-risk-for-lokoregionala-aterfall/klinisk-undersokning-stadium-i--iii/2023-12-04 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/information-till-patienten-och-sjalvrapportering-av-kliniska-symtom/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/nivastrukturering/2024-06-20 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kvalitetsregister/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kvalitetsregister/svenska-melanomregistret-swemr/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kvalitetsregister/uppfoljning-av-patientrapporterade-matt/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kvalitetsregister/individuell-patientoversikt/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kvalitetsregister/cancerregistret/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardprogram/referenser/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/2020-02-18 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/syfte/2020-02-18 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/arbetsgrupp/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/forekomst-av-familjart-melanom-i-sverige/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/definition-av-familjart-melanom/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/kanda-melanomassocierade-mutationer/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bakgrund/genomgang-av-svenska-melanomfamiljer-20152020/2024-06-24 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/handlaggning-av-melanomfamiljer/2020-02-18 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/handlaggning-av-melanomfamiljer/familjeutredning-och-pedigree/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/handlaggning-av-melanomfamiljer/vilka-bor-erbjudas-test-for-cdkn2a-mutationer-eller-mutationer-i-andra-gener/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/kontroller-och-screening/2020-02-18 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/kontroller-och-screening/kontroller-och-screening-hos-barare-av-mutation-i-cdkn2a/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/kontroller-och-screening/kontroller-och-screening-hos-barare-av-mutation-i-bap1/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/kontroller-och-screening/familjer-testade-negativt-for-mutation-i-hogrisk-gen-samt-familjer-med-okant-mutationsstatus/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/forskning/2020-02-25 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/registrering-av-melanomfamiljer/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/registrering-av-melanomfamiljer/familjekodnummer/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/patientinformation-tillganglig-via-internet/2024-06-19 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/kontaktpersoner/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/referenser/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bilagor/2020-02-18 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bilagor/patientinformation-angaende-genetisk-analys-av-arftligt-melanom/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bilagor/mall-godkannande-att-begara-in-journalhandling/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-1.-handlaggning-av-individer-inom-familjer-med-familjart-melanom/bilagor/mall-forskningsprov-for-genetisk-analys-vid-arftligt-melanom/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi/inledning/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi/bildfallen/2019-11-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi/rekommenderat-utbildningsmaterial/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi/kliniska-melanomtyper/2019-11-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi/tidig-diagnostik-av-de-olika-melanomtyperna/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-2.-melanom-kliniska-fall-med-dermatoskopi/referenser/2019-11-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/inledning/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/aldersfordelning/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/lokalisation-och-riskmarkorer/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/melanomtyper-hos-aldre/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/tjocklek-och-prognos/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/viktiga-kliniska-symtom-for-melanomtyper-vanliga-hos-aldre-personer/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/2019-12-03 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivningar-nodulara-melanom/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivning-akrolentiginosa-melanom-alm/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivningar-lentigo-maligna-lm-och-lentigo-maligna-melanom-lmm/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivningar-dysplastic-nevus-of-the-elderly-eller-atypical-lentiginous-junctional-nevus-of-the-elderly-of-kossard-kossards-nevus/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivning-av-extrafaciell-lentigo-maligna/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivningar-melanom-med-ytligt-vaxtsatt-ssm/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivningar-av-dysplastic-nevus-of-the-elderly--eller-atypical-lentiginous-junctional-nevus-of-the-elderly-of-kossard/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivning-av-extrafaciell-lentigo-maligna2/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/fallbeskrivningar/fallbeskrivningar-av-melanom-med-ytligt-vaxtsatt-ssm/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-3.-melanom-hos-aldre.-kliniska-fall-med-dermatoskopi/referenser/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/bakgrund/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/incidens/2020-10-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/utredning/2020-10-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/histopatologi/2020-10-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/prognos/2020-10-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/behandling/2020-10-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/systemisk-onkologisk-behandling/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/uppfoljning/2020-10-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/framtiden/2020-10-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-4.-mukosala-melanom/referenser/2020-10-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/bakgrund/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/forstadier-till-uveala-melanom-atypiska-chorioidala-nevi/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/primart-melanom-i-koroidea-och-corpus-ciliare/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/melanom-i-iris/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/prognos-for-patienter-behandlade-for-uvealt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/uppfoljning-av-patienter-som-behandlats-for-uvealt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/uveala-melanom/metastaserande-uvealt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/2022-06-27 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/forstadier-till-konjunktivalt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/primart-konjunktivalt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/prognos-for-patienter-efter-behandling-av-konjunktivalt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/uppfoljning-av-patienter-behandlade-for-konjunktivalt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/behandling-av-patienter-med-spridning-till-lokoregionala-lymfkortlar/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/konjunktivalt-melanom/metastaserande-konjunktivalt-melanom/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-5.-ogonmelanom--uvealt-och-konjunktivalt/referenser/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga2025-01-22 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/klinisk-bakgrundsinformation-och-patologins-roll-i-den-diagnostiska-processen/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/hudpreparat-melanom-melanom-in-situ-dysplastiskt-nevus-och-utvidgad-excision/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/portvaktskortel/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/terapeutisk-lymfkortelutrymning/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/excision-av-metastaslymfkortelutrymning-for-bedomning-av-preoperativ-neoadjuvant-behandlingseffekt/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/Immunhistokemi-och-mutationsanalyser/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/rekommenderat-klassifikationssystem/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/koder-och-beteckningar/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/kvalitetsarbete-for-patologin/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/hud-kvast-gruppen/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/rekommenderad-litteratur/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/bilaga-6.-kvalitetsbilaga-for-patologi-kvast-bilaga/referenser/2023-12-01 https://kb.localhost:5000/diagnoser/melanom/vardprogram/prognosinstrument/2023-08-14 https://kb.localhost:5000/diagnoser/melanom/vardprogram/ladda-ner-pdf/2024-07-04 https://kb.localhost:5000/diagnoser/melanom/vardprogram/prognosinstrument2/2025-11-07 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/introduktion/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/ingang-till-standardiserat-vardforlopp2/2019-11-27 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2024-06-13 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/ingang-till-standardiserat-vardforlopp2/valgrundad-misstanke/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-for-utredning-vid-valgrundad-misstanke/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/ingang-till-standardiserat-vardforlopp2/hantering-av-aterfall-recidiv-ny-primartumor-eller-flera-samtidiga-melanom/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/utredning-och-beslut-om-behandling/remiss-till-patolog-vid-diagnostisk-excision/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling2/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/arbetsgruppens-sammansattning2/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall-eller-ny-primartumor/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-flera-samtidiga-melanom/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/frivillig-kod-under-utredning/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2025-07-09 https://kb.localhost:5000/diagnoser/melanom/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2025-07-09 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/2022-04-07 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/sammanfattning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-05-10 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/forandringar-jamfort-med-foregaende-version/2024-05-10 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/standardiserat-vardforlopp/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/lagstod/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/evidensgradering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/inledning/begreppsforklaringar-och-forkortningar/2023-11-21 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/mal-med-vardprogrammet/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/alder-och-kon/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/trender/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/tobak/2020-01-11 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/tobak/rokning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/tobak/passiv-rokning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/tobak/snus/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/alkohol/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/alkohol-och-rokning-i-kombination/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/dalig-munhalsa/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/hogrisk-hpv/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/riskfaktorer/andra-riskfaktorer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/premaligna-forandringar/2023-11-24 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/etiologi-riskfaktorer-och-prevention/kost/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bakgrund-och-orsaker/prevention/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/screening/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/arftlighet/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/symtom-och-tidig-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd-vid-huvud-och-halscancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd-vid-huvud-och-halscancer/symtom-som-bor-foranleda-misstanke-om-cancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd-vid-huvud-och-halscancer/symtom-som-bor-foranleda-misstanke-om-cancer/symtom-relaterade-till-respektive-tumorlokal/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/vardkedjan-vid-utredning-och-behandling-av-patienter-med-huvud--och-halscancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/klinisk-diagnostik/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/2020-01-11 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/cytologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/histologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/lymfkorteldiagnostik/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/utlatandet/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/cell--och-molekylaranalyser/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/ebv-diagnostik/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/cytologisk-och-histologisk-diagnostik/hpv-diagnostik/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/2023-11-21 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/datortomografi-dt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/magnetisk-resonanstomografi-mr/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/pet-ct/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/ultraljud-ul/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/viktigt-att-notera-om-kontrastmedel/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/portvaktskortelskintigrafi-sentinel-node/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/utredning/radiologisk-diagnostik/portvaktskortelskintigrafi-sentinel-node/metodbeskrivning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/diagnosbesked/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnostik/omvardnad-och-rehabilitering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/tumorklassifikation/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/tumorklassifikation/patologins-roll-i-den-diagnostiska-processen/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/tumorklassifikation/anvisningar-for-provtagarens-hantering-av-provet/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/tumorklassifikation/anamnestisk-remissinformation/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/tumorklassifikation/klassificering-av-tumoren/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/tumorklassifikation/klassificering-av-tumoren/sentinel-node-diagnostik/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/multidisciplinar-konferens/2023-11-21 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/behandling-vid-huvud-och-halscancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/2023-12-12 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-primartumoren/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-halsen-neck-dissection/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-halsen-neck-dissection/halslymfkortelutrymning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-halsen-neck-dissection/halslymfkortelutrymning/utrymning-av-niva-i-ii-iii-iv-och-v/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-halsen-neck-dissection/halslymfkortelutrymning/utrymning-av-niva-i-ii-och-iii/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-halsen-neck-dissection/salvagekirurgi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-behandling-av-halsen-neck-dissection/rekonstruktion/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/kirurgisk-behandling/omvardnad-och-rehabilitering-efter-kirurgisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/dosnivaer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktionering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktionering/hyperfraktionering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktionering/hypofraktionering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktionering/accelererad-fraktionering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktioneringsscheman/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktioneringsscheman/konventionell-fraktionering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktioneringsscheman/dahanca-fraktionering-danish-head-and-neck-cancer-group/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktioneringsscheman/hypofraktionering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/fraktionering-vid-palliativ-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/praktiskt-genomforande/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/riskorgan/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/behandlingstekniker/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/behandlingstekniker/tekniker-som-ofta-anvands/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/behandlingstekniker/sib/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/behandlingstekniker/protonbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/extern-stralbehandling/brakyterapi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/biverkningar-vid-onkologisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/biverkningar-vid-onkologisk-behandling/skoldkortel/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/kurativt-syftande-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/kurativt-syftande-behandling/induktionscytostatikabehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/kurativt-syftande-behandling/konkomitant-cytostatika--och-stralbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/kurativt-syftande-behandling/dosering-av-cisplatin/2023-11-21 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/kurativt-syftande-behandling/stralbehandling-med-annan-konkomitant-medicinsk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/kurativt-syftande-behandling/postoperativ-cytostatika--och-stralbehandling-samt-adjuvantcytostatikabehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/palliativ-medicinsk-tumorbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/palliativ-medicinsk-tumorbehandling/palliativ-behandling-vid-skivepitelcancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/palliativ-medicinsk-tumorbehandling/11.3.3.2.2palliativ-behandling-vid-spottkortelcancer2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/medicinsk-tumorbehandling/palliativ-medicinsk-tumorbehandling/11.3.3.2.3palliativ-behandling-med-elektrokemoterapi2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/primar-behandling/onkologisk-behandling/omvardnad-och-rehabilitering-vid-biverkningar-av-onkologisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/kirurgisk-behandling-vid-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/kirurgisk-behandling-vid-aterfall/kurativ-intention/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/kirurgisk-behandling-vid-aterfall/palliativ-intention/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/onkologisk-behandling-vid-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/onkologisk-behandling-vid-aterfall/stralbehandling-vid-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/onkologisk-behandling-vid-aterfall/rebestralning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/onkologisk-behandling-vid-aterfall/medicinsk-tumorbehandling-vid-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/onkologisk-behandling-vid-aterfall/medicinsk-tumorbehandling-vid-aterfall/kurativ-intention/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/behandling-av-aterfall/onkologisk-behandling-vid-aterfall/medicinsk-tumorbehandling-vid-aterfall/palliativ-intention/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/understodjande-vard/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/understodjande-vard/levnadsvanor/2024-05-10 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/palliativ-vard/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/2020-01-11 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/fortlopande-cancerrehabilitering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/fortlopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/fortlopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/tandvard/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/nutrition/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/nutrition/preoperativ-nutrition/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/nutrition/postoperativ-nutrition/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/nutrition/nutrition-vid-onkologisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/dysfagi-och-tuggsvarigheter/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/dysfagi-och-tuggsvarigheter/dysfagi-vid-kirurgisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/dysfagi-och-tuggsvarigheter/dysfagi-och-tuggsvarigheter-vid-onkologisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/smarta/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/illamaende/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/munhalebesvar/2020-01-11 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/munhalebesvar/oral-mukosit/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/munhalebesvar/oral-mukosit/farmakologisk-smartbehandling-vid-mukosit/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/munhalebesvar/oral-candidos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/munhalebesvar/muntorrhet/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/munhalebesvar/omvardnadsatgarder-och-egenvard/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/smak--och-luktforandringar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/hudreaktion-vid-onkologisk-behandling/2023-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/maligna-tumorsar/2023-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/rost-och-talpaverkan/2020-01-11 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/rost-och-talpaverkan/vid-kirurgisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/rost-och-talpaverkan/vid-onkologisk-behandling/2023-11-24 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/trismus/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/trakeostomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/problem-med-lambaer-och-fistlar-efter-kirurgi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/facialispares/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/stortblodning-blow-outblodning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/lymfodem/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/nedsatt-skulderfunktion/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/osteoradionekros/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/fatigue/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/sex-och-samlevnad/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/psykosociala-aspekter/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/omvardnad-och-rehabilitering/specifik.omvardnad/psykosociala-aspekter/patient--och-narstaendeforening/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/nationella-riktlinjer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/levnadsvanor/2023-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/levnadsvanor/matvanor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/levnadsvanor/rokning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/levnadsvanor/alkohol/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/levnadsvanor/fysisk-aktivitet/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/egenvard/komplementar-och-alternativ-medicin/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering-och-levnadsvanor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/kontroll-av-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/ansvar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/nivastrukturering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-24 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/oversikt/epidemiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/oversikt/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/utredning/radiologisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/behandling/primartumor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/behandling/regionala-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lappcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/oversikt/epidemiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/oversikt/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/utredning/radiologisk-utredning/2023-11-25 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/behandling/primartumor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/behandling/behandling-av-regionala-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/behandling/behandling-av-regionala-lymfkortlar/n0/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/behandling/behandling-av-regionala-lymfkortlar/n/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/behandling/medicinsk-tumorbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munhalecancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/behandling/primartumor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/behandling/halsens-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/behandling/stadium-i-och-ii/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/behandling/stadium-iii-och-iv/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/tungcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/mindre-tumorer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/mindre-tumorer/resektionsgranser/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/kirurgi-vid-avancerade-tumorer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/kirurgi-vid-avancerade-tumorer/benengagemang/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/kirurgi-vid-avancerade-tumorer/gingivalcancer-i-mandibel/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/kirurgi-vid-avancerade-tumorer/gingivalcancer-i-maxilla/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/behandling/halsens-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/gingivalcancer-i-mandibel-eller-maxilla/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/behandling/primartumor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/behandling/halsens-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/behandling/stadium-i-och-ii/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/behandling/stadium-iii-och-iv/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/munbottencancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/behandling/primartumor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/behandling/stadium-i-och-ii/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/behandling/stadium-iii-och-iv/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/buckalcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/behandling/primar-tumor/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/behandling/halsens-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/behandling/stadium-iii/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/behandling/stadium-iiiiv/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/cancer-i-harda-gommen/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/ovrig-cancer-i-munhalan/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-12-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/oversikt/epidemiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/utredning/radiologisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/behandling/stralbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/behandling/cytostatikabehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/behandling/kirurgisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/behandling/behandlingsutvardering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/orofarynxcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/oversikt/epidemiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/oversikt/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/utredning/radiologisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/behandling/stralbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/behandling/medicinsk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/behandling/kirurgisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/behandling/behandlingsutvardering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/behandling/behandling-av-aterfall/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nasofarynxcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/oversikt/incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/oversikt/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/utredning/radiologisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/hypofarynxcancer/prognos2/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/etiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/etiologi-och-incidens/incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/oversikt/etiologi-och-incidens/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/utredning/radiologisk-utredning/2023-11-25 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/glottisk-larynxcancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/glottisk-larynxcancer/glottisk-tis-carcinoma-in-situ-d02.02023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/glottisk-larynxcancer/glottisk-t1-n0/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/glottisk-larynxcancer/glottisk-t2-n0/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/glottisk-larynxcancer/glottisk-t2-n1n3-och-t3-n0n3/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/glottisk-larynxcancer/glottisk-t4-n0n3/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/supraglottisk-larynxcancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/supraglottisk-larynxcancer/supraglottisk-t1t3-n0n3/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/supraglottisk-larynxcancer/supraglottisk-t4-n0n3/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/subglottisk-larynxcancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/behandling/larynxcancer-vid-icke-skivepitelcancer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/Behandlingsutvardering-och-rehabilitering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/Behandlingsutvardering-och-rehabilitering/behandlingsutvardering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/Behandlingsutvardering-och-rehabilitering/rostfunktion-och-rehabilitering/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/Behandlingsutvardering-och-rehabilitering/rostfunktion-och-rehabilitering/fore-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/Behandlingsutvardering-och-rehabilitering/rostfunktion-och-rehabilitering/efter-genomgangen-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/Behandlingsutvardering-och-rehabilitering/observandum-vid-laryngektomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/larynxcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/epidemiologi-etiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/epidemiologi-etiologi-och-incidens/incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/epidemiologi-etiologi-och-incidens/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/adenokarcinom-nos-20-/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/mukoepidermoid-cancer-15-/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/acinic-cell-cancer-16-/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/adenoidcystisk-cancer-15-/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/skivepitelcancer-6-/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/oversikt/patologi/andra-mindre-vanliga-cancerformer/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/utredning/radiologisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/kirurgi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/kirurgi/primartumor-i-glandula-parotis/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/kirurgi/primartumor-i-glandula-submandibularis/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/kirurgi/primartumor-i-glandula-sublingualis/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/halsens-lymfkortlar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/onkologisk-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/onkologisk-behandling/stralbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/behandling/onkologisk-behandling/medicinsk-tumorbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/spottkortelcancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/anatomi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/epidemiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/epidemiologi-och-incidens/epidemiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/epidemiologi-och-incidens/etiologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/oversikt/epidemiologi-och-incidens/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/symtom/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/utredning/radiologisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/principer-for-kurativ-behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/principer-for-kurativ-behandling/t1t2-tumorer-kirurgi---postoperativ-stralbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/principer-for-kurativ-behandling/t3t4-tumorer-kombinationsbehandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/behandlingsprinciper-for-sarskilda-histopatologier/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/onkologisk-behandling--sarskilda-overvaganden/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/kirurgi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/behandling/kirurgi/kirurgi--generella-overvaganden/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/uppfoljning/19.14.5.1klinisk-och-radiologisk-uppfoljning2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/uppfoljning/19.14.5.1klinisk-och-radiologisk-uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/uppfoljning/19.14.5.1klinisk-och-radiologisk-uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/nas-och-bihalecancer/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/oversikt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/oversikt/tnm-klassifikation-och-stadieindelning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/oversikt/epidemiologi-och-incidens/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/oversikt/patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/utredning/klinisk-utredning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/utredning/radiologisk-utredning/2023-11-25 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/behandling/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/behandling/stralbehandling--val-av-behandlingsvolym/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/behandling/kirurgi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/uppfoljning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/uppfoljning/ar-12/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/uppfoljning/ar-35/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/diagnosgrupper/lymfkortelmetastas-pa-halsen-med-okand-primartumor-cup-hh/prognos/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsregister/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsregister/svenskt-kvalitetsregister-for-huvud--och-halscancer-swehncr/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsregister/svenskt-kvalitetsregister-for-huvud--och-halscancer-swehncr/inklusionskriterier/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsregister/svenskt-kvalitetsregister-for-huvud--och-halscancer-swehncr/exklusionskriterier/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsregister/svenskt-kvalitetsregister-for-huvud--och-halscancer-swehncr/20.1.3rekommenderad-logistik-for-att-rapportera-in-till-registret2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsregister/cancerregistret/2024-03-01 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-05-10 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/referenser2/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/forslag-pa-fordjupningslitteratur/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/24.1vardprogramgruppens-sammansattning2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/24.2vardprogramgruppens-medlemmar2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/patientforetradare/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/stodjande-funktioner/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-05-10 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who/datortomografi-dt-av-huvud-hals-och-thorax/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who/magnetisk-resonanstomografi-mrt/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who/pet-ct-positronemissionstomografi-ct/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who/portvaktskortelskintigrafi-sentinel-node/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who/kontrastmedel/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-1.-definition-performance-status-enligt-who/referenser/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsdokument-for-patologi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsdokument-for-patologi/analyser/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2023-11-25 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/kvalitetsdokument-for-patologi/koder-och-beteckningar/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bedomning-av-allmantillstandet-performance-status/2023-11-25 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-3.-kortfattad-preparatoversikt-vid-medicinsk-tumorbehandling2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-5.-behandlingar-under-utveckling2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-5.-behandlingar-under-utveckling/elektrokemoterapi/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-5.-behandlingar-under-utveckling/referenser/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-6-sarskilt-tandvardsbidrag/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-6-sarskilt-tandvardsbidrag/sarskilt-tandvardsbidrag/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardprogram/bilaga-6-sarskilt-tandvardsbidrag/f-tandvard-vid-vissa-langvariga-sjukdomar-eller-funktionsnedsattning/2023-11-18 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-12-17 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-for-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall-recidiv-och-ny-primartumor/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet2/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall-eller-ny-primartumor/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/huvud-och-halscancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-11-08 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/2022-04-11 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/sammanfattning/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/inledning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/mal-med-vardprogrammet/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/bakgrund-och-orsaker/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/bakgrund-och-orsaker/bakgrund-och-orsaker-till-indolenta-bcellslymfom-och-harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/arftlighet/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/alarmsymtom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/utredning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/stadieindelning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/ovrig-utredning/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/Diagnosbesked/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/diagnostik/omvardnad-och-rehabilitering/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/vavnad-for-diagnostik/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/molekylargenetisk-diagnostik/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/follikulart-lymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/follikulart-lymfom/immunfenotyp/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/follikulart-lymfom/genetik/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/follikulart-lymfom/varianter/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/spleniskt-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/nodalt-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/malt-lymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/klassisk-harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/patologi/morfologi2/spleniskt-b-cellslymfomleukemi-oklassificerbart/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/multidisciplinar-konferens/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/bakgrund-och-orsaker/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/flipi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/flipi-2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/prima-pi-eller-2-mikroglobulin-samt-ld/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/pod24-och-efs24/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/ovrigt-prognostiskt/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/kliniska-prognosfaktorer/prognosfaktorer-som-inte-ar-i-bruk/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/speciella-former/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/speciella-former/primart-kutant-follikelcenterlymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/speciella-former/primart-duodenalt-follikulart-lymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/speciella-former/follikulart-lymfom-in-situ-intrafollikular-neoplasi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/speciella-former/follikulart-lymfom-grad-3b/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/primar-behandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/primar-behandling/behandlingsindikationer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/primar-behandling/primarbehandling-av-lokaliserad-sjukom-stadium-I-och-begransat-stadiumII/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/primar-behandling/spridd-sjukdom-iiiv-utan-behandlingsindikation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/primar-behandling/primarbehandling-av-spridd-sjukdom-med-behandlingsindikation/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/lokalt-symtomgivande-aterfallprogress/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-inom-2-ar-efter-rituximab-utan-kemoterapi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-inom-2-ar-efter-rituximab-utan-kemoterapi/tidigt-aterfall-inom-2-ar-efter-primart-rituximab-utan-kemoterapi/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-mer-an-2-ar-efter-rituximab-utan-kemoterapi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-mer-an-2-ar-efter-rituximab-utan-kemoterapi/utan-aggressiv-klinik/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-mer-an-2-ar-efter-rituximab-utan-kemoterapi/med-aggressiv-klinik/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-inom-2-ar-efter-forsta-linjens-rkemoterapi/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/aterfallprogress/behandlingskravande-aterfallprogress-mer-an-2-ar-efter-forsta-linjens-rkemoterapi/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/mosunetuzumab/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/mosunetuzumab/behandlingsschema/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/mosunetuzumab/tillagg-med-lenalidomid/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/mosunetuzumab/ovrig-profylax/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/mosunetuzumab/forslag-till-radiologiska-utvarderingar--aterbesok/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/biverkningar-vid-bsak-behandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/biverkningar-vid-bsak-behandling/cytokinfrisattningssyndrom-crs/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/biverkningar-vid-bsak-behandling/immuneffektorcells-associerat-neurotoxicitetssyndrom-icans/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/behandling-vid-upprepade-aterfall-och-palliation/biverkningar-vid-bsak-behandling/infektionsproblem-vid-bsak/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/rituximab-refraktaritet/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/anti-cd20ak-biverkningar/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/anti-cd20ak-biverkningar/sen-neutropeni-lon/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/anti-cd20ak-biverkningar/rituximab-inducerade-interstitiella-lungforandringar-r-ild/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/follikulart-lymfom/anti-cd20ak-biverkningar/progressiv-multifokal-encefalopati-pml/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/marginalzonslymfom--oversikt2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/marginalzonslymfom--oversikt2/inledning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/marginalzonslymfom--oversikt2/hepatit-c-associerade-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/marginalzonslymfom--oversikt2/multipla-och-besvarliga-recidiv-av-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/marginalzonslymfom--oversikt2/multipla-och-besvarliga-recidiv-av-marginalzonslymfom/bispecifika-antikroppar-vid-marginalzonslymfom/2025-07-07 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/marginalzonslymfom--oversikt2/transformation-av-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/bakgrund-och-orsaker/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/prognosfaktorer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/sarskilda-aspekter-vid-utredning-av-nmzl/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/primarbehandling/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/behandling-vid-symtomgivande-progressbehandlingssvikt/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nodalt-marginalzonslymfom/multipla-recidiv-eller-besvarlig-sjukdom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/bakgrund-och-orsaker/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/sarskilda-aspekter-vid-utredning-av-smzl/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/sarskilda-former-av-spleniska-indolenta-lymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/sarskilda-former-av-spleniska-indolenta-lymfom/spleniskt-lymfom-med-diffust-engagemang-av-mjaltens-roda-pulpa/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/sarskilda-former-av-spleniska-indolenta-lymfom/harcellsleukemivariant/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/prognosfaktorer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/primarbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/primarbehandling/behandlingsindikationer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/primarbehandling/behandlingsalternativ/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/behandling-vid-symtomgivande-progressbehandlingssvikt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/multipla-recidiv-eller-besvarlig-sjukdom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/spleniskt-marginalzonslymfom/sarskilda-aspekter-vid-uppfoljning-av-smzl/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/bakgrund-och-orsaker/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/sarskilda-aspekter-vid-utredning-av-gmalt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/prognosfaktorer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/primarbehandling-vid-begransat-gmalt-tom.-paragastriska-kortlar-musshoff-stadium-i-ii12025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/primarbehandling-vid-begransat-gmalt-tom.-paragastriska-kortlar-musshoff-stadium-i-ii1/om-eradikeringsbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/primarbehandling-vid-begransat-gmalt-tom.-paragastriska-kortlar-musshoff-stadium-i-ii1/om-kompletterande-antitumorala-behandlingar-efter-eradikeringsbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/primarbehandling-vid-spritt-gmalt-bortom-paragastriska-kortlar-musshoff-stadium-ii2-iv/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/multipla-recidiv-eller-besvarlig-sjukdom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/gastriskt-malt-gmalt/sarskilda-hansyn-vid-uppfoljning-av-gmalt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/sarskilda-aspekter-vid-utredning-av-icke-gastriskt-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/prognosfaktorer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/spottkortel-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/spottkortel-malt/primarbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/skoldkortel-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/skoldkortel-malt/primarbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/skoldkortel-malt/sarskilda-hansyn-vid-uppfoljning-av-skoldkortel-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/orbitaadnexa-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/orbitaadnexa-malt/primarbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/lung-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/lung-malt/primarbehandling/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/tjocktarms-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/tjocktarms-malt/primarbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/hud-malt/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/lever-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/brost-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/dura-malt/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/extranodala-marginalzonslymfom-malt/icke-gastriskt-malt/multipla-recidiv-eller-besvarlig-sjukdom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/indolenta-b-cellslymfom-uns/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/bakgrund-och-orsaker/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/behandlingsindikationer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/primarbehandling/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/behandling-till-gravida/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/behandlingskravande-forsta-aterfallprogress/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/behandlingskravande-forsta-aterfallprogress/16.3.3.1-symtomatiskt-recidiv-3-ar-efter-primarbehandling2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/behandlingskravande-forsta-aterfallprogress/16.3.3.2-symtomatiskt-progress-3-ar-efter-primarbehandling2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/klassisk-harcellsleukemi/multipla-aterfall/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/harcellsleukemivariant-samt-ighv4-34-uttryckande-harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/harcellsleukemivariant-samt-ighv4-34-uttryckande-harcellsleukemi/primarbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/harcellsleukemivariant-samt-ighv4-34-uttryckande-harcellsleukemi/recidivbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/transformation-av-harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/harcellsleukemi/responskriterier-for-harcellsleukemi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-ct/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-ct/komplett-remission-cr/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-ct/partiell-remission-pr/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-ct/aterfall-eller-progressiv-sjukdom-pd/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-ct/stabil-sjukdom-sd/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-ct/minor-response-mr/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/responskriterier/responsutvardering-med-pet-ct/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/inledning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/utredning-av-misstankt-transformation/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/utredning-av-misstankt-transformation/klinisk-transformationsdiagnos/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/utredning-av-misstankt-transformation/morfologisk-transformationsdiagnos-och-mycdubbelhit/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/behandling-av-transformation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/behandling-av-transformation/konsolidering-efter-antracyklin-innehallande-behandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/behandling-av-transformation/konsolidering-efter-icke-antracyklin-innehallande-behandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/behandling-av-transformation/car-t-cellsbehandling-vid-transformation/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/transformation/behandling-av-transformation/annan-behandling-vid-transformation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/stamcellsskord/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/stamcellsskord/indikationer-for-stamcellsskord-vid-follikulart-lymfom/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/stamcellsskord/indikationer-for-stamcellsskord-vid-ovriga-indolenta-b-cellslymfom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/autolog-stamcellstransplantation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/autolog-stamcellstransplantation/indikationer/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/allogen-stamcellstransplantation/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/stamcellstransplantation/allogen-stamcellstransplantation/indikationer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/levnadsvanor--generella/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/levnadsvanor--lymfomspecifika/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/blodprodukter/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/infektionsprofylax-efter-hogdosterapi/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/hepatit-b/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/herpesvirus/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/pneumocystis-jiroveci/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/allman-svampprofylax-candida-etc/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/g-csf/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/understodjande-vard/infektionsbehandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/kontaktsjukskoterska/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/cancerrehabilitering/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/sexualitet/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitet/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitet/kvinnor/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/fertilitet/man/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/fysisk-aktivitet/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/hygien-och-isolering/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/omvardnad-och-rehabilitering2/munvard/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/levnadsvanor/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/komplementar-och-alternativ-medicin/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/infektionskanslighet/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/munhygien/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/fysisk-aktivitet2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/hud/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/mage-och-tarm/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/vaccinationer/2025-06-05 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/egenvard2/feber/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/palliativ-vard-och-insatser2/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/inledning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/Mal-med-uppfoljningen/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/24.3-fornyad-behovsbedomning-for-rehabilitering-och-levnadsvanor2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/kontroll-av-obehandlad-patient/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/kontroll-efter-avslutad-behandling/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/kontrollernas-innehall/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/ansvar/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning/uppfoljning-av-sena-biverkningar/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/nivastrukturering/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/syfte-och-mal/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/innehall/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/Inklusionskriterier/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/exklusionskriterier/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/kvalitetsindikatorer/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/referenser/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/vardprogramgruppen/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardprogram/bilaga-1-termlista/2025-06-04 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/introduktion/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/introduktion/flodesschema-for-vardforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2021-09-02 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/indolenta-b-cellslymfom/vardforlopp/arbetsgruppens-sammansattning2/2021-09-02 https://kb.localhost:5000/diagnoser/kll/2022-04-07 https://kb.localhost:5000/diagnoser/kll/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/kll/vardprogram/sammanfattning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/2020-01-11 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/malgrupp/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/lagstod/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/inledning/forkortningsordlista/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/mal-med-vardprogrammet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bakgrund-och-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/kll/vardprogram/bakgrund-och-orsaker/epidemiologi/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bakgrund-och-orsaker/naturalhistoria/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bakgrund-och-orsaker/etiologi-och-arftlighet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/primar-prevention/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/symtom-och-tidig-utredning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/kll/vardprogram/diagnostik/diagnoskriterier/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/diagnostik/differentialdiagnostik/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/diagnostik/smacelligt-lymfocytiskt-lymfom-sll/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/diagnostik/monoklonal-b-cellslymfocytos-mbl/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/diagnostik/diagnosbesked/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/basal-utredning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/kompletterande-utredning-infor-behandling/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/utredning-vid-misstanke-om-transformation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/stadieindelning-enligt-rai-och-binet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/prognostiska-score-och-index/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/blod--och-serummarkorer/2022-01-25 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/blod--och-serummarkorer/lymfocytfordubblingstid-ldt/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/blod--och-serummarkorer/beta-2-mikroglobulin/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/genetiska-avvikelser--fish-och-gensekvensering/2022-01-25 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/genetiska-avvikelser--fish-och-gensekvensering/interfas-fish/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/genetiska-avvikelser--fish-och-gensekvensering/genmutationer-pavisade-med-sekvensering/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/genetiska-avvikelser--fish-och-gensekvensering/resistensmutationer-pavisade-med-sekvensering/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/immunogenetik--ighv-mutationsstatus/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/prognostiska-markorer-som-kan-vara-av-varde-men-som-enbart-ska-anvandas-i-studier/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/prognostiska-markorer-som-kan-vara-av-varde-men-som-enbart-ska-anvandas-i-studier/genetiska-markorer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/prognostiska-markorer-som-kan-vara-av-varde-men-som-enbart-ska-anvandas-i-studier/subsets-baserat-pa-b-cellsreceptorns-konfiguration/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/prognostiska-markorer-som-kan-vara-av-varde-men-som-enbart-ska-anvandas-i-studier/komplex-karyotyp-ck/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kategorisering-av-tumoren/stadieindelning/prognostiska-markorer-som-kan-vara-av-varde-men-som-enbart-ska-anvandas-i-studier/minimal-residual-disease-mrd/2024-10-02 https://kb.localhost:5000/diagnoser/kll/vardprogram/multidisciplinar-konferens/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/behandlingsindikation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/primarbehandling/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/primarbehandling/val-av-behandling/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/primarbehandling/forsta-linjens-behandling/2023-09-12 https://kb.localhost:5000/diagnoser/kll/vardprogram/primarbehandling/forsta-linjens-behandling/kll-utan-del17ptp53-mutation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/primarbehandling/forsta-linjens-behandling/behandlingsalternativ-for-kll-med-omuterad-ighv-utan-del17ptp53-mutation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/primarbehandling/forsta-linjens-behandling/kll-med-del17ptp53-mutation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/hypertoni/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/formaksflimmer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/ventrikulara-arytmier/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/blodningsrubbning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/ovriga-biverkningar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/progress-vid-behandlingsuppehall-och-avslut/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/interaktioner/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/btki/btki-resistens/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/bcl2i/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/bcl2i/venetoklaxresistens/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/cd20-antikroppar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/cd20-antikroppar/late-onset-neutropenia-lon/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/bendamustin/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/idelalisib/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/lakemedelsbehandling-vid-kll--fordjupad-information/behandling-av-skora-och-aldre/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/responsbedomning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/responsbedomning/klinisk-och-radiologisk-responsbedomning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/responsbedomning/measurable-residual-disease-mrd/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/uppfoljning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/behandling-vid-aterfall-eller-refraktar-kll/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/behandling-vid-aterfall-eller-refraktar-kll/val-av-behandling/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/behandling-vid-aterfall-eller-refraktar-kll/behandling-vid-aterfall-eller-refraktar-kll/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/behandling-vid-aterfall-eller-refraktar-kll/allogen-stamcellstransplantation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/behandling-vid-aterfall-eller-refraktar-kll/chimeric-antigen-receptor-t-cells-car-t-och-bispecifika-antikroppar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/2019-11-27 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/tumorlysprofylax/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/infektionsprofylax/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/infektionsprofylax/herpesvirus/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/infektionsprofylax/pneumocystis-jirovecii/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/infektionsprofylax/profylax-vid-genomgangen-hepatit-b/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/vaccinationer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/vaccinationer/influensa/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/vaccinationer/pneumokocker/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/vaccinationer/sars-cov-2/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/vaccinationer/levande-forsvagade-vaccin/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/vaccinationer/ovriga-vaccinationer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/understodjande-vard/sekundar-immunglobulinbrist/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/sjukdomsrelaterade-komplikationer/2022-01-25 https://kb.localhost:5000/diagnoser/kll/vardprogram/sjukdomsrelaterade-komplikationer/immunologiskt-betingade-cytopenier/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/sjukdomsrelaterade-komplikationer/immunologiskt-betingade-cytopenier/behandling-av-immunmedierad-hemolys-och-trombocytopeni/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/sjukdomsrelaterade-komplikationer/immunologiskt-betingade-cytopenier/behandling-av-prca/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/sjukdomsrelaterade-komplikationer/immunologiskt-betingade-cytopenier/behandling-av-autoimmun-neutropeni/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/sjukdomsrelaterade-komplikationer/transformation/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/krisreaktion--psykologiska-aspekter/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/sjukdomsspecifika-och-behandlingsrelaterade-komplikationer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/infektioner/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/fatigue-och-fysisk-svaghet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/illamaende/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/elimination/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/hud/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/sexualitet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/omvardnad-och-rehabilitering/fertilitet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/levnadsvanor/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/levnadsvanor/tobak/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/levnadsvanor/alkohol/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/levnadsvanor/fysisk-aktivitet/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/levnadsvanor/matvanor/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/vaccinationer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/naturlakemedel/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/egenvard/kunskap-och-stod/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/palliativ-vard-och-insatser/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/palliativ-vard-och-insatser/brytpunktssamtal/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/palliativ-vard-och-insatser/narstaendepenning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/palliativ-vard-och-insatser/palliativa-lakemedel-specifika-for-kll-patienter/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/underlag-for-nivastrukturering/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/uppfoljning-av-cancervarden/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/uppfoljning-av-cancervarden/svenska-kll-registret/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kvalitetsregister/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kvalitetsregister/kvalitetsindikatorer-faststallda-i-samrad-med-svensk-forening-for-hematologi/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/kvalitetsregister/andra-kvalitetsindikatorer/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/referenser2/2022-01-25 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/2020-01-11 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bedomning-av-allmantillstandet-funktionsstatus/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-1-information-till-dig-som-har-fatt-diagnosen-kronisk-lymfatisk-leukemi/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-1-information-till-dig-som-har-fatt-diagnosen-kronisk-lymfatisk-leukemi/de-flesta-behover-ingen-behandling-i-borjan/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-1-information-till-dig-som-har-fatt-diagnosen-kronisk-lymfatisk-leukemi/immunforsvaret-kan-bli-samre/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-1-information-till-dig-som-har-fatt-diagnosen-kronisk-lymfatisk-leukemi/det-finns-stod-att-fa-om-du-ar-orolig/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-1-information-till-dig-som-har-fatt-diagnosen-kronisk-lymfatisk-leukemi/ta-hand-om-dig-sjalv/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/malriktad-behandling/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/cytostatikabehandling/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/biverkningar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/biverkningar/forsamrat-immunforsvar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/biverkningar/illamaende/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/biverkningar/andra-biverkningar/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/levnadsvanor/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-2-information-till-dig-som-behandlas-for-kronisk-lymfatisk-leukemi/vaccination/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/komplett-remission-cr/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/komplett-remission-med-kvarstaende-cytopeni-cri/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/partiell-remission-med-lymfocytos-pr-l/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/partiell-remission-pr/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/progressiv-sjukdom-pd/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/stabil-sjukdom-sd/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-4.-responsbedomning/referenser/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-5-svenska-kll-gruppens-nationella-biobank/2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardprogram/bilaga-6.-definition-av-tumorlys-syndrom-enligt-cairo-bishop2024-09-29 https://kb.localhost:5000/diagnoser/kll/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/kll/vardforlopp/introduktion/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/introduktion/flodesschema-for-vardforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/kll/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/kll/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/kll/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2020-01-22 https://kb.localhost:5000/diagnoser/kll/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2020-01-22 https://kb.localhost:5000/diagnoser/kll/vardforlopp/utredning-och-beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/kll/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2021-09-02 https://kb.localhost:5000/diagnoser/kll/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/kll/vardforlopp/arbetsgruppens-sammansattning2/2020-01-22 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/2022-03-23 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/2022-03-23 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-12 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/ingang-till-standardiserat-vardforlopp/2022-03-23 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2022-03-23 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2022-03-23 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/utredning-och-beslut-om-behandling/2022-03-23 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-12 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling2/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/arbetsgruppens-sammansattning2/2024-11-12 https://kb.localhost:5000/diagnoser/maligna-lymfom-och-kll/vardforlopp/bilaga-1-kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/kml/2020-02-28 https://kb.localhost:5000/diagnoser/kml/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/kml/vardprogram/sammanfattning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-05-26 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/version-3.22025-05-27 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/version-3.12025-05-27 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/version-3.02025-05-27 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/vardprogrammets-forankring/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/vardprogramgruppens-sammansattning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/evidensgradering/2025-05-26 https://kb.localhost:5000/diagnoser/kml/vardprogram/inledning/forkortningsordlista/2025-05-27 https://kb.localhost:5000/diagnoser/kml/vardprogram/mal-med-vardprogrammet/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bakgrund-och-orsaker/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bakgrund-och-orsaker/incidens/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/bakgrund-och-orsaker/prognos/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/bakgrund-och-orsaker/prevalens/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/bakgrund-och-orsaker/etiologi/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/primar-prevention/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/primar-prevention/levnadsvanor/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/arftlighet/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/symtom-kliniska-fynd-och-diagnostik/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/morfologisk-bild/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/hur-pavisas-bcr-abl1/2023-06-08 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/hur-pavisas-bcr-abl1/bcrabl1-fusionen-kan-pavisas-med-tre-olika-metoder/2023-06-08 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/ovriga-utredningar/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/ovriga-atgarder-vid-nypptackt-kml/2023-04-20 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnostik-och-fortsatt-utredning/ovriga-atgarder-vid-nypptackt-kml/molekylar-uppfoljning-av-behandlingssvar/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/diagnostik-och-fortsatt-utredning/diagnosbesked/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kategorisering-i-sjukdomsfaser-samt-riskgruppering/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kategorisering-i-sjukdomsfaser-samt-riskgruppering/kategorisering-i-sjukdomsfaser/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kategorisering-i-sjukdomsfaser-samt-riskgruppering/riskgruppering-i-kronisk-fas/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kategorisering-i-sjukdomsfaser-samt-riskgruppering/riskgruppering-i-kronisk-fas/eutos-long-term-survival-elts-score/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kategorisering-i-sjukdomsfaser-samt-riskgruppering/riskgruppering-i-kronisk-fas/sokal-score/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kategorisering-i-sjukdomsfaser-samt-riskgruppering/riskgruppering-efter-behandlingssvar/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/multidisciplinar-konferens/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/bakgrund-och-overgripande-behandlingsmal/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/inledande-behandling/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/val-av-forsta-linjens-tki-behandling/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/behandling-med-andra-lakemedel-an-tki/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/behandling-med-andra-lakemedel-an-tki/cytogenetisk-och-molekylargenetisk-monitorering/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/behandling-med-andra-lakemedel-an-tki/uppfoljning-av-svar-efter-3-manaders-behandling/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/behandling-med-andra-lakemedel-an-tki/foljsamhet-till-behandlingen/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/behandling-med-andra-lakemedel-an-tki/interaktion-mellan-tki-och-andra-lakemedel/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--forsta-linjens-behandling-inklusive-uppfoljning/behandling-med-andra-lakemedel-an-tki2/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/imatinib/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/nilotinib/2025-06-04 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/bosutinib/2025-06-04 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/dasatinib/2025-06-04 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/ponatinib/2025-06-04 https://kb.localhost:5000/diagnoser/kml/vardprogram/tyrosinkinashammare-for-forsta-linjens-behandling-av-kml-i-kronisk-fas/tyrosinkinashammare/asciminib/2025-06-04 https://kb.localhost:5000/diagnoser/kml/vardprogram/biverkningar/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/biverkningar/foljsamhet-compliance/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/biverkningar/foljsamhet-compliance/biverkningar-vid-tki-behandling--generella-synpunkter/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/forsok-att-avsluta-tki-behandling/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/forsok-att-avsluta-tki-behandling/bakgrund/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kardiovaskular-riskvardering-och-uppfoljning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kardiovaskular-riskvardering-och-uppfoljning/kardiovaskular-riskvardering-infor-tki-behandling/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kardiovaskular-riskvardering-och-uppfoljning/kardiovaskular-uppfoljning-under-tki-behandling/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/bakgrund/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/behandlingssvikt-och-forekomst-av-mutationer-i-bcr-abl1/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/behandlingssvikt-och-forekomst-av-mutationer-i-bcr-abl1/handlaggning-vid-fynd-av-mutation-t315i-i-bcrabl1/2023-04-20 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/val-av-behandling-nar-behandlingsmal-inte-uppnatts-pa-forsta-linjens-tki/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/val-av-andra-linjens-tki-behandling-vid-intolerans-mot-tidigare-tki/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/uppfoljning-av-behandlingssvar-under-andra-linjens-tki-behandling/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kronisk-fas--andra-linjens-behandling-och-senare-inklusive-uppfoljning/uppfoljning-av-behandlingssvar-under-andra-linjens-tki-behandling/molekylargenetisk-och-cytogenetisk-monitorering/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/Behandling-i-accelererad-fas-och-blastkris/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/Behandling-i-accelererad-fas-och-blastkris/bakgrund-och-utredning/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/Behandling-i-accelererad-fas-och-blastkris/behandlingsrekommendation-for-ap/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/Behandling-i-accelererad-fas-och-blastkris/behandlingsrekommendation-for-blastkris/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/konception-graviditet-och-amning/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/konception-graviditet-och-amning/icke-planerad-graviditet-hos-tki-behandlad-patient/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/konception-graviditet-och-amning/planerad-graviditet-hos-kand-tki-behandlad-kml-patient/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/konception-graviditet-och-amning/kml-diagnos-under-graviditet/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/konception-graviditet-och-amning/amning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/konception-graviditet-och-amning/man/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/bakgrund/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/indikationer-for-allo-sct/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/indikationer-for-allo-sct/blastkris/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/indikationer-for-allo-sct/accelererad-fas/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/indikationer-for-allo-sct/svikt-eller-intolerans-pa-andra-generationens-tki-i-kronisk-fas/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/indikationer-for-allo-sct/forekomst-av-t315i-mutationen/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/indikationer-for-allo-sct/sjukdomsborda-och-utvardering-fore-allo-sct/2023-04-20 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/allo-sct--procedurfragor/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/allo-sct--procedurfragor/prediktiva-score/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/allo-sct--procedurfragor/val-av-donator/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/allo-sct--procedurfragor/konditionering-infor-allo-sct/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/allo-sct--procedurfragor/stamcellskalla/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/uppfoljning-och-behandling-efter-sct/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/uppfoljning-och-behandling-efter-sct/tki--underhallsbehandling-efter-allo-sct/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/uppfoljning-och-behandling-efter-sct/monitorering-efter-allo-sct/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/behandling-vid-kvarvarande-sjukdom-och-aterfall/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/behandling-vid-kvarvarande-sjukdom-och-aterfall/tki-behandling-vid-aterfall-efter-allo-sct/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/allogen-stamcellstransplantation-vid-kml/behandling-vid-kvarvarande-sjukdom-och-aterfall/behandling-med-donatorlymfocyter-dli/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/understodjande-vard/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/understodjande-vard/tumorlyssyndrom-tls--profylax/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/understodjande-vard/infektionsprofylax/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/understodjande-vard/behandling-med-tillvaxtfaktorer/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/Palliativ-vard-och-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/kml/vardprogram/Palliativ-vard-och-behandling/palliativ-behandling-i-kronisk-fas-kml/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/Palliativ-vard-och-behandling/palliativ-behandling-i-accelererad-fas-och-blastfas-kml/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/Palliativ-vard-och-behandling/generell-palliativ-behandling/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/oversikt/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/personalresurser-for-psykosocialt-stod/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-specialiserad-rehabilitering/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/fatigue-och-fysisk-svaghet/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/omvardnad-och-rehabilitering/sexualitet-och-fertilitet/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/egenvard/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/egenvard/levnadsvanor/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/egenvard/levnadsvanor/tobak/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/egenvard/levnadsvanor/alkohol/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/egenvard/levnadsvanor/fysisk-aktivitet/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/egenvard/levnadsvanor/matvanor/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/Underlag/2023-05-01 https://kb.localhost:5000/diagnoser/kml/vardprogram/svenska-kml-registret/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/svenska-kml-registret/cancerregistret/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer-faststallda-i-samrad-med-svensk-forening-for-hematologi/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/kvalitetsindikatorer-och-malnivaer/andra-kvalitetsparametrar/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/referenser/2023-04-20 https://kb.localhost:5000/diagnoser/kml/vardprogram/forslag-pa-fordjupning/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-05-26 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-05-26 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-05-26 https://kb.localhost:5000/diagnoser/kml/vardprogram/relevanta-lankar/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bilaga-1/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bilaga-2/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bilaga-2/definition-av-molekylar-respons-vid-rt-qpcr-for-bcrabl1-/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bilaga-2/definition-av-molekylar-respons-vid-rt-qpcr-for-bcrabl1-/internationella-skalan-is/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bilaga-2/definition-av-molekylar-respons-vid-rt-qpcr-for-bcrabl1-/graden-av-molekylar-respons/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardprogram/bilaga-2/definition-av-cytogenetisk-respons/2023-04-19 https://kb.localhost:5000/diagnoser/kml/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/kml/vardforlopp/vardforlopp-for-kronisk-myeloisk-leukemi/2019-11-27 https://kb.localhost:5000/diagnoser/levercellscancer/2022-04-07 https://kb.localhost:5000/diagnoser/levercellscancer/forkortat-vardforlopp/2025-11-20 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/levercellscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/2020-08-21 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/sammanfattning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/2020-01-22 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/malgrupp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/standardiserat-vardforlopp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/lagstod/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/evidensgradering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/inledning/jav-och-andra-bindningar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/mal-med-vardprogrammet/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/inledning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/epidemiologi/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/epidemiologi/incidens/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/epidemiologi/prognos-och-overlevnad/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/orsaker/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-viral-hepatit/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-viral-hepatit/kronisk-viral-hepatit/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-viral-hepatit/behandling-av-kronisk-viral-hepatit/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-viral-hepatit/screening-for-viral-hepatit/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/alkohol/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/kaffe-och-te/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/rokning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/overvikt-och-fysisk-aktivitet/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/levercirros-av-annan-icke-viral-orsak/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Bakgrund-och-orsaker/primar-prevention-vid-icke-viral-leversjukdom/porfyri/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/genomforande-av-hcc-overvakning-surveillance/2020-01-22 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/genomforande-av-hcc-overvakning-surveillance/definition-av-hcc-overvakning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/genomforande-av-hcc-overvakning-surveillance/genomforande-av-hcc-overvakning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/genomforande-av-hcc-overvakning-surveillance/genomforande-av-hcc-overvakning/kvalitetsaspekter/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/genomforande-av-hcc-overvakning-surveillance/genomforande-av-hcc-overvakning/modell-for-kallelse-aterkoppling-och-handlaggning-enligt-svf/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/genomforande-av-hcc-overvakning-surveillance/genomforande-av-hcc-overvakning/likformig-handlaggning-av-misstankta-fynd/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/metod-for-hcc-overvakning/2020-01-22 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/metod-for-hcc-overvakning/ultraljud/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/metod-for-hcc-overvakning/dr-och-mrt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/metod-for-hcc-overvakning/biokemiska-test-serummarkorer/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/intervall-for-hcc-overvakning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/patienturval/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/levercirros/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/kronisk-hepatit-b/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/kronisk-hepatit-c/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/alkoholleversjukdom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/primar-biliar-cirros-pbc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/autoimmun-hepatit-aih/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/arftlig-hemokromatos-hh/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/alfa-1-antitrypsinbrist/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/wilsons-sjukdom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/masld-metabolic-dysfunction-associated-steatotic-liver-disease-tidigare-benamnt-nafld/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/akut-intermittent-porfyri-aip/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/underliggande-diagnoser/porfyria-cutanea-tarda-pct/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/screening--overvakning-surveillance-av-riskgrupper/kostnadseffektivitet-av-hcc-overvakning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/arftlighet/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/symtom-och-tidig-utredning/2020-01-22 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/symtom-och-tidig-utredning/Symtom-och-kliniska-fynd/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/val-av-metod/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/val-av-metod/kontrastforstarkt-ultraljud-ceus/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/val-av-metod/datortomografi/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/val-av-metod/mrt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/radiologiska-kriterier-for-hcc-diagnos/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/radiologiska-kriterier-for-hcc-diagnos/icke-invasiva-kriterier/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/radiologiska-kriterier-for-hcc-diagnos/li-rads-liver-imaging-reporting-and-data-system/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/forandringar-med-atypiskt-kontrastuppladdnings-monster/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/radiologiska-aspekter-vid-hcc-i-icke-cirrotisk-lever/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/radiologisk-bedomning-av-behandlingsrespons-vid-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/radiologisk-diagnostik-av-hcc/checklista-for-radiologiskt-standardutlatande-vid-levertumorfragestallning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/indikation-for-leverbiopsi/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/tumorstorlek/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/tumorens-vaxtsatt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/antal-tumorer-och-forekomst-av-satelliter/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/malign-vaskular-invasion/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/lymfkortelmetastasering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/fjarrmetastasering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/tumorutbredning/tumormarkoren-alfa-fetoprotein/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/child-turcotte-pugh-ctp/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/child-turcotte-pugh-ctp/poangbedomning-av-ascites-enligt-child-turcotte-pugh-skalan-ctp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/child-turcotte-pugh-ctp/gradering-av-encefalopati-enligt-child-turcotte-pugh-skalan-ctp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/preoperativ-bedomning-av-leverfunktion/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/ecog/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/leverfunktion/samsjuklighet-och-asa/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/stadieindelning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/stadieindelning/tnm/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/stadieindelning/bclc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/staging-vid-hcc/stadieindelning/svensk-behandlingsalgoritm/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/diagnosbesked/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/diagnostik/8.6omvardnad-och-rehabilitering2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/diagnostisk-biopsi-och-finnalsaspirat/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/kvalitetsuppfoljning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2020-01-23 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/leverbiopsi/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/leverresektat/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/leverresektat/radiala-resektionsytor-pa-operationspreparat/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/biopsier-och-cytologi/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/operationspreparat/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/diagnostik-av-biopsier/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/diagnostik-av-operationspreparat/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/diagnostik-av-operationspreparat/hepatocellullart-carcinom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/diagnostik-av-operationspreparat/blandat-hepatocellulart-kolangiocarcinom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/diagnostik-av-operationspreparat/hepatocellulart-adenom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/diagnostik-av-cytologiskt-material-fnac/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kategorisering-av-tumoren/tillaggsanalyser/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/multidisciplinar-konferens/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/multidisciplinar-konferens/kompetens/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/multidisciplinar-konferens/nivastrukturering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/multidisciplinar-konferens/vilka-patienter-ska-bedomas-vid-hepatobiliar-mdk/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/multidisciplinar-konferens/ny-medicinsk-bedomning-second-opinion/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/primar-behandlingsoversikt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/primar-behandlingsoversikt/forutsattningar-for-kurativt-syftande-behandlingar--ablation-resektion-och-levertransplantation/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/primar-behandlingsoversikt/forutsattningar-for-kurativt-syftande-behandlingar--ablation-resektion-och-levertransplantation/icke-cirrotisk-lever/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/primar-behandlingsoversikt/forutsattningar-for-kurativt-syftande-behandlingar--ablation-resektion-och-levertransplantation/cirrotisk-lever/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/primar-behandlingsoversikt/forutsattningar-for-kurativt-syftande-behandlingar--ablation-resektion-och-levertransplantation/betydelsen-av-tumorstorlek-och-antal/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/primar-behandlingsoversikt/forutsattningar-och-indikation-for-transarteriella-och-systemiska-behandlingar-vid-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/forutsattningar-for-ablativ-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/val-av-ablationsmetod/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/val-av-ablationsmetod/mwa-och-rfa/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/val-av-ablationsmetod/lokalablativ-metod-med-lagt-eller-otillrackligt-vetenskapligt-stod/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/val-av-ablationsmetod/kombination-av-lokoregionala-behandlingar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/accessvagar-och-tekniker-for-att-overbrygga-svarigheter/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/resektion-ablation-och-transplantation/komplikationer-efter-ablation/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/leverresektion/2020-01-23 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/leverresektion/forutsattningar-for-leverresektion/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/leverresektion/anatomisk-resektion-eller-kilresektioner/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/leverresektion/oppen-eller-minimalinvasiv-teknik/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/leverresektion/metoder-for-volymtillvaxt-av-flr/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/leverresektion/komplikationer-efter-leverresektion/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/selektionskriterier-for-ltx-vid-hcc/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/bridging-i-vantan-pa-ltx/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/downstaging-for-ltx/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/11.4.4tumorovervakning-under-vantetiden-for-ltx2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/komplikationer-efter-ltx/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/levertransplantation-ltx-vid-hcc/immunsuppression-efter-ltx/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/inledning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/indikationer-och-kontraindikationer-for-transarteriell-behandling/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kemoembolisering-tace/2020-01-23 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kemoembolisering-tace/effekt-av-konventionell-transarteriell-kemoembolisering-ctace/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kemoembolisering-tace/effekt-av-drug-eluting-bead-tace-deb-tace/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kemoembolisering-tace/transarteriell-kemoinfusion-tai/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kemoembolisering-tace/transarteriell-embolisering-tae/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kemoembolisering-tace/biverkningar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/selective-internal-radiation-therapy-sirt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/selective-internal-radiation-therapy-sirt/biverkningar-kopplade-till-sirt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/tace-eller-sirt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/tace-vid-pvt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/tace-vid-pvt/sirt-vid-pvt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/kombination-av-lokoregionala-behandlingar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/transarteriell-lokoregional-behandling/downstaging-samt-neoadjuvant-och-adjuvant-transarteriell-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/neoadjuvant-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/adjuvant-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/leverfunktion-och-systemisk-onkologisk-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/atezolizumab-bevacizumab/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/tremelimumab-durvalumab/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/immunterapi-singelregim/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/sorafenib/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/lenvatinib/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/11.6.3forsta-linjen-palliativ-systemisk-behandling/lokaliserad-hcc-med-god-respons-pa-palliativ-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/regorafenib/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/cabozantinib/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/ramucirumab/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/immunterapi-efter-forsta-linjen/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/information-om-behandlingsregimer/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/komplikationer-till-onkologisk-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/primar-behandling-inklusive-pre--och-postoperativ-behandling/systemisk-behandling/palliativ-onkologisk-behandling-efter-forsta-linjen/11.6.7stereotaktisk-stralbehandling2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/behandling-av-aterfall/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/behandling-av-aterfall/prognostiska-faktorer-vid-tumoraterfall/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/behandling-av-aterfall/hcc-aterfall-efter-resektion-och-ablation/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/behandling-av-aterfall/hcc-aterfall-efter-transplantation/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/behandling-av-aterfall/hcc-aterfalltumorprogress-efter-transarteriell-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/portal-hypertension-och-varicer-vid-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/portal-hypertension-och-varicer-vid-hcc/riskbedomning-och-primarprofylax/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/portal-hypertension-och-varicer-vid-hcc/behandling-av-varixblodning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/portal-hypertension-och-varicer-vid-hcc/sekundarprofylax/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/portal-hypertension-och-varicer-vid-hcc/systemisk-behandling-av-hcc-och-risk-for-varixblodning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/blodningsrisk-vid-portatrombos-och-makrovaskular-spridning-av-hcc/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/ascites/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/ascites/diagnostik-och-tappning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/ascites/spontan-bakteriell-peritonit-sbp/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/ascites/ovrig-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/ascites/hepatisk-hydrotorax/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/ascites/omvardnad/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/leverencefalopati/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/leverencefalopati/diagnostik/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/leverencefalopati/behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/leverencefalopati/vardniva/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/cirroskomplikationer/leverencefalopati/omvardnad/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionstatus/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/nutritionsbehandling-vid-levercirros-och-hcc/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/nutritionsbehandling-vid-kirurgi-och-transplantation/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/nutritionsbehandling-vid-kirurgi-och-transplantation/preoperativt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/nutritionsbehandling-vid-kirurgi-och-transplantation/postoperativt/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/nutritionsbehandling-vid-kirurgi-och-transplantation/postoperativ-leversvikt-och-nutrition/2025-01-15 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/nutrition/nutritionsbehandling/nutritionsbehandling-vid-palliativ-tumorbehandling-och-vid-palliativ-vard/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/understodjande-vard/klada/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/bekraftande-omvardnad/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/cancerrehabilitering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/att-framja-halsorelaterad-livskvalitet-genom-symtomlindring/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/att-framja-halsorelaterad-livskvalitet-genom-symtomlindring/halsorelaterad-livskvalitet/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/att-framja-halsorelaterad-livskvalitet-genom-symtomlindring/bedoma-halsorelaterad-livskvalitet-och-symtom-under-sjukdomsforloppet/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/fatigue/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/fatigue/bedoma-och-behandla-fatigue/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/smarta/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/omvardnad-och-rehabilitering/smarta/bedoma-och-behandla-smarta/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/egenvard/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/egenvard/fysisk-aktivitet/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/egenvard/komplementar-och-alternativ-medicin/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/egenvard/riskbruk-alkohol-narkotika-och-tobak/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/palliativ-vard-och-insatser/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/palliativ-vard-och-insatser/16.1nutritionsbehandling-vid-palliativ-vard2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/palliativ-vard-och-insatser/symtom-i-sen-palliativ-fas/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering-och-levnadsvanor/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/kontroll-av-aterfall/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsschema-efter-hcc-behandling/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/ansvar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/17.8livslang-symtomkontroll-efter-avslutad-uppfoljning2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/underlag-for-nivastrukturering/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning-av-cancervarden/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning-av-cancervarden/sweliv/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/referenser/2022-04-06 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Vardprogramgruppen/2020-01-23 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Vardprogramgruppen/vardprogramgruppens-sammansattning/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Vardprogramgruppen/vardprogramgruppens-medlemmar-i-denna-revision/2025-01-13 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Vardprogramgruppen/jav-och-andra-bindningar/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/Vardprogramgruppen/vardprogrammets-forankring/2024-12-12 https://kb.localhost:5000/diagnoser/levercellscancer/vardprogram/kvalitetsdokument-for-patologi/2024-12-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/2022-06-27 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/sammanfattning/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/standardiserat-vardforlopp/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/lagstod/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/evidensgradering/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/inledning/forkortningar-och-begreppsforklaringar/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/mal-med-vardprogrammet/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/epidemiologi-och-screening-for-forstadier/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/infektion-med-hpv/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/utveckling-av-forstadier-till-livmoderhalscancer-och-invasiv-cancer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/anvandning-av-hpv-testning-i-screeningprogrammet/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/profylaktisk-hpv-vaccination-och-annan-primarprevention/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/bakgrund-orsaker-och-prevention/terapeutiska-vacciner/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/symtom/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/symtom/blodning/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/symtom/flytning/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/symtom/smartor/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/symtom/ovriga-symtom/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/primarutredning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/handlaggning-enligt-standardiserat-vardforlopp-svf/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/palpation-i-narkos-pin/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/magnetresonanstomografi-mrt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/magnetresonanstomografi-mrt/mrt-vid-utvardering-av-behandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/transvaginalt-ultraljud-tvs/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/datortomografi-dt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/positronemissionstomografi-datortomografi-pet-dt-med-fdg/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/positronemissionstomografi-datortomografi-pet-dt-med-fdg/stadieindelning-fore-behandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/positronemissionstomografi-datortomografi-pet-dt-med-fdg/planering-infor-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/positronemissionstomografi-datortomografi-pet-dt-med-fdg/utvardering-av-behandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/primarutredning-av-diagnostiserad-livmoderhalscancer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/primarutredning-av-diagnostiserad-livmoderhalscancer/lokal-tumorutbredning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/primarutredning-av-diagnostiserad-livmoderhalscancer/lokal-tumorutbredning/mrt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/primarutredning-av-diagnostiserad-livmoderhalscancer/lokal-tumorutbredning/transvaginalt-ultraljud-tvs/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/utredning/bilddiagnostik/primarutredning-av-diagnostiserad-livmoderhalscancer/tumorspridning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/Stadieindelning-av-livmoderhalscancer-enligt-TNM-och-FIGO-ar-2018/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/stadieindelning-av-invasiv-vaginalcancer-enligt-AJCC-TNM-och-FIGO-klassifikationen-from-2023-01-01/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/patologi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/patologins-roll-i-den-diagnostiska-processen/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anvisningar-for-provtagarens-hantering-av-provet/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anvisningar-for-provtagarens-hantering-av-provet/biopsi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anvisningar-for-provtagarens-hantering-av-provet/slyngkon/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anvisningar-for-provtagarens-hantering-av-provet/koniseringsmaterial/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anvisningar-for-provtagarens-hantering-av-provet/hysterektomi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anamnestisk-remissinformation/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anamnestisk-remissinformation/portvaktskortelbiopsi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/anamnestisk-remissinformation/PDL1-analys/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/skivepitelforandringar-i-cervix/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/skivepitelforandringar-i-cervix/icke-invasiva-skivepitelforandringar-i-cervix/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/skivepitelforandringar-i-cervix/Invasiv-skivepitelcancer-i-cervix/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/glandular-neoplasi-i-cervix2/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/glandular-neoplasi-i-cervix2/adenokarcinom-in-situ-ais/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/glandular-neoplasi-i-cervix2/invasivt-adenokarcinom-uns/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/glandular-neoplasi-i-cervix2/adenocarcinom-hpv-oberoende/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/stadieindelning/ovriga-epiteliala-tumorer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/vid-operation/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/skivepitelcancer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/klarcellscancer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/ovriga-adenocarcinom/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/ovriga/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/ovriga/mesenchymala-tumorer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/ovriga/bifasiska-tumorer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kategorisering-av-tumoren/patologi-vid-vaginalcancer/ovriga/malignt-melanom/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/multidisciplinar-konferens/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/multidisciplinar-konferens/nationell-mdk-trakelektomi/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/overlevnad-i-olika-stadier/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/spridning-till-lymfkortlar/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/spridning-av-cancer-till-lymf--och-blodkarl-lvi-lvsi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/histologi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/tumorstorlek/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/alder/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/marginaler/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/infiltrationsdjup/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/parametrieengagemang/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/prognos/prognostiska-faktorer/9.2.9-hpv-status2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/oversikt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-metoder/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-principer-for-radikal-hysterektomi-rh/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-principer-for-radikal-hysterektomi-rh/generella-kirurgiska-principer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-principer-for-radikal-hysterektomi-rh/radikal-hysterektomi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-principer-for-radikal-hysterektomi-rh/nervsparande-kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-principer-for-radikal-hysterektomi-rh/salpingo-ooforektomi-SOE/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgiska-principer-for-radikal-hysterektomi-rh/ooforopexi2/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgisk-lymfkorteldiagnostik/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgisk-lymfkorteldiagnostik/lymfadenektomi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgisk-lymfkorteldiagnostik/Portvaktskorteldiagnostik/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgisk-lymfkorteldiagnostik/peroperativa-fynd-av-lymfkortelmetastaser-vid-primar-kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/fertilitetsbevarande-kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/komplikationer-efter-primar-kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/komplikationer-efter-primar-kirurgi/skador-pa-urinvagar-och-tarm/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/komplikationer-efter-primar-kirurgi/skador-pa-nerver/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/komplikationer-efter-primar-kirurgi/vaginaltopp/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/komplikationer-efter-primar-kirurgi/lymfvagar/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgi-vid-lokalt-avancerad-sjukdom/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/hysterektomi-vid-resttumor-efter-primar-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/kirurgisk-lymfkortelutrymning-infor-definitiv-kombinerad-cytostatika-och-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/Kirurgisk-behandling-efter-incidentellt-fynd-av-livmoderhalscancer-ockult-livmoderhalscancer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/stumpcancer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/neoadjuvant-cytostatikabehandling-NACT/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/kirurgi/vantetid-till-kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/bakgrund2/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/bakgrund2/extern-stralbehandling-ebrt-external-beam-radiation-therapy/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/bakgrund2/konkomitant-cytostatikabehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/bakgrund2/brachyterapi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/targetdefinition-ebrt/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/Stralbehandling-riktad-mot-paraaortala-lymfkortelstationer-pa-falt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/toleransnivaer-och-riskorgan-vid-ebrt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/teknik/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/targetdefinition-brachyterapi-bt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/total-behandlingstid-och-total-dos/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/straldoser-vid-brachyterapi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/toleransnivaer-och-riskorgan-vid-brachyterapi-bt/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/resurser-for-igart/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/brachyterapi-bt/kompetenskrav/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/protonterapi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/faktorer-som-paverkar-resultatet-vid-stralbehandling/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/faktorer-som-paverkar-resultatet-vid-stralbehandling/total-behandlingstid-ott/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/faktorer-som-paverkar-resultatet-vid-stralbehandling/vantetid-till-start-av-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/faktorer-som-paverkar-resultatet-vid-stralbehandling/anemi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/faktorer-som-paverkar-resultatet-vid-stralbehandling/rokning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/faktorer-som-paverkar-resultatet-vid-stralbehandling/organrorelser/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/definitiv-kombinerad-cytostatika-och-stralbehandling/adaptiv-stralbehandling-igart/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/postoperativ-adjuvant-behandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/postoperativ-adjuvant-behandling/bakgrundindikation/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/postoperativ-adjuvant-behandling/bakgrundindikation/radiokemoterapi-kombinerad-cytostatika--och-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/postoperativ-adjuvant-behandling/bakgrundindikation/lymfkortlar-tumorstorlek-djupvaxt-lvsi-och-kirurgiska-marginaler/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/postoperativ-adjuvant-behandling/bakgrundindikation/hogmalign-histologi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/Stralbehandling/postoperativ-adjuvant-behandling/targetdefinition/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/spridd-sjukdom-fjarrmetastaser-cytostatikabehandling-vid-aterfall/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/adjuvant-cytostatikabehandling-efter-kombinerad-cytostatika-och-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/nact-innan-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/differentialdiagnostik-klinik-och-utredning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/prognostiska-faktorer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/handlaggning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/kirurgi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/Kombinerad-cytostatika-och-stralbehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/cytostatikabehandling/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/Stralbehandling/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/brachyterapi-vid-lokalt-avancerad-sjukdom/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/behandling-vid-avancerad-sjukdom-och-aterfall/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-behandling/neuroendokrin-livmoderhalscancer-nec/malriktad-och-immunmodulerande-terapi-nytt-forskningsfalt/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/epidemiologi/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/etiologi-och-riskfaktorer/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/patologi-och-hantering-av-operationspreparat/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/prognostiska-faktorer/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/klassifikation-och-stadieindelning/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/spridningsvagar/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/symtom/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/diagnostik/2024-08-06 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/allmanna-synpunkter/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/allmanna-synpunkter/stralbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/allmanna-synpunkter/bildbaserad-adaptiv-brachyterapi-IGABT-2/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/allmanna-synpunkter/cytostatikabehandling-2/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/Behandling-stadium-I/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/Behandling-stadium-I/stralbehandling/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/Behandling-stadium-I/kirurgi/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/behandling-stadium-ii/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/behandling-stadium-III-IVA/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandling/behandling-stadium-ivb/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/uppfoljning/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/behandlingskomplikationer-och-seneffekter-av-behandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/primar-vaginalcancer/prognos-och-aterfall/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/graviditetslangd/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/klinisk-cytologisk-och-histopatologisk-utredning/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/klinisk-cytologisk-och-histopatologisk-utredning/stadieindelning-och-bilddiagnostik/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/klinisk-cytologisk-och-histopatologisk-utredning/laparoskopisk-lymfkortelutrymning/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/klinisk-cytologisk-och-histopatologisk-utredning/histologisk-typ/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/behandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/behandling/behandling-om-kvinnan-inte-onskar-fortsatta-graviditeten/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/behandling/Behandling-om-kvinnan/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/behandling/Behandling-om-kvinnan/livmoderhalscancer-diagnostiserad-fore-graviditetsvecka-15/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/behandling/Behandling-om-kvinnan/livmoderhalscancer-diagnostiserad-i-graviditetsvecka-1522/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/behandling/Behandling-om-kvinnan/livmoderhalscancer-diagnostiserad-efter-graviditetsvecka-22/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/neoadjuvant-cytostatikabehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/antiemetika/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/graviditet-och-livmoderhalscancer/graviditetsavslut/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-07-07 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-diagnos/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-diagnos/information-i-samband-med-diagnos-och-behandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-diagnos/diagnosbesked/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-diagnos/diagnosbesked/diagnosbesked-i-oppenvard-hemsjukhus/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-diagnos/diagnosbesked/diagnosbesked-pa-behandlande-klinikforsta-lakarbesok-pa-behandlande-klinik/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Omvardnad-vid-kirurgisk-behandling/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Omvardnad-vid-kirurgisk-behandling/preoperativ-omvardnad/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Omvardnad-vid-kirurgisk-behandling/postoperativ-omvardnad/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Omvardnad-vid-kirurgisk-behandling/utskrivningssamtal/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Omvardnad-vid-kirurgisk-behandling/uppfoljningssamtal/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/gastrointestinala-symtom/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/urinvagar/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/genitala-slemhinnor-och-paverkan-pa-sexualitet/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/alopeci-haravfall/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/hudpaverkan/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/lymfodem/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/rokning/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-stralbehandling/benmarg/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-brachyterapi/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/illamaende/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/forstoppning/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/nutritionsproblem/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/slemhinnor/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/benmarg/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/alopeci-haravfall/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/neuropatier/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/muskel--och-ledvark/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/tarmpaverkan/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/fatigue/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/kognitiv-paverkan/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling/hudbesvar/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-i-samband-med-cytostatikabehandling-vid-aterfall/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aterfallskirurgi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aterfallskirurgi/stomier/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Sexualitet-i-samband-med-livmoderhalscancer-och-vaginalcancer/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Sexualitet-i-samband-med-livmoderhalscancer-och-vaginalcancer/efter-kirurgi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Sexualitet-i-samband-med-livmoderhalscancer-och-vaginalcancer/efter-stralbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Sexualitet-i-samband-med-livmoderhalscancer-och-vaginalcancer/efter-cytostatikabehandling/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/Sexualitet-i-samband-med-livmoderhalscancer-och-vaginalcancer/rad-hjalpmedel-och-behandling-vid-sexuell-dysfunktion/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/infertilitet/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/MHT-menopausal-hormonterap-och-lokal-ostrogenbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/tarmbesvar-efter-kirurgi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/tarmbesvar-vid-och-efter-stralbehandling/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/los-avforing-avforingsinkontinens/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/gasbildning/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/magknip/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/tarmflora/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/bakteriell-overvaxt-pa-tunntarmen/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/gallsyramalabsorption-rubbad-pankreasenzymfunktion/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/blodning-fran-andtarmen/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/behandling-av-tarmbesvar/naringsbrist/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/symtom-fran-urinblasan/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/symtom-fran-urinblasan/allmanna-rad-vid-overaktiv-blasa-och-urininkontinens/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/symtom-fran-urinblasan/rad-vid-blastomningssymtom/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/symtom-fran-urinblasan/rad-och-behandling-vid-lokal-ostrogenbrist/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/rad-vid-ovriga-fysiska-biverkningar-efter-livmoderhalscancer/symtom-fran-urinblasan/rad-och-behandling-vid-upprepade-symtom-pa-urinvagsinfektion-uvi/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/hyperbar-oxygenbehandling-hbo-tryckkammarbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/mikrofrakturer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/mikrofrakturer/behandling-av-smartor-fran-backenskelettet-efter-stralbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/lymfodem/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/omvardnad-och-rehabilitering/krisreaktion-stodinsatser/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/klinisk-uppfoljning/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/klinisk-uppfoljning/uppfoljning-efter-kirurgi/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/klinisk-uppfoljning/uppfoljning-efter-stralbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/klinisk-uppfoljning/uppfoljningsduration-och-syfte/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/klinisk-uppfoljning/bilddiagnostik/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/klinisk-uppfoljning/aterfall/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/uppfoljning/utredning-vid-aterfall/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/prognos/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/efter-primaroperation-tidigare-ej-stralbehandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/efter-stralbehandling/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/spridd-sjukdom/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/kirurgisk-behandling-av-aterfall/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/kirurgisk-behandling-av-aterfall/prognos-efter-kirurgisk-behandling/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandling-av-aterfall/kirurgisk-behandling-av-aterfall/palliativ-exenteration/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/blodning/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/skelettmetastaser/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/smarta/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/hydronefros-nefrostomi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/tarm--och-urinvagshinder-fistlar/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/tarm--och-urinvagshinder-fistlar/fistlar-omvardnad/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/palliativ-vard-och-insatser/cancersar/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/underlag-for-nivastrukturering/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/underlag-for-nivastrukturering/sakkunniggruppens-forslag/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/underlag-for-nivastrukturering/rcc-i-samverkans-beslut/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsregister/2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsregister/svenska-kvalitetsregistret-for-gynekologisk-cancer-sqrgc/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsregister/miqa/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsregister/palliativregistret/2024-08-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsregister/nationella-kvalitetsregistret-for-cervixcancerprevention-nkcx/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsregister/18.5-cancerregistret2024-02-29 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/referenser2/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/vardprogramgruppen/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/vardprogramgruppen/stodteam-verksamma-vid-rcc-vast/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/riktlinjer-for-bestamning-av-ctv-vid-imrtrapid-arcvmat-vid-definitiv-stralbehandling-vid-livmoderhalscancer/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/behandlingsteknik/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/applikatorer/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/3d-bildunderlag/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/targetinritning-brachyterapi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/doser-vid-brachyterapi/2024-08-05 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/dosplanering/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/kvalitetssakring-av-behandling-vid-brachyterapi/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/behandlingsteknik-vid-brachyterapi/referenser/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/targetdefinitioner-vid-bt/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/riktlinjer-for-bestamning-av-ctvn-vid-imrtvmat-vid-postoperativ-radioterapi-av-cervixcancer/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/bildunderlag-for-volymsdefinitioner-och-dosberakning/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/specifikation-av-behandlingsordination/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/targetvolymer/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/riskorgan/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/diagnosspecifik-strukturbenamning-enligt-standard/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/ordinerad-dos-och-behandlingstid/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/kompensation-for-oundvikliga-avbrott-i-planerad-behandling-inkl.-extra-helgdagar2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/relation-till-andra-behandlingar/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/dosplanering-och-behandling/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/kvalitetssakring/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/extern-radioterapi/referenser/2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/checklista-uppfoljning-cervixcancer/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/stadieindelning-av-vaginalcancer-enligt-tnm-och-figo-ar-2002-2022/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/1.-forkortningar2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/2.-patologins-roll-i-den-diagnosiska-processen2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/3.-anvisningar-till-kirurgen2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/4.-klassificering-av-tumoren2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/4.-klassificering-av-tumoren/4.1-icke-invasiva-skivepitelforandringar2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/4.-klassificering-av-tumoren/4.2-adenocarcinom-in-situ2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/4.-klassificering-av-tumoren/4.3-matning-och-bedomning-av-tidig-invasion2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/4.-klassificering-av-tumoren/4.4-invasiv-skivepitelcancer2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/4.-klassificering-av-tumoren/4.5-invasiva-adenocarcinom--subtyper2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/5.-utskarningsanvisningar2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/6.-analyser2020-09-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/6.-analyser/6.1-rekommenderade-rutin--och-specialfargningar2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/6.-analyser/6.2-rekommenderad-immunhistokemi2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/6.-analyser/6.3-Antal-snitt2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/7.-information-i-remissens-svarsdel2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/7.-information-i-remissens-svarsdel/7.1-allmanna-kommentar-kring-rapportering2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/7.-information-i-remissens-svarsdel/7.2-rapportering-beroende-av-preparat2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/8.-koder-och-beteckningar2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/9.-kvalitetsindikatorer2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/10.-kvast-grupp-gynekologisk-patologi-20162022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/cervix-histopatologi/11.-referenser2022-08-25 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardprogram/forandringar-jamfort-med-tidigare-version/2024-08-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/introduktion/forandringar-jamfort-med-foregaende-version/2024-11-12 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-02-17 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/utredning-och-beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderhals-och-vaginalcancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/2020-02-28 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/2022-03-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandring-i-svensk-livmoderhalsscreening/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/uppdatering-juni-2025/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/uppdatering-november-2022/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/uppdatering-april-20212/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/uppdaterat-kvast-kompendium-september-20192/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/korrigeringar-februari-20192/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/uppdatering-november-20182/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/uppdatering-maj-20182/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/vardprogrammets-malgrupper-och-forankring/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/evidensgradering/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/inledning/termer-och-forkortningar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/mal-med-vardprogrammet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/socialstyrelsens-rekommendation-om-screening-for-livmoderhalscancer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/socialstyrelsens-rekommendation-om-screening-for-livmoderhalscancer/motivering-till-rekommendationen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/socialstyrelsens-rekommendation-om-screening-for-livmoderhalscancer/uppdatering-av-foreskrift-och-vardprogram/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/socialstyrelsens-rekommendation-om-screening-for-livmoderhalscancer/socialstyrelsens-bedomning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/socialstyrelsens-rekommendation-om-screening-for-livmoderhalscancer/uppfoljning-av-screeningprogrammen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/socialstyrelsens-rekommendation-om-screening-for-livmoderhalscancer/utvardering/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/epidemiologi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/epidemiologi/epidemiologi-och-etiologi/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/epidemiologi/screening-och-tidig-upptackt/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/epidemiologi/screening-och-tidig-upptackt/organiserad-screening/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/epidemiologi/screening-och-tidig-upptackt/screeningens-effekt-pa-cancerincidens-och-dodlighet-i-olika-aldrar/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/humant-papillomvirus/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/humant-papillomvirus/hpv-typer-och-cancerrisk/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/humant-papillomvirus/overforing-av-hpv/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/humant-papillomvirus/risk-for-infektion/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/humant-papillomvirus/risk-for-persistens/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/primarprevention/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/hpv-vaccin/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/hpv-vaccin/vilka-hpv-vaccin-finns-och-vad-skyddar-de-emot/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/hpv-vaccin/hur-det-fungerar/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/hpv-vaccin/nytta-och-risker/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/vaccination-i-sverige/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/vaccination-i-sverige/vaccination-utanfor-vaccinationsprogrammet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/vaccination-i-sverige/registrering-av-vaccinationer/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/vaccination-i-sverige/vaccinationstackning/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/vaccination-i-sverige/deltagande-i-gynekologisk-cellprovskontroll-for-hpv-vaccinerade-kvinnor/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/effektivitet-av-hpv-vaccination-i-befolkningen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/effektivitet-av-hpv-vaccination-i-befolkningen/utfall-avseende-kondylom/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/effektivitet-av-hpv-vaccination-i-befolkningen/utfall-allvarliga-forstadier-cin-2/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/primarprevention-och-hpv-vaccination/snabbare-utrotning-av-hpv-och-livmoderhalscancer-i-sverige/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/bakgrund/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/behandling-av-personuppgifter-inom-halso--och-sjukvarden/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/kallelse-ombokning-och-sparrande-av-kallelse/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/kallelse-ombokning-och-sparrande-av-kallelse/kallelsen-och-urval-av-vem-som-ska-kallas/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/kallelse-ombokning-och-sparrande-av-kallelse/internetbaserade-ombokningssystem/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/kallelse-ombokning-och-sparrande-av-kallelse/sparrlista/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/kallelse-ombokning-och-sparrande-av-kallelse/kvinnor-med-skyddade-personuppgifter/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/cellprovtagning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/cellprovtagning/provtagning-efter-kallelse-till-gynekologisk-cellprovskontroll-gck/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/cellprovtagning/provtagning-utan-kallelse-till-gck/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/cellprovtagning/provtagning-utanfor-egen-region-enligt-patientlagen/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/analyshantering--laboratoriets-ansvar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/svarshantering-och-remittering-till-vidare-utredning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/tumoranmalan-till-cancerregistret/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/uppfoljning-av-tidigare-behandlade-kvinnor/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/ovriga-formella-lagkrav/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-och-formella-krav/organisation-och-ansvar-for-processen/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kallelse-till-gynekologisk-cellprovskontroll/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kallelse-till-gynekologisk-cellprovskontroll/kallelsens-utformning/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kallelse-till-gynekologisk-cellprovskontroll/utskick-av-kallelsen/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kallelse-till-gynekologisk-cellprovskontroll/ombokning-och-avbokning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/definition-av-malpopulation/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-som-kan-avsta-fran-att-ta-cellprov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-som-inte-ska-kallas/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-som-inte-ska-kallas/avregistrering-fran-kallelsesystemet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-som-inte-ska-kallas/avregistrering-fran-kallelsesystemet/medicinsk-eller-anatomisk-orsak-cervix-saknas/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-som-inte-ska-kallas/avregistrering-fran-kallelsesystemet/egen-begaran/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-som-inte-ska-kallas/export-av-sparrlistadata-till-nkcx/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-med-skyddad-identitet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/personer-utan-folkbokforingsadress/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kvinnor-med-funktionshinder/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/graviditet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/personer-som-bytt-juridiskt-kon/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/kompletterande-screening/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/opportunistisk-cellprovtagning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/provtagning-av-skora-grupper/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screeningpopulation--vilka-ska-kallas-och-nar/utrotningsscreening/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/atgarder-for-att-underlatta-och-stimulera-deltagande/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/atgarder-for-att-underlatta-och-stimulera-deltagande/faktorer-som-paverkar-deltagande-i-gynekologisk-cellprovskontroll/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/atgarder-for-att-underlatta-och-stimulera-deltagande/atgarder-som-kan-oka-deltagande-i-gynekologisk-cellprovskontroll/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/organisation/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/information-i-samband-med-provtagning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/livmoderhalsens-anatomi/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/provtagningsverktyg-och-teknik2/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/faktorer-vid-provtagning-som-kan-paverka-diagnostiken2/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/faktorer-vid-provtagning-som-kan-paverka-diagnostiken2/misstanke-om-livmoderhalscancer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/faktorer-vid-provtagning-som-kan-paverka-diagnostiken2/menstruation/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/faktorer-vid-provtagning-som-kan-paverka-diagnostiken2/graviditet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/faktorer-vid-provtagning-som-kan-paverka-diagnostiken2/testosteronbehandling/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/provtagning-hos-vardgivare/kvalitetsindikator/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/krav-pa-utvidgad-genotypning-vid-hpv-analys/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/indelning-av-hpv-av-hogrisktyper/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/indelning-av-hpv-av-hogrisktyper/hogonkogena-typer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/indelning-av-hpv-av-hogrisktyper/medelonkogena-typer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/indelning-av-hpv-av-hogrisktyper/lagonkogena-typer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/system-for-hpv-analys/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/indelning-av-hogrisk-hpv-i-hogonkogena-medelonkogena-och-lagonkogena-grupper/kodning-av-hpv-analyser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/klinisk-bakgrundsinformation/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/anvisningar-for-provtagarens-hantering-av-provet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/anvisningar-for-cytologiavdelningens-hantering-av-provet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/anvisningar-for-cytologiavdelningens-hantering-av-provet/sammanhallet-svar-for-hpv-analys-och-reflexcytologi-samt-dubbelanalyser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/anvisningar-for-cytologiavdelningens-hantering-av-provet/obedombart-prov-vid-cytologisk-analys/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/anvisningar-for-cytologiavdelningens-hantering-av-provet/dubbelgranskning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/cytologisk-analys/rekommenderade-klassifikationssystem-for-cytologisk-analys/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biomarkorer-inom-cytologisk-analys/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/anvisningar-pre-analytisk-hantering-och-remissinformation/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/anvisningar-pre-analytisk-hantering-och-remissinformation/biopsier/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/anvisningar-pre-analytisk-hantering-och-remissinformation/skrapmaterial-fran-cervix/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/anvisningar-pre-analytisk-hantering-och-remissinformation/excisionspreparat--i-synnerhet-kon-preparat/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/anamnestisk-remissinformation/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/anamnestisk-remissinformation/rekommenderade-histologiska-och-immunhistokemiska-fargningar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/analyser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/analyser/generella-krav-for-information-i-histopatologiskt-utlatande/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/analyser/sarskilda-krav-for-information-i-histopatologiskt-utlatande-for-slyngexcisionkon-preprat/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/klassificering-av-histopatologiska-forandringar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/klassificering-av-histopatologiska-forandringar/precancerosa-forandringar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/klassificering-av-histopatologiska-forandringar/laggradig-intraepitelial-skivepitellesion-lsil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/klassificering-av-histopatologiska-forandringar/hoggradig-intraepitelial-skivepitellesion-hsil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/klassificering-av-histopatologiska-forandringar/adenokarcinom-in-situ/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/histopatologisk-undersokning/snomed-kodning-for-histopatologi/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/inrapportering-av-data-och-uppfoljning-av-diagnostik/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/svarstid-pa-laboratoriet-som-kvalitetsindikator/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/arkivering-av-vatskebaserade-prover-glas-for-cytologi-och-material-fran-sjalvprovtagna-prover/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/arkivering-av-material-fran-vatskebaserade-cellprov-och-sjalvprov-for-hpv/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/arkivering-av-glas-fran-cytologisk-analys-av-vatskebaserade-cellprov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/laboratorieanalyser-hpv-genotypning-cytologisk-analys-och-histopatologisk-diagnostik/biobankning-och-kvalitetsuppfoljning/kvalitetsuppfoljning-och-arkivering-av-biobanksmaterial/fornyad-analys-av-hpv-negativa-prover-som-foregar-hoggradig-histopatologisk-forandring/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/bakgrund/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-positivitet-for-hpv-iscreeningprov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-positivitet-for-hpv-iscreeningprov/kvinnor-2370-ar-hpv-analys-med-utokad-genotypning/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-ovriga-avvikelser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-ovriga-avvikelser/ej-bedombart-hpv/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-ovriga-avvikelser/ej-bedombar-cytologi-vid-positivt-hpv/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-ovriga-avvikelser/kontrollfiler-hpv/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-vid-avvikande-provsvar-inom-gck/handlaggning-vid-ovriga-avvikelser/kontrollfil-efter-behandling-for-hsilais-eller-utlakt-pad-verifierad-hsil/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rutiner-och-information-vid-avvikande-provsvar/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rutiner-och-information-vid-avvikande-provsvar/standardiserade-svarsbrev-och-rutiner/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rutiner-och-information-vid-avvikande-provsvar/svarsalternativ-inom-gck/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rutiner-och-information-vid-avvikande-provsvar/svar-utifran-utredning-behandling-och-uppfoljning-pa-gynekologmottagning/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rutiner-och-information-vid-avvikande-provsvar/innehall-i-lokalt-formulerade-provsvar2/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/kolposkopins-roll/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/krav-pa-kolposkopist/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/krav-pa-vardenhet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/kolposkopiundersokningen/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/analysen-visar-hpv-16--eller-18-infektion-oavsett-cytologiresultat/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/analysen-visar-persistent-hpv-infektion-annan-an-hpv-16-och-18/2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/cytologiska-reflexanalysen-visar-lsilcyt-eller-ascus/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/cytologiska-analysen-visar-hsilcyt-eller-asc-h/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/cytologiska-analysen-visar-misstanke-om-skivepitelcancer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/cytologiska-analysen-visar-kortelcellsatypi-eller-atypi-i-celler-av-oklar-eller-annan-celltyp/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/handlaggning-utifran-hpv-typ-i-hpv-positivt-screeningprov/cytologiska-analysen-visar-adenocarcinoma-in-situ-eller-misstanke-om-adenokarcinom/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/vid-cytologisk-skivepitelatypi-och-ofullstandig-kolposkopi--tz-typ-3/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/vid-cytologisk-skivepitelatypi-och-ofullstandig-kolposkopi--tz-typ-3/persistent-hogonkogen-hpv-16-18-eller-45-och-ofullstandig-eller-obedombar-kolposkopi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/vid-cytologisk-skivepitelatypi-och-ofullstandig-kolposkopi--tz-typ-3/cytologiska-analysen-visar-lsilcytascus-och-kolposkopin-ar-ofullstandig-eller-obedombar/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/vid-cytologisk-skivepitelatypi-och-ofullstandig-kolposkopi--tz-typ-3/cytologiska-analysen-visar-hsilcyt-eller-asc-h-och-kolposkopin-ar-ofullstandig-eller-obedombar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/uppfoljning-av-patient-som-uteblir/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/rapportering-till-kvalitetsregister/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/kvalitetsmatt/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kolposkopi-och-utredning-vid-avvikelser-i-cellprov/ledtider/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/naturalforlopp-och-exspektans/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/medicinska-risker-med-behandling/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/rutiner-pa-mottagningen/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/lsil/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/hsil/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/behandling-av-skivepiteldysplasi/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/overvaganden-vid-hysterektomi-som-dysplasibehandling/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/histopatologisk-adenocarcinoma-in-situ/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/handlaggning-enligt-standardiserat-vardforlopp-svf-vid-screeningupptackt-livmoderhalscancer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/atgarder-for-att-minska-per--och-postoperativa-komplikationer/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/omhandertagande-av-excisionspreparat/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/matning-av-excisionspreparat/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/handlaggning-efter-utredning-som-visar-dysplasi/kvalitetsindikator/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/uppfoljning-for-att-utesluta-kvarstaende-dysplasi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/uppfoljning-for-att-utesluta-kvarstaende-dysplasi/utlakning-av-hpv-infektion-efter-behandling/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/uppfoljning-for-att-utesluta-kvarstaende-dysplasi/behandlingskontroll--uppfoljning-med-analys-for-hpv-och-cytologi-6-manader-efter-behandling-for-hsil-och-6-och-18-manader-efter-behandling-for-ais/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/uppfoljning-for-att-utesluta-kvarstaende-dysplasi/uppfoljning-av-avvikande-provsvar-vid-behandlingskontrollerna/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/uppfoljning-i-kontrollfil-efter-behandling-eller-utlakning/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/uppfoljning-efter-hysterektomi/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/uppfoljning-efter-dysplasibehandling/hpv-vaccination-efter-behandling/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/utredning-av-avvikelser-i-screeningen-diagnosticerade-strax-innan-graviditet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/screeningprov-inom-modrahalsovarden/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/utredning-vid-blodning-och-symtom-under-graviditet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/initial-utredning-av-avvikande-cellprov-under-graviditet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/fortsatt-uppfoljning-under-graviditet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/adenocarcinoma-in-situ-och-kortelcellsforandringar/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/livmoderhalscancer-under-graviditet/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/livmoderhalscancer-under-graviditet/dysplasiuppfoljning-efter-forlossning-vid-skivepiteldysplasi/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/gravida-kvinnor/livmoderhalscancer-under-graviditet/vid-kortelcellsatypi-och-ais/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/screening-av-kvinnor-som-lever-med-hiv/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/utredning-/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/utredning-/hpv-positiv-och-cytologisk-avvikelse-alternativt-hpv-positiv-for-hogonkogen-typ-16-18-45-och-normal-cytologi/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/utredning-/hpv-positiv-for-medel--eller-lagonkogen-typ-och-benign-cytologi/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/handlaggning-och-behandling/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/uppfoljning-efter-utredning-och-behandling/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/kvinnor-som-lever-med-hiv/indikatorsjukdom-for-hiv/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/transplanterade-kvinnor/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/transplanterade-kvinnor/organtransplanterade/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/transplanterade-kvinnor/allogent-stamcellstransplanterade/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/ovriga-immunsupprimerande-tillstand/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/screening-utredning-behandling-och-uppfoljning-av-sarskilda-grupper/kvinnor-med-immunsuppression/vaccination-mot-hpv/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/bakgrund/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/metod-for-hpv-sjalvprov/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-till-kvinnor-som-lange-uteblivit-fran-screening/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-till-kvinnor-som-lange-uteblivit-fran-screening/uppfoljning-av-langtidsuteblivare-med-hpv-positiv-analys-vid-sjalvprovtagning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-som-primar-screeningmetod/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-som-primar-screeningmetod/handlaggning-vid-hpv-sjalvprovtagning2/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-som-primar-screeningmetod/handlaggning-av-det-uppfoljande-cellprovet-efter-positivt-hpv-sjalvprov/2025-06-05 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-som-primar-screeningmetod/kvalitetsindikatorer-vid-hpv-sjalvprovtagning2/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/gynekologisk-cellprovskontroll-genom-sjalvprovtagning-med-analys-for-humant-papillomvirus-hpv2/hpv-sjalvprovtagning-som-primar-screeningmetod/kvalitetsindikatorer-vid-hpv-sjalvprovtagning2/kommentarer-till-kvalitetsindikatorer/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/screening/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/utredning--kolposkopi/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/blodning-och-infektion/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/stenos/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/fertilitet/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/missfall-ektopisk-graviditet/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/fortidsbord/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/fortidsbord/perinatal-dod-pa-grund-av-fortidig-forlossning-efter-excisiosbehandling/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/behandling--excision/sammanfattning-av-kunskapslaget/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/motverka-och-minimera-bieffekter-av-cervixscreening/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/motverka-och-minimera-bieffekter-av-cervixscreening/behandling-av-dysplasi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/motverka-och-minimera-bieffekter-av-cervixscreening/utredning-av-dysplasi/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/motverka-och-minimera-bieffekter-av-cervixscreening/provtagning-och-besked-om-provresultat/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bieffekter-av-cervixscreening/kvalitetsindikatorer/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/inledning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/kallelsefunktionen/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/provtagningsenheten/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/laboratoriet/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/journalsystem-utredningsenhet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/rapportering-till-kvalitetsregister/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/rapportering-till-kvalitetsregister/analysregistret/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/rapportering-till-kvalitetsregister/processregistret/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/it-system/behov-av-overforing-av-kallelsegrundande-data-mellan-regioner/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kommunikation-och-information/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kommunikation-och-information/kommunikationsplan-som-ett-stod-for-verksamheterna/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/bakgrund/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/grundlaggande-krav/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/grundlaggande-krav/kunskapsmal/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/grundlaggande-krav/utforande/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/fortbildning-av-barnmorskor-inom-screeningorganisationen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/genomforande-av-utbildningsinsatser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/genomforande-av-utbildningsinsatser/nationellt/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-barnmorskor-och-sjukskoterskor-inom-screeningorganisation-och-gynmottagning/genomforande-av-utbildningsinsatser/regionalt/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-och-fortbildning-av-cytodiagnostiker-och-av-lakare-inom-patologi-och-cytologi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-och-fortbildning-av-cytodiagnostiker-och-av-lakare-inom-patologi-och-cytologi/bakgrund/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-och-fortbildning-av-cytodiagnostiker-och-av-lakare-inom-patologi-och-cytologi/sarskilda-utmaningar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-gynekologer-i-kolposkopi-och-livmoderhalscancerprevention/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-gynekologer-i-kolposkopi-och-livmoderhalscancerprevention/bakgrund/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-gynekologer-i-kolposkopi-och-livmoderhalscancerprevention/larandemal/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-gynekologer-i-kolposkopi-och-livmoderhalscancerprevention/larandemal/kunskap-och-forstaelse/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-gynekologer-i-kolposkopi-och-livmoderhalscancerprevention/larandemal/fardighet-och-formaga/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/utbildning-av-nyckelgrupper-inom-livmoderhalscancerprevention/utbildning-av-gynekologer-i-kolposkopi-och-livmoderhalscancerprevention/larandemal/varderingsformaga-och-forhallningssatt/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/bakgrund/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/kvalitetsregistrets-syfte/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/datainsamling/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/kallelsedata--nationell-integration/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/patientoversikt--senaste-prov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/aterkoppling/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/oppenhet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/ratt-till-datauttag-och-beslutsgang-vid-datauttag/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/verksamhet/audits/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/arlig-audit-kvalitetsrevision-av-livmoderhalscancerfall/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/organisation/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/organisation/styrgrupp/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/organisation/expertgrupp/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/organisation/drift/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/organisation/landstingens-delaktighet-och-ansvar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/kvalitetsuppfoljning/kvalitetsindikatorer/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/underlag-for-samordning-och-nivastrukturering/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/referenser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/nationella-arbetsgruppen-for-livmoderhalscancerprevention-nacx/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/ovriga-medlemmar-i-vardprogramgruppen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/tidigare-medlemmar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/tidigare-medlemmar/tidigare-medlemmar-i-vardprogramgruppen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/tidigare-medlemmar/tidigare-medlemmar-i-nacx/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/tidigare-medforfattare/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-1506162022-11-21 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/dokumenthistorik/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/bakgrund/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/inledning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/inledning/om-specifikationen/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/inledning/krav-pa-det-enskilda-laboratoriet/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/inledning/overforingsrutiner/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/inledning/vilka-hpv-resultat-ska-overforas/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/inledning/ytterligare-information-om-leverans/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/oversikt/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/filnamn/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/filstruktur/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/filstruktur/xml-format/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/filstruktur/exempel-pa-xml-fil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/filstruktur/semikolonseparerad-fil/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/filformat/filstruktur/2-exempel-pa-poster-i-semikolonseparerad-fil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/kodtabeller/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/kodtabeller/koder-for-cytologiavdelningar-enligt-sosfs200615/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-1.-specifikation-for-overforing-av-hpv-testresultat.-version-9-150616/kodtabeller/virologlab/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-2.-nationella-standardremisser2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-2.-nationella-standardremisser/remiss-for-gynekologisk-cellprovskontroll-organiserad-screening/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-2.-nationella-standardremisser/klinisk-remiss-vatskebaserat-prov-tidigare-kallad-indicerad-cytologi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-2.-nationella-standardremisser/definitioner-och-ordforklaringar-till-nationell-standardremiss-for-cervixcytologi2/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/terminologi-internationella-kolposkopifederationen/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/utredning-av-atypisk-cervixcytologi-persistent-hpv-och-icke-behandlad-cervixdysplasi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/utredning-av-atypisk-cervixcytologi-persistent-hpv-och-icke-behandlad-cervixdysplasi/lagre-risk-for-utveckling-av-livmoderhalscancer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/utredning-av-atypisk-cervixcytologi-persistent-hpv-och-icke-behandlad-cervixdysplasi/hogre-risk-for-utveckling-av-livmoderhalscancer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/uppfoljning-efter-behandlad-cervixdysplasi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/uppfoljning-efter-behandlad-cervixdysplasi/radikal-excision-av-hsil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/uppfoljning-efter-behandlad-cervixdysplasi/tveksamicke-radikal-excision-hsil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/rekommendationer-vid-uteblivet-besok-pa-gynmottagning-for-cellprovsavvikelse-eller-cervixdysplasi/uppfoljning-efter-behandlad-cervixdysplasi/efter-excision-av-lsil/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-5.-beskrivning-av-preparatmatning-efter-excision2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-5.-beskrivning-av-preparatmatning-efter-excision/matning-av-konlangd/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler2025-06-13 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfiler-for-hpv/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfiler-for-hpv/inklusionskriterier/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfiler-for-hpv/kallelseintervall-for-gck-prov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfiler-for-hpv/persisterande-hpv/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfiler-for-hpv/negativt-hpv-for-aktuell-grupp-av-onkogena-typer-vid-uppfoljande-prov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfiler-for-hpv/information-som-behover-delas/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfil-efter-behandling-hsilais-eller-utlakt-pad-verifierad-hsil-keb-u/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfil-efter-behandling-hsilais-eller-utlakt-pad-verifierad-hsil-keb-u/inklusionskriterier/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfil-efter-behandling-hsilais-eller-utlakt-pad-verifierad-hsil-keb-u/kallelseintervall-vid-gck-prov/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-6.-beskrivning-av-kontrollfiler/kontrollfil-efter-behandling-hsilais-eller-utlakt-pad-verifierad-hsil-keb-u/information-som-behover-delas/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/inledning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/inledning/bakgrund/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/inledning/nulagesbeskrivning/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/inledning/konsekvent-ordval-ger-okad-tydlighet/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/inledning/avgransningar/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/syfte/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/mal/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/kommunikationsstrategi/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/informationspaket-med-tydliga-och-entydiga-budskap/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/kortfattad-och-tydlig-skriftlig-information-i-tidigt-skede/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/tillforlitliga-kallor-med-fordjupad-information-digitalt/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/behov-av-telefonradgivning-som-komplement/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/stod-for-tydlig-och-entydig-kommunikation-mellan-vardgivare-och-kvinnor/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/syfte-mal-och-kommunikationsstrategi/sarskilda-informationsinsatser/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/budskap-malgrupper-och-kanaler/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/budskap-malgrupper-och-kanaler/tydliga-budskap/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/budskap-malgrupper-och-kanaler/malgrupper-och-ambassadorer/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/budskap-malgrupper-och-kanaler/informations--och-kommunikationskanaler/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/budskap-malgrupper-och-kanaler/uppfoljning-av-kommunikationsinsatser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/ansvarsfordelning/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-7.-nationellt-underlag-till-kommunikationsplan-for-screening-mot-livmoderhalscancer/referenser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/plan-for-utbildning-av-gynekologer-for-certifiering-inom-kolposkopi-och-livmoderhalscancerprevention-enligt-nationellt-vardprogram-for-livmoderhalscancerprevention/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/plan-for-utbildning-av-gynekologer-for-certifiering-inom-kolposkopi-och-livmoderhalscancerprevention-enligt-nationellt-vardprogram-for-livmoderhalscancerprevention/bakgrund/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/plan-for-utbildning-av-gynekologer-for-certifiering-inom-kolposkopi-och-livmoderhalscancerprevention-enligt-nationellt-vardprogram-for-livmoderhalscancerprevention/bakgrund/larandemal/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/plan-for-utbildning-av-gynekologer-for-certifiering-inom-kolposkopi-och-livmoderhalscancerprevention-enligt-nationellt-vardprogram-for-livmoderhalscancerprevention/bakgrund/innehall/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/plan-for-utbildning-av-gynekologer-for-certifiering-inom-kolposkopi-och-livmoderhalscancerprevention-enligt-nationellt-vardprogram-for-livmoderhalscancerprevention/bakgrund/ovrigt/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/plan-for-utbildning-av-gynekologer-for-certifiering-inom-kolposkopi-och-livmoderhalscancerprevention-enligt-nationellt-vardprogram-for-livmoderhalscancerprevention/sarskilda-utbildningsinsatser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-8.-sfogs-kurs-inom-kolposkopi-och-livmoderhalscancerprevention/referenser2/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-9.-forteckning-kvalitetsindikatorer2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-9.-forteckning-kvalitetsindikatorer/socialstyrelsens-kvalitetsindikatorer-vid-screening-for-livmoderhalscancer-samt-nacx-nationella-kvalitetsindikatorer/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-9.-forteckning-kvalitetsindikatorer/socialstyrelsens-kvalitetsindikatorer-vid-screening-for-livmoderhalscancer-samt-nacx-nationella-kvalitetsindikatorer/nacx-nationella-kvalitetsindikatorer-for-cervixscreeningprogrammet/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-10.-sammanfattning-av-forslag-fran-nationella-arbetsgruppen-for-nationella-och-regionala-atgarder2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-10.-sammanfattning-av-forslag-fran-nationella-arbetsgruppen-for-nationella-och-regionala-atgarder/forslag-pa-nationell-niva/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-10.-sammanfattning-av-forslag-fran-nationella-arbetsgruppen-for-nationella-och-regionala-atgarder/forslag-pa-sjukvardsregional-niva/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-10.-sammanfattning-av-forslag-fran-nationella-arbetsgruppen-for-nationella-och-regionala-atgarder/forslag-pa-regional-niva/2025-06-09 https://kb.localhost:5000/diagnoser/livmoderhalscancerprevention/vardprogram/bilaga-10.-sammanfattning-av-forslag-fran-nationella-arbetsgruppen-for-nationella-och-regionala-atgarder/referenser/2025-06-03 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/2022-04-07 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/2021-07-05 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/sammanfattning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/standardiserat-vardforlopp/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/lagstod/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/evidensgradering/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/inledning/forkortningar-och-begreppsforklaringar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/mal-med-vardprogrammet/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bakgrund-och-orsaker/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bakgrund-och-orsaker/orsaker-etiologi-och-riskfaktorer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bakgrund-och-orsaker/orsaker-etiologi-och-riskfaktorer/etiologi-och-riskfaktorer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-prevention/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-prevention/levnadsvanor/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/screening/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/arftlighet/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/arftlighet/lynchs-syndrom/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/arftlighet/cowdens-syndrom/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/symtom/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/kliniska-fynd/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/endometriehyperplasi/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/malign-potential/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/symtom-och-diagnostik/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/symtom-och-diagnostik/behandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/symtom-och-diagnostik/behandling/hyperplasi-utan-atypi/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/symtom-och-diagnostik/behandling/endometrial-intraepitelial-neoplasi-ein/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/serost-endometrialt-intraepitelialt-karcinom-seic2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/symtom-och-tidig-utredning/icke-invasiva-cellforandringar-i-endometriet/serost-endometrialt-intraepitelialt-karcinom-seic2/behandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/provtagning-for-att-verifiera-livmoderkroppscancer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/provtagning-for-att-verifiera-livmoderkroppscancer/endometriebiopsi/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/provtagning-for-att-verifiera-livmoderkroppscancer/abrasioskrapning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/provtagning-for-att-verifiera-livmoderkroppscancer/hysteroskopi-med-riktad-biopsi/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/transvaginalt-ultraljud-tvs/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/magnetresonanstomografi-mrt/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/magnetresonanstomografi-mrt/myometrieinvasion/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/magnetresonanstomografi-mrt/cervixinvasion/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/magnetresonanstomografi-mrt/lymfkortelmetastaser/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/datortomografi-dt/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/positronemissionstomografi-med-datortomografi-pet-dt/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/primarutredning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/primarutredning/lokal-tumorutbredning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/bilddiagnostik/primarutredning/tumorspridning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/patologisk-diagnostik/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/diagnostik/diagnosbesked/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/provhantering/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/remissinnehall/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/klassifikationsregler/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/klassifikationsregler/gradering/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/endometrioida-adenocarcinom/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/serost-adenocarcinom/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/klarcelligt-adenocarcinom/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/ovriga-tumortyper/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/ovriga-tumortyper/blandade-mixed-adenokarcinom/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/ovriga-tumortyper/karcinosarkom-malign-mesodermal-mllersk-blandtumor/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/ovriga-tumortyper/odifferentierat-och-dedifferentierat-karcinom/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/histologiska-undergrupper/ovriga-tumortyper/neuroendokrina-tumorer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/immunhistokemi/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/molekylara-undersokningar/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/eftergranskning-av-pad/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/stadieindelning/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/multidisciplinar-konferens-mdk/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/val-av-behandling/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/val-av-behandling/preoperativ-bedomning/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/val-av-behandling/postoperativ-riskbedomning-och-prognostiska-faktorer/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/bevarande-av-aggstockar/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/portvaktskorteldiagnostik/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/portvaktskorteldiagnostik/bakgrund/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/portvaktskorteldiagnostik/implementering/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/portvaktskorteldiagnostik/kirurgisk-teknik-for-att-detektera-portvaktskortlar/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/portvaktskorteldiagnostik/adekvat-portvaktskorteldetektion/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/kirurgi2/portvaktskorteldiagnostik/restaging-kirurgi/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/cytostatikabehandling/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/preoperativ-cytostatikabehandling-nact/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/adjuvant-postoperativ-cytostatikabehandling/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/cytostatikabehandling-vid-avancerad-sjukdom/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/malriktad-behandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/hormonbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/hormonbehandling/adjuvant-postoperativ-hormonbehandling/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/hormonbehandling/behandling-vid-avancerad-sjukdom/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/angiogeneshammare/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/immunterapi/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/primar-lakemedelsbehandling/ovriga/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/stralbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/stralbehandling/primar-extern-stralbehandling-ert/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/stralbehandling/primar-intrauterin-brachyterapi/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/stralbehandling/adjuvant-postoperativ-extern-stralbehandling-ert/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/stralbehandling/planering-av-adjuvant-postoperativ-ert/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/onkologisk-behandling2/stralbehandling/adjuvant-postoperativ-vaginal-stralbehandling-vbt/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/primar-behandling/fertilitetsbevarande-handlaggning/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/bilddiagnostik/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/kirurgi/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/cytostatikabehandling/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/immunterapi/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/immunterapi/pd-1-antikropp-singelterapi/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/immunterapi/pd-1-antikropp-som-tillagg-till-karboplatinpaklitaxel/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/immunterapi/pd-1-antikropp-pembrolizumab-och-multikinashammaren-lenvatinib/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/hormonbehandling/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/angiogeneshammare/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/lakemedelsbehandling/malriktad-behandling/ovriga-lakemedel/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/stralbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/stralbehandling/vagina-och-backen/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/stralbehandling/ovriga-lokalisationer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/stralbehandling/ovriga-lokalisationer/andra-lymfkortelmetastaser2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/behandling-av-aterfall/stralbehandling/ovriga-lokalisationer/andra-metastaslokalisationer2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/palliativ-vard-och-insatser/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/bedomningsinstrument/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/fatigue/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/fertilitet/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/nutrition/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/psykosocialt-stod/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/sexuell-halsa/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad/smarta/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/prehabilitering/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/preoperativ-omvardnad/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/preoperativ-omvardnad/tobak-och-alkohol/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/preoperativ-omvardnad/fysisk-aktivitet/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/preoperativ-omvardnad/nutrition/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/postoperativ-omvardnad/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/postoperativ-omvardnad/utskrivning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling2/postoperativ-omvardnad/uppfoljningssamtal/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/benmargspaverkan/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/fatigue/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/hud-och-naglar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/haravfall-alopeci/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/horsel/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/illamaende/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/kognitiv-paverkan/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/muskelsmarta-och-ledvark/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/perifera-neuropatier/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/slemhinnebiverkningar/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/smakforandringar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/cytostatikabehandling/tarmpaverkan/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/omvardnad-i-samband-med-brachyterapi-hvb-hogdos-vaginal-bestralning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/gastrointestinala-symtom/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/urinvagar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/sexualitet-samt-besvar-fran-slemhinnor-i-underlivet/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/backenbottenrehabiltering/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/alopeci-haravfall/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/hudpaverkan/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/lymfodem-i-ben-och-underliv/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/lymfodem-i-ben-och-underliv/atgard-vid-lymfodem/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/rokning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-stralbehandling/benmarg/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling2/omvardnad-i-samband-med-immunterapi/2024-08-21 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/hormonsubstitution-i-klimakteriet/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/hormonsubstitution-i-klimakteriet/menopausal-hormonterapi-mht/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/omvardnad-och-rehabilitering/hormonsubstitution-i-klimakteriet/lokal-vaginal-substitutionsbehandling/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/levnadsvanor/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/nationella-riktlinjer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/rokning/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/komplementar-och-integrativ-medicin/2024-07-31 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/alkohol/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/fysisk-aktivitet/2024-08-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/egenvard2/patientforeningar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/mal-med-uppfoljningen/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/fornyad-behovsbedomning-for-rehabilitering/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/sjalvrapportering-av-symtom/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/kontroll-av-aterfall/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/forslag-pa-kontrollintervaller/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/uppfoljning2/ansvar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/underlag-for-nivastrukturering2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/underlag-for-nivastrukturering2/implementering-och-centralisering-av-kirurgi-vid-livmoderkroppscancer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kvalitetsregister2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kvalitetsregister2/svenska-kvalitetsregistret-for-gynekologisk-cancer/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kvalitetsregister2/cancerregistret/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kvalitetsregister2/svenska-palliativregistret/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/kvalitetsindikatorer-och-malnivaer2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/referenser/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/stodteam-verksamma-vid-rcc-vast2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar2/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring2/2024-08-15 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bilaga-1-alternativ-sekventiell-molekylar-klassificering/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/postoperativ-behandling.-kirurgiskt-stadium-i-iii.-radikalt-opererade2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bilaga-3-andringar-tidigare-versioner/2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardprogram/bilaga-4-version-2.0-remissrunda-med-remissvar-fran-regioner-och-organisationer2024-07-30 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/introduktion/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-for-utredning-vid-valgrundad-misstanke/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling2/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-01-13 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-11-08 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/livmoderkroppscancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-11-11 https://kb.localhost:5000/diagnoser/lungcancer/2022-04-07 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/2023-07-12 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/syfte/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/forandringar-och-nyheter/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/forandringar-och-nyheter/forandringar-i-version-9.0-av-vardprogrammet2025-07-04 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/evidensgradering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/standardiserat-vardforlopp/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/inledning/lagstod/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/epidemiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/epidemiologi/forekomst-och-prognos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/epidemiologi/forekomst-over-tiden/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/epidemiologi/internationellt-perspektiv/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/etiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/etiologi/tobaksrokning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/etiologi/yrkesexponering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/etiologi/radon/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/etiologi/Arftlighet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/etiologi/lungcancer-hos-aldrig-rokare/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/orsakssamband-mellan-rokning-och-lungcancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/journalfora-tobaksbruket/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/journalfora-tobaksbruket/hog-beredskap-att-sluta-med-rokning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/journalfora-tobaksbruket/lag-beredskap-att-sluta-med-rokning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/rokavvanjning-pa-vardavdelning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/farmakologisk-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/farmakologisk-behandling/nikotinlakemedel/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/farmakologisk-behandling/vareniklin/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/farmakologisk-behandling/cytisin/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/farmakologisk-behandling/bupropion/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/farmakologisk-behandling/rokstopp-och-lakemedelsmetabolism/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/att-forebygga-cancer-via-tobakssamtal/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/slutsatser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/tobaksprevention/resurser-for-rokavvanjning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lungcancerscreening/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lungcancerscreening/inledning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lungcancerscreening/potentiella-risker-med-screening/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lungcancerscreening/screening-med-lungrontgen-ocheller-sputumcytolog/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lungcancerscreening/screening-med-lagdos-datortomografi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/bakgrund/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/Tillampbarhet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/Generella-rekommendationer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/solida-nodulara-forandringar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/subsolida-nodulara-forandringar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/sma-nodulara-forandringar/riskfaktorer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/lokalsymtom/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/lokalsymtom/hosta/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/lokalsymtom/hemoptys/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/lokalsymtom/dyspne/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/lokalsymtom/thoraxsmarta/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/allmansymtom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/allmansymtom/anorexi-och-kakexi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/allmansymtom/trotthet-fatigue/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/allmansymtom/feber/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/allmansymtom/depression/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-regional-spridning/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-regional-spridning/nervpaverkan-entrapment/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-regional-spridning/kardiovaskular-paverkan/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-regional-spridning/ovrig-mediastinal-spridning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-extrathorakala-metastaser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-extrathorakala-metastaser/cns/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-extrathorakala-metastaser/skelett/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-extrathorakala-metastaser/lever/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/symtom-och-fynd-vid-extrathorakala-metastaser/binjurar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/siadh/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/ektopiskt-acth-syndrom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/hyperkalcemi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/gynekomasti/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/paramaligna-neurologiska-symtom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/tromboembolisk-sjukdom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/paramaligna-syndrom/hypertrofisk-osteoartropati/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/ingang-till-standardiserat-vardforlopp/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/symtom-och-kliniska-fynd/fordjupningslasning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/patologins-roll/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/anvisningar-for-provtagarens-hantering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/anvisningar-for-provtagarens-hantering/cytologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/anvisningar-for-provtagarens-hantering/biopsi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/anvisningar-for-provtagarens-hantering/resektat/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/Anamnestisk-remissinformation/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/adenokarcinom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/skivepitelcancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/storcellig-cancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/smacellig-cancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/storcellig-neuroendokrin-cancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/klassificering-av-tumoren/karcinoid/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/behandlingsprediktiva-molekylarpatologiska-analyser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kommentarer-till-klassifikationerna-whoiaslc-2004-och-iaslcatsers-2011/mikroskopisk-utvardering-av-neoadjuvant-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/utredning-enligt-standardiserat-vardforlopp-svf/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/anamnes/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/klinisk-undersokning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/blodprover/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/bilddiagnostik/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/bronkoskopi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/Mediastinal-stadieindelning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/Mediastinal-stadieindelning/ebuseus/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/Mediastinal-stadieindelning/transtorakal-lungpunktion/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/sputumcytologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/ovrig-metastasutredning/2023-05-29 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/ovrig-metastasutredning/pleuradiagnostik/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/ovrig-metastasutredning/intraabdominella-metastaser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/ovrig-metastasutredning/benmargsundersokning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/ovrig-metastasutredning/ytliga-metastaser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/ovrig-metastasutredning/explorativ-thorakotomi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/klinisk-bedomning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/arbetsprov/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/dynamisk-spirometri-och-co-diffusionskapacitet-dlco/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/ergospirometri/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/trapptest/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/pulmektomi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/preoperativ-funktionsbedomning-infor-stallningstagande-till-lungcancerkirurgi/formler-for-berakning-av-postoperativ-lungfunktion/2023-05-29 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/utredning/Stadieindelning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/multidisciplinar-konferens/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-i-ii-lokal-sjukdom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-iii-lokoregionalt-avancerad-sjukdom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-iv-metastaserande-sjukdom/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-iv-metastaserande-sjukdom/allmanna-principer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-iv-metastaserande-sjukdom/Malinriktad-terapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-iv-metastaserande-sjukdom/Immunterapi-och-cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/11.1-icke-smacellig-lungcancer-nsclc/tumorstadium-iv-metastaserande-sjukdom/radioterapi-och-endobronkiel-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/smacellig-lungcancer-sclc/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/smacellig-lungcancer-sclc/tumorstadium-i-iii-begransad-sjukdom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/smacellig-lungcancer-sclc/tumorstadium-iv-utbredd-sjukdom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/behandling--sammanfattande-rekommendationer/smacellig-lungcancer-sclc/behandling-vid-recidiv--progression/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/indikationer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/indikationer/12.1.1kirurgiska-utvecklingsomraden2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/indikationer/12.1.1kirurgiska-utvecklingsomraden/salvage-surgery/2025-07-09 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/indikationer/12.1.1kirurgiska-utvecklingsomraden/oligometastatisk-progressiv-sjukdom/2025-07-09 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/indikationer/12.1.1kirurgiska-utvecklingsomraden/perkutan-ablation-vid-nsclc/2025-07-09 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/indikationer/12.1.1kirurgiska-utvecklingsomraden/neoadjuvantperioperativ-behandling/2025-07-09 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/funktionsutredning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/preop-stadieindelning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/operationsteknik/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/operationsteknik/torakotomi-eller-vats/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/operationsteknik/omfattning-av-lungresektionen/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/operationsteknik/peroperativ-mediastinal-lymfkortelexploration/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/postoperativ-vard/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/komplikationer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/adjuvant-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/postoperativ-uppfoljning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kirurgisk-behandling/prognos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/inledning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/normalvavnadstolerans-och-biverkningar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/normalvavnadstolerans-och-biverkningar/pneumonit/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/normalvavnadstolerans-och-biverkningar/esophagit/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/normalvavnadstolerans-och-biverkningar/cardiotoxicitet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-i-ii/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/stadieutredning-och-dosplaneringsunderlag/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/behandlingsteknik/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/behandlingsvolymer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/behandlingsdos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/fraktionering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/kombinationsbehandling-med-kemoterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/kombinationsbehandling-med-kemoterapi/sekventiell-kontra-konkomitant-radiokemoterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/kombinationsbehandling-med-kemoterapi/val-av-cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/kombinationsbehandling-med-kemoterapi/subgruppsanalyser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/postoperativ-stralbehandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-icke-smacellig-lungcancer/stadium-iii/preoperativ-radiokemoterapi-vid-stadium-iiian2-nsclc/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/timing/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/straldos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/fraktionering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/behandlingsvolym/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-i-iii-begransad-sjukdom-ld/profylaktisk-helhjarnsbestralning-pci/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-iv-utbredd-sjukdom-ed/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-iv-utbredd-sjukdom-ed/konsoliderande-thorakal-radioterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/stralbehandling-av-smacellig-lungcancer/stadium-iv-utbredd-sjukdom-ed/pci/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/palliativ-stralbehandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/palliativ-stralbehandling/primartumor/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/palliativ-stralbehandling/endoluminal-stralbehandling-brachyterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/palliativ-stralbehandling/fjarrmetastaser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/stralbehandling2/palliativ-stralbehandling/fjarrmetastaser/stralbehandling-vid-oligometastatisk-sjukdom-omd/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-i-iii/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-i-iii/lakemedel-vid-kirurgi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-i-iii/lakemedel-vid-kirurgi/14.1.1.1.1-postoperativ-adjuvant-behandling2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-i-iii/lakemedel-vid-kirurgi/preoperativ-induktionsbehandling-vid-resektabel-tumor/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-i-iii/lakemedel-vid-kirurgi/Lakemedel-vid-radioterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/2020-06-22 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/molekylarpatologisk-testning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/egfr/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/kombinationsbehandlingar-med-egfr-tki/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/relapsbehandling-efter-tidigare-egfr-tki/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/alk/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/relapsbehandling-efter-tidigare-alk-tki/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/ros1/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/braf/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/malriktad-terapi/andra-tumorgenetiska-varianter/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/kombinerad-kemo-immunterapi/2025-07-11 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/immunterapi-enbart/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/cytostatika-som-monoterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/relapsbehandling-efter-immunterapi-och-eller-cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/immunterapi/2025-07-11 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/cytostatika/2025-07-11 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/icke-smacellig-lungcancer/nsclc-stadium-iv/Immunterapi-och-cytostatika/ovriga-preparat/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/smacellig-cancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/smacellig-cancer/allmant/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/smacellig-cancer/Behandling-vid-stadium-I-III/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/smacellig-cancer/Behandling-vid-stadium-IV/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/smacellig-cancer/Behandling-vid-stadium-IV/immunterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/lakemedelsbehandling/smacellig-cancer/Relapsbehandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/dyspne/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/dyspne/syrgasbehandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/pleuravatska/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/pleurodesbehandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/pleurodesbehandling/kvarliggande-kateter/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/pericardvatska/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/hosta/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/hemoptys/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/stambandspares/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/vena-cava-superior-syndrom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/hyperkalcemi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/siadh/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/hjarnmetastaser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Palliativa-atgarder/skelettmetastaser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/endobronkiell-tumorvaxt/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/utifran-kommande-kompression/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/kombination-av-endobronkiell-vaxt-och-kompression/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/hemoptys/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/fistlar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/brachyterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/16-endobronkiell-terapi/endobronkiell-behandling-av-perifera-lung-noduli/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/min-vardplan/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/aktiva-overlamningar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/barn-som-narstaende/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/nutrition/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/nutrition/riskbedomning-av-undernaring/2025-07-17 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/nutrition/patienter-med-risk-for-undernaring/2025-07-17 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/nutrition/nutritionsbehandling/2025-07-17 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/fysioterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/arbetsterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/sexualitet-och-fertilitet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/sexualitet-och-fertilitet/plissit-modellen/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/sexualitet-och-fertilitet/fertilitet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/halsoaspekter-och-egenvard/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/tobak/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/alkohol/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/fysisk-aktivitet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/matvanor/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/komplementar-och-alternativ-medicin/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/solvanor/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/cancerrehabilitering/kunskap-och-stod/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/fatigue-och-nedsatt-fysisk-form/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/illamaende/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/andfaddhet-och-hosta/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-andningsproblem/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-andningsproblem/andnod/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/omvardnad-vid-andningsproblem/hosta/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Omvardnad-och-rehabilitering/palliativ-vard-och-vard-i-livets-slutskede/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/psykosociala-inneborder-av-lungcancersjukdom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/relation-till-sjukvarden/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/relation-till-sjukvarden/information-och-delaktighet/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/relation-till-sjukvarden/vardagsliv-och-mentala-manovrar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/relation-till-sjukvarden/narstaende/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/psykosocialt-bemotande/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/psykosocialt-omhandertagande/psykosociala-insatser/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/inledning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/forekomst/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/etiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/patologi/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/klinik-och-symtom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/utredning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/behandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/behandling/kirurgi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/behandling/radioterapi-och-lokoregional-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/behandling/systemterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/uppfoljning-och-prognos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/karcinoider/tumorlets-och-diffus-idiopatisk-pulmonell-neuroendokrin-cellhyperplasi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/inledning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/epidemiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/etiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/naturalforlopp/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/symtom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/laboratoriefynd/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/diagnos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/patologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/stadieindelning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/prognos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/behandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/behandling/kirurgi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/behandling/radioterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/behandling/immunterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/behandling/Cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/behandling/vid-progression/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/uppfoljning-och-registrering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/Differentialdiagnoser/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/Differentialdiagnoser/pleurakarcinos/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/Differentialdiagnoser/solitar-fibros-tumor/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/malignt-pleuramesoteliom/tabeller/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/etiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/epidemiologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/symtom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/histopatologi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/stadieindelning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/utredning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/kirurgi/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/kirurgi/grundprinciper/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/kirurgi/sternotomi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/kirurgi/vatsrats/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/radioterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/radioterapi-tymuscarcinom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/cytostatika/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/annan-medicinsk-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/behandling/behandlingsresultat/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/andra-intrathorakala-tumorer/thymom-och-thymuscancer/Uppfoljning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/mal-med-uppfoljningen/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/fornyad-behovsbedomning-for-rehabilitering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/sjalvrapportering-av-symtom/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/bakgrund-och-evidenslage/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/uppfoljning-efter-avslutad-kurativt-syftande-behandling/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/uppfoljning-efter-avslutad-kurativt-syftande-behandling/stadium-ia-efter-kirurgi-och-sbrt/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/uppfoljning-efter-avslutad-kurativt-syftande-behandling/stadium-ibiiic/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/monitorering-under-och-uppfoljning-efter-palliativ-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/monitorering-under-och-uppfoljning-efter-palliativ-behandling/malriktad-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/monitorering-under-och-uppfoljning-efter-palliativ-behandling/immunterapi/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/monitorering-under-och-uppfoljning-efter-palliativ-behandling/cytostatikabehandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/forslag-till-uppfoljning-efter-kurativt-riktad-behandling/monitorering-under-och-uppfoljning-efter-palliativ-behandling/monitorering-under-paus-i-palliativ-behandling/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/ansvar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/avslut-av-uppfoljning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/uppfoljning-efter-cancerbehandling/livslang-symtomkontroll-efter-avslutad-uppfoljning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/underlag-for-nivastrukturering/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/cancerregistret/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/det-nationella-lungcancerregistret/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/det-nationella-lungcancerregistret/aterkoppling-av-data/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/uppfoljning-via-registret/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/uppfoljning-via-registret/uppfoljning-av-nationella-riktlinjer-och-kvalitetsindikatorer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/uppfoljning-via-registret/uppfoljning-av-standardiserade-vardforlopp-svf/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/utveckling-av-registret/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/utveckling-av-registret/patientrapporterade-matt/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/utveckling-av-registret/individuell-patientoversikt/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Register/utveckling-av-registret/ovriga-moduler/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/vardprogramgruppen/2021-08-27 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/vardprogramgruppen/forfattare/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/vardprogramgruppen/planeringsgruppen/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/24-referenser/2022-05-10 https://kb.localhost:5000/diagnoser/lungcancer/vardprogram/Patientinformation/2024-07-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-11 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/lungcancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/lungcancer/forkortat-vardforlopp/2025-11-20 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/2020-02-28 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-05-27 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/version-4.1-2025-04-292025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/version-4.0-2024-10-222025-05-27 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/hur-anvanda-vardprogrammet/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/vardprogrammets-malgrupper/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/lagstod/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/evidensgradering/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/inledning/forkortningsordlista/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/mal-med-vardprogrammet/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bakgrund-och-orsaker/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/ansvarsfordelning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/uppfoljningsmottagningar-efter-barncancer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/uppfoljningsmottagningar-efter-barncancer/uppfoljningsmottagning-for-barn-och-unga-under-18ars-alder-s.k.-nyckelmottagning2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/uppfoljningsmottagningar-efter-barncancer/uppfoljningsmottagning-for-vuxna-efter-barncancer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/uppnadda-mal-och-kvarvarande-brister/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/uppnadda-mal-och-kvarvarande-brister/uppnadda-mal2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/organisation/uppnadda-mal-och-kvarvarande-brister/kvarvarande-brister2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/potentiella-sena-komplikationer-av-cancerbehandling--sammanfattning/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/allmant/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/psykisk-halsa/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/fysisk-aktivitet/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/kostvikt/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/solvanor/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/rokning-och-tobak/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/alkohol/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/ovriga-droger/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/sexuell-halsa/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/risk-skyddsfaktorer/smarta/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/uppfoljning/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/kunskapsunderlag/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/kunskapsunderlag/levnadsvanor/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/livet-efter-avslutad-behandling/kunskapsunderlag/livet-efter-barncancer/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/Sena-komplikationer-perifera-nervsystemet/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/Sena-komplikationer-perifera-nervsystemet/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/Sena-komplikationer-perifera-nervsystemet/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/Sena-komplikationer-perifera-nervsystemet/uppfoljning-fore-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/Sena-komplikationer-perifera-nervsystemet/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/Sena-komplikationer-perifera-nervsystemet/kunskapsunderlag2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/malsattning2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fore-18-ars-alder2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fore-18-ars-alder2/neurologi/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fore-18-ars-alder2/epilepsi/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fore-18-ars-alder2/kognitiva-komplikationer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fore-18-ars-alder2/ovrigt/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fran-18-ars-alder2/2024-11-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fran-18-ars-alder2/motorik-och-epilepsi/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fran-18-ars-alder2/kognitiva-komplikationer2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/uppfoljning-fran-18-ars-alder2/ovrigt2/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/neurologiska-och-kognitiva-biverkningar--centrala-nervsystemet-cns/kunskapsunderlag/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/riskfaktorer/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/uppfoljning/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/lag-risk/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/lag-risk/uppfoljning-fore-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/lag-risk/uppfoljning-fran-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/mattlig-risk/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/mattlig-risk/uppfoljning-fore-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/mattlig-risk/uppfoljning-fran-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/hog-risk2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/hog-risk2/uppfoljning-fore-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/hog-risk2/uppfoljning-fran-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/hog-risk2/generella-restriktioner/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hjarta/kunskapsunderlag2/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/uppfoljning/2024-10-30 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/uppfoljning/uppfoljning-fore-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/uppfoljning/uppfoljning-fran-18-ars-alder/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/handlaggning-av-patienter-med-karlstenoser/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/karl/kunskapsunderlag/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/uppfoljning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/uppfoljning/hog-risk-for-horselnedsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/uppfoljning/lag-risk-for-horselnedsattning/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/kunskapsunderlag/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/kunskapsunderlag/horsel/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/horsel-och-balans/kunskapsunderlag/balans/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/riskfaktorer-for-skador-pa-levern/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/riskfaktorer-for-skador-pa-bukspottskorteln/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/malsattning2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/uppfoljning-fore-18-ars-alder/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/uppfoljning-fore-18-ars-alder/vid-normala-varden/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/uppfoljning-fore-18-ars-alder/vid-avvikande-varden/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/uppfoljning-fore-18-ars-alder/vid-avvikande-varden/forhojda-levervarden/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/uppfoljning-fore-18-ars-alder/vid-avvikande-varden/forhojt-ferritin/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/uppfoljning-fran-18-ars-alder/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lever-och-bukspottkortel/kunskapsunderlag2/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/riskfaktorer-for-paverkan-pa-njurar-urinvagar-och-urinblasa/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fore-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fore-18-ars-alder/vid-behandlingsavslut/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fore-18-ars-alder/ar-15-efter-behandlingsavslut/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fore-18-ars-alder/efter-5-ar-fran-behandlingsavslut/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fran-18-ars-alder/ar-15-efter-behandlingsavslut/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/uppfoljning-fran-18-ars-alder/efter-5-ar-fran-behandlingsavslut/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/njurar-urinvagar-och-urinblasa/kunskapsunderlag2/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/riskfaktorer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/riskfaktorer/paverkan-pa-spottkortlar-och-tander/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/riskfaktorer/paverkan-pa-munhalan-i-ovrigt/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/riskfaktorer/allogen-hematopoetisk-celltransplantation-allogen-hct/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/uppfoljning/2024-10-31 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/uppfoljning/ekonomisk-ersattning-for-tandvard/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/tander-munhala-och-spottkortlar/kunskapsunderlag/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/ogon-och-syn/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/ogon-och-syn/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/ogon-och-syn/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/ogon-och-syn/uppfoljning-fore-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/ogon-och-syn/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/ogon-och-syn/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/immunsystem/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/immunsystem/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/immunsystem/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/immunsystem/uppfoljning/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/immunsystem/kunskapsunderlag/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/uppfoljning-fore-18/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/uppfoljning-fore-18/allogen-hct/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/uppfoljning-fran-18-ars-alder/allogen-hct/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/lungfunktion/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/uppfoljning/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/uppfoljning/uppfoljning-fore-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/uppfoljning/uppfoljning-fran-18-ars-alder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gastrointestinalkanalen/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/riskfaktorer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/riskfaktorer/riskfaktorer-for-paverkan-pa-hypofys-och-hypotalamus/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/riskfaktorer/riskfaktorer-for-paverkan-pa-tyreoideafunktion/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/riskfaktorer/riskfaktorer-for-paverkan-pa-paratyreoidea/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fore-18-ars-alder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fore-18-ars-alder/kontroller/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/kontroller/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/kontroller/hypofys--och-hypotalamussvikt/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/kontroller/tyreoidea/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/kontroller/paratyreoidea/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/oversikt-risk-beroende-av-behandlingstyp/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/uppfoljning-fran-18-ars-alder/oversikt-typer-av-hormonbrist/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/endokrinologi-hypotalamus-hypofys-och-tyreoidea/kunskapsunderlag/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/riskfaktorer/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/riskfaktorer/riskfaktorer-for-utebliven-pubertet-tidig-menopaus-och-nedsatt-fertilitet/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/riskfaktorer/riskfaktorer-for-pubertetsstorningar-med-bade-for-tidig-och-for-sen-pubertet/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fore-18/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fore-18/patienter-som-erhallit-straldos-mot-ovarier-eller-behandlats-med-alkylerande-cytostatika/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fore-18/uppfoljning-hos-barnendokrinolog/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fran-18-ars-alder/patienter-som-erhallit-straldos-mot-ovarier-eller-behandlats-med-alkylerande-cytostatika/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fran-18-ars-alder/patienter-som-bor-foljas-upp-hos-en-reproduktionsmedicinsk-specialist-pa-universitetssjukhus/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/uppfoljning-fran-18-ars-alder/observandum-i-samband-med-graviditet-och-reproduktionsmedicinska-atgarder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/kunskapsunderlag/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--flickor/cyklofosfamidekvivalent-dos/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/riskfaktorer/riskfaktorer-for-nedsatt-fertilitet/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/riskfaktorer/riskfaktorer-for-primar-och-sekundar-testosteronsvikt/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/riskfaktorer/riskfaktorer-for-pubertetsstorningar-med-bade-for-tidig-och-for-sen-pubertet/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/uppfoljning-fore-18/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/uppfoljning-fore-18/patienter-som-erhallit-straldos-mot-testiklar-eller-hypofys-eller-behandlats-med-cyklofosfamidekvivalent-dos--4000-mgm2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/uppfoljning-fore-18/patienter-som-endast-behandlats-med-cytostatika-utan-alkylerande-cytostatika-eller-med-cyklofosfamidekvivalent-dos-4000-mgm2/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/uppfoljning-fore-18/uppfoljning-hos-barnendokrinolog2/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/uppfoljning-fran-18-ars-alder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/gonadfunktion-och-fertilitet--pojkar/cyklofosfamidekvivalent-dos2/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/konsorgan-och-sexuell-funktion/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/konsorgan-och-sexuell-funktion/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/konsorgan-och-sexuell-funktion/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/konsorgan-och-sexuell-funktion/uppfoljning-fore-18-ars-alder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/konsorgan-och-sexuell-funktion/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/konsorgan-och-sexuell-funktion/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/uppfoljning-fore-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/uppfoljning-fore-18-ars-alder/generell-uppfoljning/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/uppfoljning-fore-18-ars-alder/efter-stralbehandling-mot-pankreassvans/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/uppfoljning-fran-18-ars-alder/generell-uppfoljning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/uppfoljning-fran-18-ars-alder/efter-helkroppsbestralning-eller-bukbestralning-som-innefattar-pankreassvansen/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/definition-av-metabolt-syndrom-enligt-idf/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/metabola-syndromet/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/riskfaktorer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/riskfaktorer/brosthypoplasi/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/riskfaktorer/sekundar-brostcancer/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/uppfoljning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/uppfoljning/brosthypoplasi/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/uppfoljning/sekundar-brostcancer/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/uppfoljning/uppfoljning-fore-18-ar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/uppfoljning/uppfoljning-fran-18-ars-alder/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/kunskapsunderlag/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/kunskapsunderlag/brosthypoplasi/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/brostkortlar/kunskapsunderlag/sekundar-brostcancer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/riskfaktorer/2024-11-06 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fore-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fore-18-ars-alder/riktlinjer-for-uppfoljning-vid-tillvaxtrubbning-av-skelett-muskler-och-mjukdelar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fore-18-ars-alder/riktlinjer-for-uppfoljning-av-benmineralisering/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fore-18-ars-alder/riktlinjer-for-uppfoljning-vid-osteonekros/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fran-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fran-18-ars-alder/riktlinjer-for-uppfoljning-vid-tillvaxtrubbning-av-skelett-muskel-och-mjukdelar-och-efter-amputation/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/uppfoljning-fran-18-ars-alder/riktlinjer-for-uppfoljning-av-bentathet-och-osteoporos/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/skelett-muskulatur-och-mjukdelar/kunskapsunderlag/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/riskfaktorer-for-hudcancer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/uppfoljning/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/uppfoljning/generell-information/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/uppfoljning/hudkontroller-av-sarskilda-riskgrupper/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/hud/kunskapsunderlag/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/riskfaktorer/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/uppfoljning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/uppfoljning-fore-18-ars-alder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/uppfoljning-fran-18-ars-alder/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/ytterligare-uppfoljningsrekommendationer/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/efterfoljande-cancer/kunskapsunderlag2/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/nationellt-kvalitetsregister/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/nationellt-kvalitetsregister/tolkningsverktyg-foljsamhet-med-vardprogram/2025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/nationellt-kvalitetsregister/tolkningsverktyg-foljsamhet-med-vardprogram/uppfoljning-upp-till-18-ar/2025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/nationellt-kvalitetsregister/tolkningsverktyg-foljsamhet-med-vardprogram/uppfoljning-fran-18-ars-alder/2025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/nationellt-kvalitetsregister/tolkningsverktyg-foljsamhet-med-vardprogram/fertilitet/2025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/referenser/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/internationella-uppfoljningsrekommendationer/2024-11-01 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/forslag-till-fordjupning/2024-11-04 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/forslag-till-fordjupning/utbildning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/vardprogramgruppens-sammansattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/vardprogramgruppens-sammansattning/ordforande/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/vardprogramgruppens-sammansattning/ovrig-vardprogramsgrupp/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/vardprogramgruppens-sammansattning/adjungerade-forfattare/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/tidigare-medlemmar-vardprogramgruppen/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/jav-och-andra-bindningar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/vardprogramgrupp/vardprogrammets-forankring/2025-05-26 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-1-sammanfattning-av-cancerbehandling-med-uppfoljningsrekommendationer/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/mottagningens-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/basstandard-for-resurser-pa-barncancercentrum/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/basstandard-for-resurser-pa-lanssjukhus/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/lakares-och-sjukskoterskas-uppgifter-pa-barncancercentrum/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/lakares-och-sjukskoterskas-uppgifter-pa-barncancercentrum/lakarens-uppgift-pa-barncancercentrum/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/lakares-och-sjukskoterskas-uppgifter-pa-barncancercentrum/sjukskoterskans-uppgift-pa-barncancercentrum/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/lakares-och-sjukskoterskas-uppgifter-pa-lanssjukhus/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/lakares-och-sjukskoterskas-uppgifter-pa-lanssjukhus/lakarens-uppgifter-pa-lanssjukhus/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/lakares-och-sjukskoterskas-uppgifter-pa-lanssjukhus/sjukskoterskans-uppgifter-pa-lanssjukhus/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/beskrivning-av-nyckelbesok/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/beskrivning-av-nyckelbesok/nyckelbesok-1-vid-ca-1314-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/beskrivning-av-nyckelbesok/nyckelbesok-2-vid-ca-1617-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/beskrivning-av-nyckelbesok/nyckelbesok-3-vid-18-ars-alder/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-2-basstandard-for-uppfoljningsmottagningar-for-patienter-under-18-ar-s-k-nyckelmottagningar/beskrivning-av-nyckelbesok/ovrigt/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/2024-11-05 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/bakgrund/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/malsattning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/information/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/radgivning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/ansvar-for-uppfoljning-enligt-vardprogrammet/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/medicinsk-bedomning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/ovrig-utredning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/natverk/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/medicinsk-utredning-och-behandling/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/intyg/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/rehabilitering/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/kvalitetsregister/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/aktiv-overlamning-fran-barn-till-vuxen/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/aktiv-overlamning-fran-barn-till-vuxen/uppfoljning-pa-ufm/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/beskrivning-av-nyckelbesok/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/behovsanpassad-uppfoljning/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-roll-pa-ufm/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-roll-pa-ufm/lakarens-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-roll-pa-ufm/sjukskoterskans-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-roll-pa-ufm/kuratorns-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-roll-pa-ufm/vardadministratorens-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-roll-pa-ufm/registerkoordinatorns-uppgifter/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-kompetenser-pa-ufm/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-kompetenser-pa-ufm/lakares-kompetens/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-kompetenser-pa-ufm/sjukskoterskans-kompetens/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-kompetenser-pa-ufm/kuratorns-kompetens/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-kompetenser-pa-ufm/vardadministratorens-kompetens/2024-10-29 https://kb.localhost:5000/diagnoser/langtidsuppfoljning-efter-barncancer/vardprogram/bilaga-3-basstandard-for-uppfoljningsmottagningar-for-vuxna-efter-barncancer/mottagningens-uppgifter/olika-yrkeskategoriers-kompetenser-pa-ufm/registerkoordinatorns-kompetens/2024-10-29 https://kb.localhost:5000/diagnoser/mantelcellslymfom/2022-04-11 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/sammanfattning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/inledning/2019-11-27 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/inledning/forandringar-jamfort-med-foregaende-version/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/inledning/standardiserat-vardforlopp/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/inledning/lagstod/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/inledning/evidensgradering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/mal-med-vardprogrammet/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/bakgrund-och-orsaker2/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/bakgrund-och-orsaker2/paverkbara-faktorer-for-att-minska-risken/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/bakgrund-och-orsaker2/bakgrund-och-orsaker/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/bakgrund-och-orsaker2/etiologi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/arftlighet/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/arftlighet/arftlighet-for-mantelcellslymfom/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/symtom-och-tidig-utredning/2020-01-18 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/utredning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/utredning/rontgenologisk-utredning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/utredning/ovrig-utredning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/utredning/performance-status-whoecog/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/stadieindelning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/prognosfaktorer-i-kliniskt-bruk/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/prognosfaktorer-i-kliniskt-bruk/mantle-cell-lymphoma-international-prognostic-index-mipi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/prognosfaktorer-i-kliniskt-bruk/biologiska-prognosfaktorer/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/prognosfaktorer-i-kliniskt-bruk/cns-engagemang/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/diagnosbesked/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/diagnostik/omvardnad-och-rehabilitering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-07-05 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologi/morfologi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologi/immunfenotyp/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologi/genetik--cyklin-d1-positiva-och-cyklin-d1-negativa-mcl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologi/sox11-negativa-mcl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/patologi/indolent-mcl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/prognostiska-variabler-som-bor-analyseras-vid-morfologisk-diagnos/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/prognostiska-variabler-som-bor-analyseras-vid-morfologisk-diagnos/tp53-mutation-vid-mcl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/prognostiska-variabler-som-bor-analyseras-vid-morfologisk-diagnos/myc-rearrangering-vid-mcl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kategorisering-av-tumoren/in-situ-mantelcellsneoplasi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/multidisciplinar-konferens/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/indolent-mcl2/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/lokaliserad-sjukdom-stadium-i-iia/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-yngre-patienter/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-yngre-patienter/rekommenderade-alternativa-behandlingsregimer/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-yngre-patienter/underhallsbehandling/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-yngre-patienter/hogriskpatienter/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-aldre-patienter/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-aldre-patienter/rekommenderade-regimer/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-aldre-patienter/rekommenderade-regimer/r-bendamustin-x-6/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-aldre-patienter/aldre-patienter-aktuella-for-mer-intensiv-behandling-men-ej-autolog-sct/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/systemisk-behandling-aldre-patienter/aldre-patienter-aktuella-for-mer-intensiv-behandling-men-ej-autolog-sct/vr-cap-x-6--rituximabunderhall-var-8e-vecka-i-2-ar/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/skora-patienter/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/primar-behandling/skora-patienter/klorambucil--rituximab/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/2023-07-05 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-kemoimmunterapi--btk-hammare/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/2023-07-05 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/kriterier-for-brexu-cel/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/remitteringsgang/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/bridging-terapi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/specifika-biverkningar-av-car-t-celler/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/ovriga-patienter/2023-07-05 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/andra-aktiva-lakemedel-vid-aterfall-av-mcl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/andra-aktiva-lakemedel-vid-aterfall-av-mcl/lenalidomid---rituximab/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/cns-aterfall/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/stralbehandling/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/behandling-av-aterfall/recidiv-efter-ibrutinib--brexu-cel/klorambucil/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/levnadsvanor/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/blodprodukter/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/infektionsprofylax-efter-hogdosterapi/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/hepatit-b/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/herpesvirus/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/pneumocystis-jiroveci/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/allman-svampprofylax-candida-etc/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsprofylax/g-csf/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/infektionsbehandling/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/tumorlyssyndrom-profylax/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/sen-neutropeni-lon/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/rituximab-inducerade-interstitiella-lungforandringar-r-ild/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/akuta-infusionsreaktioner/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/understodjande-vard/psykosocialt-stod/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/palliativ-vard-och-insatser/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/psykosocialt-omhandertagande/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/psykosocialt-omhandertagande/barn-som-narstaende/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/sexualitet/2024-01-19 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/fertilitet/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/fertilitet/kvinnor/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/fertilitet/man/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/fysisk-aktivitet/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/hygien-och-isolering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/munvard/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/nutrition/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/skotsel-av-central-infart-till-blodkarl/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/infektionskanslighet/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/munhygien/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/fysisk-aktivitet/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/hud/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/mage-och-tarm/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/vaccinationer/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-patient/feber/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-kontaktsjukskoterska/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-kontaktsjukskoterska/levnadsvanor/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/egenvard/rad-riktade-till-kontaktsjukskoterska/komplementar-och-alternativ-medicin/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall-och-kontroll-av-aterfall/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/ansvar/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/avslut-av-uppfoljning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/underlag-for-nivastrukturering/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/syfte-och-mal/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/innehall/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/inklusionskriterier/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/svenska-lymfomregistret/exklusionskriterier/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsregister/cancerregistret/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/referenser/2021-09-07 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/forslag-pa-fordjupning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/vardprogramgruppen/2020-01-18 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi--generellt-for-lymfomdiagnostik2023-07-05 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardprogram/bilaga-1.-patientinformation-mantelcellslymfom2023-07-03 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/2020-02-10 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/introduktion/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/introduktion/flodesschema-for-vardforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2020-01-22 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2020-01-22 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/utredning-och-beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2021-09-02 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/mantelcellslymfom/vardforlopp/arbetsgruppens-sammansattning2/2020-01-22 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/2022-04-07 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/sammanfattning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/sammanfattning/cancer-i-matstrupe-och-ovre-magmun/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/sammanfattning/cancer-i-magsacken/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/inledning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/inledning/malgrupp/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade2/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version2/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/inledning/standardiserat-vardforlopp2/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-04-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/mal-med-vardprogrammet/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bakgrund-och-orsaker/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bakgrund-och-orsaker/incidens-och-geografisk-distribution2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bakgrund-och-orsaker/etiologi-och-prognos/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bakgrund-och-orsaker/etiologi-och-prognos/etiologi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bakgrund-och-orsaker/etiologi-och-prognos/prognos/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/arftlighet/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/arftlighet/bakgrund/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/arftlighet/patienter-som-rekommenderas-remiss-till-klinisk-genetik-for-utredning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/arftlighet/patienter-som-rekommenderas-remiss-till-klinisk-genetik-for-utredning/misstankt-hereditar-diffus-ventrikelcancer-hdgc/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/arftlighet/patienter-som-rekommenderas-remiss-till-klinisk-genetik-for-utredning/misstankt-intestinal-ventrikelcancer-ficg/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/arftlighet/patienter-som-rekommenderas-remiss-till-klinisk-genetik-for-utredning/misstankt-arftligt-ventrikelpolypos-gapps/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/symtom-och-tidig-utredning2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/symtom-vid-esofagus--och-cardiacancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/symtom-vid-ventrikelcancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/symtom-och-tidig-utredning2/ingang-till-standardiserat-vardforlopp/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning-enligt-standardiserat-vardforlopp/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/gastroskopi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/gastroskopi/diagnostisk-endoskopisk-mukosaresektion/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/anamnes-och-klinisk-bedomning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/datortomografi-dt/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/positronemissions-datortomografi-pet-dt/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/magnetisk-resonanstomografi-mr/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/kontrastforstarkt-ultraljud/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/endoskopiskt-ultraljud-eus/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/endoskopiskt-ultraljud-eus/eus-for-ct-stadieindelning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/radiologisk-och-nuklearmedicinsk-avbildning/endoskopiskt-ultraljud-eus/eus-for-cn-stadieindelning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/diagnostik2/utredning/diagnostisk-laparoskopi-vid-ventrikelcancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/anvisningar-for-provtagarens-hantering-av-provet/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/anamnestisk-remissinformation/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/klassificering-av-tumoren/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/prediktiva-analyser/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/prediktiva-analyser/pd-l1/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/prediktiva-analyser/her2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/prediktiva-analyser/mmrmsi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kategorisering-av-tumoren2/prediktiva-analyser/claudin-18.22024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/multidisciplinar-konferens2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/cervikal-esofaguscancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/cervikal-esofaguscancer/bakgrund/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/cervikal-esofaguscancer/val-av-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/cervikal-esofaguscancer/definitiv-kemoradioterapi-vid-cervikal-esofaguscancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/cervikal-esofaguscancer/kirurgisk-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/val-av-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/kirurgisk-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/kirurgisk-behandling/metoder/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/kirurgisk-behandling/kirurgisk-resektion/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/onkologisk-behandling-vid-resektabel-esofaguscancer/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/onkologisk-behandling-vid-resektabel-esofaguscancer/bakgrund/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/onkologisk-behandling-vid-resektabel-esofaguscancer/neoadjuvant-kemoradioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/onkologisk-behandling-vid-resektabel-esofaguscancer/neoadjuvant-eller-perioperativ-neoadjuvant--adjuvant-kemoterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/onkologisk-behandling-vid-resektabel-esofaguscancer/val-av-onkologisk-tillaggsbehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/onkologisk-behandling-vid-resektabel-esofaguscancer/sarskilda-situationer-och-overvaganden/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/definitiv-kemoradioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/definitiv-kemoradioterapi/bakgrund/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/definitiv-kemoradioterapi/definitiv-kemoradioterapi-vs-kirurgi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/definitiv-kemoradioterapi/kemoterapin-vid-definitiv-kemoradioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/torakal-esofaguscancer-inklusive-cardiacancer-siewert-typ-iii/definitiv-kemoradioterapi/radioterapin-vid-definitiv-kemoradioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/val-av-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/kirurgisk-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/kirurgisk-behandling/bakgrund/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/kirurgisk-behandling/lymfkorteldissektion/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/kirurgisk-behandling/typer-av-resektion/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/kirurgisk-behandling/makroskopiska-resektionsmarginaler/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/kirurgisk-behandling/rekonstruktioner/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/onkologisk-behandling-vid-resektabel-ventrikelcancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/onkologisk-behandling-vid-resektabel-ventrikelcancer/perioperativ-neoadjuvant--adjuvant-kemoterapi/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/onkologisk-behandling-vid-resektabel-ventrikelcancer/adjuvant-kemoradioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/onkologisk-behandling-vid-resektabel-ventrikelcancer/adjuvant-kemoterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/onkologisk-behandling-vid-resektabel-ventrikelcancer/kemoterapi-vs-kemoradioterapi/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ventrikelcancer-inklusive-cardia-siewert-typ-iii/onkologisk-behandling-vid-resektabel-ventrikelcancer/sarskilda-situationer-och-overvaganden/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ytlig-cancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ytlig-cancer/hoggradig-dysplasi-hgd-eller-intramukosal-cancer-imc-av-adenocarcinom-typ-i-esofagus/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ytlig-cancer/hoggradig-dysplasi-hgd-eller-intramukosal-cancer-imc-av-adenocarcinom-typ-i-esofagus/endoskopisk-resektionsbehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ytlig-cancer/hoggradig-dysplasi-hgd-eller-intramukosal-cancer-imc-av-adenocarcinom-typ-i-esofagus/ablationsbehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ytlig-cancer/hoggradig-dysplasi-hgd-eller-intramukosal-cancer-imc-av-skivepiteltyp-i-esofagus/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/ytlig-cancer/ventrikel/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/komplikationer-efter-kirurgisk-eller-onkologisk-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/komplikationer-efter-kirurgisk-eller-onkologisk-behandling/komplikationer-efter-esofaguscancerkirurgi/2025-04-01 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/komplikationer-efter-kirurgisk-eller-onkologisk-behandling/komplikationer-efter-ventrikelcancerkirurgi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/biverkningar-vid-onkologisk-behandling-av-esofagus--och-ventrikelcancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/anestesiologiska-aspekter-vid-resektionskirurgi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/anestesiologiska-aspekter-vid-resektionskirurgi/preoperativ-bedomning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/anestesiologiska-aspekter-vid-resektionskirurgi/torakal-epiduralanestesi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/anestesiologiska-aspekter-vid-resektionskirurgi/mekanisk-ventilation/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/anestesiologiska-aspekter-vid-resektionskirurgi/vatskebehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/primar-behandling2/anestesiologiska-aspekter-vid-resektionskirurgi/lungkomplikationer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/kontaktsjukskoterska/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/min-vardplan/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/aktiva-overlamningar/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/cancerrehabilitering/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/cancerrehabilitering/aterkommande-behovsbedomning-for-patienter-och-narstaende/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/koncept-for-tidig-aterhamtning-enhanced-recovery-pathway-for-esofagektomi-samt-gastrektomi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/koncept-for-tidig-aterhamtning-enhanced-recovery-pathway-for-esofagektomi-samt-gastrektomi/11.5.1.1-tidig-aterhamtning-efter-esofagektomi2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/koncept-for-tidig-aterhamtning-enhanced-recovery-pathway-for-esofagektomi-samt-gastrektomi/11.5.1.2-tidig-aterhamtning-efter-esofagektomi2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/prehabilitering/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/kirurgisk-omvardnad/2024-06-27 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/planering-infor-utskrivning-och-uppfoljning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-kirurgisk-behandling/halsorelaterad-livskvalitet/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/omvardnad-vid-onkologisk-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/fysisk-aktivitet-och-rehabilitering-under-utrednings--och-behandlingsfas/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/fysisk-aktivitet-och-rehabilitering-under-utrednings--och-behandlingsfas/under-prehabiliteringsfas/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/fysisk-aktivitet-och-rehabilitering-under-utrednings--och-behandlingsfas/under-pagaende-radio--och-kemoterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/fysisk-aktivitet-och-rehabilitering-under-utrednings--och-behandlingsfas/peri--eller-postoperativt/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/bakgrund/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/diagnostik-av-undernaring/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/preoperativ-nutrition/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/interventionell-behandling-av-nutritionsproblematik/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/nutritionsbehandling-vid-icke-botbar-sjukdom/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/omvardnad-rehabilitering-och-nutrition/nutrition/kostrad-efter-esofagektomi-eller-gastrektomi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/egenvard/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/egenvard/allmant-om-egenvard/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/egenvard/allmant-om-egenvard/rokning-och-alkohol/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/egenvard/allmant-om-egenvard/kost/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/egenvard/komplementar-och-alternativ-medicin/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/val-av-behandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/endoskopisk-stentbehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/endoskopisk-stentbehandling/vid-dysfagi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/endoskopisk-stentbehandling/vid-esofagorespiratorisk-fistel/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/endoskopisk-stentbehandling/vid-utflodesproblematik-i-ventrikeln/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/endoskopisk-stentbehandling/ovrig-stentbehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-kirurgi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-kirurgi/esofaguscancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-kirurgi/ventrikelcancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/2025-04-01 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/skivepitelcancer-i-esofagus/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/skivepitelcancer-i-esofagus/forsta-linjens-palliativa-behandling-vid-skivepitelcancer/2025-04-01 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/skivepitelcancer-i-esofagus/andra-eller-senare-linjens-palliativa-behandling-vid-skivepitelcancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/adenocarcinom-i-esofagus-och-ventrikel/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/adenocarcinom-i-esofagus-och-ventrikel/forsta-linjens-palliativa-behandling-vid-adenocarcinom/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/adenocarcinom-i-esofagus-och-ventrikel/underhallsbehandling-vid-adenocarcinom/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/adenocarcinom-i-esofagus-och-ventrikel/andra-linjens-palliativa-behandling-vid-adenocarcinom/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-onkologisk-lakemedelsbehandling/adenocarcinom-i-esofagus-och-ventrikel/tredje-eller-senare-linjens-palliativa-behandling-vid-adenocarcinom/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-radioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-radioterapi/extern-radioterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/palliativa-onkologiska-kirurgiska-och-endoskopiska-insatser/palliativ-radioterapi/brachyterapi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering-och-levnadsvanor/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/kontroll-av-aterfall/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/uppfoljning-efter-kirurgisk-eller-endoskopisk-resektionsbehandling/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/uppfoljning-efter-definitiv-kemoradioterapi-mot-esofagsucancer-patienter-som-kan-bli-aktuella-for-eventuell-salvagekirurgi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/uppfoljning-efter-definitiv-kemoradioterapi-mot-esofagsucancer-patienter-som-inte-ar-aktuella-for-salvagekirurgi/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/ansvar/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/avslut-av-uppfoljning-i-specialistvarden/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning-inom-specialistvarden/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/nivastrukturering/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning-av-cancervarden/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-esofagus--och-ventrikelcancer-nrev/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning-av-cancervarden/syfte/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning-av-cancervarden/mal/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning-av-cancervarden/inklusionskriterier2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/uppfoljning-av-cancervarden/exklusionskriterier2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer-och-malnivaer/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/referenser/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/vardprogramgruppen/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar2/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring2/2025-04-02 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/2024-06-25 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/fractionation-schedule/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/simulation/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/positioning-of-the-patient/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/definition-of-target-volumes/2023-02-06 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/normal-tissue-contouring/2024-06-13 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/dose-constraints/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/radiation-technique/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/contouring-atlas-heart/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/contouring-atlas-the-elective-lymph-nodes/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardprogram/bilaga-1-radioterapi-for-esofaguscancer/references/2022-09-05 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/introduktion2/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/introduktion2/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/22.-ingang-till-standardiserat-vardforlopp2019-11-27 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/22.-ingang-till-standardiserat-vardforlopp/misstanke/2023-02-20 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/22.-ingang-till-standardiserat-vardforlopp/2.3-filterfunktion2023-02-20 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/22.-ingang-till-standardiserat-vardforlopp/valgrundad-misstanke/2023-02-20 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/22.-ingang-till-standardiserat-vardforlopp/remiss/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/22.-ingang-till-standardiserat-vardforlopp/2.5-kommunikation-och-delaktighet2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/indikatorer-for-uppfoljning2/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/matstrups-och-magsackscancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-11-08 https://kb.localhost:5000/diagnoser/merkelcellscancer/2022-04-11 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/2023-05-11 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/sammanfattning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/standardiserat-vardforlopp/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/lagstod/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/evidensgradering/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/inledning/forkortningar/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/mal-med-vardprogrammet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/bakgrund/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/orsaker/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/orsaker/merkelcellspolyomavirusinfektion/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/orsaker/merkelcellspolyomavirusinfektion/sannolik-patogenes-for-mcpyv-associerade-respektive-mcpyv-negativa-mcc/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker/orsaker/arftlighet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker2/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker2/levnadsvanor/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker2/levnadsvanor/yttre-riskfaktorer/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker2/primarprevention/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bakgrund-och-orsaker2/sekundarprevention/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/praktiska-rad-vid-klinisk-diagnostik/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/symtom-och-kliniska-fynd/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/anamnes-klinisk-undersokning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/anamnes-klinisk-undersokning/dermatoskopi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/anamnes-klinisk-undersokning/diagnostisk-excision/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/anamnes-klinisk-undersokning/biopsier/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/ingang-till-svf/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/diagnosbesked/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/diagnosbesked/hallpunkter-for-diagnosbesked-och-uppfoljande-samtal/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/symtom-och-tidig-utredning-fram-till-pad-svar/diagnosbesked/omvardnad-vid-diagnosbesked/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/utredning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/excision-eller-utvidgad-excision-av-primartumoren/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/rad-vid-praktisk-diagnostik/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/remissuppgifter-vid-vidare-utredning-av-mcc/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/utredning-av-regionala-lymfkortlar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/utredning-av-regionala-lymfkortlar/icke-palpabla-regionala-lymfkortlar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/utredning-av-regionala-lymfkortlar/palpabla-regionala-lymfkortlar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/radiologisk-utredning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/fortsatt-utredning-efter-diagnos/algoritm-for-diagnos-och-utredning-efter-pad-svar/merkelcellspolyomavirus-serologi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/klassifikation-och-stadieindelning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/klassifikation-och-stadieindelning/klinisk-tnm-stadieindelning-av-mcc-ajcc-vicc-8e-upplagan/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/klassifikation-och-stadieindelning/patologisk-stadieindelning-av-mcc-enligt-ajcc8-uicc-8e-upplagan/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/klassifikation-och-stadieindelning/klinisk-och-patologisk-stadieindelning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/multidisciplinar-konferens/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/kirurgisk-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/portvaktskortelbiopsi-och-lymfkortelkirurgi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/portvaktskortelbiopsi-och-lymfkortelkirurgi/portvaktskortelbiopsi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/portvaktskortelbiopsi-och-lymfkortelkirurgi/lymfkortelutrymning/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-stralbehandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-stralbehandling/stod-for-adjuvant-stralbehandling-i-litteraturen/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-stralbehandling/doser-och-marginaler/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-stralbehandling/adjuvant-stralbehandling-mot-primartumoromradet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-stralbehandling/adjuvant-stralbehandling-till-regionala-lymfkortlar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-stralbehandling/tabell-adjuvant-stralbehandling-utifran-kliniskt-och-patologiskt-stadium/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-immunterapi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/adjuvant-cytostatikabehandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/onkologisk-behandling/stralbehandling-som-primar-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/primar-behandling/behandling-vid-lokoregionalt-aterfall/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/behandling-vid-avancerad-sjukdom/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/behandling-vid-avancerad-sjukdom/metastaserad-sjukdom/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/behandling-vid-avancerad-sjukdom/metastaserad-sjukdom/immunterapi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/behandling-vid-avancerad-sjukdom/metastaserad-sjukdom/cytostatika/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/behandling-vid-avancerad-sjukdom/metastaserad-sjukdom/isolerad-hyperterm-perfusion-och-elektrokemoterapi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/palliativ-vard-och-insatser/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/psykosociala-aspekter-vid-mcc/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/omvardnad-och-rehabilitering/sex-och-samlevnad/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-kirurgi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-kirurgi/kirurgi-med-hudtransplantat/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-kirurgi/kirurgi-i-huvud-halsomradet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-kirurgi/kirurgi-i-huvud-halsomradet/kirurgi-vid-lymfkortelutrymning-i-huvud-halsomradet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-kirurgi/kirurgi-vid-axill--och-inguinalutrymning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-kirurgi/senkomplikationer-efter-lymfkortelutrymning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/biverkningar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/hudreaktioner-och-omvardnad-vid-stralbehandling/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/smarta/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/nutrition/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/oral-mukosit/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/svampinfektion/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-stralbehandling/muntorrhet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-immunterapi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-immunterapi/symtommonitorering-och-patientinformation/2024-06-03 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-cytostatikabehandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-cytostatikabehandling/illamaende/2024-06-03 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-cytostatikabehandling/hand-fotsyndrom/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-i-samband-med-cytostatikabehandling/oral-mukosit/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/specifik-omvardnad-och-rehabilitering-vid-merkelcellscancer/omvardnad-av-maligna-tumorsar-vid-merkelcellscancer/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/nationella-riktlinjer/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/kontrollera-huden/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/sunda-solvanor/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/komplementar-och-alternativ-medicin-och-behandling/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/tobak/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/alkohol/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/egenvard/fysisk-aktivitet/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/uppfoljning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/underlag-for-nivastrukturering/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsregister/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsregister/diagnosspecifikt-kvalitetsregister/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsregister/palliativregistret/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsregister/cancerregistret/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/kirurgi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/onkologi/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/referenser/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar2/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring2/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/klinisk-bakgrundsinformation-och-patologins-roll-i-den-diagnostiska-processen/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/hudpreparat/2022-05-27 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/portvaktskortel/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/terapeutisk-lymfkortelutrymning/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/rekommenderat-klassifikationssystem/2023-08-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/forslag-till-mall-for-histopatologiskt-utlatande/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/koder-och-beteckningar/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/kvalitetsarbete-for-patologin/2022-05-27 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/hud-kvast-gruppen/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/rekommenderad-litteratur/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga--merkelcellscancer/referenser/2022-05-24 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bilaga-2-bildbilaga/2023-08-25 https://kb.localhost:5000/diagnoser/merkelcellscancer/vardprogram/bilaga-3-stod-for-adjuvant-cytostatikabehandling-i-litteraturen/2023-08-25 https://kb.localhost:5000/diagnoser/myelom/2022-04-07 https://kb.localhost:5000/diagnoser/myelom/vardprogram/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/inledning/2024-04-02 https://kb.localhost:5000/diagnoser/myelom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/inledning/standardiserat-vardforlopp/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/inledning/lagstod/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/inledning/evidensgradering/2024-02-14 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mal-med-vardprogrammet/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/bakgrund-och-orsaker/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-prevention-och-tidig-diagnostik/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-prevention-och-tidig-diagnostik/livsstils--och-riskfaktorer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-prevention-och-tidig-diagnostik/arftlighet/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-prevention-och-tidig-diagnostik/alarmsymtom/2024-02-21 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/symtom-och-kliniska-fynd/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/ingang-till-standardiserat-vardforlopp-svf-myelom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/S-beta-2-mikroglobulin/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/fraktionerade-proteiner-i-serum-och-urin/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/fria-latta-kedjor-i-serum-s-flc/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/benmargsundersokning/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/bilddiagnostik/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/bilddiagnostik/tekniska-aspekter-pa-mr-avseende-imwg-kriterier-for-symtomatiskt-myelom/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnostik-och-fortsatt-utredning/bilddiagnostik/tekniska-aspekter-pa-dt-myelomskelett/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/diagnoskriterier/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/diagnoskriterier/behandlingskravandesymtomatiskt-myelom/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/diagnoskriterier/behandlingskravandesymtomatiskt-myelom/icke-behandlingskravandeasymtomatiskt-myelom-smoldering-myelom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/diagnoskriterier/mgus-monoklonal-gammopati-av-oklar-signifikans/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/diagnoskriterier/solitart-plasmocytom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/diagnoskriterier/plasmacellsleukemi/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/prognosfaktorer-for-behandlingskravande-myelom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/prognosfaktorer-for-behandlingskravande-myelom/patientrelaterat/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/prognosfaktorer-for-behandlingskravande-myelom/stadium/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/prognosfaktorer-for-behandlingskravande-myelom/cytogenetiska-forandringar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kategorisering-av-tumoren/prognosfaktorer-for-behandlingskravande-myelom/andra-prognosmarkorer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mgus/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mgus/diagnoskriterier/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mgus/utredning-av-nyupptackt-m-komponent/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mgus/mgrs-m-komponent-med-renal-signifikans/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mgus/uppfoljning-av-personer-med-mgus2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/mgus/riskfaktorer-for-malign-transformation2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/multidisciplinar-konferens/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/2024-04-02 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/val-av-behandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-aldre-patienter-dar-hogdosbehandling-inte-planeras/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-aldre-patienter-dar-hogdosbehandling-inte-planeras/oversikt-over-behandlingskombinationer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-aldre-patienter-dar-hogdosbehandling-inte-planeras/behandling-av-skora-patienter2/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-aldre-patienter-dar-hogdosbehandling-inte-planeras/behandling-av-aldre-patienter-med-njursvikt2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-aldre-patienter-dar-hogdosbehandling-inte-planeras/behandling-av-aldre-patienter-med-pancytopeni2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-aldre-patienter-dar-hogdosbehandling-inte-planeras/behandling-av-mycket-skora-patienter/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/2025-03-17 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/behandlingsregimer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/hogdosbehandling-med-autologt-stamcellsstod/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/hogdosbehandling-med-autologt-stamcellsstod/mobiliseringsbehandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/hogdosbehandling-med-autologt-stamcellsstod/hogdosbehandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/konsoliderings-och-underhallsbehandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/konsoliderings-och-underhallsbehandling/konsolideringsbehandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/konsoliderings-och-underhallsbehandling/underhallsbehandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/primar-behandling/initial-behandling-for-yngre-patienter-dar-hogdosbehandling-planeras/konsoliderings-och-underhallsbehandling/patienter-med-hogriskmyelom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-primart-plasmocytom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-primart-plasmocytom/behandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-primart-plasmocytom/behandling/behandling-solitart-skelettplasmocytom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-primart-plasmocytom/behandling/behandling-solitart-extraskelettalt-plasmocytom/2024-04-02 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/mgus/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/asymtomatiska-myelom/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/uppfoljning-under-pagaende-behandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/uppfoljning-under-behandlingsuppehall/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/myelom-efter-hogdosbehandling-utan-behandling/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/12.6-kriterier-for-respons-och-progress2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/uppfoljning-och-responsvardering/kriterier-for-respons-och-progress2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/ny-hogdosbehandling/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/allogen-transplantation/2024-02-14 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/kombinationsbehandlingar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/lenalidomid-baserad-behandling/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/bortezomib-baserad-behandling-vrdvtdvcdvd/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/karfilzomib-baserad-behandling-kdkcdkrdkdd/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/kombinationer-baserade-pa-cd38-antikropp-cd38ak/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/pomalidomid/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/ixazomib/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/bendamustin/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/vtd-pace/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/melfalan-prednisolon-mpmpv/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/talidomid-baserad-behandling/2025-03-17 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/panobinostat/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/venetoclax/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/chimeric-antigenreceptor-t-cells-car-t-och-bispecifika-t-cells-antikroppar/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/selinexor/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/belantamab-mafodotin/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/elotuzumab/2024-02-22 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/tillgangliga-aterfallsbehandlingar/perorala-behandlingsregimer-i-senare-linjer/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/riktlinjer-for-val-av-behandling-vid-olika-komplikationer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/riktlinjer-for-val-av-behandling-vid-olika-komplikationer/aggressivt-aterfall-med-stor-extramedullar-tumorborda/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandling-av-aterfall/riktlinjer-for-val-av-behandling-vid-olika-komplikationer/palliativ-cytostatikabehandling/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/daratumumab-d2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/benda2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/rd2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/vd-bortezomib-dexametason2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/kd56-karfilzomib-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/kd70-karfilzomib-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/kd-underhall-27--56-karfilzomib-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/pd-pomalidomid-dexametason2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/mp2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/td-thalidomid-dexametason2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/rcd-revlimid-cyklofosfamid-dexametason2/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/dvd-daratumumab-bortezomib-dexametason/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/vrd21--28--lite-bortezomib-lenalidomid-dexametason/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/ird-ixazomib-lenalidomid-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/kcd-karfilzomib-cyklofosfamid-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/krd-karfilzomib-lenalidomid-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/pvd--pcd-pomalidomid-bortezomib-dexametasonpomalidomid-cyklofosfamid-dexametason/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/drd-daratumumab-lenalidomid-dexametason/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/dvtd-daratumumab-bortezomib-talidomid-dexametason2/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/dvcd-bortezomib-cyklofosfamid-dexametason2/2024-02-14 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/dvrd-bortezomib-lenalidomid-dexametason2/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/dmpv-daratumumab-melfalan-prednisolon-bortezomib/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/vtd-pace2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/behandlingsregimer/underhallsbehandling-efter-autolog-stamcellstransplantation/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/allogen-stamcellstransplantation/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/bisfosfonatbehandling-och-annan-osteoklasthamning/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/infektionsprofylax/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/infektionsprofylax/antibakteriell-profylax/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/infektionsprofylax/profylax-mot-reaktivering-av-varicella-zostervirus/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/infektionsprofylax/profylax-mot-pneumocystis-jirovecii/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/infektionsprofylax/immunglobulinbehandling/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/infektionsprofylax/vaccinationer/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/njursvikt/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/njursvikt/handlaggning-vid-akut-njursvikt/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/njursvikt/handlaggning-vid-kronisk-njursvikt/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/hyperkalcemi/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/hyperkalcemi/mild-hyperkalcemi-s-ca--29-mmoll-eller-joniserat-ca-145mmoll/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/hyperkalcemi/mattlig-eller-svar-hyperkalcemi-s-ca--29-mmoll-eller-joniserat-ca--145-mmoll/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/hyperkalcemi/svar-symtomgivande-hyperkalcemi/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/anemi/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/venos-tromboembolism/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/perkutan-vertebroplastik/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/understodjande-vard/ryggmargskompression/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/palliativ-vard/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/palliativ-vard/inledning/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/palliativ-vard/brytpunktssamtal/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/palliativ-vard/palliativ-stralbehandling2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/inledning/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/inledning/patientens-team/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/inledning/kontaktsjukskoterska/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/inledning/min-vardplan/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/inledning/aktiva-overlamningar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/psykosocialt-omhandertagande/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/psykosocialt-omhandertagande/information-om-diagnos/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/psykosocialt-omhandertagande/barn-som-narstaende/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/nutrition-och-munhalsa/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/nutrition-och-munhalsa/nutrition/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/nutrition-och-munhalsa/munhalsa/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/gastrointesterala-besvar-forstoppningdiarre/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/fatigue/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/smarta--skelettsjukdom/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/smarta--skelettsjukdom/smartbehandling/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/smarta--skelettsjukdom/hjalpmedel-vid-smartproblematik/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/neuropati/2024-04-02 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/kardiella-biverkningar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/sexualitet/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/sexualitet/sexuell-halsa/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/omvardnad-och-rehabilitering/fertilitet/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/levnadsvanor/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/rokning/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/alkohol/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/fysisk-aktivitet/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/matvanor/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/solvanor/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/komplementar-och-integrativ-medicin-kim/2024-02-09 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/vaccinationer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/subkutana-injektioner-i-hemmet/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/vid-akuta-besvar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/egenvard/kunskap-och-stod-till-patienter-och-narstaende/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/underlag-for-nivastrukturering2/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kvalitetsregister/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer-faststallda-i-samrad-med-svensk-forening-for-hematologi-sfh-januari-2021/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/kvalitetsindikatorer-och-malnivaer/andra-kvalitetsindikatorer/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/referenser/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/vardprogramgruppen/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/adjungerade-medlemmar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/stodteam-rcc-vast/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/stodteam-rcc-vast/sprakkonsult/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/stodteam-rcc-vast/referenshanterare/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/vardprogrammets-forankring/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardprogram/vardprogramgruppens-sammansattning/jav-och-andra-bindningar/2024-02-08 https://kb.localhost:5000/diagnoser/myelom/vardprogram/bilaga-1-tidigare-revideringar/2025-03-12 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/myelom/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/2023-07-06 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/2023-06-21 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/sammanfattning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/2.1vardprogrammets-giltighetsomrade2024-09-23 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/forandringar-jamfort-med-tidigare-versioner/2024-09-23 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/standardiserat-vardforlopp/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/lagstod/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/metod-vid-framtagning-av-vardprogrammet/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/evidensgradering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/inledning/lista-med-forkortningar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mal-med-vardprogrammet/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bakgrund-och-orsak/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bakgrund-och-orsak/epidemiologi/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bakgrund-och-orsak/naturalhistoria-och-etiologi/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bakgrund-och-orsak/paverkbara-faktorer-for-att-minska-risken-for-mds/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/arftlighet/2023-07-06 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/arftlighet/vilka-bor-overvagas-for-utredning-av-arftlig-mds/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/sjukhistoria/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/kliniska-fynd/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/nar-ska-remiss-till-hematologisk-klinik-skickas/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/differentialdiagnoser/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/klonal-hematopoes-patienter-som-inte-uppfyller-kriterier-for-mds-ccus-chip-icus-samt-idus/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/klonal-hematopoes-patienter-som-inte-uppfyller-kriterier-for-mds-ccus-chip-icus-samt-idus/ccus--clonal-cytopenia-of-undetermined-significance/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/klonal-hematopoes-patienter-som-inte-uppfyller-kriterier-for-mds-ccus-chip-icus-samt-idus/chip--clonal-hematopoiesis-of-indeterminate-potential/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/klonal-hematopoes-patienter-som-inte-uppfyller-kriterier-for-mds-ccus-chip-icus-samt-idus/icus--idiopathic-cytopenia-of-undeterminate-significance/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/symtom-och-tidig-utredning/klonal-hematopoes-patienter-som-inte-uppfyller-kriterier-for-mds-ccus-chip-icus-samt-idus/idus--idiopathic-dysplasia-of-undeterminate-significance/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/diagnostik/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/diagnostik/diagnostik/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/diagnostik/diagnostik/rekommenderade-analyser-for-diagnos/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/diagnostik/diagnostik/morfologi/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/diagnostik/diagnostik/morfologi/cytogenetisk-analys/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/diagnostik/diagnostik/morfologi/next-generation-sequencing-ngs/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/klassificering-av-mds/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/klassificering-av-mds/myelodysplastiskt-syndrom-mds/2023-07-06 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kategorisering-av-tumoren/klassificering-av-mds/mdsmpn-kronisk-myelomonocytleukemi-kmml/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/prognostiska-system/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/prognostiska-system/ipss-for-mds-international-prognostic-scoring-system/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/prognostiska-system/ipss-r-score-for-mds-revised-international-prognostic-scoring-system/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/prognostiska-system/ipss-m-score-for-mds-international-prognostic-scoring-system-molecular/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/prognostiska-system/forenklade-riskgrupper-ipss-r-och-ipss-m/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/10.1oversikt-mdsmpn-inklusive-kronisk-myelomonocytleukemi-kmml2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/10.1oversikt-mdsmpn-inklusive-kronisk-myelomonocytleukemi-kmml/kmml/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/diagnostik/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/diagnostik/diagnoskriterier/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/riskbedomning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/behandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/ovrig-mdsmpn/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/ovrig-mdsmpn/mdsmpn-u/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/ovrig-mdsmpn/mdsmpn-rs-t/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/mdsmpn-och-kronisk-myelomonocytleukemi-kmml/ovrig-mdsmpn/atypisk-kml-akml/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/multidisciplinar-konferens/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/multidisciplinar-konferens/mdk-vid-diagnos/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/multidisciplinar-konferens/mdk-vid-diskussion-om-allogen-hsct/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/multidisciplinar-konferens/mdk-vid-misstanke-om-arftlig-predisposition/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/2024-09-23 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/behandling-och-uppfoljning-av-mds-med-lagre-risk/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/behandling-och-uppfoljning-av-mds-med-lagre-risk/definition-av-lagrisk-intermediarrisk-och-hogrisk/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/bakgrund/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/behandlingsindikation-esa/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/dosering-esa/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/g-csf-behandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/lenalidomid/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/lenalidomid/dosering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/immunosuppressiv-behandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/immunosuppressiv-behandling/bakgrund/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/azacitidin/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-lagre-risk/12.2behandling-av-anemi-med-erytropoietin-stimulerande-medel-esa/luspatercept/2024-09-23 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/definition-av-hogre-risk/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/azacitidin-aza/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/azacitidin-aza/bakgrund/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/azacitidin-aza/praktisk-anvandning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/aml-lik-intensiv-cytostatikabehandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/lagdos-cytostatikabehandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/behandling/kortikosteroider/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/lakemedel-som-inte-har-indikation-for-mds-men-som-ar-bra-att-kanna-till/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/lakemedel-som-inte-har-indikation-for-mds-men-som-ar-bra-att-kanna-till/venetoclax/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/behandling-av-mds-med-hogre-risk/lakemedel-som-inte-har-indikation-for-mds-men-som-ar-bra-att-kanna-till/decitabin/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/inledning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/vilka-patienter-med-mds-ar-aktuella-for-allo-hsct/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/sjukdomsreducerande-behandling-innan-transplantationen/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/kort-om-donatorval-och-konditionering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/uppfoljning-efter-allo-hsct/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/allogen-stamcellstransplantation/aterfallsbehandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/erytrocyttransfusion/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/erytrocyttransfusion/15.1.1omvardnad-vid-transfusioner2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/kelatbehandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/kelatbehandling/bakgrund/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/kelatbehandling/indikation/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/kelatbehandling/indikation/dosering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/kelatbehandling/indikation/kombinationsbehandling/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/behandling-av-trombocytopeni/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/understodjande-vard/handlaggning-vid-okad-infektionsrisk/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/palliativ-vard-och-insatser/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/palliativ-vard-och-insatser/inledning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/palliativ-vard-och-insatser/palliativa-behandlingar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/palliativ-vard-och-insatser/palliativregistret/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/palliativ-vard-och-insatser/narstaendepenning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/palliativ-vard-och-insatser/fordjupad-information/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/oversikt/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/oversikt/kontaktsjukskoterska/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/oversikt/min-vardplan/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/oversikt/aktiva-overlamningar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/17.2lopande-cancerrehabilitering2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/17.2lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/17.2lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/psykosocialt-omhandertagande/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/fatigue/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/infektionsforebyggande-atgarder/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/infektionsforebyggande-atgarder/infarter/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/munhalsa/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/nutrition/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/nutrition/kost-vid-neutropeni/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/illamaende/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/gastrointestinala-biverkningar-forstoppning-och-diarre/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/sexualitet/2024-01-19 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/omvardnad-och-rehabilitering/omvardnad/fertilitet/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/levnadsvanor/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/rokning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/komplementar-och-alternativ-medicin/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/alkohol/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/fysisk-aktivitet/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/matvanor/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/solvanor/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/vaccinationer/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/vid-akuta-besvar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/egenvard/kunskap-och-stod-till-patienter-och-narstaende/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/uppfoljning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/uppfoljning/uppfoljning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/uppfoljning/ansvar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/underlag-for-nivastrukturering/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kvalitetsregister/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kvalitetsregister/nationellt-kvalitetsregister-for-mds-och-mdsmpn/2023-07-06 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kvalitetsregister/cancerregistret/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kvalitetsindikatorer-och-malnivaer/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kvalitetsindikatorer-och-malnivaer/22.1kvalitetsindikatorer-som-foljs-i-mds-registret2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/kvalitetsindikatorer-och-malnivaer/gemensamma-kvalitetsindikatorer-for-samtliga-delregister-i-blodcancerregistret/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/referenser/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/forslag-pa-fordjupning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/vardprogramgruppen/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/vardprogramgruppen/jav-och-andra-bindningar/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/vardprogramgruppen/vardprogrammets-forankring/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/arftliga-myeloiska-maligniteter/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bilaga-2--att-tanka-pa-vid-utredning-av-laga-blodvarden/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bilaga-3---provtagningsanvisning-for-benmarg-och-blod/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bilaga-4---klassifikation-av-mds-enligt-who-5th-edition-och-international-consensus-classification-icc/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bilaga-5---klassifikation-av-mdsmpn/2023-07-05 https://kb.localhost:5000/diagnoser/myelodysplastiskt-syndrom/nationellt-vardprogram-myelodysplastiskt-syndrom-mds/bilaga-6---uppbyggnad-av-ipss-m-och-dess-variabler/2023-07-05 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/2022-01-14 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/2022-01-14 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/ingang-till-standardiserat-vardforlopp/2022-01-14 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2022-01-14 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2022-09-02 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-for-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/utredning-och-beslut-om-behandling/2022-01-14 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/arbetsgruppens-sammansattning/2024-11-08 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardforlopp/bilaga-1-kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/2022-03-09 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/sammanfattning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/inledning/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/forandringar-som-medfor-resursbesparing/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/inledning/evidensgradering/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/mal-med-vardprogrammet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/epidemiologi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/etiologi-och-overlevnad/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/etiologi-och-overlevnad/molekylargenetik/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/etiologi-och-overlevnad/jak-2-chip-clonal-hematopoiesis-of-indeterminate-potential/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/etiologi-och-overlevnad/arftlighet-och-andra-riskfaktorer/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bakgrund-och-orsaker/etiologi-och-overlevnad/overlevnad/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/symtom-och-differentialdiagnoser/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/symtom-och-differentialdiagnoser/polycytemia-vera-pv/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/symtom-och-differentialdiagnoser/essentiell-trombocytemi-et/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/symtom-och-differentialdiagnoser/myelofibros-mf/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/symtom-och-differentialdiagnoser/oklassificerbar-myeloproliferativ-neoplasi-mpn-u/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp-mpn/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/symtom-och-tidig-utredning/symtom-som-bor-foranleda-remiss-for-utredning-utanfor-svf-mpn/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/blodprov--rekommenderade-analyser/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/blodprov--rekommenderade-analyser/blodstatus-med-differentialrakning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/blodprov--rekommenderade-analyser/molekylargenetik/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/blodprov--rekommenderade-analyser/erytropoetin-epo-i-serum/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/benmarg--rekommenderade-analyser/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/benmarg--rekommenderade-analyser/morfologi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnos/benmarg--rekommenderade-analyser/cytogenetik/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/riskstratifiering/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/diagnostik/diagnosbesked/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/patologins-roll-i-den-diagnostiska-processen/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/anvisningar-for-provtagarens-hantering-av-provet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/anamnestisk-remissinformation/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/polycytemia-vera/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/polycytemia-vera/post-pv-myelofibros/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/essentiell-trombocytemi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/essentiell-trombocytemi/post-et-myelofibros/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/primar-myelofibros/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/primar-myelofibros/prefibrotisk-myelofibros/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/primar-myelofibros/pmf-i-fibrotiskt-stadium/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/klassificering-av-mpn/klassificering-av-tumoren/oklassificerbar-myeloproliferativ-neoplasi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/multidisciplinar-konferens/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/2021-01-15 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/mal-med-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/riskstratifiering-och-indikation-for-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/flebotomi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/asa/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/hydroxyurea/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/interferon/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/busulfan/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/ruxolitinib/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/skifte-av-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/polycytemia-vera-pv/prevention-vid-hjart-karlsjukdom/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/mal-med-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/riskstratifiering-och-indikation-for-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/trombocytaggregationshammande-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/cytoreduktion/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/hydroxyurea/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/interferon/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/busulfan/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/anagrelid/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/essentiell-trombocytemi-et/prevention-vid-hjart-karlsjukdom/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/prefibrotisk-myelofibros-pre-mf/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/2025-06-18 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/mal-med-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/prognostiska-modeller-och-riskstratifiering/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/prognostiska-modeller-och-riskstratifiering/dipss-dynamic-international-prognostic-scoring-system/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/prognostiska-modeller-och-riskstratifiering/ipss-international-prognostic-scoring-system/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/prognostiska-modeller-och-riskstratifiering/mysec-pm-post-pv-och-post-et-mf/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/ovriga-riskstratiferingssystem/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/skattning-av-symtomborda/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/behandling-med-jak-hammare/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/behandling-med-jak-hammare/jak-hammare--ruxolitinib/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/behandling-med-jak-hammare/jak-hammare---fedratinib/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/andra-lakemedel-vid-myelofibros/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/andra-lakemedel-vid-myelofibros/hydroxyurea/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/andra-lakemedel-vid-myelofibros/interferon/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/andra-lakemedel-vid-myelofibros/trombocytaggregationshammande-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/behandling-av-mf-relaterad-anemi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/behandling-av-mf-relaterad-anemi/erytrocyttransfusion-och-keleringsbehandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/myelofibros-mf/allogen-stamcellstransplantation-allo-sct/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/behandling/oklassificerbar-mpn-mpn-u/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/incidens-och-prevalens/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/orsaker-till-okad-trombosrisk/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/behandling-av-trombos/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/venos-tromboembolism/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/levernara-trombos/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/tromboembolism/sinustrombos/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/blodning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/blodning/orsaker-till-okad-blodningsrisk/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/trombos-och-blodning-vid-mpn/blodning/atgarder-vid-blodning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/elektiv-kirurgi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/extramedullar-blodbildning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/klada/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/allmant-om-graviditet-vid-mpn/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/cytoreduktion-under-graviditet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/ovrig-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/overvakning-under-graviditet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/riskstratifiering/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/behandling-vid-lagriskgraviditet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/behandling-vid-hogriskgraviditet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/forlossningsanalgesi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/speciella-situationer/graviditet/amning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/leukemisk-transformation/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/leukemisk-transformation/oversikt-av-behandlingar-vid-leukemisk-transformation/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/leukemisk-transformation/oversikt-av-behandlingar-vid-leukemisk-transformation/hypometylerande-lakemedel/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/leukemisk-transformation/oversikt-av-behandlingar-vid-leukemisk-transformation/intensivbehandling-med-aml-protokoll/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/leukemisk-transformation/oversikt-av-behandlingar-vid-leukemisk-transformation/allogen-stamcellstransplantation-allo-sct/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/leukemisk-transformation/oversikt-av-behandlingar-vid-leukemisk-transformation/palliativ-och-understodjande-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/fatigue/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/existentiella-psykologiska-och-psykiatriska-aspekter/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/omvardnad-och-rehabilitering/existentiella-psykologiska-och-psykiatriska-aspekter/angest-och-depression/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/levnadsvanor/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/nationella-riktlinjer/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/rokning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/komplementar-och-alternativ-medicin/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/fysisk-aktivitet/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/kost/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/egenvard/kost/matvanor-vid-kardiovaskulara-riskfaktorer/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/palliativ-vard-och-insatser/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/palliativ-vard-och-insatser/palliativa-behandlingar/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/palliativ-vard-och-insatser/palliativa-registret/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/palliativ-vard-och-insatser/narstaendepenning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/mpn-med-nyinsatt-cytoreduktiv-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/nydiagnostiserad-pv-med-aktivt-behov-av-flebotomi/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/lagrisk-pv/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/lagrisk-et/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/pv-och-et-med-cytoreduktiv-behandling/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/valkontrollerad-pv-utan-regelbundet-behov-av-flebotomi-samt-hogrisk-et/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/mf/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/underlag-for-nivastrukturering/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning-av-cancervarden/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-myeloproliferativa-neoplasier/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/kvalitetsindikatorer-och-malnivaer/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/forslag-pa-fordjupning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/vardprogramgruppen/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-06-17 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/referenser2/2022-05-03 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/kvalitetsdokument-for-patologi/2025-06-18 https://kb.localhost:5000/diagnoser/myeloproliferativ-neoplasi/vardprogram/bilaga-3---patientinformation-vid-mpn/2025-06-17 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/2022-04-07 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/sammanfattning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/malgrupp/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/vardprogrammets-giltighetsomrade2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/standardiserat-vardforlopp2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/lagstod2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/evidensgradering2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/inledning/forkortningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/mal-med-vardprogrammet/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/paverkbara-faktorer-for-att-minska-risken/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/ventrikel-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/endokrina-pankreas-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/duodenum-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/tunntarm-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/appendix-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/kolon-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/rektum-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bakgrund-och-orsaker/incidens-och-prevalens2/neuroendokrin-cancer-nec/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/genetisk-utredning-vid-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/multipel-endokrin-neoplasi-typ-1-men1/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/multipel-endokrin-neoplasi-typ-1-men1/tumorspektrum-vid-men1/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/multipel-endokrin-neoplasi-typ-1-men1/diagnostik-av-men1/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/multipel-endokrin-neoplasi-typ-1-men1/uppfoljning-vid-konstaterad-men1/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/multipel-endokrin-neoplasi-typ-1-men1/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/von-hippel-lindaus-syndrom-vhl/2025-01-16 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/neurofibromatos-typ-1-nf1/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/tuberos-skleros-tsc/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/arftlighet/familjar-tunntarms-net/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/inledning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/klassiskt-karcinoidsyndrom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/atypiskt-karcinoidsyndrom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/diarre/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/ileus-och-subileus/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/abdominal-angina/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/epigastralgier-dyspepsi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/gastrointestinal-blodning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/ikterus/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/flush/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/nekrolytiskt-migrerande-exantem-nme/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/blekhet/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/hypoglykemi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/hyperglykemi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/takykardi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/blodtryckspaverkan/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/hjartsvikt/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/symtom-och-kliniska-fynd/obstruktiva-besvar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/ingang-till-standardiserat-vardforlopp/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/symtom-och-tidig-utredning2/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/utredning-enligt-standardiserat-vardforlopp/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/inledning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/generella-markorer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/generella-markorer/kromogranin-a/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/generella-markorer/neuronspecifikt-enolas-nse/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/serotonin-5-hydroxiindolattiksyra-5-hiaa/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/gastrin/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/insulin-c-peptid-och-proinsulin-vid-langfasta/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/glukagon/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/vasoaktiv-intestinal-peptid-vip/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/pankreatisk-polypeptid-pp/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/adrenokortikotropt-hormon-acth/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/biokemisk-diagnostik/specifika-markorer/kalcitonin/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/endoskopi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/radiologisk-diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/nuklearmedicinsk-diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/diagnostik2/diagnosbesked/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/inledning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/ventrikel/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/ventrikel/typ-1-ecl-cells-net-associerad-med-kronisk-atrofisk-gastrit/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/ventrikel/typ-2-ecl-cells-net-associerad-med-men1-och-zollinger-ellisons-syndrom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/ventrikel/typ-3-sporadisk-ecl-cells-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/ventrikel/mindre-vanliga-former/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/endokrina-pankreas/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/duodenum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/jejunum-och-ileum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/appendix/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/kolon-och-rektum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/anus/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/mixed-neuroendocrine-nonneuroendocrine-neoplasm-minen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/ventrikel/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/pankreas/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/duodenum-ampulla/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/jejunum-och-ileum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/appendix/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/kolon-och-rektum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/regionala-lymfkortlar-n-ventrikel-pankreas-duodenum-ampulla-appendix-kolon-och-rektum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/regionala-lymfkortlar-n-jejunum-och-ileum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/fjarrmetastaser-m/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/stadieindelning-ventrikel-pankreas-duodenum-ampulla-och-appendix/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/stadieindelning-jejunum-och-ileum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/histopatologi2/tnm-klassifikation-av-net-8e-utgavan/stadieindelning-kolon-och-rektum/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/multidisciplinar-konferens2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/multidisciplinar-konferens2/nationell-mdk-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/inledning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/indelning-i-subgrupper/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/indelning-i-subgrupper/typ-1-eclom-associerad-med-atrofisk-gastrit/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/indelning-i-subgrupper/typ-2-eclom-associerad-med-zollinger-ellisons-syndrom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/indelning-i-subgrupper/typ-3-sporadisk-net-i-ventrikeln/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/indelning-i-subgrupper/nec-i-ventrikeln/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/ventrikel-net/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/indelning-i-subgrupper/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/indelning-i-subgrupper/funktionella-tumorer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/indelning-i-subgrupper/icke-funktionella-tumorer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/diagnostik/genetisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/behandling/lokoregional-behandling-av-levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/endokrina-pankreas-net/incidentalom-i-pankreas/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/behandling/kirurgisk-behandling-av-pankreas/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/men1/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/indelning-i-subgrupper/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/indelning-i-subgrupper/funktionella-tumorer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/indelning-i-subgrupper/icke-funktionella-tumorer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/behandling/lokoregional-behandling-av-levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/uppfoljning/radikalt-opererade-oftast-stadium-iiiib/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/uppfoljning/icke-radikalt-opererade-ej-opererade-eller-aterfall/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/duodenal-net/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/indelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/genetisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/diagnostik/ekokardiografi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/behandling/kirurgisk-behandling--allmanna-rekommendationer/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/behandling/kirurgisk-behandling--specifika-tumorlokaler/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/behandling/perioperativ-handlaggning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/behandling/lokoregional-behandling-av-levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/nutrition/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/karcinoid-hjartsjukdom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/tunntarms-net/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/indelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/uppfoljning/radikalt-opererad/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/uppfoljning/icke-operabla/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/appendix-net/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/behandling/lokoregional-behandling-av-levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/uppfoljning/radikalt-opererade/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/uppfoljning/icke-radikalt-opererade-eller-ej-opererade/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/kolon-net/uppfoljning/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/diagnostik/laboratorieundersokning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/diagnostik/nuklearmedicinsk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/behandling/lokoregional-behandling-av-levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/behandling/systembehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/uppfoljning/radikalt-opererade/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/uppfoljning/icke-radikalt-eller-tveksamt-radikalt-opererade-alternativt-ej-opererade/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/rektum-net/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/indelning-i-subgrupper/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/prognos/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/diagnostik/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/diagnostik/laboratorieundersokningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/diagnostik/endoskopisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/diagnostik/radiologisk-utredning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/diagnostik/nuklearmedicinsk-utredning/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/histopatologi-stadie--och-gradindelning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/multidisciplinar-konferens/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/behandling/kirurgisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/behandling/systemisk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/extern-stralbehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsforberedande-diagnostik-behandling-och-uppfoljning2/neuroendokrin-neoplasi-grad-3-net-g3nec/vardniva/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/kirurgi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/kirurgi/lymfkortelmetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/kirurgi/levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/kirurgi/peritoneal-metastasering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/kirurgi/fjarrmetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/ablation-med-mikrovagor-och-radiovagor-rf/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/leverartarembolisering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/leverartarembolisering/partikelembolisering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/leverartarembolisering/kemoembolisering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/leverartarembolisering/radioembolisering/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/ablativa-metoder-for-att-behandla-levermetastaser/levertransplantation/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/patientselektion/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/patientselektion/organfunktionskriterier/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/forberedelser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/genomforande/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/dosimetri/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/biverkningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/behandling-med-radionuklidbehandling/efter-behandlingen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/somatostatinanaloger/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/cytostatika/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/cytostatika/streptozocin--5-fluorouracil/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/cytostatika/temozolomid---kapecitabin/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/cytostatika/cisplatin-eller-karboplatin--etoposid/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/mtor-hammare/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/tyrosinreceptorkinashammare/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/serotoninsynteshammare/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/alfa-interferon/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/symtomlindrande-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/symtomlindrande-behandling/behandling-av-diarre/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/symtomlindrande-behandling/behandling-av-okad-saltsyraproduktion/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/symtomlindrande-behandling/behandling-av-hypoglykemi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/behandlingsmetoder2/onkologisk-eller-medicinsk-behandling/symtomlindrande-behandling/behandling-vid-skelettmetastasering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/palliativ-behandling-vard-och-palliativa-insatser2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/palliativ-behandling-vard-och-palliativa-insatser2/palliativ-behandling-och-vard-kan-paga-i-decennier/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/palliativ-behandling-vard-och-palliativa-insatser2/riktlinjer-och-register/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsstatus/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsstatus/riskbedomning-for-undernaring/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsbehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsbehandling/vitamin--och-mineralsupplementering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsbehandling/kostrad-vid-symtom-fran-mag-tarmkanalen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsbehandling/vatskeersattning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsbehandling/kost-med-anpassad-konsistens-vid-fortrangningar-i-mag-tarmkanalen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionell-paverkan-vid-kirurgisk-och-medicinsk-behandling-for-net-i-tunntarmen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionell-paverkan-vid-kirurgisk-och-medicinsk-behandling-for-net-i-tunntarmen/vitamin-d-kalcium-pth-och-bentathet/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nutrition2/nutritionsbehandling-vid-net-i-pankreas-efter-operation-enligt-whipple/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/kontaktsjukskoterska/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/informationssamtal/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/att-forebygga-och-behandla-illamaende-och-krakningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/att-forebygga-och-behandla-illamaende-och-krakningar/att-forebygga-och-lindra-illamaende-och-krakningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/att-forebygga-och-behandla-illamaende-och-krakningar/behandlingsrekommendationer-vid-akut-illamaende/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/mage-och-tarm/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/njurfunktion-och-vatskeretention/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/haravfall/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/symtom-fran-hud-och-naglar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/neurologiska-symtom-och-horselpaverkan/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cytostatikabehandling/reproduktion/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-malriktad-per-oral-behandling/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-malriktad-per-oral-behandling/informationssamtal/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-malriktad-per-oral-behandling/symtomlindring-vid-biverkningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/informationssamtal/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/forberedelser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/administrering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/eftervard/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/biverkningar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/stralskyddsatgarder-vid-radionuklidbehandling-med-177ludotatate/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/utskrivningsplanering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/omvardnad-vid-kirurgi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-radionuklidbehandling-med-177ludotatate/psykosocialt-omhandertagande/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/egenvard2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/egenvard2/levnadsvanor/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/egenvard2/komplementar-och-alternativ-medicin/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/egenvard2/egenvard-vid-diarre/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/egenvard2/egenvard-vid-illamaende/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/egenvard2/patientforening/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/mal-med-uppfoljningen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/fornyad-behovsbedomning-for-rehabilitering/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/sjalvrapportering-av-symtom/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/kontroll-av-aterfall/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/forslag-till-uppfoljningsintervall/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/ansvar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/avslut-av-uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/livslang-symtomkontroll-efter-avslutad-uppfoljning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning2/bakgrund-och-evidenslage/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/nivastrukturering2/2025-01-09 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning-av-cancervarden/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning-av-cancervarden/kvalitetsregister-och-halsoekonomi/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/kvalitetsindikatorer2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/referenser/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/oversikter-och-lankar-som-kompletterar-vardprogrammet/2025-01-15 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/vardprogramgruppen/vardprogrammets-forankring2/2025-01-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardprogram/bilaga-1-behandling-av-diarre/2025-01-09 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/2025-01-10 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-11-12 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-filterfunktion/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-12-10 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/neuroendokrina-buktumorer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/njurcancer/2022-04-07 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/sammanfattning/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/inledning/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/inledning/termer-och-forkortningar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/mal-med-vardprogrammet/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bakgrund-och-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bakgrund-och-orsaker/epidemiologi/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bakgrund-och-orsaker/epidemiologi/incidens/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bakgrund-och-orsaker/mortalitet---overlevnad/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bakgrund-och-orsaker/riskfaktorer/2025-06-17 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/screening/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/screening/organiserad-screening/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/screening/opportunistisk-screening/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/misstanke-om-arftligt-okad-risk-for-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/arftliga-syndrom-med-forhojd-risk-for-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/arftliga-syndrom-med-forhojd-risk-for-njurcancer/von-hippel-lindaus-sjukdom-vhl/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/arftliga-syndrom-med-forhojd-risk-for-njurcancer/birt-hogg-dubes-syndrom-bhd/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/arftliga-syndrom-med-forhojd-risk-for-njurcancer/hereditar-leiomyomatos-och-njurcancer-hlrcc/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/arftlighet/uppfoljning-av-personer-med-misstankt-arftlig-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/symtom-och-tidig-utredning/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/diagnosbesked/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/klinisk-undersokning/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/laboratorieprover/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/bilddiagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/bilddiagnostik/datortomografi-magnetkameraundersokning-och-ultraljud/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/bilddiagnostik/nuklearmedicinska-metoder/2022-10-20 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/bilddiagnostik/nuklearmedicinska-metoder/skelettscintigrafi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/bilddiagnostik/nuklearmedicinska-metoder/pet-dt/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/bilddiagnostik/nuklearmedicinska-metoder/renografi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/biopsi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/biopsi/biopsiteknik/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/diagnostik/cystiska-expansiviteter/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/gradering-av-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2022-10-20 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/nefrektomier-och-resektioner/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/njurbiopsier/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kategorisering-av-tumoren/klassificering-och-utlatande-av-tumoren/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/terapikonferens-och-multidisciplinar-konferens/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/terapikonferens-och-multidisciplinar-konferens/terapikonferens/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/terapikonferens-och-multidisciplinar-konferens/multidisciplinar-konferens-mdk/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/kirurgi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/kirurgi/nefronsparande-kirurgi-eller-radikal-nefrektomi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/kirurgi/kirurgisk-teknik/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/kirurgi/kirurgisk-teknik/adrenalektomi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/kirurgi/venosa-tumortromber/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/ablativa-behandlingar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/aktiv-monitorering/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/adjuvant-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/behandling-av-arftlig-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-icke-metastaserad-sjukdom/embolisering-av-njurartar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/nefrektomi-vid-metastaserad-sjukdom/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/kirurgi-av-metastaser/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/kirurgi-vid-lokalt-tumorrecidiv/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/13.4val-av-lakemedelsbehandling-vid-metastaserad-sjukdom2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/13.4val-av-lakemedelsbehandling-vid-metastaserad-sjukdom/prognostiska-riskfaktorer-enligt-imdc-hengs-kriterier/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/13.4val-av-lakemedelsbehandling-vid-metastaserad-sjukdom/klarcellig-njurcancer---forsta-linjens-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/13.4val-av-lakemedelsbehandling-vid-metastaserad-sjukdom/klarcellig-njurcancer---andra-och-senare-linjers-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/13.4val-av-lakemedelsbehandling-vid-metastaserad-sjukdom/icke-klarcellig-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/pagaende-utveckling-av-systemisk-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/malsattning-med-lakemedelsbehandling-vid-metastaserad-sjukdom/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/malsattning-med-lakemedelsbehandling-vid-metastaserad-sjukdom/prediktiva-markorer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/malsattning-med-lakemedelsbehandling-vid-metastaserad-sjukdom/sarkomatoid-differentiering/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/malsattning-med-lakemedelsbehandling-vid-metastaserad-sjukdom/nefrektomi/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/immmunologiska-lakemedelkombinationer-godkanda-for-behandling-i-sverige/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/immmunologiska-lakemedelkombinationer-godkanda-for-behandling-i-sverige/forsta-linjen/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/immmunologiska-lakemedelkombinationer-godkanda-for-behandling-i-sverige/andra-linjen/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/malriktade-lakemedel-icke-immunologiska/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/malriktade-lakemedel-icke-immunologiska/ofta-anvanda-lakemedel/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/malriktade-lakemedel-icke-immunologiska/mer-sallan-anvanda-malriktade-lakemedel/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/malriktade-lakemedel-med-evidens-for-anvandning-som-inte-ar-godkanda-for-behandling-i-sverige/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/lakemedel-for-systemisk-behandling/malriktade-lakemedel-med-evidens-for-anvandning-som-inte-ar-godkanda-for-behandling-i-sverige/lenvatinib-i-kombination-med-everolimus/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/ovrig-farmakologisk-behandling/2022-04-06 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/ovrig-farmakologisk-behandling/skelettstarkande-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/stralbehandling/2020-01-15 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/stralbehandling/stereotaktisk-stralbehandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/stralbehandling/skelettmetastaser/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/stralbehandling/ovriga-metastaslokaler/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/behandling-av-metastaserad-sjukdom-eller-av-aterfall/omvardnad-vid-systemisk-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/understodjande-vard-vid-systemisk-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/understodjande-vard-vid-systemisk-behandling/behandling-av-kronisk-njursvikt/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/understodjande-vard-vid-systemisk-behandling/behandling-av-kronisk-njursvikt/dialys-ocheller-njurtransplantation/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/lagstod/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/specifik-omvardnad/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/specifik-omvardnad/hantering-av-biverkningar-vid-systemisk-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/egenvard/2020-01-15 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/egenvard/Levnadsvanor/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/egenvard/Levnadsvanor/tobak/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/egenvard/Levnadsvanor/alkohol/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/egenvard/Levnadsvanor/fysisk-aktivitet/2025-06-17 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/egenvard/komplementar-och-alternativ-medicin-och-behandling/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/palliativ-vard-och-insatser/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/2022-10-20 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/uppfoljning-av-njurfunktion/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/kontroll-av-aterfall/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/kontroll-av-aterfall/vilka-undersokningar-for-vilka-patienter-och-nar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/ansvar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/17.10.1sammanfattning-av-kunskapslage-och-rekommendationer-vid-uppfoljning-efter-kirurgi-eller-ablation-av-njurcancer2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/underlag-for-nivastrukturering/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/underlag-for-nivastrukturering/operationsvolym/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/underlag-for-nivastrukturering/strukturella-och-organisatoriska-forutsattningar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/underlag-for-nivastrukturering/avancerad-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning-av-cancervarden/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning-av-cancervarden/nationella-kvalitetsregistret-for-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning-av-cancervarden/nationella-kvalitetsregistret-for-njurcancer/19.1.1kirurgi--behandling-och-komplikationer2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/uppfoljning-av-cancervarden/individuell-patientoversikt-njurcancer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/vardprogramgruppen/2019-11-27 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/referenser/2022-04-06 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bilaga-1-min-vardplan/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardprogram/bilaga-3-stadieindelning-uicc-2017-8th-ed/2025-06-11 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/introduktion/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2025-06-19 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/utredning-och-beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2025-06-13 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/arbetsgruppens-sammansattning2/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/bilaga-1-kodningsvagledning/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2025-06-12 https://kb.localhost:5000/diagnoser/njurcancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2025-06-12 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/2020-02-28 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/2022-03-09 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/sammanfattning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/inledning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/inledning/vardprogrammets-giltighetsomrade/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/inledning/standardiserat-vardforlopp/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/inledning/lagstod/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/mal-med-vardprogrammet/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/bakgrund-och-orsaker/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/bakgrund-och-orsaker/epidemiologi/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/bakgrund-och-orsaker/prognos/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/bakgrund-och-orsaker/etiologi/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/symtom-och-tidig-utredning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/basutredning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/basutredning/anamnes-och-status/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/basutredning/blodprover--tumormarkorer/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/basutredning/radiologi/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/basutredning/vavnadsprov/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/basutredning/vardniva/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utokad-utredning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utokad-utredning/riktade-undersokningar/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utokad-utredning/riktade-undersokningar/tumorer-i-ovre-och-nedre-mag-tarmkanalen/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utokad-utredning/riktade-undersokningar/tumorer-i-urogenitala-regionen/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utokad-utredning/riktade-undersokningar/tumorer-i-torax/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/utokad-utredning/riktade-undersokningar/skelettmetastasering/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/diagnostik/diagnosbesked/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kategorisering-av-tumoren/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/multidisciplinar-konferens/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/cytostatikabehandling/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/malinriktad-behandling/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/stralbehandling/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/stralbehandling/intrakraniella-metastaser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/stralbehandling/medullakompression/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/stralbehandling/ovriga-metastaser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/kirurgisk-behandling/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/kirurgisk-behandling/kirurgi-vid-levermetastaser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/kirurgisk-behandling/kirurgi-vid-lungmetastaser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/kirurgisk-behandling/kirurgi-vid-lymfkortelmetastaser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/kirurgisk-behandling/kirurgi-vid-skelettmetastaser/2020-01-16 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/primar-behandling/kirurgisk-behandling/kirurgi-vid-peritoneala-metastaser/2020-01-16 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/palliativ-vard-och-insatser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/palliativ-vard-och-insatser/den-palliativa-vardens-syfte-och-genomforande/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/palliativ-vard-och-insatser/informerande-samtal-med-patient-och-narstaende/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/palliativ-vard-och-insatser/informerande-samtal-med-patient-och-narstaende/samtalstips/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/fatigue/2020-03-04 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/nutrition/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/nutrition-i-livets-slutskede/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/fysisk-aktivitet/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/barn-som-narstaende/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/egenvard/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/egenvard/nationella-riktlinjer/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/egenvard/rokning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/egenvard/komplementar-och-alternativ-medicin/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/egenvard/alkohol/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/uppfoljning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/underlag-for-nivastrukturering/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvalitetsregister/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvalitetsregister/cancerregistret/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/referenser/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/vardprogramgruppen/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2021-03-25 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2020-03-03 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/inledning/2021-03-24 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/anvisningar-for-provtagarens-hantering-av-provet/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/anamnestisk-remissinformation/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/utskarningsanvisningar/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/analyser/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/information-i-remissens-svarsdel/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/klassificering-av-tumoren/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/rekommendationer-for-utformning-av-svarstext/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/administrativt/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/allmant/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/pavisa-malignitet-i-biopsin---hog-diagnostisk-sakerhet/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/klassa-tumoren-som-melanom-lymfom-sarkom-eller-carcinom---hog-diagnostisk-sakerhet/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/om-carcinom-klassa-tumoren-som/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/adenocarcinom---varierande-diagnostisk-traffsakerhet/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/specialfall---varierande-diagnostisk-traffsakerhet/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/bestamning-av-prediktiva-markorer---hog-diagnostik-traffsakerhet/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/referenser/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/histopatologisk-diagnostik-av-cup/urval-av-anvandbara-antikroppar/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/bilaga-2-patologisk-diagnostik-vid-cupmolekylar-diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/bilaga-2-patologisk-diagnostik-vid-cupmolekylar-diagnostik/molekylarpatologisk-karakterisering-vid-cup/2021-03-24 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/ovrigt/bilaga-2-patologisk-diagnostik-vid-cupmolekylar-diagnostik/tissue-of-origin-vid-cup-som-utgangspunkt-for-terapi/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/kvast-cup--cancer-utan-kand-primartumor/cup-kvast-gruppen/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardprogram/patientinformation/2021-03-23 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/2020-01-27 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/2.-ingang-till-standardiserat-vardforlopp2019-11-27 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/valgrundad-misstanke/2019-12-05 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/remiss/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/3.-utredning-och-beslut-om-behandling2019-11-27 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/3.-utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/3.-utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/3.-utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/indikatorer-for-uppfoljning2/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/arbetsgrupp/2024-11-08 https://kb.localhost:5000/diagnoser/cancer-utan-kand-primartumor-cup/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/palliativ-vard/2020-02-28 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/sammanfattning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2022-09-15-version-3.3-nationell-remissrunda2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2021-10-21-version-3.22023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2021-05-27-version-3.12023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2021-03-11-version-3.02023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/definitioner-av-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/palliativ-vard-ur-ett-organisatoriskt-perspektiv/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/palliativ-vard-ur-ett-folkhalsoperspektiv/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/palliativ-vard-ur-ett-processperspektiv/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/lagstod/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/inledning/evidensgradering/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/mal-med-vardprogrammet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/begrepp-och-termer-i-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/begrepp-och-termer-i-palliativ-vard/4.1begrepp-och-termer-enligt-socialstyrelsens-termbank2023-11-24 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/begrepp-och-termer-i-palliativ-vard/ovriga-begrepp-och-termer/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/begrepp-och-termer-i-palliativ-vard/ovriga-begrepp-och-termer/4.2.1hospice-definierat-enligt-foretradare-for-hospice-i-sverige2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/begrepp-och-termer-i-palliativ-vard/ovriga-begrepp-och-termer/4.2.2malgruppen-for-palliativ-vard-definierat-av-psvf-och-nrpv2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-grunder-och-etiska-plattform/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-grunder-och-etiska-plattform/totalt-lidande--ett-patient--och-narstaendeperspektiv/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-grunder-och-etiska-plattform/fyra-hornstenar--vardens-arbetsredskap/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-grunder-och-etiska-plattform/vardegrund/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-grunder-och-etiska-plattform/etisk-plattform/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-grunder-och-etiska-plattform/behov-av-forberedelse/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/existentiella-aspekter/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/7.1samtalens-betydelse-i-palliativ-vard2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-olika-syften/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-olika-syften/stodjande-samtal-som-en-del-i-omvardnaden/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-olika-syften/samtal-vid-allvarlig-sjukdom/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-olika-syften/brytpunktssamtal/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-olika-syften/existentiella-samtal/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-olika-syften/terapeutiska-samtal/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/Samtal-med-patient-och-narstaende/samtal-med-narstaende--fore-och-efter-doden/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/innehallet-i-psykosocialt-stod/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/narstaende-familj-och-natverk/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/narstaendepenning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/kulturella-aspekter/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/kulturella-aspekter/8.4.1att-bemota-kulturell-mangfald-inom-palliativ-vard2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/strategier-vid-svara-livssituationer/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/strategier-vid-svara-livssituationer/exempel-pa-strategier/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/strategier-vid-svara-livssituationer/exempel-pa-strategier/pendlingsmodellen-dual-process/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/strategier-vid-svara-livssituationer/exempel-pa-strategier/hopp/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/strategier-vid-svara-livssituationer/exempel-pa-strategier/samtal-om-doden/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/strategier-vid-svara-livssituationer/exempel-pa-strategier/forberedelse/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/barn-som-narstaende/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/efterlevande-och-sorg/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/psykosocialt-stod/stod-i-sorg/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/allman-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/specialiserad-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/specialiserad-palliativ-vard/kvalitetsunderlag-for-allman-och-specialiserad-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/berakning-av-befolkningens-palliativa-vardbehov/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/rekommendationer-for-dimensionering-av-den-specialiserade-palliativa-varden/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/den-palliativa-vardens-dimensionering/rekommendationer-for-dimensionering-av-den-specialiserade-palliativa-varden/olika-obotliga-sjukdomars-forekomst-och-dodstal/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/handledning-och-reflektion/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/handledning-och-reflektion/handledning-syfte-och-behov/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/handledning-och-reflektion/kontinuerlig-reflektionsgrupp-syfte-och-behov/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/handledning-och-reflektion/spegling-syfte-och-behov/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/handledning-och-reflektion/allmanna-ramar-for-grupptraffar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/multiprofessionella-team-och-handledning-inom-palliativ-vard/teamens-sammansattning-och-organisering/etisk-reflektion/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/kvalitetsindikatorer-och-kvalitetsregister/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/kvalitetsindikatorer-och-kvalitetsregister/kvalitetsindikatorer-inom-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/kvalitetsindikatorer-och-kvalitetsregister/nationella-kvalitetsregister/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/kvalitetsindikatorer-och-kvalitetsregister/nationella-kvalitetsregister/svenska-palliativregistret/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/fast-vardkontakt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/behandlingsstrategi/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/forvaningsfragan/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/prognostisering/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/vardering-av-allmantillstand/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/prognostiska-index/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/samrad-om-behandlingsbegransning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/hjart--och-lungraddning-hlr/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/avslutande-av-livsuppehallande-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/inledning/samtal-om-dodshjalp/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/de-6-sn/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/nationell-vardplan-for-palliativ-vard--nvp/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/nationell-vardplan-for-palliativ-vard--nvp/vad-ar-nvp/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/nationell-vardplan-for-palliativ-vard--nvp/trygghet-for-patienter-narstaende-och-personal/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/nationell-vardplan-for-palliativ-vard--nvp/nvps-olika-delar/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/nationell-vardplan-for-palliativ-vard--nvp/sen-palliativ-fas--nar-doden-ar-nara/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/strukturerad-och-kontinuerlig-bedomning-av-symtom-och-problem/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/generell-och-specifik-symtomskattning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/generell-och-specifik-symtomskattning/trycksar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/generell-och-specifik-symtomskattning/fallrisk/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/generell-och-specifik-symtomskattning/munhalsobedomning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/att-arbeta-strukturerat-med-palliativ-vard-och-behandlingsstrategier/remittering-till-specialiserad-palliativ-enhet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/valbefinnande/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/symtomlindringvid-palliativ-omvardnad/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/vardmiljo/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/kommunikation/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/andning/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/elimination/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/personlig-hygien/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/personlig-hygien/hud-och-sar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/personlig-hygien/inkontinensassocierad-dermatit-iad/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/personlig-hygien/trycksar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/personlig-hygien/maligna-tumorsar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/kroppstemperatur/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/somn-och-vila/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fatigue/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fatigue/orsaker/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fatigue/bedomning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fatigue/behandlingsstrategier/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fysisk-aktivitet-och-traning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fysisk-aktivitet-och-traning/saker-och-lamplig-traning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/fysisk-aktivitet-och-traning/traningsformer/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/arbetsterapi-och-det-manskliga-gorandet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/sexualitetintimitet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/omvardnad-relaterad-till-palliativa-vardbehov/sexualitetintimitet/plissit-modellen/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/nutritionsbehandling-i-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/dalig-aptit-och-tidig-mattnad/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/illamaende/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/munproblem/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/svaljningssvarigheter/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/mag--och-tarmproblem/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/smak--och-luktforandringar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nutrition/symtom-kopplade-till-nutrition-i-palliativ-vard/nutrition-i-livets-slutskede/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/vad-ar-demens/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/orsaker/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/forekomst/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/prognos-och-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/symtombild/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/tecken-pa-livets-slutskede-vid-svar-demens/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/dialog-om-prioriteringar-i-livets-slutskede-i-tid/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/behandling-och-omvardnad/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/symtomskattning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/european-association-of-palliative-care-guidelines/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/lakemedelsbehandling-vid-demens/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/demenssjukdomar/avsluta-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/hjartsjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/hjartsjukdomar/hjartsvikt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/hjartsjukdomar/angina-pectoris-karlkramp/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/hjartsjukdomar/Narstaende-till-patienter-med-hjartsvikt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/Kroniskt-obstruktiv-lungsjukdom-KOL/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/specifika-aspekter-pa-valbefinnande/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/indikation-for-peg/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/narstaendeperspektiv/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/motorneuronsjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/muskelsjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/parkinsons-sjukdom-och-atypisk-parkinsonism/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/neurologiska-sjukdomar/progredierande-neurologiska-sjukdomar/multipel-skleros-ms/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/Stroke-och-forvarvad-hjarnskada/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/Stroke-och-forvarvad-hjarnskada/doendefasen-hos-patienter-som-avlider-som-direkt-foljd-av-den-akuta-hjarnskadan/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/Stroke-och-forvarvad-hjarnskada/doende-till-foljd-av-stroke-i-senare-skede/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/tumorsjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/tumorsjukdomar/aktuell-utveckling-inom-onkologi-som-paverkar-palliativ-vard/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/tumorsjukdomar/integration-av-onkologisk-och-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/tumorsjukdomar/onkogenetisk-utredning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/skora-aldre/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/skora-aldre/identifiera-skora-aldre/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/skora-aldre/brytpunkt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/skora-aldre/multifarmaci/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/skora-aldre/nar-patienten-behover-sjukhusvard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/psykisk-sjukdom/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/psykisk-sjukdom/pagaende-behandling-interaktioner/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/palliativ-vard-ur-olika-sjukdomsperspektiv/kronisk-njursvikt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/Definition/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/bedomning-av-andnod/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/behandling-vid-andnod/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/icke-farmakologisk-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/farmakologisk-behandling-orsaksinriktad-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/symtomlindrande-behandling-vid-andnod/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/symtomlindrande-behandling-vid-andnod/morfin-eller-annan-stark-opioid/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/symtomlindrande-behandling-vid-andnod/bensodiazepiner/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/symtomlindrande-behandling-vid-andnod/syrgasbehandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/symtomlindrande-behandling-vid-andnod/loopdiuretika/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/andnod/paverkan-pa-narstaende/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/rosslingar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/rosslingar/orsak-och-definition-av-rosslig-andning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/rosslingar/behandling-av-rosslingar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/delirium-eller-forvirring/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/olika-typer-av-delirium/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/orsaker-till-delirium-i-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/Forekomst-av-delirium/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/klinisk-hantering/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/icke-farmakologisk-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/farmakologisk-behandling/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/farmakologisk-behandling/haloperidol-och-atypiska-antipsykotika/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/farmakologisk-behandling/klometiazol/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/farmakologisk-behandling/midazolam/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/akuta-forvirringstillstand---delirium/sedering-vid-delirium/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/angest/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/angest/angest-som-normal-reaktion-pa-svara-livshandelser/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/orsaker-till-illamaende-och-krakningar/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/orsaker-till-illamaende-och-krakningar/fysiologiska-mekanismer/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/specifika-orsaker/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/specifika-orsaker/lakemedel/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/specifika-orsaker/centrala-nervsystemet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/specifika-orsaker/gastrointestinalkanalen/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/specifika-orsaker/metabola-orsaker/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/utredning-vid-illamaende-och-krakning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/prokinetiska-lakemedel/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/ovriga-d2-receptorantagonister/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/antihistaminer/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/antikolinergika/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/kortikosteroider/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/5ht3--receptorantagonister/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/illamaende-och-krakningar/lakemedel/nk1-receptorantagonister/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/svaljningssvarigheter/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/nutritionssvarigheter/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/krakningar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/subileus-och-ileus/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/ikterus/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/fistlar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/hydronefros/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/Ascites/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/symtom/kirurgiska-endoskopiska-och-interventionella-atgarder-med-palliativ-avsikt/pleuravatska/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/definition-av-smarta/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/definition-av-smarta/epidemiologi/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/smartdiagnostik/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/smartskattning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/grundprinciper-i-bedomning-och-planering-av-smartbehandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartlindring-i-palliativ-vard/kliniska-och-etiska-overvaganden/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/morfin/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/oxikodon/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/fentanyl/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/hydromorfon/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/ketobemidon/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/buprenorfin/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/metadon/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--opioider/dosforslag-vid-ny-insattning-av-opioid/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanliga-opioidbiverkningar/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanliga-opioidbiverkningar/andningsdepression/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanliga-opioidbiverkningar/forstoppning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanliga-opioidbiverkningar/illamaende/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanliga-opioidbiverkningar/trotthet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanliga-opioidbiverkningar/opioidinducerad-hyperalgesi-oih/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/byte-av-opioid/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/paracetamol/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/cox-hammarensaid/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/kortikosterioder/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/lakemedel-mot-neuropatisk-smarta/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/adjuvanta-lakemedel/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/adjuvanta-lakemedel/spasmolytika/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/preparatgenomgang--icke-opioider/adjuvanta-lakemedel/lokalanestetika/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/behandlingsstrategier-och-farmakologisk-behandling-av-cancerrelaterad-smarta-i-tidig-palliativ-fas/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/behandlingsstrategier-och-farmakologisk-behandling-av-cancerrelaterad-smarta-i-tidig-palliativ-fas/cancerrelaterad-smarta/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/behandlingsstrategier-och-farmakologisk-behandling-av-cancerrelaterad-smarta-i-tidig-palliativ-fas/opioidbehandling-och-dess-begransningar-vid-langtidsbehandling/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/behandlingsstrategier-och-farmakologisk-behandling-av-cancerrelaterad-smarta-i-tidig-palliativ-fas/behandling-med-icke-opioider/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanligt-forekommande-smarttillstand-vid-cancersjukdom-i-korthet/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanligt-forekommande-smarttillstand-vid-cancersjukdom-i-korthet/skelettmetastaser/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanligt-forekommande-smarttillstand-vid-cancersjukdom-i-korthet/genombrottssmarta/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/vanligt-forekommande-smarttillstand-vid-cancersjukdom-i-korthet/procedursmarta/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/opioidbehandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/glukokortikoider/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/paracetamol/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/nsaidcox-hammare/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/antiepileptika-gabapentinpregabalin/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/antidepressiv-medicinering-tcasnri/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/farmakologisk-behandling-av-smarta-i-sen-palliativ-fas/spasmolytika/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/ketamin/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/klonidin/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/Bisfosfonater/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/lokalanestetika-systemiskt/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/cannabinoider-och-medicinsk-cannabis/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/specialistlakemedel/smartlindrande-blockader-i-palliativ-vard/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartpumpar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartbehandling-vid-annan-diagnos-an-cancer/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartbehandling-vid-annan-diagnos-an-cancer/behandlingsstrategi-for-patienter-med-annan-diagnos-an-cancer/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartbehandling-vid-annan-diagnos-an-cancer/hjart--och-karlsjukdom/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartbehandling-vid-annan-diagnos-an-cancer/kol/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartbehandling-vid-annan-diagnos-an-cancer/demenssjukdom/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/smartbehandling-vid-annan-diagnos-an-cancer/neurologiska-sjukdomar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/smartlindring/icke-farmakologisk-behandling/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/Behandling-av-symtom-i-livets-slutskede/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/vak/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/palliativ-sedering/2023-06-27 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/efter-dodsfallet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/efter-dodsfallet/atgarder-efter-dodsfallet/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/efter-dodsfallet/transport-av-kroppen/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/nar-doden-ar-nara/efter-dodsfallet/begravning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/referenser/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/2021-03-18 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/styrgrupp/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/stodteam-fran-rcc/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-06-19 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/2022-02-10 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/2021-08-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/tala-om-sjukdomen-och-doden/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/involvera-de-narstaende-i-varden/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/anpassa-varden-efter-individens-behov-och-onskemal/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/lindra-barnets-symtom-och-lidande/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/organisering-av-palliativ-vard/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/register-och-kvalitetsindikatorer/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/sammanfattning/om-vardprogrammet/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/inledning/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/inledning/evidensgradering-och-giltighetsomrade/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/mal-med-vardprogrammet/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/bakgrund/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/bakgrund/smarta-och-lidande/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/bakgrund/palliativa-faser/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/bakgrund/whos-definition-av-palliativ-vard/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/bakgrund/palliativ-vard-av-barn/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/bakgrund/palliativ-vard-av-barn/barns-mognad-och-utveckling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/organisation-av-den-palliativa-varden-av-barn/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/perspektiv-i-den-palliativa-varden-av-barn/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/perspektiv-i-den-palliativa-varden-av-barn/barnperspektiv/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/perspektiv-i-den-palliativa-varden-av-barn/barnets-perspektiv/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/perspektiv-i-den-palliativa-varden-av-barn/barnrattsperspektiv/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/perspektiv-i-den-palliativa-varden-av-barn/barnrattsperspektiv/checklistor-och-screeningverktyg-inom-omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/strukturerat-arbete-i-palliativ-vard/team/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/brytpunktsprocessen--att-klargora-malet-med-varden/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/etik-i-barnsjukvarden-och-sjalvbestammande/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/etik-i-barnsjukvarden-och-sjalvbestammande/etik-och-moral/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/etik-i-barnsjukvarden-och-sjalvbestammande/barnets-eget-inflytande/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/etik-i-barnsjukvarden-och-sjalvbestammande/vard-i-barnets-basta-intresse/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/etik-i-barnsjukvarden-och-sjalvbestammande/barns-ratt-till-information/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/etik-i-barnsjukvarden-och-sjalvbestammande/etik-och-teambaserad-vard/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kommunikation/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kommunikation/verbal-kommunikation/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kommunikation/icke-verbal-kommunikation/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/lekterapi/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/musikterapi-for-barn/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/sjukhusclowner/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/sjukhusskola/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/social-tjanstehund/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/aktivitet-och-skola/vr-teknik-virtual-reality-glasogon/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/narstaendestod/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/psykosocialt-stod/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/syskon-till-barn-i-palliativ-vard/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/syskon-till-barn-i-palliativ-vard/stod-till-syskon/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/syskon-till-barn-i-palliativ-vard/de-sista-dygnen-fore-doden/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/syskon-till-barn-i-palliativ-vard/samtal-om-doden-med-syskon/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/syskon-till-barn-i-palliativ-vard/sorg/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/syskon-till-barn-i-palliativ-vard/syskonstodjare/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/sjukskoterskor-med-specialistuppdrag-i-barnsjukvard/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narstaende/efterlevandestod/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/vanliga-symtom-i-livets-sista-tid/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/vanliga-symtom-i-livets-sista-tid/andning-och-cirkulation/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/vanliga-symtom-i-livets-sista-tid/blasa-och-tarm/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/vanliga-symtom-i-livets-sista-tid/hud-och-slemhinnor/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/vanliga-symtom-i-livets-sista-tid/naring-och-vatska/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/planering-och-forberedelse/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/planering-och-forberedelse/behandlingsbegransningar-och-behandlingsstrategier/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/planering-och-forberedelse/att-gora-sa-lite-som-mojligt-ar-att-gora-det-mesta-mojliga/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/planering-och-forberedelse/de-narstaende/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/planering-och-forberedelse/forberedelser-infor-det-forvantade-dodsfallet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/det-doende-barnet/planering-och-forberedelse/nar-doden-intraffat/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kulturella-och-existentiellaandliga-aspekter/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kulturella-och-existentiellaandliga-aspekter/ett-barns-dod-ar-svar-att-utharda--dar-finns-inga-kulturella-granser/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kulturella-och-existentiellaandliga-aspekter/andligt-och-existentiellt-stod/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kulturella-och-existentiellaandliga-aspekter/andligt-och-existentiellt-stod/sjukhuskyrkareligiosa-samfund/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kulturella-och-existentiellaandliga-aspekter/andligt-och-existentiellt-stod/begravning/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/narhet-och-intimitet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/peroralt-via-munnen/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/intravenos-infart/2021-06-22 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/transdermalt-via-huden/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/buckalt-via-kindslemhinnan-inne-i-munnen/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/nasalt-via-nasslemhinnan/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/rektalt-via-andtarmen/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/subkutant-under-huden/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/administrationssatt-for-lakemedel/sublingualt-under-tungan/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/skattning-av-andningssymtom/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/opioider/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/bensodiazepiner/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/syrgas/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/antikolinergika/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/inhalationer/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/farmakologisk-behandling/pleuradranage-och-pleuratappning/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/icke-farmakologisk-behandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/andning-inklusive-andnod/omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/cirkulation-inklusive-blodning/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/cirkulation-inklusive-blodning/farmakologisk-behandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/cirkulation-inklusive-blodning/omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/elimination-urin-och-avforing/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/elimination-urin-och-avforing/farmakologisk-behandling/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/elimination-urin-och-avforing/farmakologisk-behandling/diarre/2021-06-22 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/elimination-urin-och-avforing/farmakologisk-behandling/forstoppning/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/elimination-urin-och-avforing/farmakologisk-behandling/urinretention/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/elimination-urin-och-avforing/icke-farmakologisk-behandling-och-omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/hud-och-vavnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/illamaende-och-krakningar/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/illamaende-och-krakningar/farmakologisk-behandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/illamaende-och-krakningar/farmakologisk-behandling/behandlingsstrategier/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/illamaende-och-krakningar/icke-farmakologisk-behandling-och-omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/mobilisering-och-fysik-aktivitet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/munvard-och-munhalsa/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/munvard-och-munhalsa/mukosit/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/munvard-och-munhalsa/mukosit/lokal-behandling-av-mukosit/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/munvard-och-munhalsa/mukosit/generell-behandling-av-mukosit/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/munvard-och-munhalsa/munvard/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/nutrition/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/nutrition/tidig-fas/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/nutrition/sen-fas/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/nutrition/i-livets-slutskede/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/oro-angest-och-forvirring/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/oro-angest-och-forvirring/farmakologisk-behandling/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/oro-angest-och-forvirring/farmakologisk-behandling/lakemedel-vid-oro-och-angest/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/oro-angest-och-forvirring/farmakologisk-behandling/lakemedel-som-kan-utlosa-oro-och-angest/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/oro-angest-och-forvirring/farmakologisk-behandling/lakemedel-vid-forvirring-delirium/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/oro-angest-och-forvirring/omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/palliativ-sedering/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/palliativ-stralbehandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/procedursmarta/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/farmakologisk-behandling/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/farmakologisk-behandling/nociceptiv-vavnadssmarta/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/farmakologisk-behandling/nociceptiv-vavnadssmarta/icke-opioider/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/farmakologisk-behandling/nociceptiv-vavnadssmarta/starka-opioider/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/farmakologisk-behandling/neuropatisk-eller-neurogen-smarta/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/farmakologisk-behandling/visceral-smartahyperalgesi/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/smarta/icke-farmakologisk-behandling-och-omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/somn-och-trotthet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/somn-och-trotthet/farmakologisk-behandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/somn-och-trotthet/icke-farmakologisk-behandling/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/symtomlindring-vid-palliativ-vard-av-barn/somn-och-trotthet/omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/andning/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/epilepsi-och-anfall/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/kommunikationsproblem/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/nutritionsproblem/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/spasticitet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/smarta/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/somnbesvar/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/speciella-symtom/trycksar-och-andra-hudbesvar/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/farmakologisk-behandling/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/farmakologisk-behandling/andningssvarigheter/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/farmakologisk-behandling/epilepsi-och-anfall/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/farmakologisk-behandling/smarta/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/farmakologisk-behandling/spasticitet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/icke-farmakologisk-behandling-och-omvardnad/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/icke-farmakologisk-behandling-och-omvardnad/andning/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/icke-farmakologisk-behandling-och-omvardnad/spasticitet/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/barn-med-neurologiska-sjukdomar-ocheller-funktionsnedsattningar--speciella-symtom-och-symtomlindring/icke-farmakologisk-behandling-och-omvardnad/trycksar-och-andra-hudbesvar/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/neonatalvard/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kvalitetsregister/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/kvalitetsindikatorer-och-malnivaer/malnivaer/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/referenser/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/forslag-pa-fordjupning/2023-04-13 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/styrgrupp/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/arbetsgrupp/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/arbete-med-layout-och-referenshantering/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/foraldrarepresentanter/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/adjungerade-forfattare/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2021-06-21 https://kb.localhost:5000/diagnoser/palliativ-vard-av-barn/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2021-06-21 https://kb.localhost:5000/diagnoser/peniscancer/2022-04-07 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/sammanfattning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/2020-01-17 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/standardiserat-vardforlopp/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/lagstod/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/forkortningsordlista/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/inledning/evidensgradering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/mal-med-vardprogrammet/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bakgrund-och-orsaker/2020-01-17 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bakgrund-och-orsaker/Epidemiologi/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bakgrund-och-orsaker/etiologi/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/primar-prevention-och-tidig-diagnostik/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/primar-prevention-och-tidig-diagnostik/livsstilsfaktorer-och-prevention/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/vanliga-symtom/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/standardiserat-vardforlopp-svf-och-remissvagar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/primartumor/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/primartumor/penil-intraepitelial-neoplasi-pin/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/primartumor/differentialdiagnoser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/primartumor/uretracancer/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/biopsitagning-infor-behandlingsbeslut/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/lymfkortelmetastaser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/lymfkortelmetastaser/radiologisk-utredning-for-bedomning-av-lymfadenopati/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/lymfkortelmetastaser/icke-palpabla-inguinala-lymfkortlar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/lymfkortelmetastaser/icke-palpabla-inguinala-lymfkortlar/dynamisk-sentinel-node-diagnostik-dsnb/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/lymfkortelmetastaser/palpabla-inguinala-lymfkortlar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/lymfkortelmetastaser/pelvina-lymkortelmetastaser-och-fjarrmetastaser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/symtom-kliniska-fynd-och-diagnostik/diagnosbesked/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/arftlighet/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/2019-11-27 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2020-01-17 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/tumorgradering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/stadieindelning-enligt-tnm/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/stadieindelning-enligt-tnm/kommentarer-till-tnm/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/tumorer-i-distala-uretra/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/multidisciplinar-konferens/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/multidisciplinar-konferens/organisation-och-deltagare/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/multidisciplinar-konferens/syfte/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/multidisciplinar-konferens/anmalan/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/multidisciplinar-konferens/uppfoljning-och-ansvarsfordelning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/behandlingens-syfte/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/val-av-behandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/val-av-behandling/behandlingsrekommendationer/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/organbevarande-behandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/organbevarande-behandling/organbevarande-kirurgi/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/organbevarande-behandling/ovrig-kirurgisk-och-topikal-krambehandling-av-penil-intraepitelial-neoplasi-pein/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/organbevarande-behandling/partiell-eller-total-amputation/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/inguinala-lymfkortelmetastaser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/inguinala-lymfkortelmetastaser/radikal-inguinal-lymfkortelutrymning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/inguinala-lymfkortelmetastaser/radikal-inguinal-lymfkortelutrymning/modifierad-inguinal-lymfkortelutrymning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/inguinala-lymfkortelmetastaser/icke-palpabla-lymfkortlar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/inguinala-lymfkortelmetastaser/palpabla-lymfkortlar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/10.5pelvin-lymfkortelutrymning-plnd2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/behandling-av-aterfall/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/behandling-av-aterfall/lokala-aterfall/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kurativt-syftande-behandling/behandling-av-aterfall/regionala-aterfall/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-kurativ-situation/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-kurativ-situation/perioperativ-onkologisk-behandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-kurativ-situation/perioperativ-onkologisk-behandling/cytostatikabehandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-kurativ-situation/perioperativ-onkologisk-behandling/primart-inoperabla-patienter-med-lagt-gfr/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-kurativ-situation/perioperativ-onkologisk-behandling/stralbehandling-postoperativt/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-kurativ-situation/perioperativ-onkologisk-behandling/onkologisk-behandling-vid-aterfall/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-palliativ-situation/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-palliativ-situation/11.2.1palliativ-lakemedelsbehandling2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/onkologisk-behandling/onkologisk-behandling-i-palliativ-situation/palliativ-stralbehandling/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/egenvard/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/egenvard/rokning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/egenvard/naturlakemedel/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/egenvard/alkohol/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/egenvard/fysisk-aktivitet/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/egenvard/nutrition/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/syfte/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterskan/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/postoperativ-omvardnad/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/lymfodem/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/lymfodem/mer-information/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/sexualitet--livskvalitet/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/sexualitet--livskvalitet/sexuell-halsa/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/omvardnad-och-rehabilitering/prom-och-prem/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/behovsbedomning-for-rehabilitering/2024-06-26 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/kontroll-av-aterfall/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/klinisk-undersokning-och-ultraljud/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/efter-behandling-for-pein/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/ansvar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2024-06-26 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/primartumor/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/regionala-metastaser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/palliativ-vard-och-insatser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/underlag-for-nivastrukturering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kvalitetsregister/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kvalitetsregister/svenska-peniscancerregistret/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kvalitetsregister/cancerregistret/2024-03-01 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/referenser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/forslag-pa-fordjupning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/vardprogramgruppen/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi2019-11-27 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi/anvisningar-preparathantering/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi/utskarningsanvisningar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi/hantering-av-prover-pa-laboratorium/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi/analyser/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi/koder-och-beteckningar/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardprogram/bilaga-1.-kvalitetsdokument-for-patologi/kvalitetsarbete-for-patologin/2023-06-20 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/introduktion/2020-01-22 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-28 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-05-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2020-01-22 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2024-05-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/utredning-och-beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-28 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-28 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/peniscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/prostatacancer/2022-04-07 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2023-10-13 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/introduktion/2024-12-17 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-28 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/misstanke/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/Undersokningar-av-man-utan-symtom/2023-09-28 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/valgrundad-misstanke-kriterier/2024-11-22 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/remiss/2024-11-28 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/ingang-efter-diagnos-inom-opt/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/2.-ingang-till-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2024-11-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/utredning-och-beslut-om-behandling/2024-11-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-22 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2020-03-19 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2023-12-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/forandringar-och-forbattringsomraden/2023-12-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/forandringar-och-forbattringsomraden/vasentliga-nyheter-och-forandringar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/forandringar-och-forbattringsomraden/forbattringsomraden/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/2023-12-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/standardiserat-vardforlopp/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/lagstod/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/evidensgradering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/vardprogrammets-giltighet-for-personer-med-prostata-som-inte-ar-man/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/inledning/forkortningar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/mal-med-vardprogrammet/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/incidens-dodlighet-och-prevalens/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/incidens-dodlighet-och-prevalens/incidens-antal-nya-fall/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/incidens-dodlighet-och-prevalens/dodlighet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/incidens-dodlighet-och-prevalens/prevalens-antal-man-som-lever-med-prostatacancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/incidens-dodlighet-och-prevalens/framtidsprognos/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/orsaker-och-riskfaktorer/paverkbara-faktorer-for-att-minska-risken/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bakgrund-och-orsaker/naturalforlopp/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-prevention/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-prevention/5alfareduktashammare/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-prevention/acetylsalicylsyra-statiner-och-metformin/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/befolkningsbaserad-screening/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/organiserad-prostatacancertestning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/organiserad-prostatacancertestning/skillnader-mellan-rekommendationerna-om-diagnostik-inom-opt-och-i-vardprogrammet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/organiserad-prostatacancertestning/kompletterande-diagnostiska-tester-i-opt/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/individbaserad-prostatacancertestning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/handlaggning-av-arftlig-riskgrupp/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/handlaggning-av-arftlig-riskgrupp/risk-for-cancer-hos-personer-med-prostatacancer-i-familjen/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/handlaggning-av-arftlig-riskgrupp/risk-for-cancer-hos-personer-med-prostatacancer-i-familjen/uppfoljning-av-man-i-den-arftliga-riskgruppen-psa-testning-fran-40-ars-alder-tills-kurativt-syftande-behandling-for-prostatacancer-inte-langre-skulle-kunna-vara-aktuellt/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/handlaggning-av-arftlig-riskgrupp/genetik/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/handlaggning-av-arftlig-riskgrupp/uppfoljning-av-arftlig-riskgrupp2/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/cancergenetisk-utredning-och-genetisk-testning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/cancergenetisk-utredning-och-genetisk-testning/testning-for-brca2/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/testning-for-tidig-diagnostik/cancergenetisk-utredning-och-genetisk-testning/ovriga-gener/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/indikationer-for-prostatapalpation-och-psa-prov-samt-kriterier-for-remiss-till-standardiserat-vardforlopp-svf/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/rekommendationer-for-fortsatt-utredning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostataspecifikt-antigen-psa/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostataspecifikt-antigen-psa/allmanna-overvaganden/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostataspecifikt-antigen-psa/felkallor-vid-bedomning-av-psa-varden/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostataspecifikt-antigen-psa/5-alfareduktashammares-effekt-pa-psa-vardet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostataspecifikt-antigen-psa/psa-densitet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostataspecifikt-antigen-psa/kvoten-fritt-till-totalt-psa-ftpsa/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/andra-diagnostiska-test/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/transrektalt-ultraljud-trul/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/mr-i-diagnostiken-av-prostatacancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/indikationer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/kontraindikationer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/forberedelser-infor-mr/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/utforande-av-mr/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/pi-rads/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/Bilddiagnostik/magnetresonanstomografi-mrt/artificiell-intelligens/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/allmanna-overvaganden/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/rekommendationer-for-att-minska-risken-for-infektion-efter-transrektala-biopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/rekommendationer-for-att-minska-risken-for-infektion-efter-transrektala-biopsier/profylax-med-povidon-jod/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/transpernieala-biopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/transpernieala-biopsier/sannolikheten-att-hitta-cancer-med-gleasonsumma--7/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/transpernieala-biopsier/infektiosa-komplikationer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/riktade-biopsier-efter-mrt/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/uppfoljning-efter-mrt-med-eller-utan-biopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/systematiska-biopsier-som-komplement-till-riktade-biopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/systematiska-biopsier-utan-samtidiga-riktade-biopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/prostatabiopsier/preparathantering-vid-riktade-och-systematiska-biopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/diagnosbesked/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/kontaktsjukskoterska/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/Kurator/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/psykosocialt-stod/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/narstaende/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/min-vardplan/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/information-om-prostatacancer-till-patienter/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/omvardnad-och-rehabilitering-vid-diagnosbesked/aktiva-overlamningar/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/klinisk-diagnostik/patientforeningar/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/inledning/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gleasongradering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/rapportering-av-procentuella-andelen-grad-4-och-gradering-av-mellannalsbiopsier/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/rapportering-av-procentuella-andelen-grad-4-och-gradering-av-mellannalsbiopsier/acinart-adenocarcinom/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/rapportering-av-procentuella-andelen-grad-4-och-gradering-av-mellannalsbiopsier/duktalt-adenocarcinom/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/rapportering-av-procentuella-andelen-grad-4-och-gradering-av-mellannalsbiopsier/neuroendokrina-tumorer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/rapportering-av-procentuella-andelen-grad-4-och-gradering-av-mellannalsbiopsier/behandlingsrelaterad-neuroendokrin-prostatacancer-t-nepc/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/gleasongradering-generellt/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/gleasongradering-av-mellannalsbiopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/gleasongradering-av-turp-och-adenomenukleationer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/gleasongradering-av-radikal-prostatektomi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/isup-gradering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/rapportering-av-procentuell-andel-grad-4/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/kribriforma-monster/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/rapportering-av-intraduktal-cancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/perineural-infiltration-pni/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/extraprostatisk-extention-samt-invasion-av-sadesblasorna-och-andra-organ/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/inflammation-i-prostatabiopsier/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/histopatologi/gradgrupper/immunhistokemi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/stadieindelning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/stadieindelning/tnm-klassifikation-enligt-uicc-2017/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/stadieindelning/lokalt-stadium-t/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/stadieindelning/regionala-lymfkortlar-n/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/stadieindelning/fjarrmetastasering-m/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kategorisering-av-tumoren/riskgruppsindelning-for-prostatacancer-utan-spridning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/multidisciplinar-konferens-mdk/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/bedomning-av-prognos-riskgrupper/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/bedomning-av-prognos-infor-kurativ-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/bedomning-av-prognos-infor-kurativ-behandling/predict-prostate/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/bedomning-av-prognos-infor-kurativ-behandling/geriatric-8-g8/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/bedomning-av-forvantad-kvarvarande-livstid/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/val-av-behandling/behandlingsvalet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/aktiv-monitorering/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/radikal-prostatektomi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/primar-extern-stralbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/brakyterapi-allmanna-principer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/lagdosrat-brakyterapi-som-singelbehandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/hogdosrat-brakyterapi-som-singelbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/kombinerad-hogdosrat-brakyterapi-och-extern-stralbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/kombinerad-lagdosrat-brakyterapi-och-extern-stralbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/stralbehandling-med-protoner/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/stralbehandling-av-regionala-lymfkortelstationer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/10.2-metoder/fokal-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/neoadjuvant-och-adjuvant-behandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/neoadjuvant-och-adjuvant-behandling/hormonbehandling-i-samband-med-kirurgi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/neoadjuvant-och-adjuvant-behandling/adjuvant-stralbehandling-efter-radikal-prostatektomi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/neoadjuvant-och-adjuvant-behandling/hormonbehandling-i-samband-med-stralbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/neoadjuvant-och-adjuvant-behandling/neoadjuvant-och-adjuvant-behandling-med-cytostatika/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/neoadjuvant-och-adjuvant-behandling/annan-neoadjuvant-och-adjuvant-behandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/primar-hormonell-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/primar-hormonell-behandling/singelbehandling-med-antiandrogen-bikalutamid/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/omvardnad-och-rehabilitering-infor-kurativt-syftande-behandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/omvardnad-och-rehabilitering-infor-kurativt-syftande-behandling/biverkningar/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-utan-spridning/omvardnad-och-rehabilitering-infor-kurativt-syftande-behandling/information-och-stod-till-patienten/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-radikal-prostatektomi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-radikal-prostatektomi/bakgrund-och-utredning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-radikal-prostatektomi/stralbehandling/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-radikal-prostatektomi/exspektans-och-hormonell-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-stralbehandling/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-stralbehandling/bakgrund/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/aterfall-stigande-psa-efter-stralbehandling/exspektans-och-hormonell-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/utredning-och-behandling-av-aterfall-efter-kurativt-syftande-behandling/omvardnad-och-rehabilitering-i-samband-med-besked-om-aterfall/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/oligometastatisk-prostatacancer/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/oligometastatisk-prostatacancer/introduktion/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/oligometastatisk-prostatacancer/primar-spridning-till-regionala-lymfkortlar-cn1m0/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/oligometastatisk-prostatacancer/primar-oligometastatisk-fjarrspridning-m1/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/oligometastatisk-prostatacancer/oligometastatiskt-aterfall-med-lymfkortelmetastaser-cn1m0/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/oligometastatisk-prostatacancer/oligometastatiskt-aterfall-med-fjarrspridning-m1/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/primar-behandling-vid-fjarrmetastaser-m1/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/bedomning-av-aldre-for-onkologisk-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/bedomning-av-aldre-for-onkologisk-behandling/exempel-pa-skattningsverktyg/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/bedomning-av-aldre-for-onkologisk-behandling/exempel-pa-skattningsverktyg/geriatric-8/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/bedomning-av-aldre-for-onkologisk-behandling/exempel-pa-skattningsverktyg/minicog/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/kirurgisk-kastration/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/medicinsk-kastration-med-gnrh-analog/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/medicinsk-kastration-med-gnrh-antagonist/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/kombinerad-androgen-blockad/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/intermittent-behandling-med-gnrh-analog/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/parenteral-ostrogenbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/nya-hormonellt-verkande-behandlingar--androgen-receptor-pathway-inhibitors-arpi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/nya-hormonellt-verkande-behandlingar--androgen-receptor-pathway-inhibitors-arpi/abirateron-med-prednisolon/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/nya-hormonellt-verkande-behandlingar--androgen-receptor-pathway-inhibitors-arpi/enzalutamid-apalutamid-och-darolutamid/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/primar-behandling-av-prostatacancer-med-spridning/olika-typer-av-kastrationsbehandling/omvardnad-och-rehabilitering-for-man-med-spridd-sjukdom/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/definition-och-initial-handlaggning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/bedomning-av-aldre-for-onkologisk-behandling-vid-kastrationsresistent-sjukdom/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-utan-pavisad-spridning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/neuroendokrin-differentiering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/uppfoljning-och-utvardering-av-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/avslutande-av-sjukdomsspecifik-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/hormonellt-verkande-behandlingar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/hormonellt-verkande-behandlingar/abirateron-med-prednisolon/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/hormonellt-verkande-behandlingar/enzalutamid/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/cytostatika/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/cytostatika/docetaxel/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/cytostatika/kabazitaxel/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/cytostatika/ovrig-cytostatikabehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/radionuklidbehandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/radionuklidbehandling/radium-223/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/radionuklidbehandling/lutetium-177-psma-617/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/parp-hammare/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/parp-hammare/behandlingsprediktiv-testning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/kortison-progesteron-ostrogen/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kastrationsresistent-prostatacancer/kastrationsresistent-prostatacancer-med-pavisad-spridning-mcrpc/framtiden/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/palliativ-stralbehandling-mot-primartumoren/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/palliativ-stralbehandling-mot-skelettmetastaser/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/ryggmargskompression/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/obstruktion-av-nedre-urinvagar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/obstruktion-av-ovre-urinvagar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/behandling-med-kortison/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/palliativ-vard-och-insatser/omvardnad-och-rehabilitering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/kontaktsjukskoterska/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/min-vardplan/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/aktiva-overlamningar/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/lopande-cancerrehabilitering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/sexuell-rehabilitering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/sexuell-rehabilitering/ehalsoverktyg-for-sexuell-rehabilitering-via-1177/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/sexuell-rehabilitering/bristande-kunskap-om-sexuell-rehabilitering-for-transpersoner/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/sexologisk-kompetens-inom-prostatacancersjukvard/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/sexuell-lust/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/orgasm-ejakulation-och-klimakturi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/penisforandring/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/erektil-dysfunktion/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/kastrationsbehandling-och-sexualitet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/sexualitet/infertilitet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/substitution-med-testosteron-i-samband-med-utredning-eller-behandling-for-prostatacancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/15.7urinlackage-efter-radikal-prostatektomi2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/15.7urinlackage-efter-radikal-prostatektomi/uroterapi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/15.7urinlackage-efter-radikal-prostatektomi/farmakologisk-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/15.7urinlackage-efter-radikal-prostatektomi/implantatkirurgi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/urinvagsbesvar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/urinvagsbesvar/behandling-av-trangningar-och-trangningsinkontinens/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/urinvagsbesvar/behandling-av-blodning-fran-urinvagarna/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/urinvagsbesvar/hyperbar-syrgasbehandling-hbo/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/tarmbesvar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/tarmbesvar/behandling-av-los-avforing-gasbildning-trangningar-och-fekal-inkontinens/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-fran-urinvagar-och-tarmar-efter-stralbehandling/tarmbesvar/rektal-blodning/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/strikturer-i-urinror-blashals-eller-anastomos/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/strikturer-i-urinror-blashals-eller-anastomos/diagnostik/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/strikturer-i-urinror-blashals-eller-anastomos/behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/fistelbildning-efter-stralbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/lymfodem-och-bensvullnad-av-venos-stas/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/lymfodem-och-bensvullnad-av-venos-stas/behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/biverkningar-av-kastrationsbehandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/skeletthalsa/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/skeletthalsa/forebyggande-av-osteoporosrelaterade-frakturer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/skeletthalsa/forebyggande-av-skelettkomplikationer-vid-kastrationsresistent-prostatacancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/omvardnad-rehabilitering-och-behandling-av-biverkningar/fysisk-aktivitet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/egenvard/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/behovsbedomning-for-rehabilitering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/patienter-som-har-fatt-kurativt-syftande-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/obehandlade-patienter-utan-kanda-fjarrmetastaser-som-forst-vid-progress-planeras-fa-hormonell-behandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/patienter-med-hormonell-behandling/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/patienter-med-fjarrmetastaser/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/ansvar/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/ansvar/remissinnehall-vid-overlamning-av-uppfoljningsansvar/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/underlag-for-nivastrukturering/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/19-uppfoljning-av-cancervarden/2023-12-08 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/19-uppfoljning-av-cancervarden/nationella-prostatacancerregistret-npcr/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/19-uppfoljning-av-cancervarden/cancerregistret/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/19-uppfoljning-av-cancervarden/individuell-patientoversikt-prostatacancer-ipo-pc/2024-10-17 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/19-uppfoljning-av-cancervarden/ratten/2024-10-14 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kvalitetsindikatorer-och-malnivaer/koll-pa-laget--urologi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/kvalitetsindikatorer-och-malnivaer/koll-pa-laget--onkologi/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/IPO-prostatacancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/referenser/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/forslag-pa-fordjupning/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar-juni-2021/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/adjungerade-experter/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-1.-socialstyrelsens-broschyr-om-psa-prov2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-2.-mrt-protokoll2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/mall-for-lokalisering-av-fynd-vid-mr-prostata/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/mall-for-patologiremiss-for-prostatabiopsier/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/klinisk-bakgrundsinformation/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/anvisningar-for-provtagarens-hantering-av-provet/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/utskarningsanvisningar/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/analyser/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/information-i-remissens-svarsdel/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/rekommenderade-klassifikationssystem/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/administrativt/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/ovrigt/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/referenser-och-lankar/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/appendix-1.-immunhistokemi2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-5.-patologi/appendix-2.-forslag-pa-standardiserat-svar-av-total-prostatektomi2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/allmant-om-behandling-av-tidigt-upptackt-prostatacancer/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/aktiv-monitorering/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/operation/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/stralbehandling/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/biverkningar-vid-behandling-av-tidigt-upptackt-prostatacancer/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/biverkningar-vid-behandling-av-tidigt-upptackt-prostatacancer/sexuella-forandringar/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/biverkningar-vid-behandling-av-tidigt-upptackt-prostatacancer/biverkningar-fran-urinblasa-och-urinror/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/biverkningar-vid-behandling-av-tidigt-upptackt-prostatacancer/tarmbiverkningar/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/biverkningar-vid-behandling-av-tidigt-upptackt-prostatacancer/ovriga-biverkningar/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-8.-patientinformation-tidigt-upptackt-prostatacancer/biverkningar-vid-behandling-av-tidigt-upptackt-prostatacancer/uppfoljning-och-kompletterande-behandling/2023-09-29 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-9.-patientinformation-egenvard2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-9.-patientinformation-egenvard/motion/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-9.-patientinformation-egenvard/rokning/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-9.-patientinformation-egenvard/alkohol/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-9.-patientinformation-egenvard/kost/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-9.-patientinformation-egenvard/komplementar-och-alternativ-medicin/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-10.-patientinformation-prostatacancer-och-sexualitet2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/nar-anvands-hormonell-behandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/olika-typer-hormonell-behandling-for-prostatacancer/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/biverkningar-av-kastrationsbehandling-medicinsk-och-kirurgisk/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/hormonbehandling-i-kombination-med-stralbehandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/behov-av-stod/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/vad-kan-du-gora-sjalv/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-11.-patientinformation-hormonell-behandling/senare-tillagg-av-annan-behandling/2023-09-27 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/bilaga-12.-uppfoljning-av-man-med-prostatacancer2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/information-om-patient--och-narstaendeforeningar-fran-prostatacancerforbundet/2024-10-11 https://kb.localhost:5000/diagnoser/prostatacancer/vardprogram/hyperbar-syrgasbehandling-exempel-pa-bedomningsmall/2024-10-11 https://kb.localhost:5000/diagnoser/sarkom/2022-04-07 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/introduktion/2025-02-04 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-02-04 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-04-15 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/sarkom/vardforlopp/bilaga-1-kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/sammanfattning/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/inledning/2019-11-27 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2022-06-27 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/inledning/standardiserat-vardforlopp/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/inledning/lagstod/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/inledning/evidensgradering/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/mal-med-vardprogrammet/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/bakgrund-och-orsaker/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-prevention/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-prevention/levnadsvanor/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/arftlighet/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/symtom-och-tidig-utredning/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd--valgrundad-misstanke/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd--valgrundad-misstanke/mjukdelstumorer/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd--valgrundad-misstanke/skelettumorer/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp2/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/basutredning-mjukdelssarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/basutredning-skelettsarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/radiologisk-utredning/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/radiologisk-utredning/mjukdelstumorer/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/radiologisk-utredning/skelettumorer/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/stadieindelning/2020-01-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/stadieindelning/stadieindelning-av-mjukdelssarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/stadieindelning/stadieindelning-av-skelettsarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/patologisk-utredning/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/diagnosbesked/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/arftlighet/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/diagnostik/omvardnad-och-rehabilitering/2021-09-24 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/biopsier/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/resektat/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/multidisciplinar-konferens/2020-02-05 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/multidisciplinar-konferens/regional-mdk/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/multidisciplinar-konferens/nationell-multidisciplinar-konferens-nmdk/2021-09-24 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/behandlingsbeslut/2020-02-05 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/behandlingsbeslut/mjukdelssarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/behandlingsbeslut/skelettsarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kirurgisk-behandling/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kirurgisk-behandling/kirurgisk-marginal/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-medicinsk-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-medicinsk-behandling/allmant-om-onkologisk-behandling/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-medicinsk-behandling/preoperativ-behandling-av-mjukdelssarkom/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-medicinsk-behandling/postoperativ-behandling-av-mjukdelssarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-medicinsk-behandling/preoperativ-behandling-av-skelettsarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-medicinsk-behandling/postoperativ-behandling-av-skelettsarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-stralbehandling-av-mjukdelssarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-stralbehandling-av-skelettsarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-stralbehandling-av-skelettsarkom/ewings-sarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-stralbehandling-av-skelettsarkom/osteosarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/primar-behandling/kurativt-syftande-stralbehandling-av-skelettsarkom/kondrosarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-lokala-aterfall/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-lokala-aterfall/lokala-aterfall-vid-mjukdelssarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-lokala-aterfall/lokala-aterfall-vid-skelettsarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/inledning/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/sarskilda-situationer/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/sarskilda-situationer/lungmetastasering/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/sarskilda-situationer/annan-begransad-metastasering/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/leiomyosarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/liposarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/angiosarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/synovialt-sarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/rabdomyosarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/aggressiv-fibromatos-desmoida-tumorer/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/mjukdelssarkom/solitary-fibrous-tumour/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/skelettsarkom/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/skelettsarkom/osteosarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/skelettsarkom/ewings-sarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/skelettsarkom/kondrosarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/skelettsarkom/kordom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/behandling-av-avancerad-sjukdom/skelettsarkom/jattecellstumorer-i-ben/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/palliativ-vard/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/2019-11-27 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/lagstod/2020-02-06 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-diagnosbesked/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-kirurgi/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-stralbehandling/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-sarkom/omvardnad-vid-cytostatikabehandling/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/rehabiliteringsinsatser-vid-sarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/lymfodem/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/sexualitet/2024-01-19 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/fertilitet/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/fysisk-aktivitet/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/omvardnad-och-rehabilitering/backenrehabilitering/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/rokning/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/komplementar-och-alternativ-medicin/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/alkohol/2025-07-07 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/fysisk-aktivitet-och-matvanor/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/egenvard-vid-onkologisk-behandling/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/egenvard-vid-onkologisk-behandling/infektionskanslighet/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/egenvard-vid-onkologisk-behandling/vaccinationer/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/egenvard-vid-onkologisk-behandling/hud/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/egenvard-vid-onkologisk-behandling/hudvard-vid-stralbehandling/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/egenvard/egenvard-vid-onkologisk-behandling/munvard/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/mal-med-uppfoljningen/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2021-09-24 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/kontroll-av-aterfall/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/hoggradiga-sarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/laggradiga-sarkom/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/ansvar/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/avslut-av-uppfoljning/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/uppfoljning/livslang-symtomkontroll-efter-avslutad-uppfoljning/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/underlag-for-nivastruktureringnationell-och-regional-organisation/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsregister/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-for-sarkom/2024-01-17 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsregister/cancerregistret/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsindikatorer-och-malnivaer/2022-06-27 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/referenser/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/vardprogramgruppen/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/vardprogramgruppens-medlemmar/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/vardprogramgruppens-tidigare-deltagare/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsdokument-for-patologi/2020-01-22 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar-och-hantering-av-prover-pa-laboratorium/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2021-09-27 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/nationella-multidisciplinara-konferenser-nmdk-for-sarkom-i-extremiteter-och-balvagg/2021-09-21 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/nationella-multidisciplinara-konferenser-nmdk-for-sarkom-i-extremiteter-och-balvagg/mall-for-anmalan-till-nationell-multidisciplinar-sarkomkonferens/2021-09-27 https://kb.localhost:5000/diagnoser/sarkom/vardprogram/forslag-till-dokumentationsmall-nationell-mdk-for-sarkom-i-extremiteter-och-balvagg/2021-09-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/2022-04-11 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/2021-05-24 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/sammanfattning/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/inledning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/inledning/vardprogrammets-giltighetsomrade/2021-12-14 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2021-12-14 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/inledning/lagstod/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/inledning/standardiserat-vardforlopp/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/inledning/evidensgradering/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/mal-med-vardprogrammet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/bakgrund/2021-05-28 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/bakgrund/aktiniska-keratoser-och-skivepitelcancer-in-situ/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/lokalisation/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/prognos/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/ultraviolett-stralning-och-andra-externa-orsaker/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/immunsuppression/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/hpv-infektion/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/lakemedel/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/genetiska-orsaker/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/orsaker-och-riskfaktorer/hog-alder-och-ljus-hy/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/arftlighet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/arftlighet/xeroderma-pigmentosum/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/arftlighet/epidermolysis-bullosa/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/arftlighet/okulokutan-albinism/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/bakgrund-orsaker-riskgrupper-och-arftlighet/arftlighet/epidermodysplasia-verruciformis/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar--och-sekundarprevention/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar--och-sekundarprevention/levnadsvanor/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar--och-sekundarprevention/primarprevention/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar--och-sekundarprevention/sekundarprevention/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/symtom-och-kliniska-fynd/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/symtom-och-kliniska-fynd/signaler-om-malignitet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/diagnostik/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/diagnostik/dermatoskopi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/diagnostik/andra-preoperativa-icke-invasiva-diagnostiska-metoder/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/diagnostik/differentialdiagnoser/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/diagnostik/patologisk-anatomisk-diagnostik-pad/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-preoperativt-komplicerad-och-okomplicerad-tumor/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-preoperativt-komplicerad-och-okomplicerad-tumor/preoperativt-komplicerad-tumor/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-preoperativt-komplicerad-och-okomplicerad-tumor/preoperativt-okomplicerad-tumor/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-postoperativa-hogrisk--och-lagrisktumorer/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-postoperativa-hogrisk--och-lagrisktumorer/postoperativ-hogrisktumor/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-postoperativa-hogrisk--och-lagrisktumorer/postoperativ-lagrisktumor/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-lokalt-avancerad-och-metastaserad-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-lokalt-avancerad-och-metastaserad-sjukdom/lokalt-avancerad-cscc/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/definitioner-av-lokalt-avancerad-och-metastaserad-sjukdom/metastaserad-cscc/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning-enligt-standardiserat-vardforlopp/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/primar-utredning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/primar-utredning/cytologi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/primar-utredning/hantering-av-cytologisvar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/primar-utredning/histopatologi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/portvaktskortelbiopsi-vid-cscc/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/radiologisk-diagnostik/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/ultraljud/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/datortomografi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/magnetisk-resonanstomografi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/pet-dt/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/utredning/kontrastmedel/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/diagnostik-och-utredning/diagnosbesked/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/generella-anvisningar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/hudpreparat/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/hudpreparat/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/lymfkortelutrymning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/specialanalyser/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/hudpreparat/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/information-i-remissens-svarsdel/lymfkortelutrymning/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/klassificering-av-primartumor-utan-metastaserad-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kategorisering-av-tumoren/klassificering-av-metastaserad-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/multidisciplinar-konferens/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar-behandling-av-lokal-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar-behandling-av-lokal-sjukdom/definitioner/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/primar-behandling-av-lokal-sjukdom/definitioner/kirurgisk-behandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/bakgrund/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/prognos/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/utredning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/utredning/vid-misstankt-spridd-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/utredning/beslut-om-behandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/var-bor-kirurgin-utforas/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/omfattning-av-kirurgin/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/omfattning-av-kirurgin/spridning-till-parotis-p/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/omfattning-av-kirurgin/spridning-till-halsens-lymfkortlar-n-fran-tumor-pa-orat-framfor-orat-och-framre-skalpen/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/omfattning-av-kirurgin/spridning-till-halsens-lymfkortlar-n-fran-omrade-bakom-orat-och-bakre-skalpen/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/behandling-av-spridd-sjukdom/kirurgi/omfattning-av-kirurgin/spridning-till-halsens-lymfkortlar-n-fran-primar-pa-lapphuden/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/extern-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/indikationer-dos-och-fraktionering-vid-kurativ-extern-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/indikationer-dos-och-fraktionering-vid-kurativ-extern-stralbehandling/radikal-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/indikationer-dos-och-fraktionering-vid-kurativ-extern-stralbehandling/adjuvant-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/indikationer-dos-och-fraktionering-vid-kurativ-extern-stralbehandling/palliativ-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/praktiskt-genomforande-vid-extern-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/kombinerad-stralbehandling-och-cytostatikabehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/brachyterapi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/systemisk-behandling-vid-avancerad-sjukdom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/cytostatikabehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/cytostatikabehandling/elektrokemoterapi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/tillvaxthammande-lakemedel--egfr-hammare/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/onkologisk-behandling/immunterapi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/palliativ-vard-och-insatser/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/diagnosbesked/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/psykosociala-aspekter-vid-cscc/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/omvardnad-och-rehabilitering/sex-och-samlevnad/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/Curettage-samt-elektrodessication-eller-kryobehandling/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/kirurgi-med-primar--eller-sekundarlakning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/kirurgi-med-hudtransplantat/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/kirurgi-i-huvud-hals-omradet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/kirurgi-i-huvud-hals-omradet/lymfkortelkirurgi-i-huvud-hals-omradet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/lymfkortelkirurgi-i-axill-och-ljumske/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-kirurgi/senkomplikationer-efter-lymfkortelutrymning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-stralbehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-stralbehandling/biverkningar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-stralbehandling/hudreaktioner/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-stralbehandling/stralbehandling-i-huvud-hals-omradet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-stralbehandling/andra-biverkningar-beroende-pa-bestralat-omrade/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-vid-immunterapi/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-egfr-hammare/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-cytostatikabehandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-cytostatikabehandling/illamaende/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-i-samband-med-cytostatikabehandling/hand-fotsyndrom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/specifik-omvardnad-vid-skivepitelcancer-i-huden/omvardnad-av-maligna-tumorsar-vid-cscc/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/nationella-riktlinjer/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/kontrollera-huden/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/sunda-solvanor/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/komplementar-och-alternativ-medicin-och-behandling/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/tobak/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/alkohol/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/egenvard/fysisk-aktivitet/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/mal-med-uppfoljningen/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2024-06-26 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/kontroll-av-aterfall/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/definition-hog--och-lagriskpatient/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/ansvar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/avslut-av-uppfoljning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/overlamning-till-primarvarden/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/uppfoljning/bakgrund-och-evidenslage/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/underlag-for-nivastrukturering/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsregister/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsregister/cancerregistret/2024-03-01 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsindikatorer-och-malnivaer/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/andra-preoperativa-icke-invasiva-diagnostiska-metoder/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/klassifikationssystem/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/portvaktskortelbiopsi-vid-cscc/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/portvaktskortelbiopsi-vid-cscc/portvaktskortel/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/radiologisk-diagnostik-inklusive-fordelar-och-nackdelar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/radiologisk-diagnostik-inklusive-fordelar-och-nackdelar/datortomografi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/radiologisk-diagnostik-inklusive-fordelar-och-nackdelar/magnetisk-resonanstomografi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/radiologisk-diagnostik-inklusive-fordelar-och-nackdelar/pet-dt/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/fordjupning/radiologisk-diagnostik-inklusive-fordelar-och-nackdelar/viktigt-att-notera-om-kontrastmedel/2023-06-30 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/referenser/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/adjungerade-forfattare/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/klinisk-bakgrundsinformation-och-patologins-roll-i-den-diagnostiska-processen/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/hudpreparat/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/portvaktskortel/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/terapeutisk-lymfkortelutrymning/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/klassifikation-av-primartumoren/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/klassifikation-av-lymfkortelmetastaser/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/snomed-koder/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/kvalitetsarbete-for-patologi/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/hud-kvast-gruppen/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/rekommenderad-litteratur/2021-05-27 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/kvalitetsbilaga-for-patologi-kvast-bilaga2/referenser/2021-05-21 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/lathund/2021-12-14 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/lathund/diagnostik/2021-12-14 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/lathund/postoperativ-utredning/2021-12-14 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/lathund/behandling/2021-12-14 https://kb.localhost:5000/diagnoser/skivepitelcancer-i-huden/vardprogram/lathund/uppfoljning/2021-12-14 https://kb.localhost:5000/diagnoser/skoldkortelcancer/2022-04-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/introduktion/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2019-11-27 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-11-27 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-01-13 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/arbetsgruppens-sammansattning2/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/forkortningar/2025-03-17 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/nationellt-kvalitetsregister/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/behandlingsoversikter/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/behandlingsoversikter/papillar-tyreoideacancer-ptc/2025-03-17 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/behandlingsoversikter/medullar-tyreoideacancer-mtc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/behandlingsoversikter/anaplastisk-tyreoideacancer-atc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/behandlingsoversikter/hoggradig-follikelcellsderiverad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/behandlingsoversikter/ovrigt/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/klassifikation-enligt-ptnm-8th-edition-enligt-ajcc-och-uicc-2017/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/sammanfattning/illustrationer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/inledning/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-03-17 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-03-17 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/inledning/standardiserat-vardforlopp/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/inledning/lagstod/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/inledning/evidensgradering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/mal-med-vardprogrammet/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bakgrund-och-orsaker/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bakgrund-och-orsaker/riskfaktorer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bakgrund-och-orsaker/prognostiska-variabler/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/primar-prevention/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/arftlighet/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/screening/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/primarvardens-roll/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/symtom-och-tidig-utredning/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/symtom-och-tidig-utredning/inom-specialistvarden/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/klinisk-bedomning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/biokemisk-undersokning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/biokemisk-undersokning/kalcitonin-och-carcinoembryonalt-antigen-cea/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/tyroglobulin-och-tyroglobulinantikroppar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/tyroglobulin-och-tyroglobulinantikroppar/calcitonin-och-carcinoembryonalt-antigen-cea/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ultraljud-i-preoperativ-utredning-av-sakerstalld-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ultraljud-i-preoperativ-utredning-av-sakerstalld-tyreoideacancer/storlek-som-selektion-for-cytologi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ovrig-bilddiagnostik/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ovrig-bilddiagnostik/dt/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ovrig-bilddiagnostik/mrt/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ovrig-bilddiagnostik/123i-scintigrafi-och-18f-fdg-petdt/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/ovrig-bilddiagnostik/68ga-dotatoc-pet-dt/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/stambandskontroll/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/utredning-av-lokalt-avancerad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/prognostisk-klassificering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/diagnosbesked/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/diagnostik/omvardnad-och-rehabilitering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnosiska-processen/2024-12-19 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-remissinformation-och-provtagarens-hantering-av-provet/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/tnm-klassifikation/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/papillar-tyreoideacancer-ptc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/follikular-tyreoideacancer-ftc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/onkocytar-tyreoideacancer-sa-kallad-hurthlecellcancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/medullar-tyreoideacancer-mtc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/hoggradig-follikelcellsderiverad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/hoggradig-follikelcellsderiverad-tyreoideacancer/lagt-differentierad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/hoggradig-follikelcellsderiverad-tyreoideacancer/differentierad-hoggradig-tyreoideacancer-dhgtc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/anaplastisk-cancer-atc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/molekylargenetiska-tillaggsanalyser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/multidisciplinar-konferens/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/2024-12-19 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/konferens/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/kirurgisk-handlaggningsniva/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/primar-tyreoideaoperation/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/primar-tyreoideaoperation2/2024-12-19 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/central-lymfkortelutrymning-niva-iv/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/modifierad-radikal-halslymfkortelutrymning-niva-ii-v/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/kompletterande-tyreoideaoperation/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/kompletterande-central-lymfkortelutrymning-niva-vi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/kirurgi/kompletterande-modifierad-radikal-halslymfkortelutrymning---niva-ii-v/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/indikationer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/indikationer/argument-for-radiojodbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/indikationer/argument-for-att-inte-ge-radiojodbehandling-till-lagriskpatienter/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/kontraindikationer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/tsh-stimulering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/tsh-stimulering/utsattning-av-tyroxinsubstitution/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/tsh-stimulering/thyrogeninjektion/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/tsh-stimulering-hos-barn-och-ungdomar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/tsh-stimulering-vid-metastatisk-sjukdom/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/intag-av-och-exponering-for-jod/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/praktiskt-genomforande/postterapeutisk-131i-scintigrafi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/aktivitetsmangd/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/aktivitetsmangd/radioaktivitetsmangd-vid-lungmetastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/aktivitetsmangd/aktivitetsmangd-vid-skelettmetastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/dosplanering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/risker-och-biverkningar-med-radiojod/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/risker-och-biverkningar-med-radiojod/akuta-biverkningar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/risker-och-biverkningar-med-radiojod/mojliga-sena-biverkningar-vid-upprepade-behandlingar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/radiojodbehandling-131i-behandling/utvardering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/postoperativ-extern-lokoregional-stralbehandling-vid-lokalt-avancerad-differentierad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/behandlingsdos-fraktionering-och-volymer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/stralbehandlingstekniker/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/biverkningar-vid-extern-stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/riskorgan2/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/extern-stralbehandling/fjarrmetastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/tyrosinkinashammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/tyrosinkinashammare/multiriktade-tyrosinkinashammare-mki/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/tyrosinkinashammare/selektiva-ret-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/tyrosinkinashammare/ntrk-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/tyrosinkinashammare/brafmek-hammare/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/redifferentiering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/systembehandling-utover-radiojod/immuncheckpointhammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/hormonell-suppressionsbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/hormonell-suppressionsbehandling/biverkningar-av-suppressionsbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/hormonell-suppressionsbehandling/biverkningar-av-suppressionsbehandling/kardiovaskulara-effekter-vid-fullstandig-suppressionsbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/hormonell-suppressionsbehandling/biverkningar-av-suppressionsbehandling/skeletteffekter-vid-fullstandig-suppressionsbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/praktisk-tillampning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/hormonell-suppressionsbehandling-vid-differentierad-tyreoideacancer/rekommendationer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/fornyad/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/fornyad/utmarkt-behandlingssvar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/fornyad/inkomplett-biokemiskt-behandlingssvar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/fornyad/inkomplett-strukturellt-behandlingssvar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/fornyad/oklart-behandlingssvar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/tyreoglobulin/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/fornyad-individualiserad-riskvardering-utifran-primart-behandlingssvar-av-differentierad-tyreoideacancer/tyreoglobulin/tolkning-av-tyreoglobulin-och-foreslagna-granser-for-atgarder/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/uppfoljning-efter-hemityreoidektomi/2025-03-17 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/atgarder-vid-misstankt-eller-pavisat-aterfall/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/atgarder-vid-misstankt-eller-pavisat-aterfall/lungmetastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/atgarder-vid-misstankt-eller-pavisat-aterfall/lymfkortelmetastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/atgarder-vid-misstankt-eller-pavisat-aterfall/skelettmetastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/atgarder-vid-misstankt-eller-pavisat-aterfall/lever--eller-cns-metastaser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/forekomst/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/utredning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/kirurgisk-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/radiojodbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/extern-stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-den-gravida-patienten/uppfoljning/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/graviditet-hos-nyligen-radiojodbehandlad-patient/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/forekomst/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/riskgrupper/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/utredning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/kirurgi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/radiojodbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/extern-stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/ptc-och-ftc-hos-barn-och-unga-vuxna/uppfoljning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/papillar-och-follikular-tyreoideacancer-behandling/behandling-av-avancerad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/diagnostik/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/diagnostik/fnac/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/diagnostik/s-calcitonin/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/diagnostik/provokationstester/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/diagnostik/sporadisk-cancer-preoperativ-utredning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/diagnostik/sporadisk-cancer-preoperativ-utredning/preoperativ-utredning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/feokromocytom-vid-men-2/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/primar-hyperparatyreoidism-vid-men-2a/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/naturalhistoria-for-men-2a-tumorutvecklingen-sker-forst-som-tidig-multifokal-bilateral-c-cellshyperplasi-cch-och-senare-som-utveckling-av-multipla-tumorhardar.-metastasering-sker-till-regionala-lymfkortlar-pa-halsen-och-mediastinum-och-senare-aven-hemat2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/men-2b/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/diagnostik-och-screening-av-mtc.-praktisk-handlaggning2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/screening-av-barn/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/arftliga-former-och-screeningdiagnostik/preimplantationsdiagnostik-vid-men-2/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-sporadisk-tumor/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-sporadisk-tumor/behandlingsprinciper/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-sporadisk-tumor/tyreoideaoperation/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-sporadisk-tumor/central-lymfkortelutrymning-niva-vi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-sporadisk-tumor/modifierad-lateral-lymfkortelutrymning-niva-iiv/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-arftlig-sjukdom/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-arftlig-sjukdom/profylaktisk-kirurgi-vid-arftlig-mtc-men-2a-men-2b-fmtc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-arftlig-sjukdom/central-lymfkortelutrymning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-arftlig-sjukdom/modifierad-lateral-lymfkortelutrymning-niva-iiv/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/kirurgi-vid-arftlig-sjukdom/paratyreoideaoperation-vid-men-2a/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/operation-av-aterfall/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/tyroxinsubstitution/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/tyrosinkinashammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/tyrosinkinashammare/ret-muterad-tumor-selektiv-ret-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/tyrosinkinashammare/multikinashammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/tyrosinkinashammare/ntrk-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/tyrosinkinashammare/ovriga-multikinashammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/cytostatikabehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/onkologisk-behandling/systemisk-behandling/immuncheckpointhammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/symtomatisk-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/skelettforstarkande-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/postoperativ-uppfoljning-efter-tyreoidektomi/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/postoperativ-uppfoljning-efter-tyreoidektomi/pad-visar-mtc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/medullar-tyreoideacancer-mtc/postoperativ-uppfoljning-efter-tyreoidektomi/pad-ar-normalt-eller-visar-c-cellshyperplasi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/lagt-differentierad---tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/lagt-differentierad---tyreoideacancer/diagnostik/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/lagt-differentierad---tyreoideacancer/preoperativ-utredning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/lagt-differentierad---tyreoideacancer/kirurgi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/lagt-differentierad---tyreoideacancer/ovrig-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/diagnostik/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/diagnostik/bilddiagnostik-vid-misstankt-atc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/val-av-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/kirurgisk-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/kirurgisk-behandling/resektabel-stadium-iva-ivb/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/preoperativ-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/preoperativ-behandling/braf-muterad-tumor-braf-mek-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/preoperativ-behandling/braf-vildtyp-tumor-kombinerad-stral--och-cytostatikabehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/preoperativ-behandling/preoperativ-extern-stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/preoperativ-behandling/preoperativ-cytostatikabehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/postoperativ-behandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/postoperativ-behandling/braf-muterad-tumor/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-resektabel-atc-stadium-iva-b-och-who-ps--2/postoperativ-behandling/braf-vildtyptumor/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/vid-icke-resektabel-atc-stadium-ivb-c-och-who-ps--2/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/systemisk-malinriktad-behandling-vid-atc-och-pdtc--nya-mojligheter/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/systemisk-malinriktad-behandling-vid-atc-och-pdtc--nya-mojligheter/brafmek-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/systemisk-malinriktad-behandling-vid-atc-och-pdtc--nya-mojligheter/ntrk-hammare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/systemisk-malinriktad-behandling-vid-atc-och-pdtc--nya-mojligheter/andra-malinriktade-lakemedel/2024-12-19 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/palliativ-behandling-for-patienter-med-omfattande-tumorsjukdom-ocheller-kraftigt-nedsatt-allmantillstand/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/forebyggande-ocheller-symtomlindrande-extern-stralbehandling-vid-stadium-ivc/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/anaplastisk-tyreoideacancer-atc/onkologisk-behandling/forebyggande-ocheller-symtomlindrande-extern-stralbehandling-vid-stadium-ivc/dosplanering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/komplikationer-efter-kirurgi/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/komplikationer-efter-kirurgi/blodning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/komplikationer-efter-kirurgi/hypoparatyreoidism/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/komplikationer-efter-kirurgi/nervpares/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/komplikationer-efter-kirurgi/infektion/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/behandling-av-aterfall/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/palliativ-vard-och-insatser/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/psykosociala-aspekter/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/psykosociala-aspekter/livskvalitet/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/barn-som-narstaende/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-kirurgisk-behandling/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-kirurgisk-behandling/sarskotsel/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-kirurgisk-behandling/mobilisering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-kirurgisk-behandling/mat-och-dryck/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-kirurgisk-behandling/smarta/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-kirurgisk-behandling/postoperativa-komplikationer/2024-12-19 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-onkologisk-behandling/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-onkologisk-behandling/radiojodbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-onkologisk-behandling/extern-stralbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/omvardnadsaspekter-vid-onkologisk-behandling/medicinsk-onkologi/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/omvardnad-och-rehabilitering/sex-och-samlevnad/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/nationella-riktlinjer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/rokning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/komplementar-och-alternativ-medicin-kim/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/alkohol/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/fysisk-aktivitet/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/egenvard/matvanor/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/uppfoljning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/fornyad-behovsbedomning-for-rehabilitering-och-levnadsvanor/2024-12-19 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/sjalvrapportering-av-symtom/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/avslut-av-uppfoljning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/uppfoljning/mal-med-uppfoljningen/livslang-symtomkontroll-efter-avslutad-uppfoljning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/underlag-for-nivastrukturering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/nationell-kvalitetssakring-av-cancersjukvarden/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/regionala-cancercentrum-och-inca-plattformen2/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/regionala-cancercentrum-och-inca-plattformen2/cancerregistret/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/nationellt-kvalitetsregister-for-skoldkortelcancer2/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/registervariabler-och-inrapportering-av-data/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/registervariabler-och-inrapportering-av-data/registervariabler/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/registervariabler-och-inrapportering-av-data/inrapportering-av-data/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsregister/registervariabler-och-inrapportering-av-data/patienter-som-inte-har-behandlats-kirurgiskt/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/patientforeningar-och-stodfunktioner/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/lankar/2025-03-17 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/referenser/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/vardprogramgruppen/2021-09-07 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-1-anatomisk-bild-over-lymfkortelnivaer-pa-halsen/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-2-riktlinjer-for-131i-behandling/2024-12-06 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-3-klassificering-av-tyreoideacytologi-enligt-bethesda/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-5-patientinformation/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-6-patientinformation-gallande-radiojodbehandling/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-7/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-8-illustrationer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-9-risknivaer-for-biverkan/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-11-vardprogramgruppens-medlemmar-version-1-2012/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-12-beslutsstod-for-ultraljudsledd-cytologi-enligt-eu-tirads/2024-12-09 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/protokoll-tsh-stimulering-utsattningsmetod-for-administrering-av-radiojodbehandling-till-patienter-med-differentierad-tyreoideacancer/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-12-protokoll-for-131i-behandling-med-rhtsh-stimulering/2024-12-05 https://kb.localhost:5000/diagnoser/skoldkortelcancer/vardprogram/bilaga-13-forandringar-i-tidigare-versioner/2024-12-05 https://kb.localhost:5000/diagnoser/t-cellslymfom/2022-04-11 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/sammanfattning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/2019-11-27 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/malgrupp/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/vardprogrammets-giltighetsomrade/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/standardiserat-vardforlopp/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/lagstod/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/inledning/evidensgradering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/mal-med-vardprogrammet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/bakgrund-och-orsaker/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/arftlighet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/symtom-och-tidig-utredning/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/symtom-och-tidig-utredning/symtom-och-kliniska-fynd/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/utredning/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/utredning/biopsi/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/utredning/radiologisk-utredning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/utredning/ovrig-utredning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/utredning/performance-status-whoecog/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/diagnostik/diagnosbesked/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/perifert-t-cellslymfom-uns/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/nodalt-perifert-t-cellslymfom-med-t-hjalparcellsfenotyp/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/nodalt-follikular-t-hjalparcellslymfom-follikulart-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/nodalt-follikular-t-hjalparcellslymfom-uns/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/alk-positivt-storcelligt-anaplastiskt-lymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/alk-negativt-storcelligt-anaplastiskt-lymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/alk-negativt-storcelligt-anaplastiskt-lymfom-associerat-med-brostimplantat/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/alk-negativt-storcelligt-anaplastiskt-lymfom-associerat-med-brostimplantat/primart-nodalt-ebv-positivt-tnk-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/extranodalt-nkt-cellslymfom-av-nasal-typ/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/enteropatiassocierat-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/monomorft-epiteliotropt-intestinalt-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/indolent-t-lymfoproliferativ-sjukdom-i-gastrointestinalkanalen/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/indolent-t-lymfoproliferativ-sjukdom-i-gastrointestinalkanalen/indolent-nk-cell-lymfoproliferativ-sjukdom-i-gastrointestinalkanalen/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/hepatospleniskt-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/subkutant-pannikulitliknande-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/t-cellsprolymfocytsleukemi/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/granular-lymfatisk-t-cellsleukemi-t-lgl-leukemi/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/kronisk-nk-lymfoproliferativ-sjukdom-clpd-nk/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/aggressiv-nk-cellsleukemi/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/systemisk-ebv-positivt-lymfom-hos-ungdomar-och-barn/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/adult-t-cellsleukemi-eller--lymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primart-kutant-gamma-delta-t-cellslymfom-pcgdtcl/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/primart-kutant-cd8-positivt-aggressivt-epidermotropt-cytotoxiskt-t-cellslymfom-provisorisk-entitet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/stadieindelning-och-prognosfaktorer/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/stadieindelning-och-prognosfaktorer/stadieindelning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/stadieindelning-och-prognosfaktorer/kliniska-prognosfaktorer/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/multidisciplinar-konferens/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/ptcl-uns--och-aitl/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/ptcl-uns-och-aitl-ovriga-stadier/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/storcelligt-anaplastiskt-t-cellslymfom-alcl-alk-positivt-och-alk-negativt/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/adult-t-cellsleukemi-eller--T-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/Granular-lymfatisk-leukemi-och-kronisk-NK-lymfoproliferativ-sjukdom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/brostimplantat/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/hepatospleniskt-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/subkutant-pannikulitliknande-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/primart-kutant-gamma-delta-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/enteropatiassocierat-t-cellslymfom-eatl-och-monomorft-epiteliotropt-intestinalt-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/extranodalt-nkt-cellslymfom-av-nasal-typ/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/extranodalt-nkt-cellslymfom-av-nasal-typ/Bakgrund-och-utredning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/extranodalt-nkt-cellslymfom-av-nasal-typ/behandling/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/extranodalt-nkt-cellslymfom-av-nasal-typ/stralbehandling/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/primar-behandling/t-pll/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/bakgrund/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/kliniska-och-laboratoriemassiga-kriterier-for-malignitetsassocierad-hlh/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/hemofagocyterande-lymfohistiocytos-hlh/behandling-av-lymfomassocierad-hlh/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/inledning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/pet-i-behandlingsutvardering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/komplett-remission-cr/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/partiell-remission-pr/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/relaps-eller-progressiv-sjukdom-pd/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/responskriterier/stabil-sjukdom-sd/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/kurativ-intention/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/kurativ-intention/alcl-och-andra-cd30-positiva-t-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/kurativ-intention/cd30-negativa-ptcl-uns-aitl-och-eatl/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/ovrig-aterfallsbehandling/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/extranodala-nkt-cellslymfom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/symtomlindrande-behandling/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/behandling-av-aterfall/aterfall-i-CNS/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/blodprodukter/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/infektionsprofylax-efter-hogdosbehandling-med-stamcellsstod/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/hepatit-b-och-c/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/herpesvirus/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/pneumocystis-jiroveci/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/allman-svampprofylax-candida-etc/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsprofylax/g-csf/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/infektionsbehandling/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/tumorlyssyndrom-profylax/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/understodjande-vard/akuta-transfusionsreaktioner/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/sexuell-halsa/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/fertilitetsbesparande-atgarder/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/fertilitetsbesparande-atgarder/kvinnor/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/fertilitetsbesparande-atgarder/man/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/fysisk-aktivitet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/hygien-och-isolering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/munvard/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/nutrition/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/skotsel-av-central-infart-till-blodkarl/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/psykosocialt-stod/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/alopeci--haravfall/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/fatigue/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/kognitiv-funktionsnedsattning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/benmargspaverkan/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/neuropati/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/illamaende/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/forstoppning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/inledning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/levnadsvanor/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/infektionskanslighet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/munhygien/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/fysisk-aktivitet/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/hud/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/mage-och-tarm/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/vaccinationer/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/feber/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/nationella-riktlinjer/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/tobak/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/komplementar-och-alternativ-medicin/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/egenvard/alkohol/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/palliativ-vard-och-insatser/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/mal-med-uppfoljningen/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/kontroll-av-aterfall/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/forslag-till-uppfoljningsintervall/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/ansvar/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/avslut-av-uppfoljning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning/livslang-seneffektskontroll/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/underlag-for-nivastrukturering/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/innehall/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/innehall/inklusionskriterier/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-lymfomregistret/innehall/exklusionskriterier/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/uppfoljning-av-cancervarden/svenska-palliativregistret/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/referenser/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/forslag-pa-fordjupning/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/vardprogramgruppen/2021-02-16 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/2021-02-17 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar-och-hantering-av-prover-pa-laboratorium/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/analyser/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/koder-och-beteckningar/2021-02-17 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/kvalitetsdokument-for-patologi/kvalitetsarbete-for-patologin/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardprogram/bedomning-av-allmantillstandet-performance-status/2023-10-24 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/2020-02-10 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/introduktion/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/introduktion/flodesschema-for-vardforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2020-01-22 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2020-01-22 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2021-09-02 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/t-cellslymfom/vardforlopp/arbetsgruppens-sammansattning2/2020-01-22 https://kb.localhost:5000/diagnoser/testikelcancer/2022-04-07 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/2020-01-30 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/introduktion/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/ingang-till-standardiserat-vardforlopp/hantering-av-aterfall/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/utredning-och-beslut-om-behandling/2020-01-22 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/arbetsgruppens-sammansattning2/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/frivillig-kod-under-utredning/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2025-06-02 https://kb.localhost:5000/diagnoser/testikelcancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2025-06-02 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/2022-04-07 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/2020-04-17 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/sammanfattning/2025-05-11 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/inledning/2021-07-12 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/inledning/evidensgradering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/mal-med-vardprogrammet/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bakgrund-och-orsaker/2021-07-12 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bakgrund-och-orsaker/uppkomst-riskfaktorer-och-primarprevention/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bakgrund-och-orsaker/uppkomst-riskfaktorer-och-primarprevention/uppkomst/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bakgrund-och-orsaker/uppkomst-riskfaktorer-och-primarprevention/riskfaktorer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bakgrund-och-orsaker/uppkomst-riskfaktorer-och-primarprevention/prevention/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/screening-for-kolorektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/arftliga-tillstand/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/nivastrukturering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/utredning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/prevention-och-tidig-diagnostik/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/kirurgisk-behandling-av-lynchs-syndrom-associerad-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/kirurgisk-behandling-av-lynchs-syndrom-associerad-krc/koloncancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/kirurgisk-behandling-av-lynchs-syndrom-associerad-krc/rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/kirurgisk-behandling-av-lynchs-syndrom-associerad-krc/samtidig-gynekologisk-riskreducerande-kirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/kirurgisk-behandling-av-lynchs-syndrom-associerad-krc/onkologisk-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/lynchs-syndrom/kirurgisk-behandling-av-lynchs-syndrom-associerad-krc/postoperativ-uppfoljning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/nivastrukturering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/adenomatosa-polypossyndrom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/adenomatosa-polypossyndrom/familjar-adenomatos-polypos-fap-och-attenuerad-fap-afap/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/adenomatosa-polypossyndrom/mutyh-associerad-polypos-map/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/adenomatosa-polypossyndrom/andra-polypossyndrom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/kontrollprogram-och-riskreducerande-kirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/hamartomatosa-polypossyndrom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/polypossyndrom/sagtandad-polypos/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/arftlig-kolorektalcancer/utredning-och-screening-for-arftliga-tillstand/familjar-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/symtom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/symtom/typer-av-symtom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/symtom/ingang-till-standardiserat-vardforlopp-svf/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/symtom/ingang-till-standardiserat-vardforlopp-svf/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/symtom/utredning-vid-misstankt-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/preoperativ-utredning-av-primar-koloncancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/preoperativ-utredning-av-primar-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/preterapeutisk-utredning-av-primar-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/preoperativ-metastasutredning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/sarskilda-situationer/2021-07-12 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/sarskilda-situationer/vid-radiologiskt-klar-cancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/sarskilda-situationer/vid-kontraindikationer-mot-mrt/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/sarskilda-situationer/vid-kliniskt-avancerad-sjukdom-med-nedsatt-allmantillstand/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/sarskilda-situationer/vid-kraftigt-nedsatt-njurfunktion-eller-njursvikt/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bedomning-av-preoperativ-bilddiagnostisk-utredning-av-primartumoren/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bedomning-av-preoperativ-bilddiagnostisk-utredning-av-primartumoren/primartumor-t/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bedomning-av-preoperativ-bilddiagnostisk-utredning-av-primartumoren/regionala-lymfkortlar-n/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bedomning-av-preoperativ-bilddiagnostisk-utredning-av-primartumoren/fjarrmetastaser-m/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bilddiagnostik-efter-neoadjuvant-behandling-samt-uppfoljning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bedomning-av-bilddiagnostik-efter-neoadjuvant-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/bedomning-av-bilddiagnostik-efter-neoadjuvant-behandling/bedomning-av-lymfkortlar-efter-neoadjuvant-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/8.2.8bilddiagnostik-vid-misstankta-recidiv2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/8.2.8bilddiagnostik-vid-misstankta-recidiv/recidiv-lokoregionalt/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/bilddiagnostik/bilddiagnostik/8.2.8bilddiagnostik-vid-misstankta-recidiv/recidiv-peritonealt/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologins-roll-i-den-diagnostiska-processen/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/anvisningar-for-provtagarens-hantering-av-provet/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/anamnestisk-remissinformation/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/polypektomipreparat-och-mukosaresektat/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/biopsier/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/tarmresektat/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/farska-operationspreparat/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/fixerade-operationspreparat/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologens-hantering/histologiska-subtyper-av-adenokarcinom/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/lymfkortelstatus/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/klassificering-av-tumoren-med-tnm/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/klassificering-av-tumoren-med-tnm/peritonealiserad-tarmyta/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/radikalitetsbedomning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/tumour-deposits-td/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/karlinvasion/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/nervinvasion/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/tumour-budding/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/tumorkrympning-efter-neoadjuvant-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/molekylarpatologiska-analyser/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/svarsmall-och-rapportering/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/histo--och-molekylarpatologi2/patologisk-bedomning-vid-metastaskirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/multidisciplinar-konferens/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/multidisciplinar-konferens/preterapeutisk-utvarderande-och-postoperativ-mdk/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/multidisciplinar-konferens/nationell-hogspecialiserad-vard-nhv/2025-05-30 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-koloncancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-koloncancer/cytostatikabehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-koloncancer/stralbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/bakgrund/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/bakgrund/stralbehandling-vid-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/bakgrund/total-neoadjuvant-terapi-tnt/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/bakgrund/tidstrender/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/behandlingsrekommendationer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/behandlingsrekommendationer/lagrisktumor/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/behandlingsrekommendationer/intermediarrisktumor/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/behandlingsrekommendationer/hogrisktumor/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/behandlingsrekommendationer/lathund-stralbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/organbevarande-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-strategier/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-strategier/neoadjuvant-cytostatika-utan-stralbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-strategier/immunterapi-vid-dmmr-msi-high/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-strategier/postoperativ-stralbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/rebestralning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-straltekniker2/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-straltekniker2/brakyterapi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/alternativa-straltekniker2/protonbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/biverkningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/biverkningar/akuta-biverkningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/biverkningar/sena-biverkningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/neoadjuvant-preoperativ-behandling2/neoadjuvantpreoperativ-behandling-av-rektalcancer/biverkningar/sekundara-maligniteter/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/diagnostik-och-stadieindelning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/definitioner/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/behandling-av-tidig-koloncancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/behandling-av-tidig-koloncancer/behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/behandling-av-tidig-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/behandling-av-tidig-rektalcancer/behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/uppfoljning-av-tidig-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/uppfoljning-av-tidig-krc/lagriskcancer-kolon-och-rektum/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/uppfoljning-av-tidig-krc/hogriskcancer-kolon/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/behandling-av-tidig-kolorektalcancer/uppfoljning-av-tidig-krc/hogriskcancer-rektum/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/allmanna-principer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/2021-07-12 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/hogersidig-hemikolektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/utvidgad-hogersidig-hemikolektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/vanstersidig-hemikolektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/sigmoideumresektion/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/kolektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/hartmanns-operation/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-koloncancer/rekommenderad-lasning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-rektalcancer/framre-resektion/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-rektalcancer/hartmanns-operation/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-rektalcancer/abdominoperineal-excision-ape/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-rektalcancer/intersfinkterisk-ape/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-rektalcancer/transanal-tme-tatme/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/allmanna-principer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/kirurgi-vid-lokalt-avancerad-koloncancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/kirurgi-vid-lokalt-avancerad-rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/kirurgi-vid-lokalrecidiv/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/kirurgi-vid-misstanke-om-laterala-lymfkortelmetastaser/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgisk-behandling-av-kolorektalcancer/kirurgi-vid-lokalt-avancerad-krc/kirurgi-vid-appendixneoplasier/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgi-vid-akut-kolorektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgi-vid-akut-kolorektalcancer/bakgrund/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgi-vid-akut-kolorektalcancer/utredning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/kirurgi-vid-akut-kolorektalcancer/operation/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/palliativ-kirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kirurgi/perioperativt-omhandertagande/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/behandlingens-syfte/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/bedomning-av-risk-for-recidiv/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/alder/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/tidpunkt-for-start-av-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/koloncancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/koloncancer/behandlingstid/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/koloncancer/regimval/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/rektalcancer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/adjuvant-behandling-efter-neoadjuvant-eller-konverterande-cytostatikabehandling-av-primartumor-i-kolon/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/adjuvant-cytostatikabehandling/biverkningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/inledning-terminologi-och-behandlingsintention/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/inledning-terminologi-och-behandlingsintention/inledning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/inledning-terminologi-och-behandlingsintention/terminologi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/inledning-terminologi-och-behandlingsintention/behandlingsintention/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/multidisciplinar-konferens-mdk-vid-metastaserad-sjukdom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/bakgrund/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/preoperativ-diagnostisk-utredning-av-krlm/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/bedomning-av-krlm-resektabilitet/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/val-av-behandlingssekvens-for-krlm/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/val-av-leverkirurgisk-eller-ablativ-metod-for-krlm/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/levertransplantation-for-krlm/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/komplikationer-efter-kirurgisk-behandling-av-krlm/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/levermetastaser-se-bilaga-2/uppfoljning-av-patienter-som-genomgatt-leverresektion-eller-ablation-for-krlm/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/bakgrund/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/indikationer-for-lungmetastasektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/preoperativ-utredning-infor-lungmetastasektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/funktionsutredning-infor-planerad-lungmetastasektomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/val-av-thoraxkirurgisk-eller-ablativ-metod-vid-lungmetastaser/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/lungmetastaser/uppfoljning-efter-lungmetastasektomi-vid-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/peritoneal-carcinos/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/peritoneal-carcinos/bakgrund/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/peritoneal-carcinos/utredning-av-peritoneal-metastasering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/peritoneal-carcinos/hipec-behandlingen/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/peritoneal-carcinos/perioperativ-systemisk-cytostatikabehandling-vid-isolerad-peritoneal-metastasering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/peritoneal-carcinos/appendixtumorer-med-peritonealt-engagemangspridning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/kirurgi-vid-metastaserad-sjukdom/kirurgisk-behandling-av-paraaortala-lymfkortelmetastaser-vid-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/prediktiva-tumorrelaterade-faktorer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/cytostatika/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/malriktade-lakemedel/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/malriktade-lakemedel/egfr-hammande-antikroppar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/malriktade-lakemedel/angiogeneshammande-antikroppar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/malriktade-lakemedel/tyrosinkinashammare/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/malriktade-lakemedel/ovriga-malriktade-lakemedel/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/lakemedel-vid-metastaserad-sjukdom/immunterapi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-kurativ-intention/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-kurativ-intention/systemisk-behandling-vid-primart-resektabla-metastaser/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-kurativ-intention/systemisk-behandling-vid-primart-resektabla-metastaser/enbart-adjuvant-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-kurativ-intention/systemisk-behandling-vid-primart-resektabla-metastaser/neoadjuvant-och-adjuvant-perioperativ-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-kurativ-intention/systemisk-behandling-vid-potentiellt-resektabla-metastaser-konvertering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/2025-05-30 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/palliativ-behandling-till-patient-i-gott-allmantillstand/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/palliativ-behandling-till-patient-i-gott-allmantillstand/palliativ-behandling-till-patienter-utan-akuta-tumorrelaterade-symtom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/palliativ-behandling-till-patient-i-gott-allmantillstand/palliativ-behandling-till-patient-i-behov-av-tumorkrympande-effektmaximal-respons/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/palliativ-behandling-till-aldre-ocheller-skora-patienter/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/behandlingstidens-langd-vid-palliativ-behandlingsintention/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/behandlingstidens-langd-vid-palliativ-behandlingsintention/behandlingsfria-intervall/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/underhallsbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/underhallsbehandling/sarskilda-terapeutiska-val-av-underhallsbehandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/behandlingsval-efter-andra-linjen/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/behandlingsval-efter-andra-linjen/trifluridintipiracil-tas-102/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandling-av-metastaserad-sjukdom/antitumoral-lakemedelsbehandling-vid-metastaserad-kolorektalcancer-mcrc/systemisk-behandling-med-palliativ-intention/behandlingsval-efter-andra-linjen/malriktade-lakemedel/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/kontaktsjukskoterska/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/min-vardplan/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/aktiva-overlamningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/lopande-cancerrehabilitering/rehabiliteringsplan/2025-05-30 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/prehabilitering/2025-05-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/prehabilitering/fysisk-formaga/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/prehabilitering/nutritionsstatus/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/prehabilitering/psykosociala-aspekter/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/levnadsvanor/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/levnadsvanor/tobak/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/levnadsvanor/alkohol/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/fertilitetsbevarande-atgarder/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/perioperativt-omhandertagande-och-omvardnad/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/perioperativt-omhandertagande-och-omvardnad/preoperativ-forberedelse-och-postoperativ-aterhamtning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/perioperativt-omhandertagande-och-omvardnad/postoperativa-komplikationer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/perioperativt-omhandertagande-och-omvardnad/omvardnad-efter-metastaskirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/biverkningar-vid-onkologisk-behandling/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/biverkningar-vid-onkologisk-behandling/diarre/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/biverkningar-vid-onkologisk-behandling/hudbiverkningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/biverkningar-vid-onkologisk-behandling/slemhinnor/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/biverkningar-vid-onkologisk-behandling/neuropati/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/omvardnad-vid-onkologisk-behandling/biverkningar-vid-onkologisk-behandling/hand--och-fotsyndrom/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/seneffekter-efter-behandling-av-krc/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/stomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/stomi/omvardnad-infor-stomioperation/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/stomi/omvardnad-och-rehabilitering-efter-stomioperation/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/stomi/omvardnadsaspekter-vid-tillfallig-loopileostomi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/stomi/stomirelaterade-komplikationer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/understodjande-vard-omvardnad-och-rehabilitering/stomi/stomirelaterade-komplikationer/stomifloden/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/palliativ-vard-och-insatser/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/2021-07-12 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/patientgrupper-som-rekommenderas-uppfoljning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/undersokningsmetoder/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/uppfoljningsintervall/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/uppfoljning-av-hogriskpatienter/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/uppfoljning-efter-metastaskirurgi/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/uppfoljning-i-sarskilda-situationer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/uppfoljningsrekommendationer/uppfoljning-av-metakrona-adenom-och-tumorer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/avslutande-av-sjukhusstyrd-uppfoljning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/uppfoljning/uppfoljning-for-att-upptacka-recidiv/sammanfattande-tabell/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/underlag-for-nivastrukturering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/underlag-for-nivastrukturering/sammanfattning/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/underlag-for-nivastrukturering/behovs-och-kompetensstyrd-regional-nivastrukturering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/underlag-for-nivastrukturering/nationell-nivastrukturering/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsregister/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsregister/registrering-och-rapportering/2025-05-30 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsregister/arsrapporter/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsregister/syfte/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsregister/cancerregistret/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/kvalitetsindikatorer-som-rapporteras-i-scrcr/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/vardprogramgruppen/2021-07-12 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar2/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/vardprogramgruppen/forfattare/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/referenser2/2025-05-11 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/stralbehandling-rektalcancer/2025-05-23 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/stralbehandling-rektalcancer/stralbehandlingsplanering-och--teknik/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandlingslinjer-vid-metastaserad-kolorektal-cancer/2025-05-23 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/behandlingslinjer-vid-metastaserad-kolorektal-cancer/bakgrund/2025-05-20 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/beslutsstod-for-preterapeutisk-mdk-vid-diagnos-av-metastaserad-tjock-och-andtarmscancer/2025-05-23 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/2025-05-23 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/bakgrund/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/vagledning-till-vardgivare/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/remisskriterier-for-stallningstagande-till-mojlig-levertransplantation/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/1.-stallningstagande-till-levertransplantation2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/2.-onkologisk-behandling--induktionsbehandling-och-bridging2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/3.-synkron-krlm--remiss-till-nhv-ltx-enhet-infor-kirurgi-av-primartumor2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/4.-metakron-krlm-eller-utvidgad-ltx-bedomning-vid-radikalt-op-primartumor2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/flodesschema-ltx-vid-metakront-metastaserad-krlm-recidiv/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/flodesschema-ltx-vid-synkront-metastaserad-krlm/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/selektionskriterier-for-att-sattas-pa-vantelista-till-ltx/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/5.-handlaggning-vid-klartecken-for-patienten-att-sattas-upp-pa-vantelista-for-levertransplantation2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/6.-levertransplantation2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/7.-handlaggning-postoperativt-uppfoljning-efter-ltx2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardprogram/nationella-rekommendationer-for-levertransplantation-vid-kolorektala-levermetastaser/forkortningar/2025-05-21 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2022-04-28 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2022-04-28 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-11 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-08 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancer/vardforlopp/kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/2024-03-18 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/sammanfattning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/inledning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/inledning/introduktion/2022-10-04 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/inledning/forsta-version/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/inledning/standardiserat-vardforlopp-for-tjock--och-andtarmscancer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/inledning/evidensgradering/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/inledning/forkortningar/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/mal-med-screeningvardprogrammet/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/testmetoder-fekalt-blod/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/effekt-stadiereduktion-och-dodlighet/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/negativa-effekter/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/etiska-aspekter/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/halsoekonomi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/organisationskrav/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/bakgrund/uppfoljning-och-utvardering/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/socialstyrelsens-rekommendationer/sammanfattning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/bakgrund-och-orsaker-till-tjock--och-andtarmscancer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/vad-ar-screening/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/screening-for-tjock--och-andtarmscancer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/screening-for-tjock--och-andtarmscancer/screeningprogram-for-tjock--och-andtarmscancer-internationellt/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/screening-for-tjock--och-andtarmscancer/erfarenheter-fran-regionerna-stockholm-och-gotland/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/screening-for-tjock--och-andtarmscancer/den-nationella-studien-for-screening-for-tjock--och-andtarmscancer-screesco-screening-of-swedish-colons/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/etiska-stallningstaganden-vid-tjock--och-andtarmscancerscreening/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/etiska-stallningstaganden-vid-tjock--och-andtarmscancerscreening/gora-gott-principen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/etiska-stallningstaganden-vid-tjock--och-andtarmscancerscreening/inte-skada-principen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/etiska-stallningstaganden-vid-tjock--och-andtarmscancerscreening/autonomiprincipen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screening--bakgrund-och-principiella-fragor/etiska-stallningstaganden-vid-tjock--och-andtarmscancerscreening/rattviseprincipen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/psykosociala-effekter-av-screening/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/psykosociala-effekter-av-screening/screeningen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/psykosociala-effekter-av-screening/positivt-avforingsprov/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/psykosociala-effekter-av-screening/atgarder-for-att-minimera-och-ta-hand-om-psykosociala-reaktioner/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/definition-av-individ-och-patient-inom-screening/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/lagstod/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/ansvarsfordelning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningprocess-och-ansvarsfordelning/screeningprocess/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/vilka-personer-ska-kallas-och-nar/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/sparrlista/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/polypvardprogram/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/cancervardprogram/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/kolit-uppfoljningsprogram/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/arftlig-cancer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-som-kan-avsta-fran-provtagning/samsjuklighet/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/skyddade-personuppgifter/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/utlandssvenskar/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/screeningpopulation/personer-med-funktionsnedsattning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/bakgrund/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/faktorer-som-hindrar-eller-mojliggor-deltagande/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/faktorer-som-hindrar-eller-mojliggor-deltagande/brist-pa-information-och-kunskap/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/faktorer-som-hindrar-eller-mojliggor-deltagande/oro-och-radsla/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/faktorer-som-hindrar-eller-mojliggor-deltagande/attityder-och-varderingar/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/faktorer-som-hindrar-eller-mojliggor-deltagande/screeningmetod/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/atgarder-for-att-underlatta-och-stimulera-deltagande/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/atgarder-for-att-underlatta-och-stimulera-deltagande/organisation/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/information-och-kunskap/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/information-och-kunskap/screeninginbjudans-utformning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/information-och-kunskap/utformande-av-instruktioner-for-fit/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/information-och-kunskap/information-och-kunskap-till-halso--och-sjukvarden/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/information-och-kunskap/kallor-for-information-och-kommunikation/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/webbsidor/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/atgarder-for-att-underlatta-och-stimulera-informerat-deltagande/telefonsupport/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/provtagning-fit/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/provtagning-fit/provtagningsinstruktion-for-screeningdeltagaren/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/provtagning-fit/felkallor/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/fit/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/fit/kvantitativ-immunkemisk-analys-av-hemoglobin-i-feces/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/fit/krav-pa-analyserande-laboratorium-och-analysmetod/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/introduktion/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/testegenskaper/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/upprepad-testning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/anatomisk-lokalisation/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/individrelaterade-faktorer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/differentierade-gransvarden/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/gransvarde-i-relation-till-koloskopiresurser/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/riskbaserade-gransvarden/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/gransvarde-cutoff/slutsats/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/laboratorieanalys-fit/handlaggning-avvikande-prov/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/koloskopins-roll/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/koloskopins-roll/dt-kolografi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-koloskopist/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-endoskopienhet/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/screeningsjukskoterskan-pa-endoskopienheten/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/bokning-av-screeningpatient--rekommenderat-arbetsflode/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/uppfoljning-av-patient-som-ombokar-eller-uteblir/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-forberedelser/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-forberedelser/provtagning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-forberedelser/patientinformation/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-forberedelser/kostrestriktioner/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-forberedelser/laxering/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-forberedelser/vardering-av-tarmrengoring/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/koloskopi/krav-pa-undersokningen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/normal-undersokning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/polyper/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/misstankt-cancer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/inledning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/inskickat-material-och-remissuppgifter/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/fynd-som-kan-forvantas-for-fokala-lesioner/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/dysplasi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/polypcancer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/msi-och-mmr/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/pad/molekylarpatologiska-analyser/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/information-till-patient-och-vardgivare/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/ofullstandig-undersokning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/normal-undersokning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/inget-behov-av-endoskopisk-uppfoljning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/inget-behov-av-endoskopisk-uppfoljning/antal/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/inget-behov-av-endoskopisk-uppfoljning/villos-histologi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/inget-behov-av-endoskopisk-uppfoljning/sessila-serrata-lesioner/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/behov-av-endoskopisk-uppfoljning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/behov-av-endoskopisk-uppfoljning/antal/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/behov-av-endoskopisk-uppfoljning/storlek/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/behov-av-endoskopisk-uppfoljning/hoggradig-dysplasi/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/behov-av-endoskopisk-uppfoljning/sessila-serrata-lesioner/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/handlaggning-efter-pad/intervall-vid-endoskopisk-uppfoljning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/handlaggning-under-och-efter-koloskopi/komplikationer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/kommunikation/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/oversiktlig-beskrivning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/behov-av-nationellt-gemensamt-kallelsesystem/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/behov-av-it-integration-med-it-system-hos-analyslaboratoriet/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/behov-av-it-integration-med-it-system-hos-analyslaboratoriet/provsvarshantering/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/behov-av-it-integration-med-it-system-hos-brevdistributoren/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/behov-av-it-integration-med-it-system-hos-skatteverket/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/behov-av-it-integration-med-kvalitetsregistret-sverekks/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/it-system-gas/overgripande-behov-av-och-krav-pa-it-stodsystemet-inom-screeningverksamheten/framtida-behov-hos-gsk/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/gsk--gemensamt-samordningskansli/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/samordnings-sjukskoterska/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/utbildning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/utbildning/screeningsjukskoterskan-pa-endoskopienheten/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/utbildning/endoskopisten/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/kvalitetsuppfoljning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/kvalitetsuppfoljning/sverekks/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/kvalitetsuppfoljning/kvalitetsindikatorer/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/kvalitetsuppfoljning/utdata/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/referenser/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/medforfattare/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2022-09-29 https://kb.localhost:5000/diagnoser/tjock-och-andtarmscancerscreening/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2022-09-29 https://kb.localhost:5000/diagnoser/trofoblast/2022-04-07 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/2020-01-28 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/sammanfattning2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/2.1vardprogrammets-giltighetsomrade2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/2.2forandringar-jamfort-med-tidigare-version2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/2.3standardiserat-vardforlopp2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/lagstod/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/evidensgradering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/inledning2/forkortningar-och-begreppsforklaringar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/mal-med-vardprogrammet2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/bakgrund/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/epidemiologi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/epidemiologi/incidens/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/epidemiologi/incidens-av-molor/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/epidemiologi/incidens-av-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/epidemiologi/gtd-i-cancerregistret/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/etiologi-och-genetik/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/etiologi-och-genetik/komplett-mola/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/etiologi-och-genetik/partiell-mola/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/etiologi-och-genetik/imprinting/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bakgrund-och-orsaker2/etiologi-och-genetik/gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-prevention-och-riskfaktorer-for-gtd/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-prevention-och-riskfaktorer-for-gtd/levnadsvanor/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-prevention-och-riskfaktorer-for-gtd/riskfaktorer/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/screening/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/arftlighet/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/arftlighet/arftliga-molor/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/symtom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/symtom/mola-hydatidosa/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/symtom/invasiv-mola/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/symtom/koriokarcinom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/symtom/placental-site-trophoblastic-tumor/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/symtom/epitelioid-trofoblasttumor/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/klinisk-kemi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/klinisk-kemi/humant-koriongonadotropin-hcg/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/klinisk-kemi/analysmetoder-for-hcg/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/klinisk-kemi/8.2.3potentiella-felkallor-vid-hcg-matningar2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/9.1utredning-enligt-standardiserat-vardforlopp2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/klinisk-undersokning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/radiologi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/transvaginalt-och-transabdominellt-ultraljud-inklusive-dopplerundersokning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/lungrontgen/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/datortomografi-dt/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/magnetresonanstomografi-mrt/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/positronemissionstomografi-datortomografi-pet-dt/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/angiografi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/ultraljud/uppfoljning-med-radiologiska-metoder/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/utredning-av-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/utredning-av-gtn/lagriskpatient/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/utredning/utredning-av-gtn/hogriskpatient/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/stadieindelning-och-riskgruppsindelning/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/diagnosbesked/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/diagnostik/omvardnad-och-rehabilitering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/patologi/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/patologi/anvisningar-for-provtagarens-hantering-av-provet/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/patologi/anamnestisk-remissinformation/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/mola-hydatidosa/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/mola-hydatidosa/histologi-vid-mola-hydatidosa/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/mola-hydatidosa/komplett-mola-hydatidosa/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/mola-hydatidosa/partiell-mola-hydatidosa/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/mola-hydatidosa/kompletterande-analyser/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/invasiv-mola/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/koriokarcinom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/koriokarcinom/gestationellt-koriokarcinom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/koriokarcinom/intraplacentara-eller-tidiga-koriokarcinom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/koriokarcinom/10.4.3icke-gestationellt-koriokarcinom2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/placental-site-trophoblastic-tumor-pstt/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/placental-site-trophoblastic-tumor-pstt/differentialdiagnoser/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/epitelioid-trofoblasttumor-ett/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/epitelioid-trofoblasttumor-ett/differentialdiagnoser/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/benigna-forandringar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/benigna-forandringar/placental-site-nodule-psn-och-plack/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/benigna-forandringar/atypisk-psn-apsn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kategorisering-av-tumoren/benigna-forandringar/exaggerated-placental-site-reaction-eps/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/multidisciplinar-konferens2/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-mola-hydatidosa/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-mola-hydatidosa/postoperativ-uppfoljning-i-vantan-pa-histopatologisk-diagnos/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-mola-hydatidosa/tvillinggraviditet-med-mola-och-ett-normalt-foster/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/lagriskfall/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/lagriskfall/monitorering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/hogriskfall/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/ultrahogriskfall/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/placental-site-trophoblastic-tumorepitelioid-trofoblasttumor/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/primar-behandling2/behandling-av-gtn/kirurgins-roll-i-primarbehandling/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/behandling-av-primar-behandlingssvikt-och-aterfall/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/behandling-av-primar-behandlingssvikt-och-aterfall/lagriskfall/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/behandling-av-primar-behandlingssvikt-och-aterfall/hogriskfall/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/behandling-av-primar-behandlingssvikt-och-aterfall/kirurgins-roll-vid-behandlingssvikt-eller-aterfall/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/palliativ-vard-och-insatser/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/bedomningsinstrument/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/haravfall-alopeci/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/illamaende-vid-cytostatikabehandling/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/slemhinnebiverkningar-av-cytostatikabehandling-med-metotrexat-daktinomycin-och-emaco/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/slemhinnebiverkningar-av-cytostatikabehandling-med-metotrexat-daktinomycin-och-emaco/omvardnadsatgarder-och-egenvard/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/neuropatier/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/trotthet-fatigue/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/trotthet-fatigue/egenvard/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognitiv-paverkan/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/kognitiv-paverkan/egenvard/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/nutrition/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/uppfoljning-efter-kirurgi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/sexualitet-och-fertilitet/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/sexualitet-och-fertilitet/samtal-om-sexualitet/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/omvardnad-och-rehabilitering/omvardnad/psykosocialt-omhandertagande-rehabilitering/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/nationella-riktlinjer/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/rokning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/komplementar-och-integrativ-medicin/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/alkohol/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/fysisk-aktivitet/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/egenvard/matvanor/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/uppfoljning-av-mola/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/uppfoljning-av-mola/ny-graviditet-efter-mola/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/uppfoljning-av-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/uppfoljning-av-gtn/postmolar-gtn-och-koriokarcinom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/uppfoljning-av-gtn/pstt-och-ett/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/uppfoljning-av-gtd/uppfoljning-av-gtn/ny-graviditet-efter-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/fertilitet-och-graviditetsutfall-efter-gtd/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/fertilitet-och-graviditetsutfall-efter-gtd/mola-hydatidosa/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/fertilitet-och-graviditetsutfall-efter-gtd/lagrisk-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/fertilitet-och-graviditetsutfall-efter-gtd/hogrisk-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/fertilitet-och-graviditetsutfall-efter-gtd/ultrahogrisk-gtn/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/fertilitet-och-graviditetsutfall-efter-gtd/pstt-och-ett/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/underlag-for-nivastrukturering2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kvalitetsregister2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/kvalitetsindikatorer-och-malnivaer2/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/referenser/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/forslag-pa-fordjupning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/forslag-pa-fordjupning/relevanta-lankar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/stockholm-gotland/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/syd/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/sydost/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/norr/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/mellansverige/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/vast/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/patientrepresentant/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/stodjande-rcc/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/i.-innehallsforteckning2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/ii.-klinisk-bakgrundsinformation2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/iii.-anvisningar-for-provtagarens-hantering-av-provet2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/iv.-anamnestisk-remissinformation2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/v.-hantering-av-prover-pa-patologlaboratorietutskarningsanvisningar2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vi.-analyser2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vi.-analyser/rekommenderade-rutin--och-specialfargningar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vi.-analyser/specialanalyser/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/benigna-forandringar/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/vii.i-komplett-mola-hydatidosa2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/vii.ii-partiell-mola-hydatidosa2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/vii.iii-invasiv-mola2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/viiiv-koriocarcinom/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/viiv-placental-site-trofoblastic-tumor-pstt/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/vii.-rekommenderade-klassifikationssystem/viivi-epitelioid-trofoblasttumor-ett/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/viii.-information-i-remissens-svarsdel2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/viii.-information-i-remissens-svarsdel/forslag-till-svarsmall-hysterektomi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/ix.-administrativt2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/ix.-administrativt/a.-snomed-koder2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/ix.-administrativt/b.-kvalitetsindikatorer2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/ix.-administrativt/c.-nationell-hogspecialiserad-vard-inkl.-eftergranskning-av-patologi2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/x.-ovrigt2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/x.-ovrigt/a.-kvast-gruppens-medlemmar2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/x.-ovrigt/b.-klinisk-organisation-som-granskat-och-godkant-dokumentet2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/x.-ovrigt/c.-lank-till-nationellt-vardprogram2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/x.-ovrigt/d.-multidisciplinar-konferens-mdk2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/xi/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-1/xi/referenser/2023-07-04 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-2--bedomning-av-allmantillstandet-performance-status/2023-07-05 https://kb.localhost:5000/diagnoser/trofoblast/vardprogram/bilaga-3---tidigare-medlemmar-i-vardprogramgruppen/2023-07-05 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/2022-04-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/introduktion/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2024-05-24 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke-kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2025-02-27 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2025-02-27 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2025-02-27 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/arbetsgruppens-sammansattning/2024-11-11 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardforlopp/kodningsvagledning/2024-11-12 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/2022-03-09 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-03-06 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-03-04 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/standardiserat-vardforlopp/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/lagstod/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/inledning/forkortningar/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/mal-med-vardprogrammet/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/blascancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/njurbacken--och-uretarcancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/epidemiologi/uretracancer2/2025-03-06 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/etiologi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bakgrund-och-orsaker/primar-prevention/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/screening/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/arftlighet/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/urotelial-cancer-vid-lynchs-syndrom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/urotelial-cancer-vid-lynchs-syndrom/bakgrund/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/urotelial-cancer-vid-lynchs-syndrom/kontrollprogram-for-urotelial-cancer-vid-lynchs-syndrom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/urotelial-cancer-vid-lynchs-syndrom/uppfoljning-och-behandling-av-urotelial-cancer-hos-individer-med-lynchs-syndrom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/symtom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/symtom/vanliga-symtom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/symtom/vanliga-symtom/ingang-till-standardiserat-vardforlopp-svf/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/symtom/forekomst-av-makrohematuri/2025-03-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/symtom/diagnostisk-fordrojning/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/2025-03-06 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/dt-urografi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/cystoskopi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/cytologi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/kompletterande-diagnostik---urinmarkorer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/stadieindelning-blascancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/stadieindelning-blascancer/dt-urografi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/stadieindelning-blascancer/turb2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/stadieindelning-blascancer/mrt/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/stadieindelning-blascancer/fdg-pet-dt/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/sarskilda-tekniker/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/sarskilda-tekniker/fluorescensdiagnostik-narrow-band-imaging-och-image1-s/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/utredning-av-njurbacken--och-uretar-cancer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/diagnostik/utredning-av-urotelial-cancer-i-prostatiska-uretra-och-prostata/2025-03-06 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/cytologi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/patologi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/cytologi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/patologi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/2025-03-06 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/molekylara-subtyper-vid-blascancer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren--tnm/panelsekvensering/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/multidisciplinar-konferens/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/icke-muskelinvasiv-blascancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/icke-muskelinvasiv-blascancer/tag1-g2-tumorer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/icke-muskelinvasiv-blascancer/tag1-g2-tumorer/prediktion-av-progression/2025-03-06 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/icke-muskelinvasiv-blascancer/aterfall-efter-bcg-behandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/icke-muskelinvasiv-blascancer/carcinoma-in-situ-tis/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/muskelinvasiv-blascancer-t2t4b/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/muskelinvasiv-blascancer-t2t4b/kurativ-behandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/muskelinvasiv-blascancer-t2t4b/induktionskemoterapi-vid-lokalt-avancerad-sjukdom-lymfkortelmetastaserad-sjukdom-eller-solitar-fjarrmetastas/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/muskelinvasiv-blascancer-t2t4b/neoadjuvant-cytostatikabehandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/behandling-muskelinvasiv-blascancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/urinavledning/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/robotassisterad-radikal-cystektomi-rarc/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/kurativ-extern-stralbehandling-och-radiokemoterapi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/adjuvant-systemisk-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/adjuvant-systemisk-behandling/adjuvant-cytostatika/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/adjuvant-systemisk-behandling/adjuvant-immunterapi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/blascancer/komplikationsregistrering-efter-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/njurbacken--och-uretarcancer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-man/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-man/tag1/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-man/uretracancer-hos-man-ovriga-t-stadier/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-man/uretrarecidiv-efter-cystoprostatektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-kvinnor/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-kvinnor/tag1/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/uretracancer-hos-kvinnor/uretracancer-hos-kvinnor-ovriga-t-stadier/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/uretracancer/ovrig-behandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/primar-behandling/urotelial-cancer-i-prostatiska-uretra-och-prostata/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/bedomning-av-tolerans-for-platinum/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/kemo-immunoterapi-till-patienter-som-ar-cisplatin-fit/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/kemoterapi-till-patienter-som-ar-cisplatin-fit2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/kemoterapi-till-patienter-som-ar-cisplatin-unfit2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/underhallsbehandling-med-immunterapi-efter-primarbehandling-med-platinum-innehallande-kombinationsterapi2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/immunterapi-till-patienter-som-ar-cisplatin-unfit2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-forsta-linjen/behandling-av-patienter-som-ar-platinum-unfit2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-andra-linjen/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-andra-linjen/andra-linjens-behandling-med-immunterapi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-andra-linjen/andra-linjens-behandling-med-kemoterapi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-andra-linjen/andratredje-linjens-behandling-med-targetlakemedel-mot-fgfr-23/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/behandling-i-andra-linjen/behandling-med-antikropp-lakemedelskonjugat-efter-tidigare-platinumbaserad-kemoterapi-samt-tidigare-immunterapi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/systemisk-immunterapi-for-patienter-med-lynchs-syndrom/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/prediktiva-biomarkorer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/systemisk-behandling/immunrelaterade-biverkningar-av-immunterapi-med-checkpoint-inhibitorer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/mojliga-systemiska-behandlingar-i-framtiden/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/lakemedelsbehandling-av-skelettmetastaser/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/behandling-vid-metastatisk-sjukdom/stralbehandling-vid-metastaserad-sjukdom/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/kontaktsjukskoterska/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/stomiterapeut-och-uroterapeut/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/dietist/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/arbetsterapeut-och-fysioterapeutsjukgymnast/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/kurator/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/centrala-aktorer/sexolog/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/krisreaktioner/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/patientforening/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/fortlopande-cancerrehabilitering/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/fortlopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/fortlopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/elimination/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/smarta/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/sexualitet/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/sexualitet/cystoskopi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/sexualitet/tur-b/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/sexualitet/instillationsbehandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/psykosocialt-stod/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-vid-cystoskopiundersokning-turb-och-intravesikal-instillation/instillationsbehandling-utford-av-sjukskoterska/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cystektomi/prehabilitering-infor-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cystektomi/infor-beslut-om-urinavledning/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-cystektomi/under-vardtiden/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/aktivitet-och-traning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/sexualitet-efter-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/mag-tarmbesvar/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/besvar-relaterade-till-urinavledning/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/kroppsliga-forandringar-relaterade-till-urinavledning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-cystektomi/lymflackage-och-lymfodem/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-kemoterapi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-kemoterapi/neuropatibiverkningar-efter-neoadjuvant-kemoterapi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/omvardnad-och-rehabilitering2/omvardnad-och-rehabilitering-efter-stralbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/palliativ-vard-och-insatser2/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/palliativ-vard-och-insatser2/planering-av-det-palliativa-skedet/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/palliativ-vard-och-insatser2/palliativ-behandling-av-behandlingsrefraktar-hematuri/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/mal-med-uppfoljningen/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/behovsbedomning-for-rehabilitering/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--blascancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--blascancer/patienter-med-icke-muskelinvasiv-blascancer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--blascancer/efter-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--blascancer/efter-kurativt-syftande-stralbehandling/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/efter-nefrouretarektomi-for-tumor-med-lag-risk-for-recidiv-och-metastasering-unifokal-och--2-cm-och-ta-och-g1g2lg/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/efter-nefrouretarektomi-for-ovriga-tumorer/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/efter-organbevarande-endoskopisk-behandling-med-eller-utan-adjuvant-instillationsbehandling-av-urotelial-tumor-i-ovre-urinvagarna/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/patienter-med-carcinoma-in-situ-i-ovre-urinvagarna-efter-bcg-behandling2/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/patienter-med-uretarcancer-behandlade-med-uretarresektion/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/uppfoljningsintervall--njurbacken--och-uretarcancer/patienter-med-cancer-i-uretra2/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/ansvar/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/ansvar/cystoskopi-utford-av-sjukskoterska/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/avslut-av-uppfoljning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/forslag-till-uppfoljningsprotokoll/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/tumoraterfall-i-kvarvarande-urotel-efter-radikal-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning/bakgrund-och-evidenslage/komplikationer-relaterade-till-urinavledning/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/underlag-for-nivastrukturering/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-urinblasecancer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-urinblasecancer/primar-anmalan/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-urinblasecancer/uppfoljning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-urinblasecancer/cystektomikomplikationsregistrering/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-urinblasecancer/registrering-av-onkologisk-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/nationellt-kvalitetsregister-for-urinblasecancer/registrering-av-tumorer-i-njurbacken-uretar-och-uretra/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/uppfoljning-av-cancervarden/cancerregistret/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/relevanta-lankar/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/adjungerade-forfattare/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/checklista-infor-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/checklista-infor-cystektomi/referenser/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-man-som-genomgar-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-man-som-genomgar-cystektomi/infor-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-man-som-genomgar-cystektomi/efter-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-man-som-genomgar-cystektomi/uppfoljning-efter-insatt-ed-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-man-som-genomgar-cystektomi/praktiska-tips/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-kvinnor-som-genomgar-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-kvinnor-som-genomgar-cystektomi/infor-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-kvinnor-som-genomgar-cystektomi/efter-cystektomi/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-kvinnor-som-genomgar-cystektomi/uppfoljning-av-sexuell-rehabilitering/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/sexualitet-for-kvinnor-som-genomgar-cystektomi/praktiska-tips/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sexuell-rehabilitering-efter-cystektomi/referenser2/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/transuretral-resektion-av-blastumor-turb/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/transuretral-resektion-av-blastumor-turb/checklista-vid-turb/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/transuretral-resektion-av-blastumor-turb/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/endoskopisk-behandling-av-tumoraterfall-i-lokalbedovning-pa-mottagningen/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/endoskopisk-behandling-av-tumoraterfall-i-lokalbedovning-pa-mottagningen/teknik-enligt-sahlgrenska/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/endoskopisk-behandling-av-tumoraterfall-i-lokalbedovning-pa-mottagningen/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/intravesikal-behandling-med-bcg/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/intravesikal-behandling-med-bcg/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/intravesikal-behandling-med-mitomycin/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/intravesikal-behandling-med-mitomycin/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/adjuvant-instillation-av-epirubicin-eller-mitomycin-i-endos-efter-transuretral-resektion/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/adjuvant-instillation-av-epirubicin-eller-mitomycin-i-endos-efter-transuretral-resektion/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/radikal-cystektomi/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/radikal-cystektomi/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/patienter-ej-lampliga-for-cisplatin/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/intrauretral-cytostatikabehandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/intrauretral-cytostatikabehandling/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/en-rok--och-alkoholfri-operation/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/en-rok--och-alkoholfri-operation/rokfri-operation/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/en-rok--och-alkoholfri-operation/alkoholfri-operation/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/en-rok--och-alkoholfri-operation/alkoholfri-operation/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/innehallsforteckning/2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/ii.-klinisk-bakgrundsinformation2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/iii.-anvisningar-for-provtagarens-hantering-av-provet2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/iv.-anamnestisk-remissinformation2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/v.-hantering-av-prover-pa-patologlaboratorietutskarningsanvisningar2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/vi.-analyser2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/vii.-rekommenderade-klassifikationssystem2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/viii.-information-i-remissens-svarsdel2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/ix.-administrativt2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/x.-ovrigt2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/xi.-referenser2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/appendix-1.-immunhistokemiska-fargningar2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/cancer-i-urinvagarna/appendix-2.-forslag-pa-svarsmall-for-cystektomi2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/i.-innehallsforteckning2025-03-07 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/ii.-klinisk-bakgrundsinformation2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/iii.-anvisningar-for-provtagarens-hantering-av-provet2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/iv.-anamnestisk-remissinformation2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/v.-hantering-av-prover-pa-laboratorietanvisningar2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/vi.-analyser2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/vii.-rekommenderade-klassifikationssystem2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/viii.-information-i-remissens-svarsdel2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/ix.-administrativt2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/x.-ovrigt2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/anvisningar-for-cytologi-och-histologi/urinvagscytologi/xi.-referenser2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/prognostisk-modell-for-beraknande-av-progressionsrisk-for-muskelinvasion-for-icke-muskelinvasiva-tumorer-eau-2021/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/antibiotikaprofylax/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/antibiotikaprofylax/urinodling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/antibiotikaprofylax/vanliga-riskfaktorer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/antibiotikaprofylax/antibiotikaval/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/antibiotikaprofylax/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/anvandningsomraden/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/kontraindikationer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/preterapeutisk-genomgang/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/preparat/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/administrering/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/behandlingsintervall/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/underhallsbehandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/biverkningar/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/sekventiell-instillation-med-gemcitabin-och-docetaxel/referenser/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-16.-intravesikal-termokemoterapi-och-emda-electromotive-drug-administration2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-16.-intravesikal-termokemoterapi-och-emda-electromotive-drug-administration/referenser2/2025-03-14 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/indikationer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/diagnoskriterier-tis-ovre-urinvagarna/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/kontraindikationer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/instillationstekniker/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/instillationstekniker/a-antegrad-instillation-enligt-m-brehmer/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/instillationstekniker/b-retrograd-instillation-via-uretarkateter-i-trendelenburglage/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/instillationstekniker/c-retrograd-instillation-via-uretra-och-dubel-j-kateter-i-trendelenburglage/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/uppfoljningsschema/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-17.-instillationsbehandling-iovre-urinvagarna/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-18.-dt-urografi-vid-hematuriutredning2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-18.-dt-urografi-vid-hematuriutredning/protokoll/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-18.-dt-urografi-vid-hematuriutredning/rontgenutlatande-blastumor/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-18.-dt-urografi-vid-hematuriutredning/rontgenutlatande-njurbacken--eller-uretartumor/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-19.-radiologi-vid-uppfoljning-av-urotelial-cancer2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-19.-radiologi-vid-uppfoljning-av-urotelial-cancer/protokoll/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-20.-handlaggning-av-radiologiskt-pavisad-urachusrest-utan-overt-malignt-utseende-med-eller-utan-symptom2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-20.-handlaggning-av-radiologiskt-pavisad-urachusrest-utan-overt-malignt-utseende-med-eller-utan-symptom/referenser/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-21.-stralbehandlingsprotokoll-vid-blascancer2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-21.-stralbehandlingsprotokoll-vid-blascancer/patientforberedelser-innan-behandling/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-21.-stralbehandlingsprotokoll-vid-blascancer/bildtagning-infor-behandlingsplanering/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-21.-stralbehandlingsprotokoll-vid-blascancer/behandlingsordination/2025-02-28 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-21.-stralbehandlingsprotokoll-vid-blascancer/andra-terapier/2025-03-03 https://kb.localhost:5000/diagnoser/urinblase-och-urinvagscancer/vardprogram/bilaga-21.-stralbehandlingsprotokoll-vid-blascancer/kvalitetskontroll/2025-03-03 https://kb.localhost:5000/diagnoser/vulvacancer/2022-04-07 https://kb.localhost:5000/diagnoser/vulvacancer/forkortat-vardforlopp/2025-11-18 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/sammanfattning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/vardprogrammets-giltighetsomrade/2024-10-02 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/lagstod/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/2.3forandringar-jamfort-med-tidigare-version2024-09-23 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/standardiserat-vardforlopp/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/evidensgradering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/inledning/forkortningar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/mal-med-vardprogrammet/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/epidemiologi/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/epidemiologi/vulvas-anatomi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/epidemiologi/histologi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/epidemiologi/incidens-och-mortalitet/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/riskfaktorer/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/riskfaktorer/allmanna-riskfaktorer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/epidemiologi-och-riskfaktorer/riskfaktorer/infektion-med-humant-papillomvirus-hpv/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/definition-av-dysplasi-i-vulva/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/forekomst/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/behandling-av-hsil/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/behandling-av-hsil/lokal-kirurgi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/behandling-av-hsil/topikal-behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/behandling-av-hsil/fotodynamisk-behandling-pdt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/behandling-av-dvin/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/uppfoljning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/uppfoljning/hsil/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/vulvadysplasi-hsil-och-dvin/uppfoljning/dvin/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/lichen-sclerosus/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/lichen-sclerosus/klinisk-bild-och-symtom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/lichen-sclerosus/behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/lichen-planus/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/lichen-planus/symtom-och-fynd/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/lichen-planus/behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/symtom-och-fynd/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/behandling/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/behandling/kirurgisk-behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/behandling/topikal-behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/behandling/fotodynamisk-behandling-pdt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/morbus-paget/uppfoljning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/premaligna-tillstand-i-vulva/basaliom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/primar-prevention--vaccination/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/metoder-for-screening/2024-06-26 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/immunsuppression/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/kvinnor-som-lever-med-hiv/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/transplanterade-kvinnor/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/ovriga-immunsupprimerande-tillstand/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/ovriga-immunsupprimerande-tillstand/sle/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/ovriga-immunsupprimerande-tillstand/inflammatoriska-tarmsjukdomar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/reumatologiska-sjukdomar/2024-06-26 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/screening/lichen-sclerosus/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/sekundar-prevention/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-prevention-och-screening/arftlighet/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/symtom-och-tidig-utredning/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/symtom-och-tidig-utredning/symtom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/symtom-och-tidig-utredning/utredning-och-misstanke-om-cancer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2024-06-25 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/primarutredning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/primarutredning/klinisk-och-gynekologisk-undersokning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/primarutredning/undersokning-i-narkos/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/primarutredning/stadieindelning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/val-av-bilddiagnostisk-metod/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/specialistultraljud-ljumskar-kombinerat-med-punktion/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/magnetresonanstomografi-mrt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/datortomografi-dt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/bilddiagnostiska-metoder/positronemissionstomografi-pet-dt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/remissforfarande/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/utlatande-lokal-tumorutbredning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/utlatande-lymfkortel--och-fjarrmetastaser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/bilddiagnostik/postoperativ-kompletterande-diagnostik/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/diagnostik/diagnosbesked/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/cytologi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/biopsi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/excisioner-och-partiell-eller-total-vulvektomi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/sentinel-node-portvaktskortel/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/ovriga-lymfkortlar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/intraepiteliala-skivepitellesioner/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/intraepiteliala-skivepitellesioner/laggradig-intraepitelial-skivepitellesion-lsil/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/intraepiteliala-skivepitellesioner/hoggradig-intraepitelial-skivepitellesion-hsil/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/intraepiteliala-skivepitellesioner/hpv-oberoende-vin/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/skivepitelcancer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/skivepitelcancer/skivepitelcancer-hpv-associerad/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/skivepitelcancer/skivepitelcancer-hpv-oberoende/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/skivepitelcancer/skivepitelcancer-hpv-oberoende/9.5.1.2.1prognostiska-faktorer-i-skivepitelcancer2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/basalcellscancer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/morbus-paget/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/epiteliala-tumorer/adenokarcinom-i-vulvakortlar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/melanom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kategorisering-av-tumoren/mjukdelstumorer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/tumorklassificering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/tumorklassificering/stadieindelning-enligt-figo/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/tumorklassificering/ptnm-klassificering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/multidisciplinar-konferens/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/multidisciplinar-konferens/organisation-och-deltagare/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/multidisciplinar-konferens/syfte/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/multidisciplinar-konferens/anmalan/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/multidisciplinar-konferens/ansvarsfordelning-och-uppfoljning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/tumorlokalisation-och-dess-betydelse/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/tumoranpassad-resektion/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/fria-marginalers-betydelse/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/kirurgi-vid-lokalt-avancerad-tumor-4-cm/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/orientering-och-markering-av-resektionsranderna/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/vulvakirurgi/rekonstruktioner-och-lambaer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/anatomiska-begransningar-vid-lymfkortelutrymning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/indikation-for-lymfkortelingrepp/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/syfte-med-lymfkortelutrymning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/superficiell-eller-radikal-utrymning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/uni--eller-bilateral-utrymning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/handlaggning-av-bulky-nodes/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/handlaggning-av-pelvina-lymfkortelmetastaser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/evidenslage/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/sn-teknik-vid-borttagen-tumor/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/risk-for-ovriga-lymfkortelmetastaser-vid-positiv-sn/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/kompletterande-lymfkortelutrymning-vid-metastas-i-sn/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/bilateral-eller-unilateral-utrymning-efter-positiv-sn/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/lymfkortelkirurgi-i-ljumskar/sentinel-node-teknik-sn-teknik/sn-teknikaspekter/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/forekomst-av-komplikationer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/preoperativa-riskfaktorer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/kirurgisk-teknik/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/postoperativa-rad/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/postoperativa-rad/generella-rad/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/postoperativa-rad/dran/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/postoperativa-rad/sarruptur/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/postoperativa-rad/lymfocele/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/forebyggande-av-komplikationer-vid-kirurgi/postoperativa-rad/lymfodem/2024-06-26 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/principer-for-radioterapi-adjuvant-och-definitiv/2024-06-25 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/adjuvant-radiokemoterapi/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/adjuvant-radiokemoterapi/indikationer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/adjuvant-radiokemoterapi/lymfkortelmetastaser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/adjuvant-radiokemoterapi/planering-av-adjuvant-behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/adjuvant-radiokemoterapi/doser-for-adjuvant-radioterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/definitiv-radioterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/radioterapi-och-radiokemoterapi/definitiv-radioterapi/planering-av-behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/neoadjuvant-radioterapiradiokemoterapikemoterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/konkomitant-kemoterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/primar-behandling/palliativ-radioterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/kirurgi/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/kirurgi/aterfallskirurgi-i-vulva/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/kirurgi/aterfallskirurgi-i-ljumskar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/onkologisk-behandling/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/onkologisk-behandling/radioterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/behandling-av-aterfall/onkologisk-behandling/kemoterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/melanoma-in-situ/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/forekomst/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/stadieindelning-av-mukosala-maligna-melanom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/lokalisation-och-symtom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/diagnos-och-preoperativ-utredning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/lymfkortlar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/generaliserad-sjukdom/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/prognos/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/malignt-melanom/malignt-melanom-och-mukosala-maligna-melanom/uppfoljning/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/palliativ-vard-och-insatser/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/palliativ-vard-och-insatser/kirurgisk-palliation/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/palliativ-vard-och-insatser/palliativ-kemoterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/palliativ-vard-och-insatser/palliativ-radioterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/palliativ-vard-och-insatser/malstyrda-lakemedel/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/palliativ-vard-och-insatser/elektrokemoterapi-ekt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/sexualitet/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/forberedelser-i-hemmet/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/inskrivning-infor-operation/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/oversikt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/sarvard/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/forband/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/dranage/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/elimination/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/mobilisering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-kirurgisk-behandling/perioperativ-omvardnad/lymfodem/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/smarta/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/kirurgisk-behandling/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/kemoterapi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/psykosocialt-omhandertagande/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/nutrition-och-elimination/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/illamaende/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/alopeci-haravfall/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/hud--och-slemhinnepaverkan/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/lymfodem/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/sexualitet/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/vaginalstav/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/rokning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/benmarg/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/smarta/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/omvardnad-och-rehabilitering/onkologisk-behandling/stralbehandling/fatigue/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/egenvard/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/egenvard/nationella-riktlinjer/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/egenvard/rokning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/egenvard/komplementar-och-alternativ-medicin/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/egenvard/alkohol/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/uppfoljning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/underlag-for-nivastrukturering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsregister/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsregister/20.1-cancerregistret2024-02-29 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsindikatorer-och-malnivaer/2024-09-23 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/referenser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/vardprogramgruppen/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2024-10-02 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/teknisk-och-metodologisk-beskrivning-av-bilddiagnostik/2020-02-06 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/teknisk-och-metodologisk-beskrivning-av-bilddiagnostik/lymfkorteldiagnostik-med-ultraljud/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/teknisk-och-metodologisk-beskrivning-av-bilddiagnostik/magnetresonanstomografi-mrt-av-lilla-backenet-vid-utredning-av-lokal-tumorutbredning-och-regionala-lymfkortlar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/teknisk-och-metodologisk-beskrivning-av-bilddiagnostik/datortomografi-dt-av-buk/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/teknisk-och-metodologisk-beskrivning-av-bilddiagnostik/positronemissionstomografi-pet-dt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/teknisk-och-metodologisk-beskrivning-av-bilddiagnostik/referenser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/lymfkortelkirurgi-vid-olika-scenarier/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/flodesschema-behandlingsval/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/forkortningar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/klinisk-bakgrundsinformation/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/anvisningar-till-kirurgen/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/anamnestisk-remissinformation/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/utskarningsanvisningar/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/analyser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/information-i-remissens-svarsdel/2024-10-02 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/rekommenderade-klassifikationssystem/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/administrativt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/ptnm-klassificering/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/stadieindelning-enligt-figo/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/kvalitetsarbete-for-patologin2/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/ovrigt/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/kvalitetsdokument-for-patologi/referenser/2023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardprogram/vardprogramgruppens-medlemmar-for-version-1.02023-05-04 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/introduktion/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/ingang-till-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2023-12-19 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/ingang-till-standardiserat-vardforlopp/filterfunktion/2019-12-17 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-12-17 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/berakning-av-ledtider/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/uppfoljning-av-standardiserat-vardforlopp/ovrig-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/arbetsgruppens-sammansattning2/2024-11-11 https://kb.localhost:5000/diagnoser/vulvacancer/vardforlopp/kodningsvagledning/2024-11-11 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/2020-02-28 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/sammanfattning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/inledning/2019-11-27 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/inledning/vardprogrammets-giltighetsomrade/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2021-09-21 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/inledning/standardiserat-vardforlopp/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/inledning/lagstod/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/inledning/evidensgradering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/mal-med-vardprogrammet/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/bakgrund-och-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/bakgrund-och-orsaker/incidens/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/bakgrund-och-orsaker/orsaker/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/bakgrund-och-orsaker/overlevnad/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-prevention/2019-11-27 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-prevention/levnadsvanor/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-prevention/riskfaktorer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/screening/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/arftlighet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/symtom-och-tidig-utredning/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/symtom-och-tidig-utredning/symtom-orsakade-av-benmargsinfiltration/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/symtom-och-tidig-utredning/symtom-orsakade-av-igm-m-komponenten/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/symtom-och-tidig-utredning/andra-symtom-och-fynd/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/hyperviskositet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/amyloidos/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/bingneels-syndrom-bns/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/kryoglobulinemi/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/koldhemolys-chronic-cold-agglutinin-disease-ellercad/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/speciella-problem-vid-wm/neuropati-19/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/utredning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/utredning/utredning-av-m-komponent-av-igm-typ/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/utredning/rontgenologisk-utredning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/utredning/ovrig-utredning/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/utredning/performance-status-whoecog/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/diagnoskriterier/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/prognosfaktorer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/prognosfaktorer/international-prognostic-scoring-system-for-wm-ipsswm/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/prognosfaktorer/andra-prognosfaktorer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/diagnosbesked2/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/registrering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/diagnostik/biobank/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kategorisering-av-tumoren/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kategorisering-av-tumoren/Anamnestisk-remissinformation/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kategorisering-av-tumoren/Klassificering-av-tumoren/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kategorisering-av-tumoren/nya-diagnostiska-markorer-och-differentialdiagnostik/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/multidisciplinar-konferens/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/behandlingsindikation/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/val-av-behandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/plasmaferes/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/rituximab-som-singelbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/rituximab-i-kombination-med-cytostatika/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/bendamustin/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/drc/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/bortezomib/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/systemisk-behandling/Ibrutinib/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/mutationsstatus-inverkan-pa-behandlingssvar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/behandling-av-skora-patienter/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/behandling-av-skora-patienter/klorambucil/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/behandling-av-skora-patienter/rituximab-som-singelbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/behandling-av-skora-patienter/Ibrutinib/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/underhallsbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/neuropati/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/amyloidos/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/bingneels-syndrom-bns/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/transformation-till-aggressivt-lymfom/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/koldhemolys-cad/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/kryoglobulinemi/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/primar-behandling/speciella-behandlingsproblem/bedomning-av-behandlingssvar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/behandling-av-icke-symtomgivande-aterfall/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/behandling-av-tidigt-symtomgivande-aterfall-2ar-efter-avslutad-primarbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/behandling-av-sent-symtomgivande-aterfall-2-ar-efter-avslutad-primarbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/etablerad-regim-som-anvands-allt-mindre-idag/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/etablerad-regim-som-anvands-allt-mindre-idag/fludarabin/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/kommande-behandlingar-som-inte-ar-godkanda/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/kommande-behandlingar-som-inte-ar-godkanda/behandlingar-som-finns-tillgangliga-i-sverige-for-annan-diagnos-an-wm/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/kommande-behandlingar-som-inte-ar-godkanda/behandlingar-som-inte-finns-tillgangliga/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/autolog-stamcellstransplantation/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/behandling-av-aterfall/allogen-stamcellstransplantation/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/blodprodukter/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/infektionsprofylax-efter-hogdosbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/hepatit-b/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/herpesvirus/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/pneumocystis-jiroveci/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/allman-svampprofylax-candida-etc/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/infektionsbehandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/infektionsprofylax/vaccinationer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/sen-neutropeni-lon/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/rituximabinducerade-interstitiella-lungforandringar-rild/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/akuta-infusionsreaktioner/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/understodjande-vard/handlaggning-av-biverkningar-relaterade-till-rituximab/rituximab-flare/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/palliativ-vard-och-insatser/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/sexualitet/2024-01-19 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/fertilitetsbesparande-atgarder/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/fysisk-aktivitet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/hygien-och-isolering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/munvard/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/nutrition/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/skotsel-av-central-infart-till-blodkarl/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/psykosocialt-stod/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/fatigue/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/benmargspaverkan/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/neuropati/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/omvardnad-och-rehabilitering/information-om-biverkningar/illamaende/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/rokning-och-alkohol/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/infektionskanslighet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/munhygien/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/fysisk-aktivitet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/hud/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/mage-och-tarm/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/vaccinationer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/feber/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/koldhemolys/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/inledning/neuropati/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/nationella-riktlinjer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/rokning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/komplementar-och-alternativ-medicin/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/alkohol/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/fysisk-aktivitet/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/egenvard/matvanor/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/inledning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/mal-med-besoken/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/fornyad-behovsbedomning-for-rehabilitering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/sjalvrapportering-av-symtom/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/uppfoljning-for-patienter-utan-behandlingskravande-sjukdom-med-diagnos-wmlpl/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/uppfoljning-av-patienter-som-fatt-behandling/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/uppfoljning-av-mgus-med-mkomponent-av-igm-typ/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/ansvar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/uppfoljning/avslut-av-uppfoljning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/underlag-for-nivastrukturering/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/svenska-lymfomregistret/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/svenska-lymfomregistret/syfte-och-mal/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/svenska-lymfomregistret/innehall/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/svenska-lymfomregistret/inklusionskriterier/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/svenska-lymfomregistret/exklusionskriterier/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsregister/cancerregistret/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/kvalitetsindikatorer-och-malnivaer/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/referenser/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/forslag-pa-fordjupning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/vardprogramgruppen/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/vardprogramgruppen/tidigare-medlemmar-i-vardprogramgruppen/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2021-09-16 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/patientinformation/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardprogram/igm-mgus-monoklonal-gammopati-av-oklar-signifikans/2021-09-17 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/2020-02-10 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/introduktion/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/introduktion/syfte-med-standardiserade-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/introduktion/om-maligna-lymfom-och-kll/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/introduktion/flodesschema-for-vardforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/ingang-till-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/ingang-till-standardiserat-vardforlopp/misstanke/2021-09-06 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/ingang-till-standardiserat-vardforlopp/valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2020-01-22 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/ingang-till-standardiserat-vardforlopp/remiss-vid-valgrundad-misstanke/2020-01-22 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/ingang-till-standardiserat-vardforlopp/kommunikation-och-delaktighet/2020-01-22 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/utredning-och-beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/utredning-och-beslut-om-behandling/terapikonferens/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2021-09-06 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2021-09-06 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ledtider-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/ingaende-ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-nationell-uppfoljning/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/indikatorer-for-uppfoljning-av-standardiserat-vardforlopp/indikatorer-for-kvalitet/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/nationellt-vardprogram/2021-09-06 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-standardiserat-vardforlopp/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/hantering-av-aterfall-recidiv/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/utredningsforloppet/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/inklusion-i-kliniska-studier/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/ledtider/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/koordinatorsfunktion/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/samarbete-over-landstingsgranser/2021-09-02 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/generellt-om-standardiserat-vardforlopp/uppdatering/2021-09-06 https://kb.localhost:5000/diagnoser/waldenstroms-makroglobulinemi/vardforlopp/arbetsgruppens-sammansattning2/2020-01-22 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/2022-04-07 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/sammanfattning/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/sammanfattning/stadieindelning-enligt-figo/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/inledning/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/inledning/vardprogrammets-giltighetsomrade/2025-04-29 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/inledning/forandringar-jamfort-med-tidigare-version/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/inledning/standardiserat-vardforlopp/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/inledning/lagstod/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/inledning/evidensgradering/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/mal-med-vardprogrammet/2023-03-16 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/epidemiologi/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/epidemiologi/incidens/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/epidemiologi/dodlighet-och-relativ-overlevnad/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/orsaker/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/arftlighet-och-genetiska-riskfaktorer/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/arftlighet-och-genetiska-riskfaktorer/nedarvda-mutationer/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/arftlighet-och-genetiska-riskfaktorer/forvarvade-mutationer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/alder-vid-menarche-och-menopaus/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/hormonell-substitutionsterapi/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/infertilitet-och-fertilitetsstimulerande-lakemedel/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/riskfaktorer/endometrios/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/skyddande-faktorer/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/skyddande-faktorer/graviditet-och-paritet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/skyddande-faktorer/amning/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/skyddande-faktorer/p-piller/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/skyddande-faktorer/tubarligation-salpingektomi-salpingooforektomi-hysterektomi/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bakgrund-och-orsaker/skyddande-faktorer/nsaid-och-aspirin/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/levnadsvanor/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/levnadsvanor/kost/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/levnadsvanor/fysisk-aktivitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/levnadsvanor/langd-och-vikt/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/levnadsvanor/rokning/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primar-prevention-och-faktorer-som-paverkar-risken-for-aggstockscancer/levnadsvanor/alkohol/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/screening-av-asymtomatiska-kvinnor-utan-pavisad-arftlig-risk/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/arftlighet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/arftlighet/utredning-av-misstankt-arftlighet/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/arftlighet/arftliga-varianter/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/arftlighet/arftliga-varianter/hereditara-brost--och-ovarialcancersyndromet-hboc--brca1-och-brca2/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/arftlighet/arftliga-varianter/lynchs-syndrom--mlh1-msh2-msh6-pms2-och-epcam/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/arftlighet/arftliga-varianter/gener-associerade-med-mattligt-forhojd-aggstockscancerrisk--brip1-rad51c-och-rad51d/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/bakgrund/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/hereditara-brost--och-ovarialcancersyndromet-hboc/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/lynchs-syndrom/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/brip1-rad51c-och-rad51d/2023-03-16 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/profylaktisk-kirurgi-vid-hereditara-brost--och-ovarialcancersyndromet-hboc/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/profylaktisk-kirurgi-vid-hereditara-brost--och-ovarialcancersyndromet-hboc/profylaktisk-kirurgi-vid-lynchs-syndrom/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/profylaktisk-kirurgi-vid-hereditara-brost--och-ovarialcancersyndromet-hboc/profylaktisk-kirurgi-vid-mutation-i-brip1-palb2-rad51c-och-rad51d/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/screening-och-arftlighet/uppfoljning-och-omhandertagande-vid-arftlighet-for-aggstockscancer/hormonell-antikonception-och-substitution/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/symtom-och-tidig-utredning/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/symtom-och-tidig-utredning/alarmsymtom-och-kliniska-fynd/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/symtom-och-tidig-utredning/utredning-av-patienter-som-inte-uppfyller-kriterierna-for-valgrundad-misstanke/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/filterfunktion/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/berakning-av-risk-of-malignancy-index-rmi/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/simple-rules--ultraljudsdefinition/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/simple-rules--ultraljudsdefinition/pattern-recognition--ultraljudsdefinition/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/datortomografi-och-positionemissionsdatortomografi/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/utredning-enligt-standardiserat-vardforlopp/magnetresonanstomografi/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/handlaggning-av-adnexexpansivitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/handlaggning-av-stic-vid-riskreducerande-salpingooforektomi/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/diagnosbesked/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/diagnostik/omvardnad-och-rehabilitering/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/patologins-roll-i-den-diagnostiska-processen/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/patologins-roll-i-preoperativ-tumordiagnostik/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/patologins-roll-i-preoperativ-tumordiagnostik/preoperativ-diagnostik-material/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/patologins-roll-i-preoperativ-tumordiagnostik/preoperativ-diagnostik-material/material-for-preoperativ-diagnostik/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/patologins-roll-i-preoperativ-tumordiagnostik/preoperativ-diagnostik--eftergranskning-av-pad/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/preparatomhandertagande/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/preparatomhandertagande/peroperativ-diagnostikfryssnitt/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/preparatomhandertagande/cytologiskt-material/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/anvisningar-for-provtagarens-hantering-av-provet/preparatomhandertagande/operationsmaterial/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/anamnestisk-remissinformation/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-tumoren/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/om-seros-cancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/om-seros-cancer/hoggradig-seros-cancer-hgsc/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/om-seros-cancer/laggradig-seros-cancer-lgsc/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/endometrios/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/endometrioid-aggstockscancer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/klarcellig-aggstockscancer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/mucinos-aggstockscancer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/angaende-de-vanligaste-tumortyperna/metastas/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/seros-borderlinetumor-icd-o-84421-mikropapillar-typ-84602/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/seros-borderlinetumor-icd-o-84421-mikropapillar-typ-84602/peritoneala-tumormanifestationer-implantat/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/seros-borderlinetumor-icd-o-84421-mikropapillar-typ-84602/mikroinvasion/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/seros-borderlinetumor-icd-o-84421-mikropapillar-typ-84602/lymfkortlar/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/mucinos-borderlinetumor-icd-o-84721/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/seromucinos-borderlinetumor-icd-o-84741/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/endometrioid-borderlinetumor-icd-o-83801/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/klarcellig-borderlinetumor-icd-o-83131/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kategorisering-av-tumoren/klassificering-av-borderlinetumorer/borderline-brennertumor-icd-o-90001/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/multidisciplinar-konferens/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/val-av-behandling/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-i/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiiib/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/patientselektion/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/bakgrund/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/bedomning-av-resektabilitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/radikalitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/lymfkortelutrymning/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/kvalitetsmatt-for-kirurgi/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/var-utfors-aggstockscancerkirurgi-i-sverige-och-av-vem/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/operationsberattelsen/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/kirurgi-vid-stadium-iiiciv/nomenklatur/2023-04-12 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/per--och-postoperativa-komplikationer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/perioperativ-vard/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/fertilitetsbevarande-kirurgisk-behandling-vid-stadium-i/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/kirurgisk-behandling-av-epitelial-aggstockscancer/laparoskopisk-kirurgi-vid-tidig-aggstockscancer/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-i/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-i/behandlingsrelaterad-toxicitet-och-livskvalitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/karboplatin-och-paklitaxel/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/behandlingsrelaterad-toxicitet-och-livskvalitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/docetaxel-och-karboplatin/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/pegylerat-liposomalt-doxorubicin-och-karboplatin/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/trippelkombinationer-sekventiell-behandling-och-hogdosbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/cytostatikaregimer/dostat-eng.-dose-dense-paklitaxel-eller-karboplatin2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/intraperitoneal-cytostatikabehandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/medikamentell-onkologisk-primarbehandling-vid-stadium-iiiv/hyperterm-intraperitoneal-cytostatikabehandling-hipec/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/angiogeneshammande-behandling-vid-primarbehandling/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/angiogeneshammande-behandling-vid-primarbehandling/bevacizumab-vid-primarbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/homolog-rekombinationsdefekt-homologous-recombination-deficiency-hrd/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/behandling-med-parp-hammare-i-forsta-linjen/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/hematologisk-toxicitet/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/mdsaml/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/gastrointestinal-toxicitet/2025-04-29 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/njurtoxicitet/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/fatigue/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/levertoxicitet/2025-04-29 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare/biverkningar-av-parp-hammare/ovanliga-biverkningar/2025-04-29 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare-i-forhallande-till-kirurgi-och-stralbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/parp-hammare-i-forhallande-till-kirurgi-och-stralbehandling/biverkningar-av-kombinationen-parp-hammare-och-bevacizumab/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/immunterapi-vid-primarbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/medikamentell-onkologisk-primarbehandling/tumorutvardering-under-medicinsk-behandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/primarbehandling/fertilitetsbevarande-behandling/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/kirurgi/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/medikamentell-onkologisk-behandling-vid-aterfall/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/endokrin-behandling-och-stralbehandling/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/angiogeneshammare/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/2025-05-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/olaparib/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/niraparib/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/rucaparib/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/kombinationsbehandling-med-parp--och-angiogeneshammare/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/parp-hammare-och-immunterapi/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/parp-hammare-vid-aterfall2/behandling-med-parp-hammare-vid-aterfall/biverkningar-av-parp-hammare/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/immunterapi-vid-aterfall/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/behandling-vid-aterfall/braf--och-mek-hammare-vid-aterfall-av-laggradig-seros-cancer/2025-05-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/epidemiologi/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/borderlinetumorer--prognostiska-faktorer/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/borderlinetumorer--kirurgi/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/borderlinetumorer--kirurgi/kirurgisk-modalitet/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/borderlinetumorer--kirurgi/invasiva-implantat--laggradig-seros-cancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/medicinsk-behandling-ges-inte-vid-borderlinetumorer/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/aterfall/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/borderlinetumorer/uppfoljning/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/diagnostiska-metoder-under-graviditet/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/differentialdiagnostik-och-handlaggning-vid-misstankt-malign-adnexexpansivitet/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/kirurgi/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/platinumpreparat/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/mitoshammare/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/taxaner/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/podofyllotoxinderivat/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/alkylerare/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/antracykliner/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/onkologisk-behandling/antimetaboliter/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/graviditet-och-aggstockscancer/komplikationer-och-langtidseffekter-hos-barn/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/palliativ-vard-och-insatser/2023-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/palliativ-vard-och-insatser/behandling-av-subileusileus/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/palliativ-vard-och-insatser/behandling-av-malign-ascites/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/kontaktsjukskoterska/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/min-vardplan/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/aktiva-overlamningar/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/regelbunden-behovsbedomning-for-patienter-och-narstaende/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/lopande-cancerrehabilitering/bedomningsinstrument/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/haravfall-alopeci/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/illamaende-och-krakningar-som-ar-cytostatikautlosta/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/trotthet-fatigue/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/kognitiv-paverkan/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/nutrition/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/lymfodem/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/fysisk-aktivitet-under-behandling-med-cytostatika/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/komplikationer-vid-kirurgi/2024-06-26 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/perifer-neuropati/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/symtomkontroll-och-uppfoljning-under-behandling/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/benmargspaverkan/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/illamaende/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/trotthet-orkesloshet-och-sjukdomskansla/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/nedsatt-aptit-och-forandrad-smak-matsmaltningsbesvar-och-magsmartor-halsbranna-och-tarmbesvar/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/hypertoni/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/hjartklappning-andfaddhet/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/huvudvark-yrsel/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/infor-kirurgiska-ingrepp-och-stralbehandling/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/omvardnad-vid-behandling-med-parp-hammare/vaccination/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/ppe-hand-fotsyndromet/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/prematur-menopaus/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/sexuell-funktion-vid-aggstockscancer/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/sexuell-funktion-vid-aggstockscancer/samtal-om-sexualitet/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/omvardnad-och-rehabilitering/omvardnad-vid-aggstockscancer/dyspareuni--smarta-vid-samlag/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/egenvard/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/egenvard/nationella-riktlinjer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/egenvard/rokning/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/egenvard/komplementar-och-alternativ-medicin/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/egenvard/alkohol/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/egenvard/egenvard-vid-komplikationer-och-biverkningar/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/hitta-aterfall/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/vad-vill-patienterna-sjalva-med-uppfoljningsbesoket/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/vardniva-for-kontroller/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/utredning-och-behandling-av-behandlingsrelaterade-biverkningar/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/postoperativ-uppfoljning-specifikt-efter-aggstockscancerkirurgi/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/uppfoljning-av-borderlinetumorer/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/uppfoljning-av-asymtomatiska-kvinnor-med-arftlig-risk/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/hormonsubstitution-hrt-efter-avslutad-primarbehandling/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/uppfoljning/hormonell-antikonception-och-substitution-vid-hboc-brca-mutation-och-lynchs-syndrom/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/underlag-for-nivastrukturering/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/underlag-for-nivastrukturering/motivering-och-forutsattningar-for-rcc-i-samverkans-rekommendationer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kvalitetsregister/2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kvalitetsregister/20.1-cancerregistret2025-05-30 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/kvalitetsindikatorer-och-malnivaer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/referenser2/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/lankar-definitioner-forkortningar/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/lankar-definitioner-forkortningar/internationella-vardprogram/2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/lankar-definitioner-forkortningar/definitioner-och-statistiska-begrepp/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/lankar-definitioner-forkortningar/forkortningar/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/vardprogramgruppen/2020-01-13 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/vardprogramgruppen/adjungerade-forfattare/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/vardprogramgruppen/jav-och-andra-bindningar/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-1.-bilddiagnostik2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-1.-bilddiagnostik/diagnostik-vid-adnexexpansivitet/2023-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-1.-bilddiagnostik/bild--och-funktionsmedicinsk-preoperativ-utredning-vid-misstankt-aggstockscancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-1.-bilddiagnostik/referenser/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt2022-01-20 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/ca-125-vid-epitelial-aggstockscancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/provtagningsvariation-och-felkallor-vid-tolkning-av-analysresultat/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/berakning-av-risk-of-malignancy-index-rmi/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/uppfoljning-med-ca-125/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/ca-125-nivaer-vid-mucinos-aggstockscancer-eller-suspekt-tidig-aggstockscancer/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/kompletterande-tumormarkorer-i-preoperativ-differentialdiagnostik/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/fordjupningslitteratur/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-2.-biomarkorer-bt/referenser/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-3.-infertilitet-efter-cytostatikabehandling2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-3.-infertilitet-efter-cytostatikabehandling/profylax-mot-ovariell-insufficiens/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-3.-infertilitet-efter-cytostatikabehandling/fertilitetsbevarande-tekniker/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-3.-infertilitet-efter-cytostatikabehandling/referenser/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-4.-performance-status-enligt-ecogwhozubrod2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-5.-recist-version-1.12023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-5.-recist-version-1.1/referenser/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-6.-tumorutvardering-enligt-gcig-ca-125-och-recist2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-7.-eras-interventioner-innefattar-i-korthet2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/bilaga-7.-eras-interventioner-innefattar-i-korthet/referenser/2023-03-05 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardprogram/tidigare-revideringar/2025-04-29 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/introduktion/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/introduktion/beskrivningens-syfte-och-malgrupp/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/introduktion/om-aggstockscancer/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/introduktion/flodesschema/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-filterfunktion/2023-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/filterfunktion/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/Valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2023-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/kommunikation-och-delaktighet/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/utredning-och-beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/behandling-och-uppfoljning/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/indikatorer-for-uppfoljning2/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-kvalitet/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/nationellt-vardprogram/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/inklusion-i-standardiserat-vardforlopp/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/utredningsforloppet/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/inklusion-i-kliniska-studier/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/ledtider/2023-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/koordinatorsfunktion/2023-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/samarbete-over-landstingsgranser/2019-11-27 https://kb.localhost:5000/diagnoser/aggstockscancer-epitelial/vardforlopp/arbetsgrupp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/2022-04-07 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/2022-03-23 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/sammanfattning/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/malgrupp/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/vardprogrammets-giltighetsomrade2/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/forandringar-jamfort-med-tidigare-version2/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/vardering-av-det-vetenskapliga-underlaget/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/standardiserat-vardforlopp2/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/inledning/forkortningar-och-begreppsforklaringar/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/mal-med-vardprogrammet/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/incidens/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/tumortyper/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/tumortyper/germinalcellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/tumortyper/konsstrangs--och-stromacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/relativ-overlevnad/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/naturalhistoria-och-orsak/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/naturalhistoria-och-orsak/germinalcellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/epidemiologi/naturalhistoria-och-orsak/konsstrangs--och-stromacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-prevention/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/screening/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/germinalcellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/stromacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/stromacellstumorer/sertoli-leyligcellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/stromacellstumorer/smacellig-aggstockscancer-av-hyperkalcemisk-typ-sccoht/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/stromacellstumorer/von-hippel-lindaus-syndrom-vhl/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/screening-och-arftlighet/arftlighet/stromacellstumorer/gorlin-goltz-syndrom-g-gs/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/symtom-och-tidig-utredning/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/symtom-och-tidig-utredning/symtom-germinalcellstumorer/2025-03-27 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/symtom-och-tidig-utredning/symtom-konsstrangs--och-stromacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/symtom-och-tidig-utredning/ingang-till-standardiserat-vardforlopp2/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/adnexexpansiviteter/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/adnexexpansiviteter/ultraljud/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/adnexexpansiviteter/magnetkamera/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/bild--och-funktionsmedicinsk-och-annan-preoperativ-utredning-vid-misstankt-icke-epitelial-aggstockscancer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/bild--och-funktionsmedicinsk-och-annan-preoperativ-utredning-vid-misstankt-icke-epitelial-aggstockscancer/generella-rekommendationer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/bild--och-funktionsmedicinsk-och-annan-preoperativ-utredning-vid-misstankt-icke-epitelial-aggstockscancer/ovrig-utredning/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/bilddiagnostik/remissinformation/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/germinalcellstumorer-tumormarkorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/germinalcellstumorer-tumormarkorer/alfafetoprotein-afp/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/germinalcellstumorer-tumormarkorer/humant-koriongonadotropin-hcg/2025-03-27 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/germinalcellstumorer-tumormarkorer/anvandning-av-afp-och-hcg-i-serum-for-att-monitorera-behandlingseffekt/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/konsstrangs--och-stromacellstumorer-tumormarkorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/konsstrangs--och-stromacellstumorer-tumormarkorer/fsh-och-ostradiol/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/konsstrangs--och-stromacellstumorer-tumormarkorer/inhibin/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/tumormarkorer-vid-icke-epitelial-aggstockscancer/konsstrangs--och-stromacellstumorer-tumormarkorer/anti-mullerskt-hormon-amh-eller-mis/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/diagnostik/diagnosbesked/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/kategorisering-av-tumoren/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/patologins-roll-i-den-diagnostiska-processen/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/anvisningar-for-hantering-av-provet/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/anvisningar-for-hantering-av-provet/preoperativ-morfologiskcytologisk-diagnostik/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/anvisningar-for-hantering-av-provet/peroperativ-diagnostik-fryssnitt/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/anvisningar-for-hantering-av-provet/operationsmaterial-kvalitetsrutiner/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/anvisningar-for-hantering-av-provet/genetiska-analyser/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/anamnestisk-remissinformation/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/klassificering-av-tumoren/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/histopatologi/innehall-i-ett-pad-utlatande/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/multidisciplinar-konferens-mdk/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-av-germinalcellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-av-germinalcellstumorer/gonadoblastom/2025-03-19 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-av-germinalcellstumorer/germinalcellstumorer-hos-barn/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/lakemebehandling-behandling-av-germinalcellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/lakemebehandling-behandling-av-germinalcellstumorer/primar-lakemedelsbehandling-vid-dysgerminom/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/lakemebehandling-behandling-av-germinalcellstumorer/primar-lakemedelsbehandling-vid-dysgerminom/stadium-i/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/lakemebehandling-behandling-av-germinalcellstumorer/primar-lakemedelsbehandling-vid-dysgerminom/stadium-iiiv/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-av-ovriga-germinalcellstumorer-omogna-teratom-embryonala-karcinom-gulesackstumor-icke-gestationella-koriokarcinom/2025-03-27 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-av-ovriga-germinalcellstumorer-omogna-teratom-embryonala-karcinom-gulesackstumor-icke-gestationella-koriokarcinom/stadium-i/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-av-ovriga-germinalcellstumorer-omogna-teratom-embryonala-karcinom-gulesackstumor-icke-gestationella-koriokarcinom/stadium-ii-iv/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-av-ovriga-germinalcellstumorer-omogna-teratom-embryonala-karcinom-gulesackstumor-icke-gestationella-koriokarcinom/mogna-teratom-med-malign-transformation/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-av-ovriga-germinalcellstumorer-omogna-teratom-embryonala-karcinom-gulesackstumor-icke-gestationella-koriokarcinom/gliomatosis-peritonei/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-av-ovriga-germinalcellstumorer-omogna-teratom-embryonala-karcinom-gulesackstumor-icke-gestationella-koriokarcinom/vaxande-teratomsyndrom/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/granulosacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/granulosacellstumorer/stadium-i/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/granulosacellstumorer/kirurgi-vid-stadium-i/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/granulosacellstumorer/stadium-ib-iv/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/tekom/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/fibrom/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/fibrosarkom/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/sertolileydigcellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/kirurgisk-behandling-vid-konsstrangs--och-stromacellstumorer/sertolileydigcellstumorer/fertilitetsbevarande-kirurgi-vid-granulosacellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-for-konsstrangs--och-stromacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-for-konsstrangs--och-stromacellstumorer/adulta-granulosacellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/primar-lakemedelsbehandling-for-konsstrangs--och-stromacellstumorer/sertoli-leydigcellstumorer2/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/behandling-ovriga-ovanliga-icke-epiteliala-aggstockstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/behandling-ovriga-ovanliga-icke-epiteliala-aggstockstumorer/smacellig-cancer-hyperkalcemisk-typ/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/behandling-ovriga-ovanliga-icke-epiteliala-aggstockstumorer/smacellig-cancer-hyperkalcemisk-typ/kirurgisk-behandling/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/behandling-ovriga-ovanliga-icke-epiteliala-aggstockstumorer/smacellig-cancer-hyperkalcemisk-typ/lakemedelsbehandling/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/behandling-ovriga-ovanliga-icke-epiteliala-aggstockstumorer/smacellig-cancer-pulmonell-typ/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/behandling-ovriga-ovanliga-icke-epiteliala-aggstockstumorer/storcellig-neuroendokrin-cancer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/bepstandardbehandling-av-icke-epiteliala-aggstockstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/bepstandardbehandling-av-icke-epiteliala-aggstockstumorer/cisplatin/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/bepstandardbehandling-av-icke-epiteliala-aggstockstumorer/etoposid/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/bepstandardbehandling-av-icke-epiteliala-aggstockstumorer/bleomycin/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/primar-behandling/bepstandardbehandling-av-icke-epiteliala-aggstockstumorer/behandling-av-bleomycininducerad-pneumonit-bip/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/tumorutvardering/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/prognostiska-faktorer-vid-granulosacellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/uppfoljning/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/utredning-av-aterfall/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/behandling-av-aterfall/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/behandling-av-aterfall/aterfallsbehandling-vid-germinalcellstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/behandling-av-aterfall/stralbehandling-vid-aterfall/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/tumorutvardering-uppfoljning-och-behandling-av-aterfall/behandling-av-aterfall/aterfallsbehandling-vid-konsstrangstumorer/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/understodjande-vard/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/understodjande-vard/hormonsubstitution-mht-efter-avslutad-primarbehandling/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/kontaktsjukskoterska/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/min-vardplan/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/aktiva-overlamningar/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/aterkommande-behovsbedomning-for-patienter-och-narstaende/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/grundlaggande-och-specialiserad-rehabilitering/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/lopande-cancerrehabilitering/bedomningsinstrument/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/fatigue/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/fertilitet/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/nutrition/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/psykosocialt-stod/2025-03-17 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/sexuell-halsa/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/sexuell-halsa/samtal-om-sexualitet/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad/smarta/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/prehabilitering/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/preoperativ-omvardnad/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/preoperativ-omvardnad/tobak-och-alkohol/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/preoperativ-omvardnad/fysisk-aktivitet/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/preoperativ-omvardnad/nutrition/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/postoperativ-omvardnad/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-kirurgisk-behandling/postoperativ-omvardnad/uppfoljningssamtal/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/benmargspaverkan/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/fatigue/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/hosta-och-andnod/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/hud-och-naglar/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/haravfall-alopeci/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/horsel/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/illamaende/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/kognitiv-paverkan/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/muskelsmarta-och-ledvark/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/perifera-neuropatier/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/slemhinnebiverkningar/2025-03-27 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/smakforandringar/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/omvardnad-och-rehabilitering2/omvardnad-vid-onkologisk-behandling/cytostatikabehandling/tarmpaverkan-eller-risk-for-tarmpaverkan/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/egenvard2/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/egenvard2/levnadsvanor/2025-03-27 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/egenvard2/levnadsvanor/rokning/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/egenvard2/levnadsvanor/alkohol/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/egenvard2/levnadsvanor/fysisk-aktivitet/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/egenvard2/komplementar-och-integrativ-medicin/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/fertilitet-graviditet-och-aggstockscancer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/fertilitet-graviditet-och-aggstockscancer/fertilitetsbevarande-kirurgi/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/fertilitet-graviditet-och-aggstockscancer/fertilitetsbevarande-atgarder/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/fertilitet-graviditet-och-aggstockscancer/fertilitet-efter-cytostatikabehandling/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/fertilitet-graviditet-och-aggstockscancer/cancer-under-graviditet/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/palliativ-vard-och-insatser2/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/underlag-for-nivastrukturering/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/kvalitetsregister-och-indikatorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/kvalitetsregister-och-indikatorer/cancerregistret/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/referenser/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/relevanta-lankar/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/vardprogramgruppen/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/vardprogramgruppen/vardprogramgruppens-sammansattning/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/vardprogramgruppen/vardprogramgruppens-medlemmar/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/vardprogramgruppen/adjungerade-forfattare/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/vardprogramgruppen/stodteam/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/vardprogramgruppen/vardprogrammets-forankring/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/dysgerminom/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/omogna-teratom/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/gulesackstumor/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/koriokarcinom/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/granulosacellstumorer/2025-03-14 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/fibrom-fibrotekom-och-tekom/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/sertoli-leydig-tumorer/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/metastaser-till-ovariet/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardprogram/bilaga-1-ultraljudsdiagnostik-icke-epiteliala-aggstockscancer/referenser/2025-03-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/2020-01-28 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/introduktion/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/introduktion/beskrivningens-syfte-och-malgrupp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/introduktion/om-aggstockscancer/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/introduktion/flodesschema/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-filterfunktion/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/filterfunktion/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/Valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/ingang-till-standardiserat-vardforlopp2/kommunikation-och-delaktighet/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/utredning-och-beslut-om-behandling/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/utredning-och-beslut-om-behandling/multidisciplinar-konferens-mdk/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/utredning-och-beslut-om-behandling/omvardnad-rehabilitering-och-understodjande-vard/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/utredning-och-beslut-om-behandling/kommunikation-och-delaktighet/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/behandling-och-uppfoljning/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/indikatorer-for-uppfoljning2/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-kvalitet/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/nationellt-vardprogram/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/inklusion-i-standardiserat-vardforlopp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/utredningsforloppet/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/inklusion-i-kliniska-studier/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/ledtider/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/koordinatorsfunktion/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/generellt-om-standardiserade-vardforlopp/samarbete-over-landstingsgranser/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer-icke-epitelial/vardforlopp/arbetsgrupp/2019-12-18 https://kb.localhost:5000/diagnoser/aggstockscancer/2022-04-07 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/2022-03-23 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/introduktion/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/introduktion/forandringar-jamfort-med-tidigare-version/2024-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/ingang-till-standardiserat-vardforlopp2/2022-03-22 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/ingang-till-standardiserat-vardforlopp2/misstanke/2024-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/ingang-till-standardiserat-vardforlopp2/filterfunktion/2024-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/ingang-till-standardiserat-vardforlopp2/Valgrundad-misstanke--kriterier-for-start-av-utredning-enligt-standardiserat-vardforlopp/2024-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/ingang-till-standardiserat-vardforlopp2/remiss-till-utredning-vid-valgrundad-misstanke/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/ingang-till-standardiserat-vardforlopp2/kommunikation-och-delaktighet/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/utredning-och-beslut-om-behandling/2022-03-22 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/utredning-och-beslut-om-behandling/flodesschema-for-vardforloppet/2025-01-07 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/utredning-och-beslut-om-behandling/utredningsforlopp2/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/utredning-och-beslut-om-behandling/beslut-om-behandling2/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/indikatorer-for-uppfoljning2/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/indikatorer-for-uppfoljning2/ledtider-for-nationell-uppfoljning/2024-12-19 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/indikatorer-for-uppfoljning2/ingaende-ledtider/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/indikatorer-for-uppfoljning2/indikatorer-for-nationell-uppfoljning/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/arbetsgrupp/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-start-av-svf/hantering-av-recidiv-aterfall/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-vid-overflyttning-mellan-regioner/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-vid-start-av-behandling/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/obligatorisk-kod-for-avslut/koder-nar-svf-avslutas-av-annan-orsak/2024-11-08 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/frivilliga-koder-for-lokal-uppfoljning/2024-11-11 https://kb.localhost:5000/diagnoser/aggstockscancer/vardforlopp/bilaga-1-kodningsvagledning/forandringar-i-kodningsvagledningen/2024-11-11 https://kb.localhost:5000/vardprogram/2022-02-10 https://kb.localhost:5000/vardforlopp/2022-02-10 https://kb.localhost:5000/stoddokument-gammal/2024-05-25 https://kb.localhost:5000/uppdateringar/2022-04-07 https://kb.localhost:5000/uppdateringar/vardprogram/2022-02-10 https://kb.localhost:5000/uppdateringar/vardforlopp/2022-02-10 https://kb.localhost:5000/uppdateringar/regimbiblioteket/2022-02-10 https://kb.localhost:5000/basfakta/2022-02-10 https://kb.localhost:5000/basfakta/abemaciklib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/abirateron-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/afatinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/aflibercept-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/akalabrutinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/alektinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/alemtuzumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/alpelisib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/amivantamab-intravenos-infusion/2023-12-08 https://kb.localhost:5000/basfakta/amsakrin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/anastrozol-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/apalutamid-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/aprepitant-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/anagrelid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/atropin-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/atropin-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/belantamab-mafodotin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/cardioxane-dexrazoxan-mot-hjarttoxicitet-intravenos-infusion/2025-01-10 https://kb.localhost:5000/basfakta/cyanokobalamin-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/cyanokobalamin-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/cyanokobalamin-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/cytarabin-intratekal-injektion-liposomalt/2022-02-10 https://kb.localhost:5000/basfakta/daunorubicin-intravenos-infusion-liposomalt/2022-02-10 https://kb.localhost:5000/basfakta/dexrazoxan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/fosaprepitant-intravenos-infusion2/2022-02-24 https://kb.localhost:5000/basfakta/kaliumklorid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/kladribin-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/krisantaspas-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/letrozol-per-oral-tablett2/2022-02-24 https://kb.localhost:5000/basfakta/mifamurtid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/natriumklorid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/natriumklorid-intravenos-infusion2/2022-02-24 https://kb.localhost:5000/basfakta/natriumvatekarbonat-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/natriumvatekarbonat-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/necitumumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/ofatumumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/olaparib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/olaratumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/pemetrexed-intravenos-infusion2/2022-02-24 https://kb.localhost:5000/basfakta/radiumra-223diklorid-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/ranitidin-intravenos-infusion/2022-02-24 https://kb.localhost:5000/basfakta/ranitidin-intravenos-injektion/2022-02-24 https://kb.localhost:5000/basfakta/ranitidin-per-oral-tablett/2022-02-24 https://kb.localhost:5000/basfakta/tropisetron-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/tropisetron-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/vinblastin-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/arseniktrioxid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/atezolizumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/atezolizumab-subkutan-injektion/2024-03-06 https://kb.localhost:5000/basfakta/avelumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/axitinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/azacitidin-subkutan-injektion-suspension/2022-02-10 https://kb.localhost:5000/basfakta/bendamustin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/betametason-intravenos-infusion/2024-04-22 https://kb.localhost:5000/basfakta/betametason-intravenos-injektion/2024-04-22 https://kb.localhost:5000/basfakta/betametason-per-oral-tablett/2024-04-22 https://kb.localhost:5000/basfakta/bevacizumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/bexaroten-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/bikalutamid-per-oral-tablett/2022-04-01 https://kb.localhost:5000/basfakta/binimetinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/bleomycin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/blinatumomab-intravenos-infusion-barbar-infusionspump/2022-02-10 https://kb.localhost:5000/basfakta/bortezomib-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/bortezomib-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/bosutinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/brentuximab-vedotin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/brigatinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/buserelin-subkutan-injektion/2023-03-03 https://kb.localhost:5000/basfakta/busulfan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/busulfan-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/cemiplimab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/ceritinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/cetuximab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/cisplatin-intraperitoneal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/cisplatin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/cyklofosfamid-peroral-oral-losning/2024-07-22 https://kb.localhost:5000/basfakta/cyklofosfamid-monohydrat-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/cyklofosfamid-monohydrat-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/cytarabin-intratekal-injektion/2022-02-10 https://kb.localhost:5000/basfakta/cytarabin-intravenos-infusion/2023-05-05 https://kb.localhost:5000/basfakta/cytarabin-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/cytarabin-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/dabrafenib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/dakarbazin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/dakomitinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/daktinomycin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/daktinomycin-intravenos-injektion/2023-05-27 https://kb.localhost:5000/basfakta/daratumumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/daratumumab-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/darolutamid-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/dasatinib-vattenfri-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/daunorubicin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/daunorubicincytarabin-intravenos-infusion-liposomalt/2023-06-20 https://kb.localhost:5000/basfakta/decitabin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/degarelix-subkutan-injektion/2023-04-20 https://kb.localhost:5000/basfakta/denosumab-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/dexametason-per-oral-losning/2024-04-22 https://kb.localhost:5000/basfakta/dexametason-per-oral-tablett/2024-04-22 https://kb.localhost:5000/basfakta/dexrazoxan-intravenos-infusion2/2025-06-18 https://kb.localhost:5000/basfakta/dinutuximab-beta-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/docetaxel-vattenfri-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/docetaxel-vattenfri-intravesikal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/dostarlimab-intravenos-infusion/2022-09-11 https://kb.localhost:5000/basfakta/doxorubicin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/doxorubicin-intravenos-infusion-barbar-infusionspump/2022-02-10 https://kb.localhost:5000/basfakta/doxorubicin-intravenos-infusion-liposomalt/2022-02-10 https://kb.localhost:5000/basfakta/durvalumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/elranatamab-subkutan-injektion/2024-08-23 https://kb.localhost:5000/basfakta/enfortumab-vedotin-intravenos-infusion/2022-06-30 https://kb.localhost:5000/basfakta/enkorafenib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/entrektinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/enzalutamid-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/epirubicin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/epirubicin-intravesikal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/epkoritamab-subkutan-injektion/2025-02-08 https://kb.localhost:5000/basfakta/erdafitinib-peroral-tablett/2025-06-18 https://kb.localhost:5000/basfakta/eribulin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/erlotinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/estramustinnatriumfosfat-peroral-kapsel/2023-03-29 https://kb.localhost:5000/basfakta/etoposid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/etoposid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/etoposidfosfat-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/etoposidfosfat-intravenos-infusion-barbar-infusionspump/2022-02-10 https://kb.localhost:5000/basfakta/everolimus-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/exemestan-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/filgrastim-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/fludarabin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/fludarabin-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/fluorouracil-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/fluorouracil-intravenos-infusion-barbar-infusionspump/2022-02-10 https://kb.localhost:5000/basfakta/fluorouracil-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/fosaprepitant-intravenos-infusion/2024-04-22 https://kb.localhost:5000/basfakta/fulvestrant-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/furosemid-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/furosemid-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/gefitinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/gemcitabin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/gemcitabin-intravesikal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/gemtuzumabozogamicin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/gilteritinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/glofitamab-intravenos-infusion/2024-05-24 https://kb.localhost:5000/basfakta/goserelin-subkutan-injektion/2022-03-11 https://kb.localhost:5000/basfakta/granisetron-intravenos-injektion/2024-04-22 https://kb.localhost:5000/basfakta/granisetron-per-oral-tablett/2024-04-22 https://kb.localhost:5000/basfakta/hydrokortison-intravenos-injektion/2023-01-06 https://kb.localhost:5000/basfakta/hydroxikarbamid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/hydroxokobalamin-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/hydroxokobalamin-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/ibrutinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/idarubicin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/idarubicin-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/idelalisib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/ifosfamid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/imatinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/infliximab-intravenos-infusion/2025-06-18 https://kb.localhost:5000/basfakta/infusion-av-stamceller-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/inotuzumabozogamicin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/ipilimumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/irinotekan-intraperitoneal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/irinotekan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/irinotekan-intravenos-infusion-liposomalt/2022-02-10 https://kb.localhost:5000/basfakta/isatuximab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/ixazomib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/kabazitaxel-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/kabozantinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/kabozantinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/kalciumfolinat-vattenfritt-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/kalciumfolinat-vattenfritt-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/kalciumfolinat-vattenfritt-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/kapecitabin-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/karboplatin-intraperitoneal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/karboplatin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/karfilzomib-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/karmustin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/ketokonazol-peroral-tablett/2023-03-29 https://kb.localhost:5000/basfakta/kladribin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/klemastin-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/klemastin-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/klofarabin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/klorambucil-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/kobimetinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/krizotinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/lanreotid-subkutan-injektion/2022-05-11 https://kb.localhost:5000/basfakta/lapatinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/larotrektinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/larotrektinib-per-oral-oral-losning/2022-06-10 https://kb.localhost:5000/basfakta/lenalidomid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/lenvatinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/letrozol-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/leuprorelin-subkutan-injektion/2023-02-21 https://kb.localhost:5000/basfakta/lomustin-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/lonkastuximabtesirin-intravenos-infusion/2024-03-06 https://kb.localhost:5000/basfakta/lorazepam-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/lorlatinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/medroxiprogesteronacetat-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/medroxiprogesteronacetat-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/meklozin-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/melfalan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/melfalan-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/merkaptopurin-monohydrat-per-oral-losning/2022-02-10 https://kb.localhost:5000/basfakta/merkaptopurin-monohydrat-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/mesna-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/mesna-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/mesna-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/metoklopramid-intravenos-infusion/2024-04-22 https://kb.localhost:5000/basfakta/metoklopramid-intravenos-injektion/2024-04-22 https://kb.localhost:5000/basfakta/metoklopramid-per-rektum-suppositorium/2024-04-22 https://kb.localhost:5000/basfakta/metoklopramid-per-oral-tablett/2024-04-22 https://kb.localhost:5000/basfakta/metotrexat-via-dosa-intraventrikular-injektion/2024-07-22 https://kb.localhost:5000/basfakta/metotrexat-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/metotrexat-intratekal-injektion/2022-02-10 https://kb.localhost:5000/basfakta/metotrexat-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/metotrexat-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/metylprednisolon-intravenos-injektion/2022-02-10 https://kb.localhost:5000/basfakta/midostaurin-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/mitomycin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/mitomycin-intravesikal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/mitotan-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/mitoxantron-intraperikardiell-instillation/2022-02-10 https://kb.localhost:5000/basfakta/mitoxantron-intraperitoneal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/mitoxantron-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/mogamulizumab-intravenos-infusion/2022-04-20 https://kb.localhost:5000/basfakta/mosunetuzumab-l01fx25-intravenos-infusion/2024-11-22 https://kb.localhost:5000/basfakta/mycobacterium-bovis-bacillus-calmette-guerin-bcg-rivm-deriverad-stam-1173-p2-levande-forsvagad-intravesikal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/mycobacterium-bovis-bacillus-calmette-guerin-bcg-stam-tice-levande-forsvagad-intravesikal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/natriumtiosulfat-intravenos-infusion/2025-06-20 https://kb.localhost:5000/basfakta/nelarabin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/neratinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/netupitant-palonosetron-per-oral-kapsel/2024-04-22 https://kb.localhost:5000/basfakta/nilotinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/nintedanib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/niraparib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/niraparib-peroral-tablett/2023-02-15 https://kb.localhost:5000/basfakta/nivolumab-relatlimab-opdualag-intravenos-infusion/2025-03-12 https://kb.localhost:5000/basfakta/nivolumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/obinutuzumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/oktreotid-subkutan-injektion/2022-11-01 https://kb.localhost:5000/basfakta/olanzapin-per-oral-tablett/2024-04-22 https://kb.localhost:5000/basfakta/olaparib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/ondansetron-intravenos-infusion/2024-04-22 https://kb.localhost:5000/basfakta/ondansetron-intravenos-injektion/2024-04-22 https://kb.localhost:5000/basfakta/ondansetron-per-oral-tablett/2024-04-22 https://kb.localhost:5000/basfakta/osimertinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/oxaliplatin-intraperitoneal-instillation/2022-02-10 https://kb.localhost:5000/basfakta/oxaliplatin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/paklitaxel-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/paklitaxel-intravenos-infusion-micellar/2022-02-10 https://kb.localhost:5000/basfakta/paklitaxel-intravenos-infusion-nab/2022-02-10 https://kb.localhost:5000/basfakta/palbociklib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/palbociklib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/palonosetron-intravenos-injektion/2024-04-22 https://kb.localhost:5000/basfakta/palonosetron-per-oral-kapsel/2024-04-22 https://kb.localhost:5000/basfakta/panitumumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/panobinostat-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/pazopanib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/pegaspargas-intramuskular-injektion/2022-02-10 https://kb.localhost:5000/basfakta/pegaspargas-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/pegfilgrastim-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/pembrolizumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/pemetrexed-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/pemigatinib-peroral-tablett/2024-10-15 https://kb.localhost:5000/basfakta/pertuzumab-trastuzumab-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/pertuzumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/polatuzumab-vedotin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/pomalidomid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/ponatinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/pralsetinib-per-oral-kapsel/2022-05-12 https://kb.localhost:5000/basfakta/prednisolon-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/prednisolonnatriumsuccinat-intratekal-injektion/2022-02-10 https://kb.localhost:5000/basfakta/prednison-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/prokarbazin-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/propranolol-peroral-tablett/2022-11-08 https://kb.localhost:5000/basfakta/radiumra-223diklorid-intravenos-injektion2/2023-08-11 https://kb.localhost:5000/basfakta/ramucirumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/rasburikas-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/regorafenib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/ribociklib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/rituximab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/rituximab-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/rukaparib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/ruxolitinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/sacituzumabgovitekan-intravenos-infusion/2022-07-02 https://kb.localhost:5000/basfakta/selperkatinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/sirolimus-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/sonidegib-peroral-kapsel/2024-07-22 https://kb.localhost:5000/basfakta/sorafenib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/sotorasib-peroral-tablett/2022-09-05 https://kb.localhost:5000/basfakta/streptozocin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/sunitinib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/tafasitamab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/talazoparib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/talidomid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/tamoxifen-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/tebentafusp-intravenos-infusion/2024-11-13 https://kb.localhost:5000/basfakta/tegafur-gimeracil-oteracil-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/teklistamab-subkutan-injektion/2024-03-01 https://kb.localhost:5000/basfakta/temozolomid-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/temozolomid-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/temsirolimus-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/tepotinib-peroral-tablett/2023-05-16 https://kb.localhost:5000/basfakta/tioguanin-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/tiotepa-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/tivozanib-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/tocilizumab-intravenos-infusion/2025-07-04 https://kb.localhost:5000/basfakta/topotekan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/topotekan-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/toremifen-peroral-tablett/2024-05-24 https://kb.localhost:5000/basfakta/trabektedin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/trametinib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/trastuzumab-deruxtekan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/trastuzumab-emtansin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/trastuzumab-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/trastuzumab-subkutan-injektion/2022-02-10 https://kb.localhost:5000/basfakta/tremelimumab-intravenos-infusion/2023-08-11 https://kb.localhost:5000/basfakta/treosulfan-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/tretinoin-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/trifluridin-tipiracilhydroklorid-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/triptorelin-intramuskular-injektion/2023-04-21 https://kb.localhost:5000/basfakta/trofosfamid-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/tukatinib-per-oral-tablett/2022-05-12 https://kb.localhost:5000/basfakta/vandetanib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/vedolizumab-intravenos-infusion/2025-07-12 https://kb.localhost:5000/basfakta/vemurafenib-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/venetoklax-per-oral-tablett/2022-02-10 https://kb.localhost:5000/basfakta/vinblastin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/vindesin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/vinflunin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/vinkristin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/vinkristin-intravenos-infusion-barbar-infusionspump/2022-02-10 https://kb.localhost:5000/basfakta/vinorelbin-intravenos-infusion/2022-02-10 https://kb.localhost:5000/basfakta/vinorelbin-per-oral-kapsel/2022-02-10 https://kb.localhost:5000/basfakta/vismodegib-peroral-kapsel/2024-05-24 https://kb.localhost:5000/basfakta/zanubrutinib-peroral-kapsel/2023-10-03 https://kb.localhost:5000/basfakta/zoledronsyra-vattenfri-intravenos-infusion/2024-07-22 https://kb.localhost:5000/lakemedelsregimer/2022-04-07 https://kb.localhost:5000/lakemedelsregimer/akut-lymfatisk-leukemi-all/2024-03-19 https://kb.localhost:5000/lakemedelsregimer/akut-lymfatisk-leukemi-all/nopho-all-2008-hr-18-45-ar-induktion/2024-03-19 https://kb.localhost:5000/lakemedelsregimer/akut-lymfatisk-leukemi-all/nopho-all-2008-sr-och-ir-18-45-ar-induktion/2024-03-19 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-ace/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-induktion-atraato-lag--och-intermediar-risk/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-konsolidering-123-lag--och-intermediar-risk/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-konsolidering-4-lag--och-intermediar-risk/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-preinduktion-hogrisk/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-a-5/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-ace/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-d-idac/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-da-25/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-da-34/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-da-35/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-fa-ida/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-ham/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2012-idac/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-a-5/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-a-5-reducerad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-ace/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-da-25/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-da-25-reducerad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-da-34-reducerad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-da-35/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-fa-ida/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2014-ham/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-ham/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-induktion-enligt-aida-hogrisk/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-konsolidering-i-enligt-aida-protokoll/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-konsolidering-ii-enligt-aida-protokoll/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-konsolidering-iii-enligt-aida-protokoll/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-underhallsbehandling-kur-1-6-enligt-aida-protokoll/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/apl-underhallsbehandling-kur-7-enligt-aida-protokoll/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/azacitidin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/azacitidin-venetoklax-kur-1/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/azacitidin-venetoklax-kur-2-osv/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-a-5/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/cytarabin--midostaurin/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-a-5-reducerad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-da-34-reducerad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-da-25/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/cytarabin-daunorubicin-52-d--midostaurin/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-da-25-reducerad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-da-35/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/cytarabin-daunorubicin-53-d--midostaurin/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-da-35-med-mylotarg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/fav-ida-induktion/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/aml2019-fa-ida/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/akut-myeloisk-leukemi-aml/gilteritinib-singel/2023-07-18 https://kb.localhost:5000/lakemedelsregimer/analcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/analcancer/cisplatin-mitomycin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/analcancer/fluorouracil-4-dygnsinfusion-mitomycin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/analcancer/kapecitabin-mitomycin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/analcancer/karboplatin-paklitaxel-dag-1-8-15-28-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/analcancer/karboplatin-paklitaxel-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/antiemetika/2024-05-13 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-1/2025-02-21 https://kb.localhost:5000/lakemedelsregimer/antiemetika/ae-steg-2a-1-dag.-ondansetron-olanzapin2024-09-17 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2a-2dgr/2025-02-08 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2a-3d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2a-4d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2a-5d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2b-1d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2b-2d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2b-3d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2b-4d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-2b-5d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-3-1d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-3-2d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-3-3d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-3-4dgr/2025-02-08 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-3-5d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-4-1d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-4-2d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-4-3d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-4-4d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-4-5d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/ae-steg-5a-1-dag.-palonostetron-betametason-olanzapin2024-09-17 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5a-2d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5a-3d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5a-4d/2025-02-08 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5a-5d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/steg-5b-1-dag/2024-03-19 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5b-2d/2025-02-08 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5b-3d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5b-4d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-5b-5d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/steg-6-1-dag/2024-03-19 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-6-2dgr/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-6-3d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-6-4d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-6-5d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-7-1d/2025-02-18 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-7-2d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-7-3d/2025-02-21 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-7-4d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/antiemetika/forebyggande-mot-illamaende-steg-7-5d/2025-02-20 https://kb.localhost:5000/lakemedelsregimer/brostcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/brostcancer/abemaciklib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/alpelisib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/anastrozol/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/brostcancer/atezolizumab---paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/bevacizumab2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/bevacizumab/2025-01-27 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-metotrexat-po2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-75-dose-dense2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/gemcitabin-karboplatin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-iv-pertuzumab-laddningsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-iv-pertuzumab-underhallsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-sc-pertuzumab-laddningsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-sc-pertuzumab-underhallsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/atezolizumab--nab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/bevacizumab-paklitaxel-28-d/2025-01-29 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-docetaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-docetaxel-doxorubicin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-metotrexat-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/cyklofosfamid-metotrexat-fluorouracil/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-100/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-75-dose-dense/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-80/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-epirubicin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/docetaxel-karboplatin-auc-5/2023-06-08 https://kb.localhost:5000/lakemedelsregimer/brostcancer/doxorubicin-liposomalt/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ec-100/2024-03-01 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ec-60/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ec-75/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ec-90/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ec-90-dose-dense/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/epirubicin-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/epirubicin-kapecitabin-cyklofosfamid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/eribulin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/everolimus-exemestan/2022-11-12 https://kb.localhost:5000/lakemedelsregimer/brostcancer/exemestan/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/brostcancer/fec-100/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/fec-60/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/fec-75/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/fulvestrant/2024-12-17 https://kb.localhost:5000/lakemedelsregimer/brostcancer/gemcitabin-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/gemcitabin-karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/goserelin-zoladex/2024-12-17 https://kb.localhost:5000/lakemedelsregimer/brostcancer/kapecitabin-1000/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/kapecitabin-1250/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/kapecitabin-vinorelbin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/karboplatin-paklitaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/karboplatin-paklitaxel-veckovis-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/karboplatin-veckovis/2023-03-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/lapatinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/letrozol/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/brostcancer/nab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/nab-paklitaxel-veckovis/2024-01-31 https://kb.localhost:5000/lakemedelsregimer/brostcancer/neratinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/olaparib-tablett/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/paklitaxel-veckovis-21-dagar-kontinuerlig/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/paklitaxel-veckovis-21-dagar-med-paus/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/paklitaxel-veckovis-28-dagar-med-paus/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/palbociklib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/palbociklib---tablett/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab--karboplatin-paklitaxel-veckovis/2022-07-02 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-var-6e-vecka-ec-90-dd/2024-01-31 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-ec-90/2022-07-02 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-karboplatin-auc-5-nabpaklitaxel/2024-07-02 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-karboplatin-auc-2--gemcitabin/2022-03-23 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-karboplatin-auc-5--gemcitabin/2022-03-23 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-nab-paklitaxel-veckovis-21-dagar-med-paus/2022-03-23 https://kb.localhost:5000/lakemedelsregimer/brostcancer/pembrolizumab-paklitaxel-veckovis-21-dagar-med-paus/2022-03-23 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ribociklib-400/2025-01-11 https://kb.localhost:5000/lakemedelsregimer/brostcancer/ribociklib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/sacituzumabgovitekan/2022-07-02 https://kb.localhost:5000/lakemedelsregimer/brostcancer/talazoparib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/tamoxifen/2022-04-06 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-pertuzumab-sc-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-pertuzumab-sc-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-emtansine/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-iv-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-iv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-iv-pertuzumab-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-iv-pertuzumab-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-sc/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-sc-pertuzumab-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-sc-pertuzumab-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-deruxtekan/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-kapecitabin-tukatinib-laddningsdos-kur-1/2022-07-02 https://kb.localhost:5000/lakemedelsregimer/brostcancer/trastuzumab-kapecitabin-tukatinib-underhallsdos-kur-2-osv/2022-07-02 https://kb.localhost:5000/lakemedelsregimer/brostcancer/vinorelbin-iv-25-och-po-60-kontinuerlig/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/vinorelbin-iv-30/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/vinorelbin-iv-30-och-po-80-med-paus/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/brostcancer/vinorelbin-po-60-veckovis-21-dagar-kontinuerlig/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/gemcitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/gemcitabin-kapecitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/gemcitabin-nab-paklitaxel2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/folfirinox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/gemcitabin-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/gemcitabin-nab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/bukspottkortelcancer/mfolfirinox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/2023-05-04 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/capox/2024-07-02 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/cisplatin-gemcitabin/2023-05-04 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/durvalumab-cisplatin-gemcitabin/2024-09-19 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/fliri/2024-08-23 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/flox/2024-08-23 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/flv/2024-08-23 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/folfiri/2024-08-23 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/folfox/2024-08-23 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/gemcitabin-kapecitabin/2023-05-04 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/gemcitabin-oxaliplatin/2023-05-04 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/kapecitabin/2023-05-04 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/pembrolizumab-cisplatin-gemcitabin/2024-07-02 https://kb.localhost:5000/lakemedelsregimer/gallblase--och-gallvagscancer/teysuno-tegafur-gimeracil-oteracil/2024-07-02 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/bevacizumab-lomustin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/bevacizumab-monoterapi/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/karmustin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/lomustin-monoterapi2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/pcv2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-monoterapi-underhallsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-konkomitant-med-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-monoterapi-startdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/bevacizumab-lomustin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/ccv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/karbo-ei/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/karmustin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/lomustin-monoterapi/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/lomustin-temozolomid-konkomitant-med-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/pcv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/pei/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-konkomitant-med-stralbehandling-40-gy-perry/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-konkomitant-med-stralbehandling-60-gy-stupp/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-monoterapi-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/hjarntumorer/temozolomid-monoterapi-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cap/2024-11-05 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-infor-stralbehandling-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-veckovis-under-stralbehandling-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-cisplatin-fluorouracil-4-dygn-kur-1-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-cisplatin-fluorouracil-4-dygn-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-cisplatin-fluorouracil-5-dygn-kur-1-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-cisplatin-fluorouracil-5-dygn-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-karboplatin-fluorouracil-4-dygn-kur-1-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-karboplatin-fluorouracil-4-dygn-kur-2-osv.-underhallsdos2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-karboplatin-paklitaxel-kur-1-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cetuximab-karboplatin-paklitaxel-kur-2-osv.-underhallsbehandling2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-100-var-3e-vecka-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-80-var-3e-vecka-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-veckovis-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-veckovis-under-stralbehandling-50-mg-fast-dos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-docetaxel/2024-09-05 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-etoposid-iv-dag-1-3/2023-11-23 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-etoposid-iv-dag-1-kapslar-dag-2-3/2023-11-23 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-fluorouracil-4-dygn/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-fluorouracil-5-dygn/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/cisplatin-kapecitabin/2023-05-12 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/docetaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/docetaxel-veckovis-konkomitant-med-stralbehandling/2024-09-03 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/docetaxel-cisplatin-fluorouracil-4-dygn/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/docetaxel-karboplatin-fluorouracil-4-dygn/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/gemcitabin/2023-05-11 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/kapecitabin/2023-05-11 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin---etoposid-iv-dag-1---3/2023-12-12 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin---etoposid-iv-dag-1-kapslar-dag-2-3/2023-11-23 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin-auc-6-paklitaxel-200/2023-05-12 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin-fluorouracil-4-dygn/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin-fluorouracil-5-dygn/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin-kapecitabin/2023-05-12 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/karboplatin-veckovis-under-stralbehandling/2023-05-12 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/metotrexat-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/nivolumab-var-4e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/paklitaxel-veckovis-21-dagar-kontinuerlig/2023-05-11 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pax/2024-11-05 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pembrolizumab-cis-fluorouracil/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pembrolizumab-karboplatin-auc-6-paklitaxel-200/2023-11-23 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pembrolizumab-karboplatin-auc5--paklitaxel-175/2023-11-23 https://kb.localhost:5000/lakemedelsregimer/huvud--och-halscancer/pembrolizumab-karboplatin-fluorouracil/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/akalabrutinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/akalabrutinib-obinutuzumab-kur-2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/akalabrutinib-obinutuzumab-kur-3-7/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/fc-intravenos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/fc-peroral/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/ibrutinib2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/klorambucil-14-dagar-1-dos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/obinutuzumab-klorambucil-28-dagar-klorambucil-2-doser-kur-1-startdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/obinutuzumab-klorambucil-28-dagar-klorambucil-2-doser-kur-2-osv-underhallsdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/obinutuzumab-venetoklax-kur-1-startdoser/2024-09-26 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/obinutuzumab-venetoklax-kur-2/2024-09-26 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/obinutuzumab-venetoklax-kur-3-6/2024-09-26 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/ofatumumab-klorambucil-28-dagar-klorambucil-7-doser-kur-1-startdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/ofatumumab-klorambucil-28-dagar-klorambucil-7-doser-kur-2-osv-underhallsdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-f-intravenos-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-f-intravenos-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-fc-intravenos-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-fc-intravenos-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-fc-peroral-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-fc-peroral-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-klorambucil-kur-1-startdos/2022-02-25 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-klorambucil-kur-2-osv-underhallsdos/2022-02-25 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/ibrutinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-bendamustin-70-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-bendamustin-70-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-bendamustin-90-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-bendamustin-90-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-cyklofosfamid-dexametason-14-dagar-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-cyklofosfamid-dexametason-14-dagar-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-cyklofosfamid-dexametason-28-dagar-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-cyklofosfamid-dexametason-28-dagar-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-idelalisib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-venetoklax-kur-1-startdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/rituximab-venetoklax-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/venetoklax/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/venetoklax-400---obinituzumab-1000/2024-09-26 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/venetoklax-400-obinutuzumab-start/2024-09-26 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/venetoklax-dostitrering/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/kronisk-lymfatisk-leukemi-kll/zanubrutinib/2024-01-24 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/atezolizumab-bevacizumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/durvalumab-var-4e-vecka/2024-10-05 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/durvalumab-tremelimumab/2024-10-05 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/lenvatinib/2023-04-29 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/ramucirumab/2025-02-13 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/regorafenib/2025-02-13 https://kb.localhost:5000/lakemedelsregimer/levercellscancer/sorafenib/2023-04-29 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/bevacizumab-15-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/cemiplimab/2023-03-14 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/cisplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/cisplatin-veckovis-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/cisplatin-etoposid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/cisplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/cisplatin-topotekan-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/paklitaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/paklitaxel-topotekan/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/pembrolizumab-var-3e-vecka/2022-10-13 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/pembrolizumab-var-6e-vecka/2022-10-13 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/pembrolizumab-cisplatin-paklitaxel/2022-11-11 https://kb.localhost:5000/lakemedelsregimer/livmoderhals--och-vaginalcancer/pembrolizumab-karboplatin-paklitaxel/2022-10-13 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/doxorubicin-liposomalt-caelyx2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/cisplatin-doxorubicin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/dostarlimab-monoterapi--kur-1-4/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/dostarlimab-monoterapi-kur-5-osv/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/dostarlimab-karboplatin-paklitaxel/2024-03-14 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/karboplatin-doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/paklitaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/pembrolizumab-var-3e-vecka-lenvatinib/2023-05-11 https://kb.localhost:5000/lakemedelsregimer/livmoderkroppscancer/pembrolizumab-var-6e-vecka-lenvatinib/2024-03-14 https://kb.localhost:5000/lakemedelsregimer/lungcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/lungcancer/afatinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/alektinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-bevacizumab2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-bevacizumab-karboplatin-paklitaxel2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-cisplatin-pemetrexed-i-glukos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-karboplatin-gemcitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-karboplatin-paklitaxel2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/ceritinib2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-veckovis-under-stralbehandling2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-etoposid-iv-dag-1-po-dag-2-32/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-pemetrexed-i-glukos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-etoposid2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-etoposid-iv-dag-1-po-dag-2-32/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-etoposid-iv-dag-1-po-dag-2-33/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-gemcitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-irinotekan2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-paklitaxel2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-pemetrexed-i-glukos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-pemetrexed-i-glukos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-pemetrexed-i-natriumklorid2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-vinorelbin-iv2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-vinorelbin-iv-dag-1-po-dag-82/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-vinorelbin-po2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-andra-linjen/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pemetrexed-i-glukos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-s.c.-var-3e-vecka2024-03-19 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-var-4e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-bevacizumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-bevacizumab-karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-etoposid-karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-karboplatin-etoposid-iv-dag-1-po-dag-2-3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/atezolizumab-karboplatin-nab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-cisplatin-pemetrexed-i-natriumklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-cisplatin-vinorelbin-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-erlotinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-karboplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/bevacizumab-karboplatin-pemetrexed-i-natriumklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/binimetinib-enkorafenib/2025-02-25 https://kb.localhost:5000/lakemedelsregimer/lungcancer/brigatinib-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/brigatinib-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cemiplimab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cemiplimab-cisplatin-pemetrexed/2023-06-06 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cemiplimab-karboplatin-paklitaxel/2023-06-06 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cemiplimab-karboplatin-pemetrexed/2023-06-06 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cemiplimab-pemetrexed/2024-03-15 https://kb.localhost:5000/lakemedelsregimer/lungcancer/ceritinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-veckovis-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-docetaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-etoposid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-etoposid-iv-dag-1-po-dag-2-3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-pemetrexed-i-natriumklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-vinorelbin-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-vinorelbin-iv-dag-1-po-dag-8/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/cisplatin-vinorelbin-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/coav/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/dabrafenib-trametinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/dakomitinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/docetaxel-75/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/docetaxel-nintedanib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-karbo-eto-iv-dag-1-po-dag-2-3/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-peme/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-trem/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-trem-cis-peme/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-trem-karbo-gem/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-trem-karbo-peme/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durva-trem-peme/2025-04-11 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durvalumab-var-4e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/durvalumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/entrektinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/erlotinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/gefitinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/gemcitabin-vinorelbin-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/ipilimumab-nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/ipilimumab-nivolumab-cisplatin-pemetrexed/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/ipilimumab-nivolumab-karbo-pemetrexed/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/ipilimumab-nivolumab-karpak/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin---nab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-etoposid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-etoposid-iv-dag-1-po-dag-2-3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-irinotekan/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-pemetrexed-i-natriumklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-vinorelbin-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-vinorelbin-iv-dag-1-po-dag-8/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/karboplatin-vinorelbin-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/krizotinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/larotrektinib/2022-06-02 https://kb.localhost:5000/lakemedelsregimer/lungcancer/lorlatinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/mitoxantron-intraperikardiellt/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nintedanib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nivolumab-cisplatin-gemcitabin/2024-03-15 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nivolumab-cisplatin-pemetrexed/2024-10-09 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nivolumab-gemcitabin--karboplatin/2024-06-26 https://kb.localhost:5000/lakemedelsregimer/lungcancer/nivolumab-karboplatin-pemetrexed/2024-10-09 https://kb.localhost:5000/lakemedelsregimer/lungcancer/osimertinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-cisplatin-pemetrexed/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-karboplatin-nab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-karboplatin-pemetrexed/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pembrolizumab-pemetrexed/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pemetrexed-i-natriumklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/pralsetinib/2022-06-02 https://kb.localhost:5000/lakemedelsregimer/lungcancer/selperkatinib/2023-02-21 https://kb.localhost:5000/lakemedelsregimer/lungcancer/sotorasib-singel/2022-09-15 https://kb.localhost:5000/lakemedelsregimer/lungcancer/tepotinib/2023-06-06 https://kb.localhost:5000/lakemedelsregimer/lungcancer/topotekan-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/topotekan-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/vinorelbin-iv-25-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/vinorelbin-iv-30/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/vinorelbin-iv-30-och-po-80/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/vinorelbin-po-60-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lungcancer/vinorelbin-po-80-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/abvd/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-142/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-143/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-eskalerad-dosintensiv2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-eskalerad-dosintensiv3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beam2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bendamustin-1002/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bendamustin-1202/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-a24/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-a4/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-aa24/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-b24/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-b4/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-bb24/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-cc/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/chap-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/choep-142/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cisplatin-gemcitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cisplatin-gemcitabin3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cytarabin-hogdos-cns-profylax2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/dhap2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/forbehandling-gmall---cyklofosfamid-prednisolon/2022-12-21 https://kb.localhost:5000/lakemedelsregimer/lymfom/gemcitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/gemcitabin-oxaliplatin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/gemcitabin-oxaliplatin3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ike2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ime--mie2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/karmustin-tiotepa/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/matrix2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/metotrexat-hogdos-cns-profylax2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/obinutuzumab-kur-1-startdoser2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/obinutuzumab-kur-2-osv-underhallsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-1002/2022-06-30 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-702/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-902/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-cytarabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-choep-142/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-choep-212/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-212/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-mini2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-hdmtx-212/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-cisplatin-gemcitabin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-cytarabin-hogdos-kur-2-4-62/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-cytarabin-hogdos-kur-2-4-63/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-dhap2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-dhax2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-fc-intravenos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-fc-peroral2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-lenalidomid-enligt-sakknlg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-maxi-chop-kur-1-3-52/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-mpv-kur-13572/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-mpv-kur-1357/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-mpv-kur-246/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-mpv-kur-2462/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-temozolomid-fore-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/avd/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beac/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopdac-eskalerad/2022-12-21 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-14/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-eskalerad-dosintensiv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beacopp-standard-baseline/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/beam/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bendamustin-100/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bendamustin-120/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bendamustin-brentuximab-vedotin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-a24-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-a4-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-aa24-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-b24-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-b4-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-bb24-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-cc-rituximab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bfm-2004-forbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/brecadd-dosintensiv/2024-05-29 https://kb.localhost:5000/lakemedelsregimer/lymfom/brentuximab-vedotin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bv-chep-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/bv-chp/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ceop-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/choep-14/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/choep-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/chop-14/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/chop-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cisplatin-gemcitabin-pegaspargas-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/comla/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/fludarabin-30-cyklofosfamid-300---konditionering-infor-car-t-med-liso-cel/2024-11-05 https://kb.localhost:5000/lakemedelsregimer/lymfom/cyklofosfamid-500--fludarabin-30---konditionering-infor-car-t-med--axi-cel-eller-brexu-cel/2024-11-20 https://kb.localhost:5000/lakemedelsregimer/lymfom/cyklofosfamid-hogdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cytarabin-hogdos-cns-profylax/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cytarabin-hogdos-primart-cns-lymfom/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cytarabin-etoposid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cyve-60-ar-eller-aldre/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cyve-yngre-an-60-ar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/dhap/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/epkoritamab-startdoser---kur-1-dlbcl/2025-07-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/epkoritamab-varannan-vecka-kur-4-9/2025-07-11 https://kb.localhost:5000/lakemedelsregimer/lymfom/epkoritamab-veckovis-kur-2-3/2025-07-12 https://kb.localhost:5000/lakemedelsregimer/lymfom/etoposid-vid-hlh/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/fc-intravenos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/fc-peroral/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/cisplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/gemcitabin-oxaliplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/glofitamab-kur-2-12/2025-06-04 https://kb.localhost:5000/lakemedelsregimer/lymfom/glofitamab-startdoser-kur-1/2025-06-04 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-forbehandling---cyklofosfamid-prednisolon/2024-02-09 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-b-allnhl-02---kur-a/2022-12-21 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-b-allnhl-02---kur-a---aldre/2023-03-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-b-allnhl-02---kur-b/2022-12-21 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-b-allnhl-02---kur-b---aldre/2023-03-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-b-allnhl-02---kur-c/2022-12-21 https://kb.localhost:5000/lakemedelsregimer/lymfom/gmall-b-allnhl-02---rituximab/2022-12-21 https://kb.localhost:5000/lakemedelsregimer/lymfom/hyper-cvad-kur-1357/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/mtxhidac-kur-2468/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ibrutinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ike/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ike-polikliniskt/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/ime--mie/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/karmustin-tiotepa-konditionering/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/klorambucil-po-enligt-lister/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/lcal-99-block-a/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/lcal-99-block-b/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/lcal-99-block-p-forbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/lenalidomid-enligt-augment-kur-6-12/2024-08-24 https://kb.localhost:5000/lakemedelsregimer/lymfom/lvpp/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/matrix/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/metotrexat-hogdos-cns-profylax/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/metotrexat-po-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/mogamulizumab-kur-1-startdoser/2025-06-05 https://kb.localhost:5000/lakemedelsregimer/lymfom/mogamulizumab-kur-2-osv/2025-06-05 https://kb.localhost:5000/lakemedelsregimer/lymfom/metotrexat-prokarbazin-vinkristin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/nivolumab-avd/2025-05-15 https://kb.localhost:5000/lakemedelsregimer/lymfom/obinutuzumab-kur-1-startdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/obinutuzumab-kur-2-osv-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/obinutuzumab-underhallsdos-varannan-manad/2024-02-09 https://kb.localhost:5000/lakemedelsregimer/lymfom/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/polatuzumab-vedotin-rituximab-bendamustin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-acvbp/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-100/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-70/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-90/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-bendamustin-cytarabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-ceop-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-choep-14/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-choep-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-14/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-mini/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-chop-hdmtx-21/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-ciep-oral/2022-06-16 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-cytarabin-hogdos-kur-2-4-6/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-da-epoch/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-dhap/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-dhax/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-fc-intravenos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-fc-peroral/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-cisplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-gemox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-ike/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-ike-polikliniskt/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-ime--mie/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-klorambucil/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-lenalidomid-enligt-augment-kur-1-startdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-lenalidomid-enligt-augment-kur-2-osv-underhallsdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-lenalidomid-enligt-sakknlg-18-veckor/2024-01-03 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-maxi-chop-kur-1-3-5/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-mpv-kur-13573/2023-03-08 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-mpv-kur-2463/2023-03-08 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-temozolomid-fore-stralbehandling2/2025-04-03 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-underhallsdos-var-3e-manad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/rituximab-underhallsdos-varannan-manad/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/smile/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/temozolomid-konkomitant-med-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/temozolomid-monoterapi---underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/vacop-b/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/vinblastin-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/vr-cap/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/wollner-induktion-konsolidering/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/lymfom/wollner-underhallsbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/ipilimumab-nivolumab3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/ipilimumab-nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/ipilimumab-nivolumab-1--3-mgkg2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/nivolumab/2022-04-21 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/pembrolizumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/binimetinib-enkorafenib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/dabrafenib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/dabrafenib-trametinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/dakarbazin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/ipilimumab-nivolumab2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/ipilimumab-nivolumab-1--3-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/nivolumab-var-4e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/nivolumab-relatlimab/2025-03-28 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/tebentafusp-startdoser-kur-1/2025-01-29 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/tebentafusp-underhallsbehandling-kur-2-osv/2025-01-29 https://kb.localhost:5000/lakemedelsregimer/malignt-melanom/temozolomid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/capox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/eox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/epirubicin-oxaliplatin-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flot2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flot3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flot/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flot-pump2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flot-pump3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folfiri2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folfox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/oxaliplatin-fluorouracil-5-x-24-tim/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/oxaliplatin-fluorouracil-5-x-24-tim-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/oxaliplatin-fluorouracil-5-dygnsinfusion2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/oxaliplatin-fluorouracil-5-dygnsinfusion-under-stralbehandling2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/paklitaxel2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/ramucirumab-paklitaxel2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/sox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/trastuzumab-iv-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/xelox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/capox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/cisplatin-fluorouracil-5-x-24-timmar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/cisplatin-fluorouracil-5-dygnsinfusion/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/docetaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/docetaxel-flv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/ecf/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/eox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/fliri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flot-pump/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/flv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folf/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folfiri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folfox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folfox-4-modifierad-vid-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/folftax/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/ipilimumab-1-mgkg--nivolumab-3-mgkg/2022-05-19 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/ipilimumab-1-mgkg--nivolumab-360-mg/2022-05-19 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/irinotekan/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/kapecitabin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/karboplatin-fluorouracil-5-x-24-timmar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/karboplatin-fluorouracil-5-dygnsinfusion/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/karboplatin-paklitaxel-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/lonsurf-trifluridin-tipiracilhydroklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/nivolumab-tillagg-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/nivolumab-tillagg-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/oxaliplatin-fluorouracil-5-dygnsinfusion/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/oxaliplatin-fluorouracil-5-dygnsinfusion-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/ramucirumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/ramucirumab-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/siri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/sox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/teysuno-tegafur-gimeracil-oteracil/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/tfox-pump/2023-12-19 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/trastuzumab-iv-laddningsdos-6-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/trastuzumab-iv-laddningsdos-8-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/trastuzumab-iv-underhallsdos-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/matstrups--och-magsackscancer/trastuzumab-iv-underhallsdos-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-daratumumab-iv-talidomid-dexametason-induktion-kur-1-2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-daratumumab-iv-talidomid-dexametason-induktion-kur-3-4/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-daratumumab-iv-talidomid-dexametason-konsolidering-kur-5-6/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-melfalan-prednison/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-vecka-1-8/2022-06-30 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-vecka-9-24/2022-06-30 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-dexametason-kur-1-startdoser2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-dexametason-kur-2-osv-underhallsdoser2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/melfalan-prednison/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/melfalan-prednison-talidomid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-cyklofosfamid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-daratumumab-sc-talidomid-dexametason-induktion-kur-1-2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-daratumumab-sc-talidomid-dexametason-induktion-kur-3-4/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-daratumumab-sc-talidomid-dexametason-konsolidering-kur-5-6/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-dexametason-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-dexametason-35-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-lenalidomid-dexametason-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-lenalidomid-dexametason-28-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-melfalan-prednisolon/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/bortezomib-talidomid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/cyklofosfamid-stamcellsmobilisering/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/cyklofosfamid-talidomid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumab-underhallsdos-manadsvis/2022-03-03 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-vecka-1-82/2022-06-16 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-vecka-9-242/2022-06-16 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-bortezomib-dexametason-21-dagar-kur-1-3/2024-11-27 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-lenalidomid-dexametason-kur-1-2/2022-07-04 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-lenalidomid-dexametason-kur-3-6/2022-07-04 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-lenalidomid-dexametason-kur-7-osv/2023-01-12 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-lenalidomid-underhallsdoser/2022-03-15 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumab-mpv-kur-1/2022-03-08 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumab-mpv-kur-2-9/2022-03-03 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-vrd-induktion-kur-1-4/2022-03-15 https://kb.localhost:5000/lakemedelsregimer/myelom/daratumumab-vrd-konsolidering-kur-5-6/2022-03-15 https://kb.localhost:5000/lakemedelsregimer/myelom/ixazomib-lenalidomid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-1v-cyklofosfamid-dexametason-kur-1-startdoser/2024-11-27 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-1v-cyklofosfamid-dexametason-kur-2-osv-underhallsdoser/2024-11-27 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-2v-cyklofosfamid-dexametason-kur-2-osv-underhallsdoser/2024-11-27 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-dexametason-kur-1-startdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/karfilzomib-dexametason-kur-2-osv-underhallsdoser/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/lenalidomid-cyklofosfamid-dexametason/2024-11-27 https://kb.localhost:5000/lakemedelsregimer/myelom/lenalidomid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/melfalan-prednisolon/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/melfalan-prednisolon-talidomid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/pomalidomid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/myelom/talidomid-dexametason/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/karboplatin---etoposid-iv-dag-1---32/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/karboplatin---etoposid-iv-dag-1-po-dag-2-32/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-underhallsdos-2-dagar-streptozocin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-underhallsdos-2-dagar-streptozocin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---fluorouracil-laddningsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---fluorouracil-underhallsdos-2-dagar-streptozocin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---fluorouracil-underhallsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin-laddningsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin-underhallsdos-2-dagar-streptozocin2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin-underhallsdos2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/karboplatin---etoposid-iv-dag-1---3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/karboplatin---etoposid-iv-dag-1-po-dag-2-3/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-laddningsdos2/2022-03-18 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-underhallsdos-2-dagar-streptozocin3/2022-03-18 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---doxorubicin-underhallsdos2/2022-03-18 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---fluorouracil-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---fluorouracil-underhallsdos-2-dagar-streptozocin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin---fluorouracil-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin-underhallsdos-2-dagar-streptozocin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/streptozocin-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/temozolomid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/neuroendokrina-tumorer/temozolomid---kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/njurcancer/arkiverad-everolimus/2025-01-11 https://kb.localhost:5000/lakemedelsregimer/njurcancer/avelumab-axitinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/axitinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/axitinib-pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/axitinib-pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/everolimus/2025-01-14 https://kb.localhost:5000/lakemedelsregimer/njurcancer/ipilimumab-nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/kabozantinib/2025-01-14 https://kb.localhost:5000/lakemedelsregimer/njurcancer/kabozantinib-nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/nivolumab-var-4e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/njurcancer/pazopanib/2025-01-14 https://kb.localhost:5000/lakemedelsregimer/njurcancer/pembrolizumab-var-3e-vecka/2022-04-27 https://kb.localhost:5000/lakemedelsregimer/njurcancer/pembrolizumab-var-3e-vecka-lenvatinib/2023-07-14 https://kb.localhost:5000/lakemedelsregimer/njurcancer/pembrolizumab-var-6e-vecka/2022-04-27 https://kb.localhost:5000/lakemedelsregimer/njurcancer/pembrolizumab-var-6e-vecka-lenvatinib/2024-04-27 https://kb.localhost:5000/lakemedelsregimer/njurcancer/sunitinib/2023-07-14 https://kb.localhost:5000/lakemedelsregimer/peniscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/peniscancer/cisplatin-docetaxel-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/peniscancer/cisplatin-kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/peniscancer/cisplatin-veckovis-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/peniscancer/pic/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/abirateron/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/apalutamid/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/bikalutamid/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/buserelin/2023-09-07 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/cyklofosfamid-prednisolon-po/2023-08-23 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/darolutamid/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/degarelix/2023-09-08 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/docetaxel-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/docetaxel-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/docetaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/enzalutamid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/goserelin/2023-09-07 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/kabazitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/karboplatin---etoposid-iv-dag-1---3/2023-09-08 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/karboplatin---etoposid-iv-dag-1-po-dag-2-3/2023-09-08 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/leuprorelin/2023-09-07 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/olaparib-tablett/2023-09-08 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/triptorelin/2023-09-07 https://kb.localhost:5000/lakemedelsregimer/prostatacancer/xofigo/2025-02-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/2024-04-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/cevaie---i2va-cws-2014-kur-1-och-2/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/cevaie---i2va-cws-2014-kur-3-och-4/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/euramos-i---a/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroewing-2012-ie/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroewing-2012-vdc/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroewing-2012-vdc2/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/bevacizumab-temozolomid/2022-12-20 https://kb.localhost:5000/lakemedelsregimer/sarkom/cws-2014---i2va-kur-1-och-2/2023-09-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/cws-2014---i2va-kur-3-och-4/2023-09-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/cws-2014---i2vad-kur-1/2023-08-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/cws-2014---i2vad-kur-2-osv/2023-08-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/cws-2014---va/2023-08-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/cyklofosfamid-topotekan/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/dakarbazin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/docetaxel-100-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/docetaxel-80-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/doxorubicin-60/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/doxorubicin-75/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/doxorubicin-dakarbazin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/doxorubicin-ifosfamid-enl-ssg-xx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/doxorubicin-ifosfamid-enl-ssg-xx-poliklinisk/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/eribulin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/etoposid-trofosfamid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/euramos-i---ma/2023-01-20 https://kb.localhost:5000/lakemedelsregimer/sarkom/map/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroboss-i---cisplatin-doxorubicin/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroboss-i---ifosfamid-cisplatin/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroboss-i---ifosfamid-doxorubicin/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroboss-i---metotrexat/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroewing-2012-ie2/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/euroewing-2012-vdc3/2023-06-03 https://kb.localhost:5000/lakemedelsregimer/sarkom/ifosfamid-hogdos/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/imatinib/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/ipilimumab-nivolumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/kabozantinib/2023-08-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/maid/2023-08-26 https://kb.localhost:5000/lakemedelsregimer/sarkom/metotrexat-propranolol-vinblastin/2022-12-20 https://kb.localhost:5000/lakemedelsregimer/sarkom/nivolumab-var-4e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/paklitaxel-veckovis/2023-03-16 https://kb.localhost:5000/lakemedelsregimer/sarkom/pazopanib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/pembrolizumab-var-3e-vecka/2023-03-30 https://kb.localhost:5000/lakemedelsregimer/sarkom/pembrolizumab-var-6e-vecka/2023-03-30 https://kb.localhost:5000/lakemedelsregimer/sarkom/pembrolizumab-axitinib/2024-04-25 https://kb.localhost:5000/lakemedelsregimer/sarkom/regorafenib/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/sorafenib/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/sunitinib/2022-10-15 https://kb.localhost:5000/lakemedelsregimer/sarkom/trabektedin-yondelis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/sarkom/trofosfamid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/doxorubicin-veckobehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/kabozantinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/kabozantinib-tabletter/2024-08-20 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/lenvatinib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/paklitaxel-postop-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/paklitaxel-postop-veckovis-28-dagar-med-paus/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/paklitaxel-veckovis-konkomitant-med-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/sorafenib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/skoldkortelcancer/vandetanib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/stodregimer/2025-06-12 https://kb.localhost:5000/lakemedelsregimer/stodregimer/test-av-aibw/2025-06-12 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/ema-co/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/bep/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/bep-ifosfamid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/ema-co2/2022-04-05 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/ep/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/gop/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/irinotekan-oxaliplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/karboplatin-etoposid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/pei/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/testikelcancer-och-extragonadal-konscellstumor/tip/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/aflibercept/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-folfiri-14-dagar2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-folfox-14-dagar2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-kapecitabin-21-dagar2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/capox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/flox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folfirinox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folfoxiri2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/sox2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/xeliri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/xelox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-capox/2024-04-20 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-fliri/2023-09-04 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-flox/2023-09-04 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-flv/2023-09-15 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-folf/2023-09-04 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-folfiri-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-folfox-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-kapecitabin-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-lonsurf-dag-1-5-15-19/2024-12-20 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-lonsurf-dag1-5-8-12/2024-12-20 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/bevacizumab-teysuno-tegafur-gimeracil-oteracil/2023-08-13 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/capiri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/capox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetux-enko-folfox/2025-07-12 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-7-dagar-laddningsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-7-dagar-underhallsdos/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-enkorafenib/2023-11-07 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-folfiri-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-folfox-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/cetuximab-irinotekan-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/fliri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/flox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/flv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folf/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folfiri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folfirinox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folfox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/folfoxiri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/hipec-oxaliplatin-ip-flv-iv-dag1/2025-07-12 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/ipilimumab-nivolumab-1mgkg--3-mgkg/2024-11-27 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/irinotekan-14-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/irinotekan-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/irox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/kapecitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/kapecitabin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/kapecitabin900-5dv-under-stralbehandling/2025-05-21 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/lonsurf-trifluridin-tipiracilhydroklorid/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/nivolumab-6-mgkg-var-4e-vecka/2025-07-09 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/panitumumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/panitumumab-folfiri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/panitumumab-folfox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/pembrolizumab-4-mgkg-var-6e-vecka/2025-05-21 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/pembrolizumab-var-3e-vecka/2023-09-04 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/regorafenib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/siri/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/sox/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/tjock--och-andtarmscancer/teysuno-tegafur-gimeracil-oteracil/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/daktinomycin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/ema-cns-co/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/ema-cns-ep/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/ema-coa/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/ema-cob/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/ep-induktionsbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/ep-ema/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/metotrexat-im/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/metotrexat-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/trofoblastsjukdomar/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/cisplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/cisplatin-gemcitabin-21-dagar2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/cisplatin-gemcitabin-28-dagar2/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/gemcitabin-docetaxel-intravesikal-flerdosinstillation/2023-01-04 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/atezolizumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/avelumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/bcg-intravesikal-flerdosinstillation/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/cisplatin-dag-1-och-2-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/cisplatin-gemcitabin-21-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/cisplatin-gemcitabin-28-dagar/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/enfortumab-vedotin/2023-01-31 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/epirubicin-intravesikal-endosinstillation/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/fluorouracil-4-dygnsinfusion-mitomycin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/fluorouracil-5-dygnsinfusion-mitomycin-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/gemcitabin-intravesikal-flerdosinstillation/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/gemcitabin-docetaxel-intravesikal-flerdosinstillation2/2023-01-04 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/gemcitabin-karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/gemcitabin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/m-vac-14/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/mitomycin-intravesikal-endosinstillation/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/mitomycin-intravesikal-flerdosinstillation/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/nivolumab-var-4e-vecka/2024-10-11 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/nivolumab-varannan-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/nivolumab-cisplatin-gemcitabin/2024-10-11 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/pembro-ev/2025-07-01 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/pembrolizumab-var-3e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/pembrolizumab-var-6e-vecka/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/vinflunin-200/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/vinflunin-250/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/vinflunin-280/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/urinblase--och-urinvagscancer/vinflunin-320/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/vulvacancer/2022-10-05 https://kb.localhost:5000/lakemedelsregimer/vulvacancer/cisplatin-veckovis-under-stralbehandling/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/bep/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/bevacizumab-10-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/bevacizumab-15-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/bevacizumab-75-mgkg/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/cisplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/cisplatin-doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/cisplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/cisplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/cyklofosfamid-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/docetaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/doxorubicin-liposomalt-caelyx-trabektedin-yondelis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/etoposid-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/extended-karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/extended-karboplatin-docetaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/extended-karboplatin-doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/extended-karboplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/extended-karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/ip-cisplatin-intraperitonealt/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/ip-mitoxantron-intraperitonealt/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/karboplatin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/karboplatin-docetaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/karboplatin-doxorubicin-liposomalt-caelyx-21-dagar/2022-04-06 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/karboplatin-doxorubicin-liposomalt-caelyx/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/karboplatin-gemcitabin/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/karboplatin-paklitaxel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/letrozol/2023-03-15 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/niraparib/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/niraparib-tabletter/2023-03-15 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/olaparib-kapsel/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/olaparib-tablett/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/paklitaxel-veckovis/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/pei/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/rukaparib/2025-05-08 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/tip/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/topotekan-iv/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/topotekan-po/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/aggstockscancer/trametinib/2024-01-20 https://kb.localhost:5000/lakemedelsregimer/oppet-arkiv/2022-04-07 https://kb.localhost:5000/lakemedelsregimer/ovrig-hudcancer/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/ovrig-hudcancer/avelumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/ovrig-hudcancer/cemiplimab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/ovrig-hudcancer/sonidegib/2025-06-18 https://kb.localhost:5000/lakemedelsregimer/ovrig-hudcancer/vismodegib/2025-06-18 https://kb.localhost:5000/lakemedelsregimer/ovriga/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/ovriga/avelumab/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/ovriga/dexrazoxan/2022-02-10 https://kb.localhost:5000/lakemedelsregimer/ovriga/filgrastim-subkutant/2024-06-14 https://kb.localhost:5000/lakemedelsregimer/ovriga/pegfilgrastim-subcutant/2024-06-14 https://kb.localhost:5000/lakemedelsregimer/ovriga/zoledronsyra-4-mg/2025-02-05 https://kb.localhost:5000/barncancer/2024-03-25 https://kb.localhost:5000/barncancer/akut-lymfatisk-leukemi-all/2024-03-11 https://kb.localhost:5000/barncancer/akut-myeloisk-leukemi-aml/2024-03-11 https://kb.localhost:5000/barncancer/binjuretumorer/2024-04-04 https://kb.localhost:5000/barncancer/cns-tumorer/2024-03-11 https://kb.localhost:5000/barncancer/hodgkin/2024-03-11 https://kb.localhost:5000/barncancer/sarkom/2024-03-25 https://kb.localhost:5000/barncancer/sarkom/a--dexrazoxan/2025-06-20 https://kb.localhost:5000/barncancer/sarkom/ap--dexrazoxan/2025-06-20 https://kb.localhost:5000/barncancer/sarkom/vc/2025-05-07 https://kb.localhost:5000/barncancer/sarkom/vdcdexrazoxan/2025-05-07 https://kb.localhost:5000/barncancer/sarkom/vinkristine-15-mgm2-far-rms/2024-03-14 https://kb.localhost:5000/barncancer/sarkom/vinocyc-iv/2025-05-07 https://kb.localhost:5000/barncancer/sarkom/vinocyc-po/2025-05-07 https://kb.localhost:5000/barncancer/neuroblastom/2024-03-11 https://kb.localhost:5000/kontakt/2022-02-10 https://kb.localhost:5000/stoddokument/2025-06-02 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/2025-03-25 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/inledning/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/inledning/vardniva-samverkan-och-remissrutiner/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/inledning/vardniva-samverkan-och-remissrutiner/remissrutiner/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/inledning/omfattning-av-kunskapsstod/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/inledning/om-halsotillstandet/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/inledning/om-halsotillstandet/forekomst/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/allmanna-symtom-som-kan-forekomma-vid-flera-olika-former-av-barncancer/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/leukemier/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/tumorer-i-centrala-nervsystemet/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/tumorer-i-centrala-nervsystemet/tumorer-i-centrala-nervsystemet-symtom-som-kan-forekomma/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/solida-tumorer/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/vanliga-debutsymtom/symtom-som-kan-forekomma-vid-lymfom-hos-barn/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/handlaggning-vid-valgrundad-misstanke/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/utredning/tillstand-med-okad-risk-att-utveckla-cancer-i-barndomen/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/arbetsgruppen/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/arbetsgruppen/arbetsgruppens-sammansattning/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/arbetsgruppen/kunskapsstodets-forankring/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/uppfoljning-av-cancervarden/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/uppfoljning-av-cancervarden/svenska-barncancerregistret/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/relaterad-information/2025-03-24 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/relaterad-information/forslag-pa-fordjupning/2025-06-30 https://kb.localhost:5000/stoddokument/alarmsymtom-vid-misstanke-om-cancer-hos-barn-och-ungdom/relaterad-information/stod-och-information-for-patient-och-narstaende/2025-06-30 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/sammanfattning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/mal-med-stoddokumentet/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/versionshantering/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/forandringar-jamfort-med-tidigare-version/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/incidens-av-cancer-under-graviditet/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/fosterutveckling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/bakgrund/cytostatikas-paverkan-pa-foster/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/team/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/bemotande-och-omhandertagande/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/modravard/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/etiska-overvaganden/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/etiska-overvaganden/autonomi-och-sjalvbestammande/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/etiska-overvaganden/etiska-diskussioner-i-teamet/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/handlaggning-och-bemotande/etiska-overvaganden/mojliga-scenarier/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/planering-av-utredning-och-behandling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/bilddiagnostik/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/bilddiagnostik/undersokningar-utan-joniserande-stralning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/bilddiagnostik/undersokningar-med-joniserande-stralning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/patologi-och-cytologi/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/laboratorieprover/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/utredning/fertilitetsbevarande-atgarder/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/uppskattad-risk-for-graviditetskomplikationer/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/cytostatikabehandling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/endokrin-behandling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/andra-cancerlakemedel/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/stralbehandling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/kirurgi/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/behandling/understodjande-lakemedelsbehandling/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/forlossning-amning-och-uppfoljning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/forlossning-amning-och-uppfoljning/forlossning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/forlossning-amning-och-uppfoljning/amning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/forlossning-amning-och-uppfoljning/uppfoljning-och-rehabilitering/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/fordjupning/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/arbetsgrupp/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/arbetsgrupp/arbetsgruppens-medlemmar/2024-09-20 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/arbetsgrupp/arbetsgruppens-tidigare-medlemmar/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/arbetsgrupp/jav-och-andra-bindningar/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/arbetsgrupp/stoddokumentets-forankring/2024-09-19 https://kb.localhost:5000/stoddokument/cancer-under-graviditet/referenser/2024-09-19 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/2024-07-06 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/bakgrund/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/bakgrund/inledning/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/bakgrund/inledning/riskfaktorer/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/bakgrund/inledning/forlopp/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/bakgrund/perifer-neuropati-symtom/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/bakgrund/perifer-neuropati-symtom/symtombild/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/vardering-av-symtom/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/vardering-av-symtom/uppfoljning-under-behandlingstiden/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/prevention/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/prevention/kryo--och-kompressionsbehandling/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/prevention/fysisk-aktivitet/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/prevention/farmakologisk-prevention/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/taxaner/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/oxaliplatin/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/oxaliplatin/akut-laryngofaryngeal-dysestesi/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/oxaliplatin/koldkanslighet/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/oxaliplatin/perifer-neuropati/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/vinkaalkaloider/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/antikroppskonjugat/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/handlaggning-av-cipn-under-behandlingstiden/sarskild-lakemedelsspecifik-information/bortezomib/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/primar-utredning/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/behandling-av-langvarig-cipn/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/behandling-av-langvarig-cipn/farmakologiska-behandlingsmetoder/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/behandling-av-langvarig-cipn/icke-farmakologiska-behandlingsmetoder/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/behandling-av-langvarig-cipn/icke-farmakologiska-behandlingsmetoder/fysisk-aktivitet/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/utredning-och-behandling-vid-kvarstaende-cipn/behandling-av-langvarig-cipn/omvardnad-och-stodjande-atgarder/2024-07-08 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/arbetsgruppen/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/arbetsgruppen/forfattare/2024-07-05 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/arbetsgruppen/stoddokumentets-forankring/2024-10-30 https://kb.localhost:5000/stoddokument/cytostatikaorsakad-perifer-neuropati/referenser/2024-07-05 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/2025-01-22 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/inledning/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/inledning/arbetsgruppen/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/inledning/dokumentets-bakgrund/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/inledning/tidigare-versioner/2025-01-22 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/inledning/forkortningsordlista/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/allmant-om-biverkningar-i-samband-med-behandling-med-checkpointhammare/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/allmant-om-biverkningar-i-samband-med-behandling-med-checkpointhammare/vanliga-lakemedel/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/allmant-om-biverkningar-i-samband-med-behandling-med-checkpointhammare/oversikt-over-de-vanligaste-biverkningarna-vid-singelbehandling-med-pd-1-hammare/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/allmant-om-biverkningar-i-samband-med-behandling-med-checkpointhammare/allmant-om-steroidbehandling-av-immunrelaterade-biverkningar/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/allmant-om-biverkningar-i-samband-med-behandling-med-checkpointhammare/allmant-om-steroidbehandling-av-immunrelaterade-biverkningar/generella-behandlingsrekommendationer/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/allmant-om-biverkningar-i-samband-med-behandling-med-checkpointhammare/allmant-om-steroidbehandling-av-immunrelaterade-biverkningar/biverkningar-av-steroidbehandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/provtagningsschema-for-blodprover/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/provtagningsschema-for-blodprover/singelbehandling-varannan-vecka/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/provtagningsschema-for-blodprover/singelbehandling-var-3e-4e-eller-var-6e-vecka/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/provtagningsschema-for-blodprover/kombinationsimmunterapi/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/provtagningsschema-for-blodprover/i-foljande-situationer-bor-patienten-remitteras-for-kardiologisk-bedomning/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/provtagningsschema-for-blodprover/extra-provtagning-vid-misstanke-om-endokrin-toxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/behandling-vid-autoimmun-sjukdom/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/vaccinering-i-samband-med-immunterapi/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/vaccinering-i-samband-med-immunterapi/effekten-av-immunterapi/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/infor-start-av-behandling/vaccinering-i-samband-med-immunterapi/toxiska-reaktioner-pa-immunterapi/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/hudtoxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/hudtoxicitet/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/hudtoxicitet/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/gastrointestinal-toxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/gastrointestinal-toxicitet/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/gastrointestinal-toxicitet/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/primar-utredning-av-endokrina-biverkningar/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/hypofyspaverkan/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/hypofyspaverkan/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/hypofyspaverkan/behandling-av-hypofysit/2025-01-22 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/skoldkortelpaverkan/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/skoldkortelpaverkan/hypotyreos/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/skoldkortelpaverkan/hypertyreos/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/skoldkortelpaverkan/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/skoldkortelpaverkan/akut-binjurebarksinsufficiens-pa-grund-av-hypofysit-sekundar-binjurebarksinsufficiens/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/diabetes/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/endokrina-biverkningar/diabetes/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/levertoxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/levertoxicitet/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/levertoxicitet/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/lungtoxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/lungtoxicitet/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/lungtoxicitet/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/ogonbiverkningar/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/ogonbiverkningar/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/ogonbiverkningar/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/myokardit/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/myokardit/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/myokardit/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/neuropatiska-biverkningar/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/neuropatiska-biverkningar/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/neuropatiska-biverkningar/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/njurtoxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/njurtoxicitet/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/njurtoxicitet/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/hematologisk-toxicitet/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/hematologisk-toxicitet/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/bedomning-och-omvardnad/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/gradering-och-behandling/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/gradering-och-behandling/inflammatorisk-sjukdom-med-artriter/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/gradering-och-behandling/sicca-syndromsjogrens-syndrom/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/gradering-och-behandling/pmr-liknande-syndrom-och-jattecellsartrit/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/hantering-av-biverkningar/reumatologiska-biverkningar/gradering-och-behandling/myosit/2024-02-12 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/bilagor/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/bilagor/bilaga-1-patientkort/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/bilagor/bilaga-2-information-till-vardpersonal-om-immunterapi-fran-ansvarig-lakare-vid-overlamning/2024-02-14 https://kb.localhost:5000/stoddokument/bedomning-och-hantering-av-biverkningar-vid-behandling-med-checkpointhammare/bilagor/bilaga-3-fordjupande-litteratur/2024-02-14 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/2024-02-16 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/bakgrund/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/allmant-om-behandlingsriktlinjen/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/ovanliga-manifestationer-som-inte-tas-upp-i-detta-stoddokument/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/kronisk-gvhd-i-leder-och-fascior-tas-inte-upp-i-detta-stoddokument/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/lasanvisning/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/diagnostik-och-gradering-av-kronisk-gvhd/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/behandling/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/seneffekter-av-kronisk-gvhd/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/allmant-om-gvhd/forkortningsordlista/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/inledning/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/kontroller-och-uppfoljning/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/kontroller-och-uppfoljning/screeningbesok-hos-hudlakare-for-vardering-av-risk-for-hudcancer/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/kontroller-och-uppfoljning/remiss-till-hudklinik-vid-uppkomst-av-lokaliserade-hudforandringar/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/symtom-och-diagnostik/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/symtom-och-diagnostik/symtom/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/symtom-och-diagnostik/diagnostik-och-bedomning-av-hudspecialist/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/hud-gvhd/behandling/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/inledning/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/kontroller-for-tidig-upptackt-av-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/symtom-gradering-och-diagnostik/2024-01-10 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/symtom-gradering-och-diagnostik/lichenoida-forandringar-och-sar-i-munslemhinnan/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/symtom-gradering-och-diagnostik/salivdysfunktion--muntorrhet/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/symtom-gradering-och-diagnostik/munskleros/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/behandling/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/behandling/lichenoida-forandringar-och-sar-i-munslemhinnan/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/behandling/salivdysfunktion--muntorrhet/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/behandling/munskleros-fibros/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/uppfoljning-efter-konstaterad-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mun-gvhd/lankar-till-blanketter-for-tandvardsbidrag/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/inledning/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/symtom-och-gradering/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/diagnostik/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/behandling/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/behandling/forslag-pa-tarsubstitut/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/behandling/serumdroppar/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/ogon-gvhd/uppfoljning-efter-konstaterad-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/inledning/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/riskfaktorer/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/regelmassiga-kontroller-for-tidig-upptackt-av-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/symtom-och-diagnostik/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/symtom-och-diagnostik/esofagus/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/symtom-och-diagnostik/ventrikel/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/symtom-och-diagnostik/tunntarm-och-kolon/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/symtom-och-diagnostik/pankreas/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/behandling/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/mag-tarm-gvhd/uppfoljning-vid-konstaterad-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/inledning/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/regelmassiga-kontroller-for-tidig-upptackt-av-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/symtom/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/riskfaktorer-for-och-differentialdiagnoser-till-leverpaverkan-efter-allo-hsct/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/diagnostik/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/behandling/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lever-gvhd/uppfoljning-efter-konstaterad-kronisk-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/inledning/2024-02-09 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/riskfaktorer-for-kronisk-lung-gvhd/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/regelmassiga-kontroller-for-tidig-upptackt-av-kronisk-gvhd/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/symtom-och-diagnostik/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/symtom-och-diagnostik/klinisk-manifestation/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/symtom-och-diagnostik/klinisk-manifestation/bos-bronchiolitis-obliterans-syndrom/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/symtom-och-diagnostik/klinisk-manifestation/cop-cryptogen-organiserande-pneumoni/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/symtom-och-diagnostik/symtom/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/diagnostik/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/behandling/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/behandling/vid-konstaterad-lung-gvhd/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/behandling/vid-utebliven-eller-otillracklig-forbattring/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/behandling/understodjande-behandling/2023-12-08 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/uppfoljning-vid-konstaterad-lung-gvhd/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/lung-gvhd/lungtransplantation/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/inledning/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/8.2uppfoljning-efter-allo-hsct-och-regelmassiga-kontroller-for-tidig-upptackt-av-kronisk-gvhd-och-dysplasi2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/symtom--inklusive-larmsymtom-som-kraver-snar-bedomning-av-organspecialist/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/diagnostik-av-kronisk-gvhd-i-kvinnliga-genitalia/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/behandling/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/kvinnlig-genital-gvhd/uppfoljning-efter-konstaterad-kronisk-gvhd/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/inledning/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/symtom/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/symtom/olika-kliniska-tecken-kan-forekomma/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/symtom/diagnostik-och-differentialdiagnoser/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/manlig-genital-gvhd/uppfoljning/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/inledning/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/riskfaktorer-for-osteoporos-och-osteoporosfraktur/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/symtom/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/diagnostik/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/behandling/kalcium-och-d-vitamin/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/behandling/benspecifik-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/behandling/benspecifik-behandling/bisfosfonat/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/behandling/benspecifik-behandling/denosumab/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/osteoporos-vid-kronisk-gvhd/uppfoljning-efter-konstaterad-osteopeni-eller-osteoporos/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/inledning/2024-02-09 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/varicella-zoster-virus-och-herpes-simplex-virus/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/varicella-zoster-virus-och-herpes-simplex-virus/bakgrund/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/varicella-zoster-virus-och-herpes-simplex-virus/rekommendation-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/varicella-zoster-virus-och-herpes-simplex-virus/uppfoljning-och-utsattande-av-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/cytomegalovirus/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/cytomegalovirus/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/cytomegalovirus/rekommendation-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/cytomegalovirus/uppfoljning-och-utsattande-av-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/epstein-barr-virus/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/epstein-barr-virus/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/epstein-barr-virus/rekommendation-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/epstein-barr-virus/uppfoljning/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/pneumocystis-jiroveci/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/pneumocystis-jiroveci/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/pneumocystis-jiroveci/rekommendation-forebyggande-behandling/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/pneumocystis-jiroveci/uppfoljning-och-utsattande-av-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/invasiva-svampinfektioner/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/invasiva-svampinfektioner/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/invasiva-svampinfektioner/rekommendation-forebyggande-behandling/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/invasiva-svampinfektioner/uppfoljning-och-utsattande-av-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/antibiotikaprofylax-bakteriella-infektioner/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/antibiotikaprofylax-bakteriella-infektioner/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/antibiotikaprofylax-bakteriella-infektioner/rekommendation-forebyggande-behandling/2024-02-09 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/antibiotikaprofylax-bakteriella-infektioner/uppfoljning-och-utsattande-av-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/bakteriella-infektioner-och-igg-brist/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/bakteriella-infektioner-och-igg-brist/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/bakteriella-infektioner-och-igg-brist/rekommendation-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/bakteriella-infektioner-och-igg-brist/behandlingsrekommendation/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/bakteriella-infektioner-och-igg-brist/uppfoljning-och-utsattande-av-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/toxoplasma/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/toxoplasma/bakgrund/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/toxoplasma/rekommendation-forebyggande-behandling/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/toxoplasma/uppfoljning/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/hepatit-b/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/infektionsprofylax-vid-kronisk-gvhd/vaccinationer/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/referenser/2023-12-15 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/arbetsgruppen/2023-12-11 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/arbetsgruppen/stoddokumentets-forankring/2024-01-25 https://kb.localhost:5000/stoddokument/diagnostik-och-behandling-av-kronisk-gvhd/bilaga-1-blanketter-for-tandvardsbidrag/2023-12-11 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/2024-10-08 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bakgrund--antiemetika-stoddokument/2024-07-08 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bakgrund--antiemetika-stoddokument/mal-med-stoddokumentet/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bakgrund--antiemetika-stoddokument/versionshantering/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bakgrund--antiemetika-stoddokument/1.3forandringar-jamfort-med-tidigare-version2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/intravenos-cytostatikabehandling/2023-11-21 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/intravenos-cytostatikabehandling/behandling-akut-och-fordrojt-illamaende-hog-emetogen-risk-90-risk/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/intravenos-cytostatikabehandling/behandling-akut-och-fordrojt-illamaende-medelemetogen-risk-30-90-risk/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/intravenos-cytostatikabehandling/behandling-akut-och-fordrojt-illamaende-lag-risk-30-risk/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/intravenos-cytostatikabehandling/behandling-akut-och-fordrojt-illamaende-minimal-risk-10-risk/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/peroral-antitumoral-behandling/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/peroral-antitumoral-behandling/behandling-av-illamaende-vid-medelhog-emetogen-risk/2024-07-07 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/peroral-antitumoral-behandling/behandling-av-illamaende-vid-minimallag-emetogen-risk/2024-07-08 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/peroral-antitumoral-behandling/behandling-av-illamaende-utan-specificerad-emetogen-risk/2024-07-08 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/arbetsgruppen/2024-07-07 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/arbetsgruppen/arbetsgruppens-medlemmar/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/arbetsgruppen/tidigare-medlemmar-i-arbetsgruppen/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/arbetsgruppen/jav-och-andra-bindningar/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/arbetsgruppen/stoddokumentets-forankring/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/fordjupande-litteratur/2024-07-07 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/2023-11-21 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-1---riskbedomningsunderlag-for-stallningstagande-till-antiemetikaprofylax/2024-07-07 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/2023-11-21 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/oversikt/2024-07-07 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/regimlangd-1-dag/2025-03-20 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/regimlangd-2-dagar/2025-03-20 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/regimlangd-3-dagar/2025-03-20 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/regimlangd-4-dagar/2025-03-20 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-2---forslag-antiemetikasteg/regimlangd-5-dagar/2025-03-20 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-3/2024-07-07 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-4/2024-09-02 https://kb.localhost:5000/stoddokument/antiemetika-vuxen/bilagor/bilaga-52/2024-07-07 https://kb.localhost:5000/stoddokument/extravasering/2025-03-19 https://kb.localhost:5000/stoddokument/extravasering/introduktion/2025-03-20 https://kb.localhost:5000/stoddokument/extravasering/introduktion/bakgrund/2023-10-24 https://kb.localhost:5000/stoddokument/extravasering/introduktion/syfte/2023-10-24 https://kb.localhost:5000/stoddokument/extravasering/forebygga-extravasering/2023-10-02 https://kb.localhost:5000/stoddokument/extravasering/riskfaktorer-for-extravasering/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/symtom/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/symtom/perifera-infarter--tidiga-symtom/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/symtom/perifera-infarter--sena-symtom/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/symtom/centrala-infarter--symtom/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/generella-atgarder-vid-perifer-infart/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/generella-atgarder-vid-central-infart/2024-02-12 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-atgarder/2023-11-07 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-atgarder/antracykliner/2025-03-19 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-atgarder/liposomala-antracykliner/2025-03-19 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-atgarder/taxaner/2025-03-19 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-atgarder/vinkaalkaloider/2025-03-19 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-atgarder/blandningar-av-flera-antitumorala-lakemedel/2024-01-30 https://kb.localhost:5000/stoddokument/extravasering/atgarder-vid-extravasering/specifika-lokala-behandlingar/2024-02-12 https://kb.localhost:5000/stoddokument/extravasering/efterkontroller/2024-02-12 https://kb.localhost:5000/stoddokument/extravasering/dokumentation/2023-11-08 https://kb.localhost:5000/stoddokument/extravasering/referenslista/2025-03-19 https://kb.localhost:5000/stoddokument/extravasering/bilagor/2023-11-21 https://kb.localhost:5000/stoddokument/extravasering/bilagor/bilaga-1---kylbehandling/2023-11-21 https://kb.localhost:5000/stoddokument/extravasering/bilagor/bilaga-2---varmebehandling/2023-11-21 https://kb.localhost:5000/stoddokument/extravasering/bilagor/bilaga-3---dokumentation/2023-11-21 https://kb.localhost:5000/stoddokument/extravasering/bilagor/bilaga-4-lakemedel---extravaseringsrisk/2025-03-25 https://kb.localhost:5000/cancerstudier-i-sverige/2025-05-27 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca0881007-myelom/2025-07-31 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hilos/2025-07-31 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ev-hcc-studien/2025-07-31 https://kb.localhost:5000/cancerstudier-i-sverige/studier/go43860/2025-07-31 https://kb.localhost:5000/cancerstudier-i-sverige/studier/c5901001-helix/2025-07-31 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk2400-001-ideate-prostate01/2025-07-22 https://kb.localhost:5000/cancerstudier-i-sverige/studier/swe-neo/2025-07-22 https://kb.localhost:5000/cancerstudier-i-sverige/studier/groinss-v-iii/2025-07-21 https://kb.localhost:5000/cancerstudier-i-sverige/studier/her2-ex-pet/2025-06-16 https://kb.localhost:5000/cancerstudier-i-sverige/studier/harmoni-3-smt112-3003/2025-06-16 https://kb.localhost:5000/cancerstudier-i-sverige/studier/flirt-studien/2025-06-16 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fourlight-3--c4391024/2025-06-10 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca071-1000-recharge/2025-06-10 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca-088-1007/2025-05-23 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ker-050-d301/2025-05-18 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hpb-multiomik/2025-05-16 https://kb.localhost:5000/cancerstudier-i-sverige/studier/soundtrack-b/2025-05-15 https://kb.localhost:5000/cancerstudier-i-sverige/studier/xaluteamgen20230005/2025-05-15 https://kb.localhost:5000/cancerstudier-i-sverige/studier/aby271-1012/2025-05-08 https://kb.localhost:5000/cancerstudier-i-sverige/studier/allo-hpv/2025-05-07 https://kb.localhost:5000/cancerstudier-i-sverige/studier/car-t-cellsprovtagning/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/origami-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pereli/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/quantum-wild-ac220-168/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/on-call/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dellphi-306-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/noac-9/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mevpro-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/codebreak301/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mevpro-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/orig-ami-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/direktstart/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/galaxies-lung-301-gsk4428859a/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/treat-ctdna/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/destiny-her2-low/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/correct-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/origami-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/akir-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tilvance-301-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dareon-7/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/melody/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/orig-ami2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/uso---bc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/qpl---brostcancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/swe-switch/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imcode004--bo45230/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fourlight-2-c4391025/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ipa-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sgndv-001kn-d74/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gsk-222730-spartacus--b7-h4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk2870-010/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hyperion/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/grand-slam/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/temozolomide-plus-lomustine-versus-temozolomide-for--mgmt-promoter-methylated-glioblastoma/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/artscan-vi/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/magstage/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/allvos/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/efs-frailty-in-lung-cancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sarong-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/jazz--zanihertwo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/solucom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk3543/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/alxn1210-tma-313/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scandium-iii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lion/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/adiuvo-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bellwave-011-mk1026-011/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/seqcureneo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/golseek-1--ca073-1020/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sprintr-real/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/trofuse-020/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sgncea5c-001-ceacam5/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/odx-mm-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/idunn/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/chro761a12101-michro/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/medal/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/guide.mrd2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/robocop/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fatigue-pet-studie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/rocknrol-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/channel/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imcode-003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cmlstop/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/espac-6/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prisma-prism-mel-301/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/relativity-127/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/beamion-lung-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/jade-studien--219885/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-2870-009/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-2870-005/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bgb-11417-301/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/golden-gate-20190360/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mdt-bridge/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/selsa/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/waveline-006/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cartitude-6/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/carma-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/v940-005/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/omaha-004/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/omaha-003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/abbvie-m18-868/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bi1808-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/veritac-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ewall/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/predict-hpv-hnc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/monumental-6/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pipn/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/teneriffa-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/caaa617a12402/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/arastep-21492/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/22-bi-1910-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/beamion-lung-1-1479-0001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/important/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/melbank-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pred-hh-markstudien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/azur2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/meteroid/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/horizon-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/merlin/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/onkovir/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/-m20-621/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/breton-bgb-16673-101/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cardiocare/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/andromeda-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bnt-113-01-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/triplex-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/haitils-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bo44426---krascendo-lung-170---studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fortitude101-amgen-552-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bio-me-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/-f8394-201-fore/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/swecraniol/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/svep53-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/v940-001-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/harbor-blu263-1201/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/effipec/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/eris/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/kartos-studien-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/kandova/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keyvibe-010/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dwell-time/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/piscatin/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/commodore-bo42161/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scan-all/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/decidualcellstudien2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/providhe/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ariadne-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/k-sab/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imole/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/peak-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tropion-breast032/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/spc11-01-110/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ac220-a-u202/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/asf-bc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/itcc-101apal2020d/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/profertil/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mesacapp/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca055-026/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ld-venex-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mimir-studien-89zr-atezolizumab-petct/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-6482-022/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cloudin-6-bnt211-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nmdsg14-b-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fapi-46fapi-pet/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/zuma-4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/19-bi-1808-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/eros/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prevent-a-call/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bi-1206-03-monkey/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cctl019g2201j--cassiopeja/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/libretto-432-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/firefly-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prodigyn/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/arm/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bnt122-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/destiny-12/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/salfladmet/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/espac-4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ascend--4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/eucharis/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ascape/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/i-conic-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/optimering-infor-stor-kolorektalcancer-kirurgi/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/majestec-9/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prias/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/optunebehandling-for-patienter-med-glioblastom--patienternas-narstaendes-och-personalens-uppfattning-av-behandlingen---en-kvalitativ-intervju-samt-enkat-studie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fibroneer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ironman/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/primordium/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cancerrehabilitering-vid-matstrups-eller-magsackscancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/advantage/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/serom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/first-rly-4008-101/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/asc4first/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sirpa-ca059-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/allovir-adeno-alvr105-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/magnetismm-7-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/certis-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/majestec-7/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/neogap-neogap-crc-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biwac-bi-1403-0001--brightline/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/in-mind/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/loxo-20022-btk/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dovacc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/asab/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk2140-004/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/postmonarche/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/neo-act/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bgb3111-lte1-roll-overstudie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/seamark/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/xnk-urotelialcancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/columbus-ad/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/brightline-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sensi-ex/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bio-melanom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/avanzar/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gemore/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/-isga-studien-pre-gat01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pro-glio/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tabanetoc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/colon-z/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/crlm-z/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dragon-sarcopenia-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mariposa-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/taormina-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/preopanc-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scanpan-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/t-rex/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/palbociclib/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nsgo-ctu-hero-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cnis793b12301/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/relativity-123/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keyform-008/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/popcorn/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/metro/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-c93gog-3064engot-en15/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lidera/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/halo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biobladder/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tropics-04/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk6482-012/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pris/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pelvex-ii-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/breakwater/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cirkos/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/costar/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/g-definer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sens-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prep-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/axsana/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/star-trec/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/salflac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/incb81776-101-axl-mer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mo41552/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/rm26/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sgns40-002-seasam/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/kartlaggning-av-hematologiska-maligniteter-hos-patienter-med-mojlig-arftlig-predisposition/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/en-fas-1b2-first-in-human-doseskalerings--och-expansionsstudie-av-xmt-1536-hos-patienter-med-solida-tumorer-som-sannolikt-uttrycker-napi2b/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/script-aml-studying-conditioning-regimen-in-pediatric-transplantation-aml/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/telepik2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/miltenyi-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cc-90010-gbm-002/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hypo-m1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/start-net/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ago-ovar-2.292025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/inotuzumab/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ludo-n/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/carfilzomib/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ponatinib/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/polargo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/inform2-nivent/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ipmn/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/parpanc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/relativity-098/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/altamira/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lbl-2018/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/b-nhl-2013/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/en-undersokning-om-smartrelaterade-erfarenheter-hos-svenska-vuxna-med-cancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ccs1477-02/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ccs1477-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/onc001-cl-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/psmaddition/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gct3013-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/modelle-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/soulmate/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/asac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/timepoint/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-365/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/enrgy/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/transcend/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/evi-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cell-protect---isa-hc-nk/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/loxo-btk-18001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/immu-lc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tinca-ii--njurcancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mypal/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dsa-ll-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gct-3013-05/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ros-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/immunologisk-aktivitet-hos-melanomtumorer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nex-18/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fas-i-studie-incb-99318-122-incyte/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/swedish-anal-carcinoma-study/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sgntuc-016/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ruby-del-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/destiny-breast09/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bite-u-20190505/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ipcm/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scan-mi/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/magsnow/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sentineo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/postmagmri/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/erfarenheter-av-vakuumassisterade-excisioner-av-forandringar-i-brost-vae/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/magtotal/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/breastcc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sentinot-2.02025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/paced/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/summist/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scandium-ii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-b21-gog.30532025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/psma-fore/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-b49/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nipu-studien--ca209-7h4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biobanksstudien-lungcancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk6482-015/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gct-3013-022/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/spencer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk6482-005/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hexabody-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/capitello-292/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/listo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prevalence/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scout/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pdm-mbc-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bio-muse/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/proper-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/navigate/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pcr1001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prommel-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/covaxid-kll/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prorect-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pacos/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/amplitude/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gsk-209012/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/transform-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/transform-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/zeal-1l-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prepec-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mermaid-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mr-divide/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-866/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/code-break-200/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/exclaim2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/phys-can-styrketraningsstudie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/genomikstudien-brost/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/induce-4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/blu-667-2303/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bite-cc93269-mm-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/heat-aml/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/momentum-sra-mmb-301/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/adore/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/re-screen/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/neo-aegis/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/needs/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/optima/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/destiny06/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ameera/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tas-120-202-soffa/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tak788-3001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/webbaserad-symtomovervaktning-vid-avancerad-lungcancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/megalit/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ho156-aml/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/polar-bear/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-a18--engot-cx11/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nordictripnbg-19-01-swebcg-19-01/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biolungstudien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/rhovac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dalia/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ipla/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cccs-covid-cast-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cor10012/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/induce-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/effect/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-7339-007-agent/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/thyro-nuke/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ruby/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/advance-ii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-76k-ca20976k/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/the-fiol-study-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ho150-aml/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/assure/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pro-hodgkin/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nordcml013/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hd21/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/beatcc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/breclim/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/psma-recidiv/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/direct/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lokon003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-73l-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lxh254x2102/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nivo-ilp/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pcia-laserstudie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/artscan-iv/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/psff-blodburna-vavnadsprov/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/exintric/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pantumime/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/down-stagingstudie-lever/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/orchard/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/karmma-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mbg453-mds/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/kllvacc-2017/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tatoo2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/relapc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ator-1017/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pcyc-1145/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/synkron-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/vigas/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imfdhac_impact-of-fixed-dentures-in-head-and-neck-cancer-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dbcg-rt-natural-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-937/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/intrigue-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/alltogether-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dream-5/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/canopy-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca209-171/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-905/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prove-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bh-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mateeo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/talapro-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ace-cl-311/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/205801-entree/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/canova/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/capitello-290/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/athena/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nucog-vi/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bgg-311-305/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bob/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/brigatinib-3001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/brigatinib-2002/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-555/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/transform/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/kiadis/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/graphite/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/a.r.r.o.w-22025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/destiny/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/clee011a2207/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/commands-ace-536-mds-002/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/probio2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/voc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fight-302/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bosupeg/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/norpact-12/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biome-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/viden/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/entree/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mir-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/racc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/iloc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/solstice/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/predix-ii-her2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/panfam1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ctc---cirkulerande-tumorcellsstudien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ipep/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tadpole-g/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gen-esofagus-studie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pilgrim/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pavo-mmy1004/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bright-b1371019/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/iso-cc-007-agent/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biobank-esofagusventrikel/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cando/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cyst-studie-saliv-studie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cyststud/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fimmun-pancreas-tumor/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/frosenor/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/adoele/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-7902-003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/predicting-fatigue-after-allo-hsct/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/matterhorn/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/-pneu-stem-v114-022/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hapirect/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/qolicol/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/watch-and-wait/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/con-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nmdsg14b/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nmdsg14a/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pci-32765can3001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/2215-cl-0302/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tempo-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/zeus/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/magnitude/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/onconova-04-302/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/54767414amy3001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bo39813/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/allopurinol-all2.02025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/seal-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/methronomic/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/asa-crclm-2014/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nmsg2415-ked/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ird-nmsg2315/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bcma-mmy1001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-7902-004/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nor-graspall-2016-akut-lymfatiskt-leukemi-all/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/phrancesca-mo40628/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prothym/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biolymph/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/expacd/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/psma-primar-prostatacancer2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ben-r/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ben-c/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/c16029-takeda-millenium/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/impower030/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ator-1015/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/eortc-vu34/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/exceptional-responders/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/canfour/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/artscan-v/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-9132/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/stop-gist-ssg-xxv/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ibru-on-off-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/valeria/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/citadel-203/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nz-dtx-001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-3475-587/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/atevacc2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/melanom-provtagning/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/glow-cll3011/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/can3001/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/javelin-blasa/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/proceed2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/vision/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/psma-pet-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/embark-mdv-3100-12/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/combi-aplus3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/intense/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/zuma-7/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pemborlizumab-mk-3475-051/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/graspanc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/17403-bay-1163877/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/achiles/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/who-cares/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/larct-us/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bemp/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/secombit/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/illuminate/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/opinion/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bgb-3111-304/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/act-on-me/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/s-ramp/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/trust2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/az-odin-pet2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/scan-b/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pemdac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/affibody-3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/genmab-gct1015-04/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/embrace-ii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/17-bi-1206-02/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca224-047/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-789/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cat-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pac203/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tulip/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/repomed/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/car-19/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hovon-141/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/b-701-u21/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imagyn050/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cpkc412a2408/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lokon002/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca017-003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/enrich/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imroz/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-908/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/aurora/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/monarche/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-5222/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tahoe-_-m16-2892/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/adaura/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/asteroid/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bold-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prodat/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-901-ca209-901/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/combi-i/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/secar-i/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dastop-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/artemids-cc-4047-mm-015/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nmsg-2013/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/opacin/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dursab/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pasiphae2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/glag/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/panorama-3-clbh589d2222/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prefer-preserve-fertility/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/onconova-04-30/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/quazar-aza-mds-003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/javelin-renal-1018/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/exelixis-xl184-401/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/trim/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/direktstudien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/prima-_-pr-30-5017-c/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/auto-lymfom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sakk-3514/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/compleement-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/iliad/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/arasens/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/profound/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cv006-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/geometry-mono-cinc280a2201/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-522/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/inspire_onconova-04-30/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-602-ca209-602/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pallas/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pepacaka/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-714/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/puma-ner-1301/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/preben/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/viable/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/solar-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/panorama_3/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cpdr001e2201/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-057/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mastiff/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mars/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-051/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lasec-studien-lymphedema-after-surgery-for-endometrial-cancer2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/alt-gist/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/podec/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lume-bionis/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/proper/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-274/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/spcg-17-pcastt/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/triangle/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/livskvalitet-for-patienter-med-malignt-melanom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/c-inc280-a2108/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/swea-studien4/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pet-boost/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/pro-cns/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nordic-8/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nordic-9/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/testiscab/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/avanova/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/melmart/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/melanomprovtagning/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cirkulerande-tumor-dna/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/icap/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/arches-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/titan-pcr3002-/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/embark--mdv-3100-13/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/rethink/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tumorfaktorers-betydelse-vid-behandling-av-malignt-melanom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/minimalinvasiv-isolerad-hyperterm-perfusion-mi-ilp/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/analys-av-exosomer-i-samband-med-isolerad-hyperterm-perfusion-for-behandling-av-metastaserande-malignt-melanom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/immunologiska-effekter-vid-behandling-av-metastaser-fran-malignt-melanom/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/aramis/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/iobt-kohortstudie/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/physsurg-b/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-451-ca209-451/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mistral/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/artscan-iii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bayer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/dna-pkinhib2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/roar2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/galahad/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fandango/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/abc-se/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/morris2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/gen701/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/i4t-mc-jvcz2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-170-pmbcl-och-richter-phase-ii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/maverric/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca209238/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/palaestra/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/phys-can/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mateo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sirt-net/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-177/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/jsbf/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/iluminet/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/et-nec/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/spcg-15/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/altaii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tailordose-ii/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/trem/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ca209067/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/male-breast-cancer-study/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/breast-cancer-in-pregnancy/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/micro-rnactc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-3475-181/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/the-scandium-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/neape_nordic-extended-abdominoperineal-excision-study--/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/paola-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nt-probnp/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/engot-ov-23ewoc-1/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/kaitlin/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/grace/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/alascca/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-199/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/abc-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-3475-252-keynote-252/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-ca-209-548/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-ca209-498/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/atlas/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/checkmate-209-401/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/m12-914-brocade/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ssgxx/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nintedanib/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-204/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mk-3475-048-keynote-048/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hovon-132-aml/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lymrit-3701/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/senomic/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/antibiotika-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/adm-studien/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/b-cap/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bevmar/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/im-201/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ici-pcrb/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/sandpiper/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/alpharadinabiraterone/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/vinsor/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/modul/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/fluoheart/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-100-mk-3475/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/ip-ov/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/engot/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-173-fas-i/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/keynote-119/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/olympia/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cobc/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/predix-her-2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bi-breeast/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/picc-pac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/neptune/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/thora/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/oligo/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/repac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/odx-003/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/artforce-headneck/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/cetmet2/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/imilt/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/rosett/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/phoneme/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/mat02/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/senomac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/tarzel/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/lumb/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/bevpac/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/impassion-130/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/flt-pet.mr2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/predix-luma/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/hilus/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/nucog-i-vingem/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/paraply/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/studier/biomarkorer-under-behandling-av-prostatacancer/2025-05-05 https://kb.localhost:5000/cancerstudier-i-sverige/anvandaradministration/2025-05-05 https://kb.localhost:5000/sok-sida-for-kort-svf/2025-11-12